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Sunday, October 15, 2017 Abstract #
1:30-3:30 PM IFSI Board meeting
5:00-5:20 PM OPENING CEREMONY
5:00-5:10 PM Opening remarks
Jacek C. Szepietowski (Poland)
5:10-5:20 PM Opening remarks
IFSI: A successful society for the future
Earl Carstens (USA)
5:20-7:00 PM Plenary Session
Chairs: Earl Carstens (USA); Elke Weisshaar (Germany)
5:20-5:50 PM Bernhard Lecture
Itchy dermatoses in the collection of Wroclaw moulages
Jacek C. Szepietowski (Poland)
OP1
5:50-6:20 PM Kuraishi Lecture 
Specificity or pattern: implications for clinical itch
Martin Schmelz (Germany)
OP2
6:20-6:50 PM Neisser Lecture
Itch and psyche
Mohammad Jafferany (USA)
OP3
Monday, October 16, 2017 AM
8:30-9:00 AM Morning session
Hot off the bench: Latest news by young investigators
Chairs: Hermann Handwerker (Germany); Adam Reich (Poland)
8:30-8:40 AM The regulation of pruritus in psoriasis and atopic dermatitis – a possible role for CD26/DPPIV
Eriko Komiya-Suyama (Japan), Ryo Hatano, Haruna Otsuka, Takumi Itoh, Hiroto Yamazaki, 
Yasushi Suga, Utako Kimura, Taketo Yamada, Mitsutoshi Tominaga, Kenji Takamori, Kei 
Ohnuma, Chikao Morimoto
OP4
8:40-8:50 AM Chronic itch in hemodialysis patients: A follow-up study of GEHIS (German Epidemiological 
Hemodialysis-Itch Study)
Natalie Plewig (Germany), Robert Ofenloch, Thomas Mettang, Elke Weisshaar
OP5
8:50-9:00 AM Attentional bias to itch-related images in a clinical itch population
Michellie Young (UK), Melanie Burke, Donna Lloyd
OP6
9:05-10:30 AM Plenary Session
Neurobiology of Itch
Chairs: Martin Steinhoff (Ireland); Matthias Ringkamp (USA); 
9:05-09:25 AM Effects of pruritogens and algogens on rostral ventromedial medullary (RVM) ON and OFF 
cells
T. Follansbee, Iodi Carstens (USA), Earl Carstens, T. Akiyama, M. Fujii, A. Davoodi, M. 
Nagamine
OP7
9:25-09:45 AM How scratching can take its “Toll” on itch, new insights into innate immune mechanisms of 
peripheral itch sensitisation
Ian McDonald (Ireland), Attila Szöllősi, Imre Szabó Lőrinc, Martin Steinhoff
OP8
9:45-10:00 AM Preferential activation of subtypes of polymodal nociceptive C-fibers in pigtail monkey 
following intradermal injection of β-alanine and bovine medullary protein 8-22
Amanda H Klein, Timothy V Hartke, Matthew Wooten, Gang Wu, Matthias Ringkamp (USA)
OP9
10:00-10:15 AM Itch as a basic constituent of somatosensation: Evidence for multi-modal capacity of primary 
C-afferents
Behrang Sharif (Canada), Ariel Ase, Alfredo Ribeiro da Silva, Philippe Séguéla
OP10
10:15-10:30 AM Sulfated CCK8 induces alloknesis via spinal CCK2 receptor in mice
Mitsutoshi Tominaga (Japan), Fumiya Kusube, Kotaro Honda, Nobuaki Takahashi, Hisashi 
Naito, Fumiyuki Yamakura, Yasushi Suga, Yasuhiro Tomooka, Kenji Takamori
OP11
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11:00 AM-12:30 
PM
Concurrent I
Special Interest Groups (SIGs)
Chairs: Thomas Mettang (Germany); Jacek C. Szepietowski (Poland)
11:00-11:15 AM SIG Sensitive Skin
Laurent Misery (France), Sonja Ständer, Jacek C. Szepietowski, Adam Reich, Joanna 
Wallengren, Andrea W.M. Evers, Kenji Takamori, Emilie Brenaut, Christelle Le Gal-Ianotto, 
Joachim Fluhr, Enzo Berardesca, Elke Weisshaar
OP12
11:15-11:30 AM SIG Scoring itch in clinical trials
Sonja Ständer (Germany), Matthias Augustin, Jacek C. Szepietowski
OP13
11:30-11:45 AM SIG Questionnaires
Elke Weisshaar (Germany), Jörg Kupfer, Antoinette van Laarhoven, Uwe Gieler, Masutaka 
Furue, Hidehisa Saeki, Andrea Evers, Gil Yosipovitch
OP14
11:45 AM-12:00 
PM
SIG Paraneoplastic itch
Elke Weisshaar (Germany), Thomas Mettang, Sonja Ständer, Frank Brennan, Hong Liang Tey, 
Gil Yosipovitch
OP15
12:00-12:15 PM SIG Uremic itch
Thomas Mettang (Germany), Jacek C. Szepietowski, Laurent Misery, Elke Weisshaar
OP16
12:15-12:30 PM Discussion
11:00 AM-12:30 
PM
Concurrent II
Skin, inflammation and itch
Chairs: Brian Kim (USA); Laurent Misery (France)
11:00-11:15 AM New insights into the pathophysiology of itch during ciguatera fish poisoning
Killian L’Herondelle (France), Laurent Misery, Christelle Le Gall-Ianotto, Réginald Philippe, 
Matthieu Talagas, Olivier Mignen, Richard Lewis, Raphaele Le Garrec
OP17
11:15-11:30 AM Intra- and extra-lesional sensitization for non-histaminergic and mechanically-evoked itch in 
atopic dermatitis
Hjalte Holm Andersen (Denmark), Jesper Elberling, Henrik Sølvsten, Gil Yosipovitch, Lars 
Arendt-Nielsen
OP18
11:30-11:45 AM Attenuated activation of endogenous glucocorticoids in keratinocytes induces alloknesis in 
atopic dermatitis via aberrant artemin production
Akira Matsumoto (Japan), Hiroyuki Murota, Mika Terao, Ichiro Katayama
OP19
11:45 AM-12:00 
PM
Neutrophil-somatosensory neuron crosstalk drives acute and chronic itch
Carolyn Walsh (USA), Jamie Schwendinger-Schreck, Jacques Deguine, Emily Brock, Rose Hill, 
Jessica Wei, Natalie Kelava Kucirek, Karsten Gronert, Greg Barton, Diana Bautista
OP20
12:00-12:15 PM Cutaneous 4-1BB/4-1BBL signaling induces severe skin inflammation and chronic itch
Stefan Tran, Verena Kupas, Kristian Holz, Marcus Maurer, Thomas A. Luger, Sonja Ständer, 
Karin Loser (Germany)
OP21
12:15-12:30 PM Sema3A expression is regulated by calcium/PKC/MAPK/AP-1 signaling axis in normal human 
epidermal keratinocytes
Yayoi Kamata (Japan), Yoshie Umehara, Azumi Sakaguchi, Yasushi Suga, Mitsutoshi 
Tominaga, Kenji Takamori
OP22
12:30-2:00 PM Lunch and poster viewing I
Chairs: Elke Weisshaar (Germany), Gil Yosipovitch (USA)
2:00-3:30 PM Plenary session
New antipruritic treatments
Chairs: Sonja Ständer (Germany); Alan Fleischer (USA)
2:00-2:15 PM Randomized, double-blind, placebo-controlled phase 2 clinical trial of serlopitant effects on 
multiple measures of pruritus in patients with prurigo nodularis
Sonja Ständer (Germany), Paul Kwon, Thomas A. Luger
OP23
2:15-2:30 PM Serlopitant for treatment of chronic pruritus: results of a randomized, multicenter, double-
blind, placebo-controlled phase 2 clinical trial
Gil Yospovitch (USA), Sonja Ständer, Matthew B. Kerby, James W. Larrick, Andrew J. Perlman, 
Edward F. Schnipper, Xiaoming Zhang, Jean Y. Tang, Thomas A. Luger, Martin Steinhoff
OP24
2:30-2:45 PM Recovery of peptidergic epidermal nerve fiber density by Tofacitinib in a mouse model of 
atopic dermatitis
Kristen Sanders (USA), Kento Sakai, Gil Yosipovitch, Tasuku Akiyama
OP25
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2:45-3:00 PM Crisaborole ointment provides early relief of pruritus in two phase 3 clinical trials in patients 
with mild or moderate atopic dermatitis
Emma Guttman-Yasky, Gil Yosipovitch (USA), Dedee Murrell, Jon Hanifin
OP26
3:00-3:10 PM New insights into the anti-pruritic activity of the neurokinin-1 antagonist Aprepitant: partial 
activation of EGFR signaling in human keratinocytes as a mechanism for reducing erlotinib 
induced-pruritus
Shawn Kwatra (USA), Cory Nanni, Yevgeniy Semenov, Callie Roberts, Madison Krischak, 
Madan Kwatra
OP27
3:10-3:20 PM Efficacy of systemic treatments of psoriasis on pruritus: A systemic literature review and meta-
analysis
Emilie Brenaut (France), Chloé Théréné, Thomas Barnetsche, Laurent Misery
OP28
3:20-3:30 PM Randomized, double-blind, placebo-controlled study of monoclonal anti-IgE antibody 
omalizumab in the management of pruritus in chronic spontaneous urticaria in the pediatric 
population.
Barnali Mitra (India), Biju Vasudevan, Reema Solanki, Debdeep Mitra
OP29
4.00-5.30 PM Concurrent I
Methods in itch research (clinical)
Chairs: Andrea Evers (The Netherlands); Jörg Kupfer (Germany)
4.00-4.20 PM How to alter placebo and nocebo effects in patients with chronic itch?
Andrea Evers (The Netherlands)
OP30
4.20-4.40 PM Methods in itch research: Arguments to improve standardization of research methods.
Joerg Kupfer (Germany), Uwe Gieler, Stephanie Kiupel, Christina Schut
OP31
4.40-4.55 PM Measuring pediatric itch severity: Does personal experience with chronic pruritus influence 
parent’s ability to be proxies?
Grace Lee, Sandy François, Shelby Smith, Caitlin Haydek, James Roberts, Kuang-Ho Chen, 
Suephy Chen (USA)
OP32
4.55-5.10 PM Validation of the peak pruritus numerical rating scale: results from clinical studies of 
dupilumab in adult patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch (USA), Matthew Reaney, Laurent Eckert, Lauren Nelson, Marci Clark, Marius 
Ardeleanu, Allen Radin, Abhijit Gadkari
OP33
5.10-5.20 PM 12-Item Pruritus Severity Scale: development and validation of new itch severity questionnaire
Adam Reich (Poland), Agnieszka Bożek, Katarzyna Janiszewska, Jacek C. Szepietowski
OP34
5.20-5.30 PM Clinical bandings of Patient-Oriented Eczema Measure (POEM) scores among Japanese atopic 
dermatitis patients
Makiko Kido-Nakahara (Japan), Yumi Yasukochi, Takeshi Nakahara, Rie Kuroki, Tetsuya 
Koga, Toshihiko Mashino, Yuichi Kurihara, Masutaka Furue
OP35
4.00-5.00 PM Concurrent II
Methods in itch research (experimental)
Chairs: Glenn Giesler (USA); Roman Rukwied (Germany)
4.00-4.15 PM Methods in experimental itch research – an introduction
Roman Rukwied (Germany)
OP36
4.15-4.30 PM Re-innervated human skin explant as a model for in vitro studies on pruritus
Nicolas Lebonvallet (France), Christelle Le Gall-Ianotto, Cecilia Brun, Thierry Oddos, 
Laurent Misery
OP37
4.30-4.45 PM Pharmacological and histochemical characterization of a mouse model of chronic renal failure-
associated pruritus
Tsugunobu Andoh (Japan), Shikai Li, Takahito Maki, Daisuke Uta, Yasushi Kuraishi
OP38
4.45-5.00 PM Depressive behavior manifested in NC/Tnd mice suffering from atopic dermatitis
Kenshiro Matsuda (Japan), Shuichi Yanai, Shogo Endo, Akane Tanaka, Hiroshi Matsuda
OP39
5.00-5.20 PM Methods in itch research (experimental)
Landon K Oetjen (USA)
OP40
5:30-6:30 PM General Assembly Meeting
6:30-7:00 PM IFSI Board Meeting
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Tuesday, October 17, 2017
8:30-9:00 AM Morning session
Hot off the bench: Latest news by young investigators
Chairs: Toshi Ebata (Japan); Andreas Kremer (Germany)
8:30-8:40 AM Reversing nocebo effects on itch by conditioning with verbal suggestion
Danielle Bartels (The Netherlands), Antoinette van Laarhoven, Michiel Stroo, Kim Hijne 
Leiden University, Kaya Peerdeman, Rogier Donders, Peter van de Kerkhof, Andrea Evers
OP41
8:40-8:50 AM Amelioration of atopic-itch sensation in NC/Tnd mice by beta-pinene, the major component 
contained in distilled Alpinia intermedia Gagnep extracts
Yosuke Amagai (Japan), Tetsuyoshi Hamasaki, Yoshihiro Nomura, Hiroshi Matsuda, Akane 
Tanaka
OP42
8:50-9:00 AM Prolonged antipruritic effect of botulinum toxin type A on cowhage-induced itch
Leigh Nattkemper (USA)
OP43
9:05-10:30 Plenary Session
The wide range of clinical presentations of itch
Chairs: Kenji Takamori (Japan); Gil Yosipovitch (USA)
9:05-9:20 AM An overview of treatment for opioid-induced itch
Kenji Takamori (Japan), Nobuaki Takahashi, Mitsutoshi Tominaga
OP44
9:20-9:35 AM Pruritus in patients with kidney transplants
Thomas Mettang (Germany), Elke Weisshaar, Jörg Kupfer
OP45
9:35-9:50 AM Urticaria and itch
Tabi Leslie (UK)
OP46
9:50-10:00 AM Essential thrombocythemia with aquagenic pruritus: an entity with more agressive clinical and 
biological profile at the diagnosis and a high morbidity during the follow-up.
Christelle Le Gall-Ianotto (France), Ronan Le Calloch, Aurélie Chauveau, Eric Lippert, 
Laurent Misery, Jean-Christophe Ianotto
OP47
10:00-10:10 AM Prevalence and clinical characteristics of pruritus in patients with cutaneous lupus 
erythematosus
Dominik Samotij (Poland), Justyna Szczęch, Emiliano Antiga, François Chasset, Aleksandra 
Dańczak-Pazdrowska, Adriana Polańska, Fukumi Furukawa, Carolyn Kushner, Hideo 
Hashizume, Mohammad Rafiqul Mowla, Aminul Islam, Minoru Hasegawa, Laurent Misery, 
Takaharu Ikeda, Zygmunt Adamski, Jacek C. Szepietowski, Victoria Werth, Adam Reich
OP48
10:10-10:20 AM Clinical characteristics of aquagenic pruritus in polycythemia vera
Edyta Lelonek (Poland), Łukasz Matusiak, Tomasz Wróbel, Jacek Kwiatkowski, Jacek C. 
Szepietowski
OP49
10:20-10:30 AM Clinical characteristics of pruritus in hidradenitis suppurativa patients.
Lukasz Matusiak (Poland), Justyna Szczęch, Karolina Kaaz, Edyta Lelonek, Jacek C. 
Szepietowski
OP50
11:15-12:45 PM Concurrent I
Patients’ perspectives and patient reported outcomes
Chairs: Christian Apfelbacher (Germany); Lidia Rudnicka (Poland)
11:15-11:30 AM Patient-reported outcomes: an introduction
Christian Apfelbacher (Germany), Pauline Nelson
OP51
11:30-11:45 AM High levels of acting with awareness go along with low levels of itch catastrophizing: First 
results of a cross-sectional study in patients with atopic dermatitis
Christina Schut (Germany), Kerry Montgomery, Kjell Lüßmann, Andrew Thompson, Uwe 
Gieler, Christoph Zick, Jörg Kupfer
OP52
11:45 AM-12:00 PM Do placebo effects work when subjects know that they receive a placebo? Effects of open-
label verbal suggestions on itch
Stefanie Meeuwis (The Netherlands), Henriët van Middendorp, Judy Veldhuijzen, Antoinette 
van Laarhoven, Jan De Houwer, Andrea Evers
OP53
12:00-12:15 PM A qualitative study to understand patients’ perception of the severity of chronic pruritus and its 
impact on health-related quality of life
Jennifer Theunis, Clementine Nordon, Ylana Chalem, Massimiliano Orri, Jesus Cuervo, Gilles 
Berdeaux, Marie Auges, Valerie Mengeaud, Laurent Misery (France)
OP54
12:15-12:30 PM The burden of chronic itch-a questionnaire based evaluation of clinical characteristics, 
associated morbidity and treatment outcomes in a cohort of patients with chronic pruritus.
Ian McDonald (Ireland), Imre Szabó Lőrinc, Attila Szöllősi, Martin Steinhoff
OP55
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12:30-12:45 PM European EADV network on assessment of severity and burden of Pruritus (PruNet): 
validation of instruments for itch intensity itch-impaired quality of life in pruritic dermatoses 
in Europe
Claudia Zeidler (Germany), Philipp Bruland, Claudia Riepe, Inaki Soto, Sabine Steinke, 
Michael Storck, Martin Dugas, Sonja Ständer
OP56
11:15-12:45 PM Concurrent II
Itch and pain
Chairs: Sarah Ross (USA); Uli Zeilhofer (Switzerland)
11:15-11:35 AM Spinal GABA-A receptor subtypes controlling itch
William T. Ralvenius, Elena Neumann, Mario A. Acuña, Martina Pagani, Dietmar Benke, 
Hendrik Wildner, Uwe Rudolph, Claude Favrot, Hanns Ulrich Zeilhofer (Switzerland)
OP57
11:35-11:55 AM Opposing effects of cervical spinal cold block on spinal itch and pain transmission
Earl Carstens (USA), Iodi Carstens, T. Akiyama, A. Davoodi, M. Nagamine
OP58
11:55 AM-12:15 PM Responses single thalamic units to pruriceptive and nociceptive stimuli in the rat.
Glenn Giesler (USA), Brett Lipshetz, Hai Truong, Sergey Khasabov, Donald Simone
OP59
12:15-12:30 PM Acupuncture for pain management in evidence-based medicine
Taqee Ansari Mohammed (India)
OP60
12:30 AM-12:45 PM Itch and pain influence on quality of life and sleep disturbances of hidradenitis suppurativa 
patients
Karolina Kaaz (Poland), Łukasz Matusiak, Jacek C. Szepetowski
OP61
12:45 PM-
2:00 PM
Lunch and poster viewing II
Chairs: Elke Weisshaar (Germany), Gil Yosipovitch (USA)
2:00-3:30 PM Concurrent I
Prurigo and other pruritic skin diseases
Chairs: Jeffrey Bernhard (USA); Joanna Wallengren (Sweden)
2:00-2:15 PM Prurigo and other pruritic skin diseases.
Joanna Wallengren (Sweden)
OP62
2:15-2:30 PM Psoriatic itch 2017
Jacek C. Szepietowski (Poland)
OP63
2:30-2:45 PM Novel definition, classification and terminology of chronic prurigo
Manuel Pedro Pereira (Germany), Sabine Steinke, Sonja Ständer
OP64
2:45-3:00 PM Aprepitant, a NK1-antagonist, administered for 16 weeks reduced itch and supported 
resolution of skin lesions in a patient with chronic prurigo
Franz J. Legat (Austria), Alexandra Gruber-Wackernagel, Angelika Hofer, Klara Waltner, 
Peter Wolf
OP65
3:00-3:15 PM Peripheral effects of targeting the neurokinin 1 receptor in chronic prurigo
Konstantin Agelopoulos (Germany), Falk Rülander, Julia Dangelmaier, Tobias Lotts, Karin 
Loser, Sonja Ständer
OP66
3:15-3:30 PM Neurophysiological studies on chronic prurigo
Manuel Pedro Pereira (Germany), Konstantin Agelopoulos, Esther Pogatzki-Zahn, Sonja 
Ständer
OP67
2:00-3:30 PM Concurrent II
New receptors, channels and pathways for itch
Chairs: Ethan Lerner (USA); Yang-Gang Sun (China)
2:00-2:15 PM Neural recruitment and Mrgpr activity are required for the development of a mouse model of 
atopic dermatitis
Ethan Lerner (USA), Tuanlian Luo, Ehsan Azimi, Vemuri Reddy, Sarina Elmariah
OP68
2:15-2:30 PM A central feedback neural circuit gates itch-scratching cycle
Yan Gang Sun (China)
OP69
2:30-2:45 PM TRPV1 regulates PAR-2-evoked intracellular Ca2+ release and inflammatory mediators 
production in differentiated keratinocytes
Olivier Gouin, Killian L’herondelle, Raphaele Le Garrec, Paul Buscaglia, Olivier Mignen, 
Christelle Le Gall-Ianotto, Virginie Buhé, Luc Lefeuvre, Laurent Misery, Nicolas Lebonvallet 
(France)
OP70
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2:45-3:00 PM Spinal release of gastrin releasing peptide (GRP) is required for suprathreshold synaptic 
activation of GRP receptor (GRPR)-positive neurons
Martina Pagani (Switzerland)
OP71
3:00-3:15 PM Effects of burn size on post-burn itch and epidermal nerve innervation in mice
Kent Sakai (USA), Kristen Sanders, Gil Yosipovitch, Tasuku Akiyama
OP72
3:15-3:30 PM Possible role of satellite glial cell derived lipocalin-2 in the pathogenesis of atopic dermatitis
Nobuaki Takahashi (Japan), Mitsutoshi Tominaga, Ryohei Kosaka, Hironori Matsuda, Yasushi 
Suga, Kenji Takamori
OP73
4:00-5:15 PM Concurrent I
Epidemiology of itch and quality of life
Chairs: Suphey Chen (USA); Andrey Lvov (Russia)
4:00-4:15 PM Epidemiological study on the prevalence of itch in Japanese dementia patients
Toshiya Ebata (Japan), Lefkos Middleton, Ryoko Fukuda, Yoshimasa Takase, Nao Taniguchi, 
Kimitoshi Takemura, Didier LeClercq, Joelle Vaglio, Michel Poncet, Akihiko Ikoma
OP74
4:15-4:30 PM Pitfalls in pediatric self-reported pruritus severity and quality of life impact
Shelby Smith, Grace Lee, Sandy François, Alix Pijeaux, Kuang-Ho Chen, James Roberts, 
Suephy Chen (USA)
OP75
4:30-4:45 PM Quality of life in patients with chronic pruritus: from the conceptual model to items generation
Jennifer Theunis, Clementine Nordon, Ylana Chalem, Massimiliano Orri, Jesus Cuervo, Gilles 
Berdeaux, Marie Auges, Valerie Mengeaud, Laurent Misery (France)
OP76
4:45-5:00 PM Chronic itch (CI) in hemodialysis patients: A follow-up study of GEHIS (German 
Epidemiological Hemodialysis-Itch Study) on incidence and mortality of patients with CI
Katarzyna Grochulska (Germany), Robert Ofenloch, Thomas Mettang, Elke Weisshaar
OP77
5:00-5:15 PM Prevalence, characteristics and burden of pruritus in chronic dermatoses
Tomasz Hawro (Germany), Katarzyna Przybylowicz, André Ellrich, Max Spindler, Karsten 
Weller, Sabine Altrichter, Ulrich Reidel, Marcus Maurer, Martin Metz
OP78
4:00-5:15 PM Concurrent II
New imaging techniques and other aspects of itch
Chairs: Clemens Forster (Germany); Ichiro Katayama (Japan)
4:00-4:15 PM New methods in brain imaging techniques
Clemens Forster (Germany)
OP79
4:15-4:30 PM Three dimensional analysis of cutaneous nervous system in pruritic atopic dermatitis and 
psoriasis skin
Hong Liang Tey (Singapore)
OP80
4:30-4:45 PM Functional connectivity reveals altered activation of brain areas in chronic cholestatic pruritus
Andreas Kremer (Germany), Theresa Buchwald, Marcel Vetter, Arnd Dörfler, Clemens Forster
OP81
4:45-4:55 PM Itch Tracker: An application software turning wearable smart devices into a tool to measure 
nocturnal scratching
Akihiko Ikoma (Japan), Kimitoshi Takemura, Didier LeClercq, Toshiya Ebata
OP82
4:55-5:05 PM Changes in tactile sensitivity after viewing itch-related images
Michellie Young (UK), Melanie Burke, Donna Lloyd
OP83
5:05-5:15 PM Keratinocyte derived cortisol regulates itch evoked- allergic cutaneous inflammation
Ichiro Katayama (Japan), Akira Matsumoto, Saori Ochi, Mika Terao, Hiroyuki Murota
OP84
5:20-6:30 PM Plenary Session
Future perspectives
Chairs: Earl Carstens (USA); Elke Weisshaar (Germany)
5:20-5:40 PM Future perspectives in treatment of itch
Sonja Ständer (Germany)
OP85
5:40-6:00 PM Future perspectives in basic research of itch: Mrgpr receptors and the biology of itch
Xingzhong Dong (USA)
OP86
6:00-6:30 PM CLOSING CEREMONY
6:00-6:15 PM Handwerker Prize, poster prizes
6:15-6:30 PM Closing remarks
Jacek C. Szepietowski (Poland), Earl Carstens (USA)
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
1006
www.medicaljournals.se/acta
9th World Congress of Itch
PP1: Myeloid GTP-Cyclohydrolase controls itch. Caroline Fischer, Katja 
Zschiebsch, Annett Häussler, Katrin Watschinger, Irmgard Tegeder 
PP2: Histamine is involved in peripheral nerve elongation into epidermis 
of mice with itching induced by surfactant. Yoshihiro Inami, Atsushi 
Sato, Hiroshi Ohtsu, Yosuke Mano, Yasushi Kuraishi, Tsugunobu Andoh
PP3: The effects of the NK-1 receptor antagonist netupitant on itch mo-
dels in mice. Girolamo Calo’, Anna Rizzi, Chiara Ruzza, Claudio Pietra
PP4: Optogenetic activation of serotonergic (5-HT) neurons in the rostral 
ventromedial medulla (RVM) facilitates touch-evoked scratching in a diet-
induced chronic dry skin mouse model. Masanori Fujii, Taylor Follansbee, 
Yuma Yasui, Susumu Ohya, Mirela Iodi Carstens, Earl Carstens
PP5: TRPV channels and post-burn pruritus. Hye One Kim, Yong Won 
Choi, Jee Hee Son, Yong Se Jo, Bo Young Jung, Chun Wook Park
PP6: Effect of [Leu11]-HK-1-derived peptides on scratching behavior in 
mice with chronic itch. Hideki Funahashi, Yu Miyahara, Ayaka Haruta-
Tsukamoto, Rumi Nakayama-Naono, Toshikazu Nishimori, Yasushi 
Ishida
PP7: Serotonin receptor subtypes involved in calcium influx in cultured 
rat dorsal root ganglion neurons. Dan Domocos, Tudor Selescu, Earl 
Carstens, Mirela Iodi Carstens, Alexandru Babes
PP8: Resistance to serotonin-induced itch in cholestatic mice. Sattar 
Ostadhadi, Nazgol-Sadat Haddadi, Arash Foroutan, Ehsan Azimi, Sarina 
Elmariah,, Ahmad-Reza Dehpour
PP9: Global gene expression profiling in prurigo nodularis. Konstantin 
Agelopoulos, Tobias Lotts, Heike Conrad, Martin Dugas, Sonja Ständer
PP10: Role of cysteinyl leukotrienes and the Cysltr2 receptor in pruri-
ception. Tiphaine Voisin, Amelie Bouvier, Yoshihide Kanaoka, K. Frank 
Austen, Isaac M. Chiu
PP11: Pharmacological evidence for the involvement of ATP-sensitive 
potassium channels in chloroquine-induced scratching behavior in mice. 
Nazgol-Sadat Haddadi, Sattar Ostadhadi, Arash Foroutan, Ahmad-Reza 
Dehpour
PP12: Modeling of itch sensitization for histaminergic and non-hista-
minergic itch? – Both UVB- and NGF-induced sensitization selectively 
increase pain, but not itch, elicited by histamine and cowhage. Silvia 
Lo Vecchio, Hjalte H. Andersen, Jesper Elberling, Lars Arendt-Nielsen
PP13: Expression Of ubiquitin C-terminal hydrolase L1/PGP9.5 in psoria-
sis. interplays between axonal nerve terminals snd epidermal keratinocytes 
in transmission of itch. Piotr Kupczyk, Marcin Hołysz, Mariusz Gajda, 
Adam Reich, Jacek C. Szepietowski
PP14: Measuring scratching and sleeping behavior besides pruritus inten-
sity. development of a new, all-encompassing pruritus symptoms score 
– the “Itch-Controlled-Days Score”. Sabine Steinke, Henk Wassmann, 
Frederik Braun, Kirstin Menne, Nani Osada, Laurie Burke, Christine 
Blome, Claudia Zeidler, Matthias Augustin, Sonja Ständer
PP15: The use of a dermocosmetic to manage pruritus related to skin 
diseases. an observational study. Sandrine Virassamynaik, Bernard Cha-
doutaud, Charlène Eydieux, Julie Riviere, Michèle Sayag
PP16: Itch as accompanying symptom in vitiligo. Elkham Karaev
PPI7: Prevalence and magnitude of itch in adolescent atopic dermatitis. 
Retrospective survey of first-year university students. Yosuke Okuda, 
Mayuko Tahara, Hiroyuki Murota, Ichiro Katayama, Keiko Yamauchi-
Takihara
PP18: Is itch a symptom of cutaneous leishmaniasis? Tizita Yosef Kidane
PP19: Assessment of pruritus among patients with viral hepatitis B and 
C. Anna Biernacka, Dawid Niżyński, Małgorzata Inglot, Adam Reich
PP20: Descending inhibition of itch and pain in humans – experimental 
paradigms for assessing endogenous itch inhibition efficacy. Hjalte Holm 
Andersen, Antoinette van Laarhoven, Jesper Elberling, Lars Arendt-
Nielsen
PP21: Pruritus in patients hospitalized in the Department of Dermatology, 
Jagiellonian University Medical College - a therapeutic approach. Magda-
lena Spałkowska, Agata Radko, Maciej Nowak, Małgorzata Werynowska, 
Anna Wojas-Pelc
PP22: Assessment of skin problems among patients with inflammatory 
bowel disease. is pruritus a major finding? Marta Idzior, Beata Jastrząb, 
Marta Laskowska, Katarzyna Neubauer, Adam Reich
PP23: Validity and reliability of various instruments for itch intensity 
measurement in patients with chronic pruritus. a prospective, multicenter 
study in Korea. Yong Hyun Jang, Gyeong-Hun Park, Byung-Soo Kim, 
Kap-sok Li, Chang Ook Park, Hye One Kim, Hei Sung Kim, Min Soo 
Jang, Kyung Duck Park, Eun Jin Doh, Dong Hun Lee, Yang Won Lee, 
Seong Jin Kim, Do Won Kim
PP24: Evaluation of the clinical characteristics of pruritus in patients with 
psoriasis using the Japanese version of the 5-D itch scale. Yozo Ishiuji, 
Yoshinori Umezawa, Norie Aizawa, Sanae Inokuchi, Akihiko Asahina, 
Koichi Yanaba, Toshiya Ebata, Hidemi Nakagawa
PP25: A Ugandan girl who had to endure thirteen years of itchy rashes 
without seeing a dermatologist. A case report from the new Gerold Jäger 
Skin Clinic in Kabale, Uganda. Leo Odongo
PP26: Itch in psoriasis – is age an important factor? Radomir Reszke, 
Rafał Białynicki-Birula, Jacek C. Szepietowski
PP27: Relationship between pruritus and serum lipocalin-2 in patients with 
psoriasis. Norie Aizawa, Yozo Ishiuji, Sanae Inokuchi, Koichi Yanaba, 
Yoshinori Umezawa, Akihiko Asahina, Nobuaki Takahashi, Mitsutoshi 
Tominaga, Kenji Takamori, Hidemi Nakagawa
PP28: Evaluation of the clinical characteristics of pruritus in patients with 
dermatomyositis using the Japanese version of the 5-D itch scale. Sanae 
Inokuchi, Yozo Ishiuji, Norie Aizawa, Koichi Yanaba, Toshiya Ebata, 
Hidemi Nakagawa
PP29: The need for linguistically and culturally adapted standard ques-
tionnaires to assess itch. Preliminary study and perspectives. Deok-Hee 
Kim-Dufor, Adèle Poulaliou, Laurent Misery
PP30: Detection of presence IgG1-IgG4, IgE, IgA, IgM, C3c, C1q and 
Fibrinogen deposits under direct immunofluorescence staining in eldery 
patients with pruritic dermatoses. Natalia Zdanowska, Agnieszka Owc-
zarczyk-Saczonek, Joanna Czerwińska, Martyna Bieniek-Kobuszewska, 
Waldemar Placek
PP31: Validation of Japanese version of ItchyQoL in chronic pruritus 
patients. Toshiya Ebata, Yuko Hayakawa, Akishi Momose, Yuko Higaki, 
Suephy C. Chen
PP32: Differences in factors that drive pruritus quality of life between 
Asian Americans and other races. Kevin Luk, BS, Alix Pijeaux, BS, Ku-
ang-Ho Chen, PhD, Glenda Wrenn, MD, MSHP, Cassandra Quave, PhD, 
Sarah Chisolm, MD, Seema Kini, MD, MSCR, Suephy Chen, MD, MS
PP33: Investigating racial disparities in pruritus quality of life in pediatric 
patients. Alix Pijeaux, Grace Lee, Shelby Smith, Sandy Francois, Kuang-
Ho Chen, Suephy Chen
PP34: Does pre-scratching reduce the itch transmission? Ravi Chandra 
Kopparaju, Chih-Cheng Chen
PP35: The relationship between stress and itch in German university 
students. Stephanie Kiupel, Joerg Kupfer, Uwe Gieler, Sophia Kottlors, 
Gil Yosipovich, Christina Schut
PP36: Sumatriptan, the anti-migranous drug, suppresses serotonin-induced 
itch. The possible involvement of opioidergic system. Nazgol-Sadat 
Haddadi, Arash Foroutan, Sattar Ostadhadi, Saeed Shakiba, Khashayar 
Afshari, Maryam Daneshpazhooh, Ahmad-Reza Dehpour
PP37: Defining a Responder on the Peak Pruritus Numerical Rating Scale 
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analysis from randomized trials of dupilumab. Eric Simpson, Abhijit 
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PP38: Significance of IL-31 expression in skin and in serum in patomecha-
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PP39: Sumatriptan attenuates CQ-induced scratching through NO-
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therapy. Dominika Ragin, Katarzyna Nowacka, Barbara Zegarska
PP41: Lysophosphatidic acid induces itch and pain in humans depending 
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Ries, Martina Stengel, Peter W. Reeh, Michael J. Fischer, Barbara Namer, 
Andreas E. Kremer
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PP43: The problem of the itch in surgical oncology - do we know everyth-
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PP46: Functional changes in the cerebral networks for itch and burning 
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BERNHARD LECTURE 
OP1
ITCHY DERMATOSES IN THE COLLECTION OF 
WROCLAW MOULAGES
Jacek C. Szepietowski 
Department of Dermatoology, Venereology and Allergology, Wroclaw 
Medical University, Wroclaw, Poland
Itch is regarded as the most common symptom in dermatology. It 
could be find in many skin diseases, including infectious diseases 
as well as inflammatory. Wroclaw Department of Dermatology 
is famous because of its collection of dermatological moulages. 
During this prestigious Bernhard Lecture some examples of itchy 
skin diseases documented as moulages of the above mentioned 
collection will be presented. The use of wax for practical purpo-
ses has a long-lasting tradition dating to ancient times. Initially 
dermatological moulages were produced with the use of plaster 
moulds, probably because of their lower cost, but in time the need 
for better quality led to the use of beewax mixture. In the process of 
constructing the moulage the skin lesions were exactly reproduced 
by casting. Colour was the only subjective part. The history of 
Wroclaw moulages dates the times of Albert Neisser, the famous 
head of the Department of Dermatology (1882–1916). Keizo Dohi, 
a Japanese physician studing dermatology in Vienna, probably 
brought the technology of moulages to Wroclaw (Breslau). The 
vast majority of current collection of moulages was produced by 
Alfons Kröner who joined the Neisser’s department in 1897. The 
last moulage was made Wroclaw in 1937. The moulages made 
by Alfons Kröner were considered the best thanks to accuracy. 
The only flaw was the yellowish tint, which seemed to be result 
of using poorer quality wax. The current collection of moulages 
contains of 323 exhibits. Among them there are sevaral dermato-
ses in which itch is a an important symptom: infections: tinea, 
impetigo, pruriens pyodermiae; inflammatory diseases: eczema, 
neurodermatitis, lichen simplex, atopic dermatitis, lichen planus, 
psoriasis; autoimmune dermatoses: blistering disease, scleroderma 
and other disorders: acne, Reclinghausen disease, skin cancers.
KURAISHI LECTURE
OP2
SPECIFICITY OR PATTERN: IMPLICATIONS FOR 
CLINICAL ITCH
Martin Schmelz
Department of Anesthesiology and Intensive Care Medicine, University of 
Heidelberg, Mannheim, Germany
The main problem for the development of targeted therapy for 
chronic itch has been a lack of pathophysiologic concepts and 
identification of specific itch mediators. Recently, new major 
discoveries in the field of specific mediators and receptors of non-
histaminergic itch were made. These include functional markers 
for primary pruriceptive afferent neurons in rodents (MrgA1, 
MrgC11, MrgD) and man (MrgX1, MrgD), peripheral mediators 
that are linked to the itch sensation (IL13, IL31, autotaxin, LPA, 
TSLP, Cathepsin S) and central transmitters specific for itch 
processing (B-type natriuretic peptide, gastrin releasing peptide). 
While most of these potential anti-pruritic targets were developed 
on the basis of itch-specific approaches along the lines of the 
specificity theory there are also targets common for nociceptors 
and pruriceptors such as NK1 antagonists or even sodium channel 
subtypes such as NaV1.7. Specific mediators for itch have been 
found in rodents based on the specificity of itch (“labeled line”). 
However, also nociceptors have a potential role in generating itch 
(“pattern theory”). Human studies are required to answer the ques-
tion whether therapeutic targets in humans should be investigated 
primarily in nociceptors or in specific pruriceptors. While pain and 
itch behavior in animals can be differentiated operationally, pa-
tients report combined itch and pain sensations both in neuropathic 
pain and neuropathic itch conditions. As pain suppresses pruritus, 
their concurrent occurrence in patients is unexpected and may 
suggest common pathophysiological mechanisms of pain and itch 
processing. Thus, a key problem to be solved in chronic itch patient 
is the question whether activity in specific pruriceptors or certain 
patterns of activity in nociceptors is the underlying mechanism.
NEISSER LECTURE
OP3
ITCH AND PSYCHE
Mohammad Jafferany, MD, FAPA
Central Michigan University, Saginaw, Michigan, USA 
Itch, also referred as pruritus is an unpleasant cutaneous sensa-
tion, provoking the desire to scratch. It is an unpleasant subjective 
sensation responsible for decreased quality of life in a variety of 
psychodermatological conditions. Comorbid psychiatric condi-
tions including depression and anxiety are frequently associated 
with itch and scratch cycle. The reciprocal and intricate relation-
ship between psych and itch has been widely studied. The neu-
robiology of itch involves the complexity of specific mediators, 
itch-related neuronal pathways and central processing of itch. 
The connection between itch and psych can be grouped under 
three headings: pruritic diseases with psychosocial sequel, pru-
ritic diseases aggravated by psychosocial factors and psychiatric 
disorders causing pruritus. Itch and pain modulation go together 
in most circumstances and involves various substances including 
histamine, interleukins, protease-activated receptors, transient 
receptor potential receptors, opioids, and cannabinoids. The close 
interaction between keratinocytes and nerve endings modulating 
pain and itch also play a major role. Management of itch associated 
with psychosomatic component is directed at underlying cause 
and adopting a holistic approach to address not only dermatologic 
and somatosensory aspects but also the cognitive, emotional and 
psychosocial components. An integrated multidisciplinary team 
consisting of dermatologist, psychiatrist, psychologist, and social 
worker, is vital in addressing multifaceted aspects of pruritus.
HOT OFF THE BENCH: LATEST NEWS BY 
YOUNG INVESTIGATORS
OP4
THE REGULATION OF PRURITUS IN PSORIASIS 
AND ATOPIC DERMATITIS - A POSSIBLE ROLE 
FOR CD26/DPPIV
Eriko Komiya-Suyama, Ryo Hatano, Haruna Otsuka, Takumi 
Itoh, Hiroto Yamazaki, Yasushi Suga, Utako Kimura, Taketo Ya-
mada, Mitsutoshi Tominaga, Kenji Takamori, Kei Ohnuma, Chikao 
Morimoto
Juntendo University Graduate School of Medicine, Department of Therapy 
Development and Innovation for Immune Disorders and Cancers, and In-
stitute for Environmental and Gender Specific Medicine, Japan
Psoriasis and atopic dermatitis are chronic inflammatory skin 
diseases frequently accompanied by itching. Because of limited 
treat ment options for this troublesome symptom, the development 
INVITED LECTURES
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of more effective treatment for pruritus is critically important. 
CD26 is a 110-kDa, type II transmembrane glycoprotein with 
known dipeptidyl peptidase IV (DPPIV) in its extracellular do-
main. CD26 is a T cell costimulatory molecule and plays an im-
portant role in T cell biology. In addition to cell surface antigen, 
a soluble form is present in sera with conservation with DPPIV 
enzyme activity (sCD26 or sDPPIV). It has been reported that 
expression levels of DPPIV in keratinocytes of psoriatic skin are 
increased. However, a mechanistic role of DPPIV enzyme has not 
yet been elucidated. The aim of this study was to evaluate the 
clinical significance and the molecular mechanisms of DPPIV 
enzyme activity in patients with pruritus of psoriasis and atopic 
dermatitis. We first analyzed levels of sCD26 protein and DPPIV 
enzyme activity in sera of patients, utilizing a house-made sand-
wich ELISA. Levels of sCD26 and DPPIV enzyme activity in 
sera were significantly increased in patients with psoriasis and 
atopic dermatitis compared to those of healthy normal adults. We 
next evaluated levels of itch-transmitting neuropeptides inclu-
ding substance-P (SP), which is a substrate for DPPIV enzyme, 
showing significant increase in sera of psoriasis and atopic der-
matitis. Moreover, we found that truncated form of SP (SP5-11) 
cleaved by DPPIV was significantly increased in both patients. 
Furthermore, utilizing pruritus model induced by SP intradermal 
injection, scratching behavior was significantly decreased with 
treatment of a DPPIV inhibitor. Finally, utilizing Imiquimod-in-
duced psoriasis model and mite extract-induced atopic dermatitis 
model, scratching behavior was significantly increased in DPPIV 
overexpressing-mice, meanwhile scratching behavior was signifi-
cantly decreased with administration of a DPPIV inhibitor. Taken 
together, our present results study suggests that DPPIV enzyme 
activity plays an important role in pruritus via truncation of SP, 
and that regulation of DPPIV enzyme may provide a more treat-
ment option for patients suffer from pruritus. 
OP5
CHRONIC ITCH IN HEMODIALYSIS PATIENTS: 
A FOLLOW-UP STUDY OF GEHIS (GERMAN 
EPIDEMIOLOGICAL HEMODIALYSIS-ITCH 
STUDY)
Natalie Plewig1, Robert Ofenloch1, Thomas Mettang2, Elke Weiss-
haar1
1Dept. of Clinical Social Medicine, Environmental and Occupational Der-
matology, University Hospital Heidelberg, 2Dept. of Nephrology, DKD He-
lios Klinik, Wiesbaden, Germany
GEHIS (German Epidemiological Hemodialysis Itch Study) is a 
representative cross-sectional cohort started in 2013 and including 
860 hemodialysis (HD) patients in 25 dialysis units in Germany. 
We recently showed 25.1% (n=217) of HD patients to suffer from 
current chronic itch (CI). Four years later, in 2017 we performed a 
follow-up study and contacted all CI patients again to investigate 
the persistence, course and characteristics of CI. Itching was as-
sessed with the same patient questionnaire about current and pre-
vious CI (during the last 3 years), severity of CI (visual analogue 
scale, VAS). HRQOL (SF-12 questionnaire) and itch-related qua-
lity of life (ItchyQoL) were assessed. As this is an ongoing study, 
results are preliminary and refer to 9 dialysis units containing 212 
HD patients being addressed so far. Of those who had previously 
reported CI (n=54), 14.8% (n=8) could not be interviewed (e.g. 
because they had moved to another place or because they were 
not on dialysis treatment anymore due to transplantation). The 
following results refer to 46 patients. 45.7% (n=21) of those had 
died in the meantime. Of the remaining 25 patients, 52.4% (n=13) 
were still suffering from CI having a mean age of 66.5 years (SD 
11.9 years). First analyses including HRQOL and ItchyQol de-
monstrate a significant impairment in those still suffering from CI 
(n=13). We compared this group to those who newly acquired CI, 
lower scores indicating lower HRQOL in the physical subscale of 
SF-12 (27.9 vs. 37.9) were detected. First analyses of the severity 
show significantly higher scores in those still suffering from CI 
compared to those who newly acquired CI (VAS 3.32 vs. 2.88). 
These new data confirm CI to be a persistent and impairing symp-
tom in hemodialysis patients.
OP6
ATTENTIONAL BIAS TO ITCH-RELATED IMAGES 
IN A CLINICAL ITCH POPULATION
Michellie Young, Melanie Burke, Donna Lloyd
University of Leeds, UK
Itch-related images have been shown to induce Visually Evoked 
Itch (VEI) in both healthy and chronic itch populations, although 
differences in how the effect manifests have been found for the 
latter group. This study investigated whether these differences are 
reflected in an attentional bias towards itch images. We tested 30 
clinical itch participants (self-reported eczema, psoriasis, etc.) and 
30 healthy control participants, using an arrow probe reaction time 
task combined with eye tracking. Participants viewed pairs of itch 
and non-itch images for 2000 ms and then reported the direction 
of an arrow probe presented either congruently or incongruently 
with the itch image. Participants’ reaction times were measured, 
as well as the direction, number, and duration of saccades towards 
the itch image. We found an attentional bias in reaction times for 
the clinical but not the healthy group; clinical participants respon-
ded faster on congruent trials, indicating that their attention was 
directed towards the itch images. Eye tracking also revealed that 
the clinical group made more saccades towards the itch images, 
spent longer looking at them, and were more likely to make their 
first saccade on each trial to the itch image. These effects appear to 
be primarily driven by images featuring skin damage (scratching, 
rashes etc.) compared to images featuring irritants. This indicates 
that VEI provoking images affect clinical groups differently to 
the healthy population. In clinical participants with a pre-existing 
propensity to experience itch, the response to viewing itch images 
may draw upon a top-down attentional mechanism, whereas the 
creation of VEI in healthy participants may be more reliant on a 
bottom-up effect with little early processing of the itch content. 
Understanding these differences will help to elucidate how psy-
chological triggers can affect people with itchy skin conditions 
and perpetuate the itch-scratch cycle.
NEUROBIOLOGY OF ITCH
OP7
EFFECTS OF PRURITOGENS AND ALGOGENS ON 
ROSTRAL VENTROMEDIAL MEDULLARY (RVM) 
ON AND OFF CELLS
Mirela Iodi Carstens1, Taylor Follansbee1, Earl Carstens1, Tasuku 
Akiyama2, Masanori Fujii1, A. Davoodi1, M. Nagamine1
1Neurobiology, Physiology & Behavior, Univ. of California, Davis CA; 
2Univ. of Miami, USA
RVM ON- and OFF cells are thought to facilitate and inhibit 
spinal nociceptive transmission, respectively. However, it is 
unknown how ON and OFF cells respond to pruritic stimuli or 
how they contribute to descending modulation of spinal itch sig-
naling. In pentobarbital-anesthetized mice, single-unit recordings 
were made in RVM from ON and OFF cells identified by their 
respective increase or decrease in firing that occurred just prior 
to nocifensive hindlimb withdrawal elicited by paw pinch. Of 
RVM ON cells, 86% (24/28) were excited by intradermal (id) 
histamine, 50% by id chloroquine, and 76% by id capsaicin. All 
units also responded to a scratch stimulus applied adjacent to the 
hindpaw injection site. Most units were unresponsive to id injec-
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tion of vehicle, but still responded to scratching. More variable 
effects were observed with OFF cells. Id histamine and scratching 
excited 50% while inhibiting or having no effect in the remainder. 
Id chloroquine was ineffective in 62% while exciting 15% and 
inhibiting 23%. Id capsaicin and scratching inhibited 64% while 
exciting 14% and having no effect in the remainder. These results 
indicate that ascending pruriceptive signals may activate RVM 
ON cells to initiate descending facilitation of spinal itch and 
pain transmission. The mainly inhibitory effect of capsaicin on 
OFF cells is consistent with decreased descending inhibition to 
facilitate spinal nociceptive transmission. The mixed effects of 
pruritogens on OFF cells suggests a more complex descending 
modulatory effect on spinal pruriceptive transmission that may 
include descending inhibition (by excitation of some OFF cells) 
that counteracts descending facilitation (by inhibition of OFF 
cells and excitation of ON cells).
OP8
HOW SCRATCHING CAN TAKE ITS “TOLL” 
ON ITCH, NEW INSIGHTS INTO INNATE 
IMMUNE MECHANISMS OF PERIPHERAL ITCH 
SENSITISATION
Ian McDonald1, Attila Szöllősi2, Imre Szabó Lőrinc3, Martin Stein-
hoff4
1UCD Charles Institute of Dermatology, Department of Dermatology St 
Vincents University Hospital, Dublin, Ireland, 2Department of Physiology, 
and 3Department of Dermatology, Faculty of Medicine, University of De-
brecen, Debrecen, Hungary, 4UCD Charles Institute of Dermatology, Dept 
of Dermatology, Hamad Medical Corporation, Qatar University, Weil Cor-
nell University Watar, Doha, Qatar
Itch is the most common symptom in dermatology is associated 
with significant physical and psychological morbidity. Our un-
derstanding of itch however is still far from complete. Toll-like 
receptors (TLRs) are cellular sensors designed to recognize 
molecular danger signals associated with exogenous or endoge-
nous threats. Recently TLR3 was found to be significant in the 
regulation of itch signaling in mice (Liu et al 2012). A detector of 
double stranded RNA, TLR3 acts as an innate biosensor of viral 
pathogens, but also responds to endogenous damage associated 
molecular patterns including RNA released from injured epider-
mal keratinocytes. We hypothesise that scratching, which leads 
to epidermal damage and the release of RNA from keratinocytes 
contributes to the peripheral sensitization of itch in humans via 
activation of TLR3. Objective: Aim: 1) Identify key itch medi-
ators released from keratinocytes following activation of TLR3. 
2) Evaluate the expression of TLR3 in chronically scratched 
skin of patients with nodular prurigo. Methods: Normal human 
epidermal keratinocytes (NHEKs) were treated with the synthetic 
ligand of TLR3, Poly(I:C) at different concentrations. Secretome 
analysis was performed at 4 and 24 hours using ELISA. Quanti-
tative RT PCR was preformed to analyse mRNA expression 
from treated cells. The expression and quantitation of TLR3 in 
lesional, perilesional and healthy control skin was performed 
using immunofluorescence. Results: Stimulation of NHEKs with 
Poly (I:C) resulted in the release of IL-6 and Endothelin-1 (ET-
1). RT-PCR showed increased mRNA levels of TLR3, TSLP and 
ET-1 following treatment. Immunofluoresence of skin showed 
significantly increased expression of TLR3 in the lesional skin 
of patients with nodular prurigo (mean VAS score 7.5), compa-
red with perilesional (non-scratched) and healthy control skin. 
Conclusions: We have demonstrated that activation of TLR3 in 
NHEKs results in the release of ET-1. This important mediator 
of non histaminergic itch in humans known to be increased in 
lesional skin of nodular prurigo patients (Kido et al 2014). We 
also found significantly increased expression of TLR3 in lesional 
skin of nodular prurigo. Therefore TLR3, an innate biosensor may 
act as an important receptor in the itch-scratch-cycle, responding 
to injured, scratched epidermal keratinocytes, increasing its ex-
pression and triggering itch through ET-1, TSLP and other pro 
inflammatory cytokines (IL-6).
OP9
PREFERENTIAL ACTIVATION OF SUBTYPES 
OF POLYMODAL NOCICEPTIVE C-FIBERS IN 
PIGTAIL MONKEY FOLLOWING INTRADERMAL 
INJECTION OF Β-ALANINE AND BOVINE 
MEDULLARY PROTEIN 8-22
Amanda H Klein, Timothy V Hartke, Matthew Wooten, Gang Wu, 
Matthias Ringkamp
Dept of Neurosurgery, School of Medicine, Johns Hopkins University, USA
In human, intradermal administration of β-alanine (ALA) and 
bovine adrenal medullary protein 8-22 (BAM8-22) cause the 
sensation of itch. These pruritogens activate non-overlapping 
populations of murine DRG neurons that differ in their expression 
of mas-related G protein-coupled receptors (Mrgprs). In primate, 
orthologous genes for some Mrgs exist (MrgD-G), whereas oth-
ers, designated as MrgX1-4, cannot be clearly assigned to any of 
the MrgA-C subfamilies described in mice. Currently, it is not 
known what types of cutaneous afferents in primate are activated 
by ALA, an MrgprD agonist, and BAM8-22, an agonist for murine 
MrgprC11 and human MrgprX1. Previously, we have shown that 
two types of heat responses are observed in cutaneous polymodal 
nociceptive C-fibers when their receptive fields (RF) are exposed 
to a stepped heat stimulus (49°C, 3s): a quick response (QCs) or 
a slow response (SCs), and that QC-fibers are preferentially acti-
vated by ALA. Whether polymodal nociceptors are activated by 
BAM8-22 and whether any fiber subclass is preferentially activated 
is currently not known. Neuronal activity of unmyelinated C fibers 
innervating the hairy skin was recorded in anaesthetized nonhuman 
male primates (Macaca nemestrina) using standard teased-fiber 
techniques. After assessing receptive properties of the afferent fiber 
under study, two blocks of intradermal injections (each 10 µl) were 
administered in random order at the RF: one block consisted of 
extracellular fluid (ECF, the solvent) followed by ALA (90 µg) and 
another block of BAM8-18 (the inactive truncated peptide, 1 µg) 
followed by BAM8-22 (1 µg). Neuronal activity was recorded for 
at least 5 minutes following each injection. We studied a total of 45 
C fibers. All of 21SCs and 17/24 QCs responded to BAM8-22, but 
responses were about 3-fold larger in SCs than in QCs. Only 4/21 
SCs but 23/24 QCs responded to ALA, and QC- responses were 
about 10-fold larger than in SCs. In SCs, responses to BAM8-22 
were about 20-fold higher than those induced by ALA, whereas in 
QCs, responses to ALA were about 2-fold larger than responses to 
BAM8-22. These results show that QCs and SCs are preferentially 
activated by ALA and BAM8-22, respectively, and suggest that QCs 
encode ALA –induced sensations, whereas activity in QCs and SCs 
likely contributes to encode sensations produced by BAM8-22. 
OP10
ITCH AS A BASIC CONSTITUENT OF SOMATO-
SENSATION: EVIDENCE FOR MULTI-MODAL 
CAPACITY OF PRIMARY C-AFFERENTS
Behrang Sharif, Ariel Ase, Alfredo Ribeiro da Silva, Philippe Sé-
guéla
Department of Physiology, McGill University, Montreal, Quebec, Canada
Undoubtedly, itch and pain are among the closest modalities of 
somatosensation. While itch can be described as an unpleasant sen-
sation that leads to scratching behavior, pain is also describable as 
an unpleasant sensation with the distinction of eliciting withdrawal 
behavior. Despite significant anatomical and behavioral overlap of 
pruriception and nociception, the underlying neurophysiological 
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basis of itch and its relation to pain is still unclear. More specifically, 
the enigma of how the somatosensory system differentiates itch 
and pain sensations and triggers distinct fight or flight behaviors 
remains to be solved. There have been several theories proposed 
for this discrimination process and one of the most popular ones, 
in the past decade, is the “labeled line” or “specificity” theory. Ac-
cording to this theory, dedicated components of the somatosensory 
system, from the periphery to the brain, are specifically specialized 
for detection, transmission and perception of each sensory mo-
dality. Whether this theory can explain all aspects of itch and its 
discrimination from pain, is currently debated among the scientists 
studying somatosensory systems. To test the validity of the labeled 
line theory for itch, we took advantage of a described subpopulation 
of primary C-fiber pruriceptors that express MrgprA3, the receptor 
for the itch-inducing compound chloroquine. In order to be able to 
evaluate the effects of a wide variety of activation conditions, we 
took advantage of Cre-dependent optogenetic and chemogenetic 
actuators, selectively expressed on the surface of these MrgprA3+ 
neurons. Behavioral experiments were performed after complete 
validation of the heterologous actuators in dorsal root ganglia 
(DRG) and trigeminal ganglia (TG) neurons. In accordance with 
previously reported data, our behavioral studies show that chemoge-
netic activation of these neurons evokes stereotypical itch behavior 
rather than pain responses. Surprisingly, optical activation of these 
neurons through ChR2 predominantly induces pain responses and 
avoidance behaviors rather than scratching. Our results show that in 
vivo a single genetically-defined population of C-fibers can convey 
itch sensation in certain conditions and pain in others. This calls 
for novel models to explain how itch and pain are distinctly coded 
in the mammalian nervous system.
OP11
SULFATED CCK8 INDUCES ALLOKNESIS VIA 
SPINAL CCK2 RECEPTOR IN MICE
Mitsutoshi Tominaga1, Fumiya Kusube1, Kotaro Honda1, Nobuaki 
Takahashi1, Hisashi Naito2, Fumiyuki Yamakura3, Yasushi Suga1, 
Yasuhiro Tomooka4, Kenji Takamori1
1Institute for Environmental and Gender Specific Medicine, Juntendo 
University Graduate School of Medicine, 2Institute of Health and Sports 
Science & Medicine, Juntendo University, 3Juntendo University Faculty of 
International Liberal Arts, 4Department of Biological Science and Tech-
nology, Faculty of Industrial Science and Technology, Tokyo University of 
Science, Japan
In the central nervous system (CNS), the neuropeptide chole-
cystokinin (CCK) is known to act as a neurotransmitter and/or 
neuromodulator in circumstances such as anxiety, feeding and 
allodynia. However, the relationship between CCK and spinal 
itch transmission remains unclear. In our gene expression analysis, 
increased expression of CCK mRNA was found in the dorsal root 
ganglia of NC/Nga mice with atopic dermatitis (AD)-like symptoms 
compared with that in non-AD control mice. Previous studies have 
also shown that sulfated CCK8 (CCK8S) is distributed widely in 
the CNS. Therefore, this study was performed to investigate the role 
of CCK8S in spinal itch transmission. Initially, we examined the 
effects of intrathecal injection of CCK8S on itch-related scratching 
behavior in mice. In behavioral analyses, intrathecal injection of 
CCK8S did not induce scratching bouts in C57BL/6J mice. We 
next tested whether spinal CCK8S induced alloknesis, namely 
touch-evoked itch using innocuous von Frey filaments. Intrathecal 
injection of CCK8S resulted in increased alloknesis scores in treated 
mice compared to control mice. Pharmacologically, intrathecal 
injection of L-365,260, a CCK2 receptor (CCK2R) antagonist, 
significantly attenuated the CCK8S-induced alloknesis, whereas 
a CCK1R antagonist did not. These findings suggest that CCK8S 
induced alloknesis via spinal CCK2R. Thus, the CCK8S-CCK2R 
pathway may be a promising candidate for anti-alloknesis treatment.
SPECIAL INTEREST GROUPS (SIGS)
OP12
SIG SENSITIVE SKIN 
Laurent Misery1,2, Sonja Ständer3, Jacek C. Szepietowski4, Adam 
Reich4, Joanna Wallengren5, Andrea W.M. Evers6, Kenji Takamo-
ri7,8, Emilie Brenaut1,2, Christelle Le Gall-Ianotto2, Joachim Fluhr9, 
Enzo Berardesca10, Elke Weisshaar11
1Department of Dermatology, University Hospital of Brest, 2Laboratory 
of Neurosciences of Brest, University of Western Brittany, Brest, France, 
3Department of Dermatology, Center for Chronic Pruritus, University Hos-
pital of Münster, Germany, 4Department of Dermatology, Venereology and 
Allergology, Wroclaw Medical University, Poland, 5Department of Derma-
tology and Venereology, University Hospital of Lund, Lund, Sweden, 6De-
partment of Health, Medical and Neuropsychology, Institute of Psychology, 
Leiden University, Leiden, The Netherlands, 7Institute for Environmental 
and Gender Specific Medicine, Juntendo University Graduate School of 
Medicine, 8Department of Dermatology, Juntendo University Urayasu 
Hospital, Urayasu, Chiba, Japan, 9Department of Dermatology and Al-
lergology, Charité-Universitätsmedizin Berlin, Germany, 10San Gallicano 
Dermatological Institute, Rome, Italy, 11Department of Social Medicine, 
Occupational and Environmental Dermatology, University of Heidelberg, 
Heidelberg, Germany
The IFSI special interest group (SIG) on sensitive skin has de-
fined sensitive skin as “a syndrome defined by the occurrence 
of unpleasant sensations (stinging, burning, pain, pruritus, and 
tingling sensations) in response to stimuli that normally should 
not provoke such sensations. These unpleasant sensations can-
not be explained by lesions attributable to any skin disease. 
The skin can appear normal or be accompanied by erythema. 
Sensitive skin can affect all body locations, especially the face”. 
This is the first international consensual definition. Translations 
and assessments of instruments of measurement as well as new 
reviews will be the next steps.
OP13
SPECIAL INTEREST GROUP (SIG): SCORING 
ITCH IN CLINICAL TRIALS
Sonja Ständer1, Matthias Augustin2, Jacek C. Szepietowski3
1Center for Chronic Pruritus, University Hospital Münster, 2German Cen-
ters for Health Services Research in Dermatology (CVderm) University 
Eppendorf Hamburg, Germany, 3University of Medicine Department of 
Dermatology, Wroclaw, Poland
Chronic pruritus is a subjective, multidimensional and highly 
debilitating symptom that is difficult to assess. The SIG Scoring 
Itch in Clinical Trials (see itchforum.net) was founded in 2008 in 
order to develop and validate instruments used to make a reliable 
assessment of its various dimensions. Several instruments asses-
sing the itch intensity (including the ItchyQuant for children), 
categorization, distribution, qualities and course over time have 
already been made available for use in clinical trials. The mini-
mal clinically important difference (MCID) has been calculated 
for both the VAS and NRS. These instruments have also been 
validated in an electronic form via the ItchApp (provider: arone.
com). Novel instruments, including the Patient Global Impres-
sion of Change (Dynamic Pruritus Score; DPS), Itch Controlled 
Days (ICD) and Patient Benefit Index (PBI) have been developed 
and validated to assess other various parameter. Patient reported 
questionnaires on reactive conditions ranging from sleep disor-
ders, anxiety, depression and impairment to quality of life have 
been used in many trials and provide reliable data. In spite of 
this, the search for objective markers, such as an approach to 
monitoring cutaneous scratch symptoms or scratch movements, 
remains ongoing.
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OP14
THE SPECIAL INTEREST GROUP (SIG) 
“QUESTIONNAIRES TO ASSESS CHRONIC ITCH” 
OF THE INTERNATIONAL FORUM ON THE 
STUDY OF ITCH (IFSI)
Elke Weisshaar1, Jörg Kupfer2, Antoinette van Laarhoven3, Uwe 
Gieler2, Masutaka Furue4, Hidehisa Saeki5, Andrea Evers3, Gil Yo-
sipovitch6
1Department of Clinical Social Medicine, Environmental and Occupational 
Dermatology, University Hospital Heidelberg, Ruprecht-Karls University, 
Heidelberg, 2Institute of Medical Psychology, Justus-Liebig-University, 
Giessen, Germany, 3Institute of Psychology, Unit Health, Medical and 
Neuropsychology, Leiden University, Netherlands, 4Department of Derma-
tology, Kyushu University, Kyushu, 5Department of Dermatology, Nippon 
Medical School, Tokyo, Japan, 6Department of Dermatology, Itch Center, 
University of Miami Hospital, Miami, USA
Chronic itch (CI) is a global disease affecting many patients and 
has a significant impact on all aspects of patient’s life including 
their well-being. It is complex, difficult to measure and bur-
densome to patients suffering from CI. The assessment of CI and 
its associated effects is an important tool of daily clinical practice 
in itch management. The number of instruments utilized has been 
constantly growing during the last years. Despite itch being a 
common complaint, there are few studies describing the use of 
structured questionnaires for evaluation and measurement of itch 
and its sensory and affective dimensions. According to the cur-
rent status of research and clinical experiences there is no single 
measurement instrument that allows an adequate and comprehen-
sive assessment of CI. In 2011, a Special Interest Group (SIG) 
on questionnaires to assess chronic itch was founded by several 
experts and members of the International Forum for the Study of 
Itch (IFSI) as an interdisciplinary team to integrate knowledge 
from different disciplines. One goal is to determine which of the 
various psychometric properties of itch questionnaires offer the 
greatest utility in the evaluation of CI. A consensus paper addressed 
the expectations and unmet needs of using itch questionnaires to 
better assess CI and guide therapy. The SIG is currently working on 
comparing the content and measurement properties of instruments 
available and providing a template for questionnaires for future use 
in different arrangements and modular configurations depending 
on the underlying disease. Future studies take aim at disease- and 
population-specific questionnaire validation. In the long-term the 
questionnaire should serve as a measurement instrument used for 
clinical practice as well as medical and health research.
OP15
THE SPECIAL INTEREST GROUP (SIG) “PARA-
NEOPLASTIC ITCH” OF THE INTERNATIONAL 
FORUM FOR THE STUDY OF ITCH (IFSI)
Elke Weisshaar1, Thomas Mettang2, Sonja Ständer3, Frank Bren-
nan4, Hong Liang Tey5, Gil Yosipovitch6
1Department of Clinical Social Medicine, Environmental and Occupational 
Dermatology, University Hospital Heidelberg, Ruprecht-Karls-University, 
2Department of Nephrology, DKD Helios Clinic, Wiesbaden, 3Department 
of Dermatology, Center for Chronic Pruritus, University of Münster, Ger-
many, 4Palliative Care, Department of Renal Medicine, St. Georg Hospital, 
Sydney, Australia, 5National Skin Center, Singapore, 6Department of Der-
matology, Itch Center, University of Miami Hospital, Miami, USA 
In 2012, an interdisciplinary interest group of physicians and re-
searchers with a special interest in paraneoplastic itch was founded. 
A position paper published in 2015 reviewed the current knowledge 
and aimed to define what can be summarized under the term “para-
neoplastic itch (PI)”. This term is used to describe itch in patients 
with both, haematological and solid tumour malignancies. The 
overall prevalence and incidence is still unclear, however, chronic 
itch without concomitant skin changes has recently been shown to 
be a risk factor for having undiagnosed hematologic and bile duct 
malignancies. Due to the rise of malignant diseases especially in 
the Western countries this topic is of increasing interest. However, 
research is hampered by the diverse, multiple and complex pathop-
hysiology of malignant diseases. PI is frequently not recognized 
and does not receive enough attention by physicians. This may be 
caused by little awareness of physicians towards this symptom and 
a lack of diagnostic tests for PI. For the future, we should try to 
gain more knowledge about PI in terms of pathophysiology, epide-
miological data, clinical characteristics and treatment modalities. 
It would be beneficial to search possible serum markers, to gain 
more knowledge on PI as a preceding symptom of malignancy and 
to identify possible risk factors for developing PI.
OP16
THE SPECIAL INTEREST GROUP (SIG) “UREMIC 
PRURITUS” OF THE INTERNATIONAL FORUM 
FOR THE STUDY OF ITCH (IFSI)
Thomas Mettang1, Jacek C. Szepietowski2, Laurent Misery3, Elke 
Weisshaar4
1Department of Nephrology, DKD Helios Clinic, Wiesbaden, Germany, 
2Department of Dermatology, Venerology and Allergology Wrocław Medi-
cal University, Poland, 3Department of Dermatology, University Brest, 
France, 4Department of Clinical Social Medicine, Environmental and Oc-
cupational Dermatology, University Hospital Heidelberg, Germany
In 2013, the special interest group “uremic pruritus” (UP) was 
founded to improve knowledge and therapeutic options on pruritus 
in patients with progressed or end-stage renal disease (ESRD). 
Since then, only a few new papers have appeared shedding light on 
the pathogenesis and therapy of UP. There are new data available 
on the prevalence of UP in children on dialysis showing that more 
young patients are afflicted than assumed before. Data of the GEHIS 
study in German patients on hemodialysis, a representative study 
using different prevalence estimates, in contrast, showed that the 
prevalence of UP is lower than former studies reported. According 
to the updated DOPPS data there is a decline in the prevalence 
of patients with severe UP worldwide. Both studies also demon-
strated that effective therapies with gabapentin or pregabalin are 
underutilized. In patients on peritoneal dialysis, the incidence of 
UP is reported to be lower than in hemodialysis patients, although 
conflicting data have been reported. After kidney transplantation, a 
relevant number of patients suffer from pruritus, although it is not 
clear whether the aetiology of pruritus is similar to that in uraemia. 
With regard to pathogenesis only little new data has emerged. It 
is still on debate whether inflammation might play a role in UP. 
CRP was not increased in patients with UP compared to patients 
without UP according to GEHIS. Further data of this study hint to a 
possible neuropathic component most likely caused by neuropathy 
in HD patients. The impact of skin salt content in uremic pruritus 
needs to be investigated, as some studies have given hints that 
salt lowering strategies may lead to lower occurrence of itch in 
dialysis patients. All this should encourage to consider a possible 
multifactorial origin of pruritus in HD patients.
SKIN, INFLAMMATION AND ITCH
OP17
NEW INSIGHTS INTO THE PATHOPHYSIOLOGY 
OF ITCH DURING CIGUATERA FISH POISONING
Killian L’Herondelle1, Laurent Misery1, Christelle Le Gall-Ianot-
to1, Réginald Philippe1, Matthieu Talagas1, Olivier Mignen1, Ric-
hard Lewis2, Raphaele Le Garrec1
1Laboratory of Interactions Neurons Keratinocytes (EA4685), University 
of Western Brittany, Brest, France, 2Institute for Molecular Bioscience, the 
University of Queensland, St. Lucia, Australia
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Ciguatera fish poisoning (CFP) is the most widespread seafood 
poisoning caused by the consumption of contaminated tropical 
fish flesh. This intoxication originates from ciguatoxins (CTXs) 
which are predominantly responsible of characteristic clinical 
cutaneous sensory disorders such as cold allodynia and severe 
pruritus. These toxins are thermostable, resistant to acidic and basic 
conditions, odourless with no suitable, quick and ready-to-use tool 
to detect them in intoxicated fish fleshes. With global climate war-
ming, growth of tourism and rise of international trade lead to the 
spreading of this unsung illness to temperate countries and more and 
more case reports are notified in non-endemic areas. Hence, cigua-
toxins are one of the major potential health issue concerning seafood 
poisoning. CTXs are potent voltage-gated sodium channel (VGSC) 
activators but the following molecular mechanisms relating to the 
sensory disorders are still poorly understood. Previously, using a 
primary coculture model of sensory neurons and keratinocytes, 
we showed that Pacific-ciguatoxin-2 is able to induce a voltage-
gated sodium channel-dependent release of substance P (SP) and 
calcitonin gene-related peptide (CGRP). Since these neuropeptides 
are key mediators involved in itch sensations, this ciguatoxin-
induced effect may contribute to explain the sensory disturbances 
of ciguatera fish poisoning. Here, based on our previous published 
coculture model, we prospected the role of several molecular 
targets involved in P-CTX-2-induced SP release. Using calcium 
imaging experiments performed on monoculture of neurons, we 
evidenced a striking role of TTX-resistant Nav channels to keep the 
intracellular calcium concentration ([Ca2+]i) imbalance within the 
time. Moreover, we showed the crucial role of calcium influx in 
the toxin-evoked calcium signal and SP release. Indeed, this is the 
first time that chronological order of calcium events regarding to 
cellular signalling, consecutive to VGSCs activation by P-CTX-2, is 
studied. Taken together, those findings give not only new molecular 
signalling consecutive to toxin-induced VGSCs activation but also 
new insights for therapeutic approaches to treat pruritus. 
OP18
INTRA- AND EXTRA-LESIONAL SENSITIZATION 
FOR NON-HISTAMINERGIC AND MECHANI-
CALLY-EVOKED ITCH IN ATOPIC DERMATITIS
Hjalte Holm Andersen1, Jesper Elberling2, Henrik Sølvsten3, Gil 
Yosipovitch4, Lars Arendt-Nielsen1
1Laboratory of Experimental Cutaneous Pain Research, SMI, Faculty of 
Medicine, Aalborg University, 2Department of Dermato-Allergology, Co-
penhagen University Hospital, Gentofte, Copenhagen, 3Dermatology Cen-
ter North, Aalborg, Denmark, 4Department of Dermatology and Itch Cen-
ter, University of Miami School of Medicine, USA
Chronic or episodic severe itch is recurrent in atopic dermatitis 
(AD). It has been suggested that the non-histaminergic neuronal 
itch pathway dominate AD itch and induces an “itch-scratch-itch” 
cycle, which maintains skin lesions, itch and pain. We hypothe-
sized that non-histaminergic neuronal sensitization plays a role 
in AD, and compared sensitivity to thermal, mechanical, and 
chemical pruritic stimuli in AD patients and controls. The study 
included 25 AD patients with chronic itch and 25 healthy controls. 
Sensory tests were conducted intra-lesionally, extra-lesionally, 
and in homologous areas of healthy controls and questionnaires 
on itch characteristics were administered to the patients. Thermal 
and mechanical quantitative sensory testing (QST) was conducted 
and conditioned pain modulation efficacy was assessed. More-
over, histamine- and cowhage-provocations were performed and 
hyperknesis as well as vasomotor reactivity were assessed. AD 
patients reported their spontaneous itch intensity at 60.7±4.3 
(VAS0-100) and their pain intensity at 39.7±5.2 (VAS0-100). Patients 
experienced significantly increased evoked itch from cowhage 
both intra- and extra-lesionally, while histamine-evoked itch 
intensity was not significantly different between groups (a trend 
toward sensitization was observed intra-lesionally). No differences 
were found for thermal sensory sensitivity or pain evoked by itch 
provocations. Patients had increased mechanical pain sensitivity 
intra- and extra-lesionally and exhibited augmented intra- and 
extra-lesional sensitivity to mechanically evoked itch, prior to, and 
after itch provocations. Increased itch following non-histaminergic 
itch provocations suggests pathway-specific sensitization in AD. 
The increased susceptibility to mechanically evoked itch and pain, 
also occurring extra-lesionally, indicates central sensitization 
mechanisms. Drugs candidates inhibiting the non-histaminergic 
(PAR2/TRPA1+) itch-pathway are promising for treating AD itch.
OP19
ATTENUATED ACTIVATION OF ENDOGENOUS 
GLUCOCORTICOIDS IN KERATINOCYTES 
INDUCES ALLOKNESIS IN ATOPIC DERMATITIS 
VIA ABERRANT ARTEMIN PRODUCTION
Akira Matsumoto, Hiroyuki Murota, Mika Terao, Ichiro Katayama
Dermatology, Department of Integrated Medicine, Graduate School of 
Medicine, Osaka University, Osaka, Japan/Kaken Pharmaceutical Co., 
Ltd. Kyoto, Japan
The enzyme 11beta-hydroxysteroid dehydrogenase-1 (HSD11b1) 
activates endogenous glucocorticoids in response to local stress 
and plays an important role in maintaining skin homeostasis. 
Although decreased epidermal HSD11b1 expression in atopic 
dermatitis (AD) is thought to cause disruption of the local stress 
regulation system, involvement of endogenous glucocorticoids 
in the pathogenesis of AD is unclear. To address this issue, we 
investigated the impact of local cortisol activation on itch, which 
is the main symptom of AD. First, we analyzed the distribution 
of protein gene product (PGP) 9.5-positive nerve fibers in skin of 
keratinocyte-specific HSD11b1-knockout (HSD11b1fl/fl Krt5-Cre; 
HSD11b1KCKO) mice using immunohistochemistry and 3D ima-
ging. Surprisingly, epidermal nerve fiber sprouting and thickening 
were observed in skin from HSD11b1KCKO mice in the absence 
of any skin lesions. HSD11b1KCKO mice frequently showed a 
scratch response to a light touch to the neck; nevertheless, there 
was no difference between HSD11b1KCKO and wild-type mice in 
the number of spontaneous scratching instances. Furthermore, 
HSD11b1KCKO mice also showed augmented pruritogen-induced 
alloknesis and hypersensitivity to thermal nociception. Next, we 
examined cytokines and neurotrophic factors, a humoral factor 
related to skin innervation from keratinocytes. Artemin (ARTN) 
production from keratinocytes was promoted in HSD11b1KCKO 
mice and suppressed by treatment with corticosterone. Then, we 
performed an immunohistochemical analysis of protein expres-
sion in skin biopsy specimens of AD and psoriasis patients. ARTN 
expression was specifically increased in AD epidermis and the 
papillary layer, and a significant negative correlation between 
ARTN and HSD11b1 expression in AD epidermis was observed. 
Taken together, these results suggest that the deficiency in active 
endogenous glucocorticoids in keratinocytes increases ARTN 
production and may contribute to the induction of alloknesis in AD. 
OP20
NEUTROPHIL-SOMATOSENSORY NEURON 
CROSSTALK DRIVES ACUTE AND CHRONIC 
ITCH
Carolyn Walsh, Jamie Schwendinger-Schreck, Jacques Deguine, 
Emily Brock, Rose Hill, Jessica Wei, Natalie Kelava Kucirek, Kar-
sten Gronert, Greg Barton, Diana Bautista
University of California at Berkeley, USA
Eczema is one of the most common chronic itch disorders. Me-
chanistic studies and therapeutic interventions have focused on the 
molecular signatures and immune cells found in mature eczematous 
lesions. However, the molecular and cellular players that contribute 
to the development of eczema have not been systematically studied. 
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Here we set out to examine the early changes that occur in the skin 
during eczema pathogenesis using the Vitamin D mouse model of 
atopic dermatitis. We find that although a variety of cytokines and 
innate immune cells infiltrate the skin within the first 5 days of the 
model, neutrophils are the sole cellular player required for the onset 
of itch. We used a variety of techniques including transcriptome 
analysis, qPCR, FACS and mouse behavior to define the molecular 
interactions between neutrophils and sensory neurons that drive itch 
behaviors in the development of atopic dermatitis. 
OP21
CUTANEOUS 4-1BB/4-1BBL SIGNALING INDUCES 
SEVERE SKIN INFLAMMATION AND CHRONIC 
ITCH
Stefan Tran, Verena Kupas, Kristian Holz, Marcus Maurer, Tho-
mas A. Luger, Sonja Ständer, Karin Loser
Department of Dermatology, University of Münster, Münster, Germany
The skin is exposed to the environment resulting in the induc-
tion of immune responses. Members of the TNF receptor family 
regulate cutaneous immunity and the interaction of immune cells 
with cutaneous nerve fibers is critically involved in the control 
of immune responses. Since the TNF family receptor 4-1BB and 
its ligand 4-1BBL are expressed on neuronal as well as immune 
cells, we hypothesized that 4-1BB/4‑1BBL signaling might con-
tribute to cutaneous immunity by regulating the communication 
of sensory neurons and immune cells. To investigate this we ge-
nerated transgenic mice overexpressing 4‑1BB in the epidermis 
(4-1BB tg). Interestingly, 4-1BB tg mice spontaneously developed 
inflammatory skin lesions, which were characterized by irregular 
acanthosis, fibrosis, collagenosis and massive immune cell infiltra-
tes consisting of mast cells, eosinophils and T cells. Moreover, tg 
mice showed an increased scratching frequency, thus pointing to the 
4‑1BB-mediated induction of pruritus. To elucidate the cellular and 
molecular mechanisms we analyzed the role of mast cells by bree-
ding 4-1BB tg mice to mast cell deficient mutants and could show 
that mast cells were of minor importance for the pathophysiology 
of 4-1BB-induced pruritic skin inflammation. Next, we quantified 
the IL-31 expression in T cells since IL-31 is known to promote 
neurogenic inflammation. Particularly CD8+ T cells from 4-1BB 
tg skin produced high levels of IL‑31 and by depleting these cells 
we could demonstrate that the absence of CD8+ T cells completely 
protected tg mice from developing itch and inflammation. Pruritic 
skin inflammation requires the interaction of T cells with cutaneous 
sensory nerve fibers, which generate currents following the stimula-
tion of the itch-related receptor IL-31RA. Hence, we next depleted 
cutaneous sensory nerve fibers in 4-1BB tg mice by injecting the 
capsaicin analogue resiniferatoxin (RTX). Notably, RTX signifi-
cantly down-regulated chronic pruritus and additionally, reduced 
inflammation. Of note, the depletion of cutaneous sensory nerve 
fibers also reduced the numbers of IL‑31 expressing CD8+ T cells in 
lesional skin from tg mice. Worth mentioning that 4‑1BB/4-1BBL 
signaling was also up-regulated in cutaneous lesions from patients 
with pruritic skin diseases, thus strengthening our hypothesis that 
4‑1BB/4-1BBL signaling might contribute to the communication 
of the immune system with the peripheral nervous system during 
the development of itch and inflammation. 
OP22
SEMA3A EXPRESSION IS REGULATED BY 
CALCIUM/PKC/MAPK/AP-1 SIGNALING AXIS IN 
NORMAL HUMAN EPIDERMAL KERATINOCYTES
Yayoi Kamata1, Yoshie Umehara1, Azumi Sakaguchi1, Yasushi 
Suga2, Mitsutoshi Tominaga1, Kenji Takamori2
1Institute for Environmental and Gender Specific Medicine, Juntendo Uni-
versity Graduate School of Medicine, 2Department of Dermatology, Jun-
tendo Urayasu Hospital, Japan
Cutaneous hyperinnervation is involved in itch sensitivity at the 
periphery. Previously, we reported that epidermal hyperinnerva-
tion is mainly caused by an imbalance between nerve elongation 
factors, including nerve growth factor (NGF), and nerve repulsion 
factors, such as semaphorin 3A (Sema3A) produced by keratinocy-
tes. However, the regulatory mechanism of endogenous Sema3A 
is unknown. In this study, we investigated the regulatory mecha-
nism of Sema3A gene in normal human epidermal keratinocytes 
(NHEK). The 5’-flanking region of Sema3A gene was cloned 
and a critical region for Sema3A promoter activity within -134 
bp from the transcription start site was identified. In this region, 
transcription factor binding sites including activator protein (AP) 
-1, retinoid related orphan receptor (ROR) alpha, Sox5/Sox9 and 
GA-binding protein (GABP) were found. Site-directed mutage-
nesis of AP-1/ROR alpha site showed significantly lower activity 
than in an intact case. Although Sema3A promoter activity was 
up-regulated by 1.4 mM calcium, AP-1/ROR alpha mutant showed 
unchanged promoter activity in the presence of 1.4 mM calcium. 
Furthermore, AP-1 and ROR alpha siRNA effectively reduced 
Sema3A expression compared with control siRNA. Chromatin 
immunoprecipitation assay revealed AP-1 bound to proximal 
promoter (-134/-24) in the presence of 0.15 or 1.4 mM calcium. 
Up-regulation of Sema3A mRNA by 1.4 mM calcium was signifi-
cantly decreased by AP-1 inhibitor (T-5224). Similarly, it was also 
decreased by protein kinase C (PKC) inhibitor (Gö6976), MAPK/
ERK kinase (MEK) 1/2 inhibitor (PD98059) and jun N-terminal 
kinase (JNK) inhibitor (SP600125). These results suggest that 
calcium-induced Sema3A expression in NHEK is mediated by 
the PKC/MEK1/2/AP-1 and/or PKC/JNK/AP-1 signaling axis in 
the proximal promoter (-134/-24), and provide a new insight to 
identify novel antipruritic drug targets. 
NEW ANTIPRURITIC TREATMENTS
OP23
RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED PHASE 2 CLINICAL TRIAL 
OF SERLOPITANT EFFECTS ON MULTIPLE 
MEASURES OF PRURITUS IN PATIENTS WITH 
PRURIGO NODULARIS
Sonja Ständer1, Paul Kwon2, Thomas A. Luger1
1Center for Chronic Pruritus, Department of Dermatology, University Hos-
pital Münster, Münster, Germany, 2Menlo Therapeutics Inc., Menlo Park, 
California, USA
Prurigo nodularis (PN) is an intensely pruritic chronic skin 
condition with suboptimal treatments available. Serlopitant is 
a neurokinin-1 receptor (NK1-R) antagonist in development for 
the treatment of chronic pruritus. A randomized, double-blind, 
placebo-controlled phase 2 clinical trial assessed the efficacy, 
safety, and tolerability of serlopitant 5 mg in patients with PN 
(NCT02196324). Key eligibility criteria were treatment-refrac-
tory PN lasting >6 weeks, lesions on multiple body areas, and 
Visual Analog Scale (VAS) pruritus score ≥70 mm within 72 
hours of baseline. Patients were randomized 1:1 to receive ser-
lopitant 5 mg or placebo once daily for 8 weeks; follow-up was 2 
weeks. The primary efficacy endpoint was change from baseline 
in the average itch VAS score. Secondary endpoints included 
Verbal Rating Scale (VRS); worst-itch VAS; Patient Global 
Assessment (PGA); Numeric Rating Scale (NRS); Investigator 
Global Assessment (IGA); and Prurigo Activity Score (PAS). 
Adverse events (AEs) and clinical and laboratory assessments 
were evaluated during treatment and follow-up. The efficacy 
population comprised 127 patients; baseline characteristics were 
well matched between the treatment groups, as was treatment 
compliance. Serlopitant produced a statistically significant de-
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crease from baseline in pruritus severity compared with placebo 
when assessed at weeks 2, 4, and 8 (p≤0.05), as measured by 
average-itch VAS score. Secondary endpoint results for VRS, 
PGA, worst-itch VAS, NRS, IGA, and PAS also demonstrated 
greater improvements in the experience of pruritus with serlopi-
tant over placebo at week 8. Rescue medication was used by a 
greater proportion of placebo- than serlopitant-treated patients. 
The most frequently reported treatment-emergent AEs (TEAEs) 
in the serlopitant group were nasopharyngitis (17.2% serlopitant, 
3.2% placebo), diarrhea (10.9% serlopitant, 4.8% placebo), and 
fatigue (9.4% serlopitant, 6.3% placebo). Most TEAEs were 
mild or moderate; severe TEAEs were reported for 9.4% and 
4.8% of serlopitant- and placebo-treated patients, respectively. 
There were no meaningful trends in laboratory abnormalities or 
changes in vital signs, and no deaths. In conclusion, multiple 
measures of pruritus consistently demonstrated that serlopitant 
provides greater reduction of pruritus than placebo in patients 
with PN. Serlopitant was well tolerated and most AEs were mild 
or moderate; no significant safety signals were detected. 
OP24
SERLOPITANT FOR TREATMENT OF CHRONIC 
PRURITUS: RESULTS OF A RANDOMIZED, 
MULTICENTER, DOUBLE-BLIND, PLACEBO-
CONTROLLED PHASE 2 CLINICAL TRIAL
Gil Yosipovitch1, Sonja Ständer2, Matthew B. Kerby3, James W. 
Larrick4, Andrew J. Perlman4, Edward F. Schnipper4, Xiaoming 
Zhang3, Jean Y. Tang5, Thomas A. Luger2, Martin Steinhoff6,7
1Miami Itch Center, Department of Dermatology and Cutaneous Surgery 
Miller School of Medicine, University of Miami, Miami, USA, 2Center for 
Chronic Pruritus, Department of Dermatology, University Hospital Müns-
ter, Münster, Germany, 3Menlo Therapeutics, Inc., Menlo Park, 4Velocity 
Pharmaceutical Development, San Francisco, 5Department of Clinical 
Dermatology, Stanford University, Stanford, USA, 6Department of Derma-
tology and UCD Charles Institute of Translational Dermatology, Univer-
sity College Dublin, Dublin, Ireland , 7Department of Dermatology, Uni-
versity of California San Diego, San Diego, USA
Chronic pruritus is a frequently debilitating skin condition, which 
results in significant morbidity and impaired quality of life. Many 
current therapies provide inadequate itch relief or can be associated 
with undesirable safety/tolerability issues; therefore, most are used 
off label. Here, we report the efficacy and safety results from a 
phase 2 clinical trial (NCT01951274) of the novel neurokinin-1 
receptor antagonist serlopitant vs placebo for the treatment of 
chronic pruritus. Key eligibility criteria were treatment-refractory 
pruritus lasting ≥6 weeks and baseline pruritus Visual Analog Scale 
(VAS) score ≥70 mm. Patients were randomized (1:1:1:1) to re-
ceive serlopitant 0.25 mg, 1 mg, 5 mg, or placebo for 6 weeks once 
daily. The primary efficacy endpoint was the pruritus VAS score 
percent change from baseline. Adverse events (AEs) and clinical 
and laboratory assessments were evaluated during treatment and 
follow-up. The study population included 257 patients (60.7% 
female; mean age was 43.7 years). Baseline characteristics were 
comparable between groups. Differences in change from baseline 
VAS pruritus score were statistically significantly greater with ser-
lopitant 1 mg at weeks 3-6 and 5 mg at weeks 4-6, compared with 
placebo. At the week 6 efficacy evaluation, the mean (SE) percent 
change in VAS pruritus scores were –28.3 (4.1) for placebo, –41.4 
(4.0; p=0.022) for serlopitant 1-mg, and –42.5 (4.1; p=0.013) for 
serlopitant 5 mg. Statistically significant improvements in severity 
of itch from baseline were also demonstrated using the Numeric 
Rating Scale – a secondary endpoint – with serlopitant 1 mg and 
5 mg at weeks 4, 5, and 6 (p<0.05) compared with placebo. The 
most common treatment-emergent AEs (TEAEs) in the serlopitant 
groups were somnolence (1.6%, 4.6%, and 4.7% for serlopitant 
0.25 mg, 1 mg, and 5 mg, respectively, and 1.6% for placebo) and 
diarrhea (0%, 6.2%, and 3.2% for serlopitant 0.25 mg, 1 mg, and 
5 mg, respectively, and 1.6% for placebo). Most TEAEs were of 
mild or moderate intensity. Six patients discontinued study drug 
due to a TEAE. There were no meaningful trends in laboratory 
abnormalities or changes in vital signs and no deaths. Serlopitant 
1 mg and 5 mg provided statistically significant improvement in 
chronic pruritus VAS score, compared with placebo, and both 
doses were safe and well tolerated. All TEAEs were of mild or 
moderate intensity, while no meaningful adverse safety trends 
were observed. 
OP25
RECOVERY OF PEPTIDERGIC EPIDERMAL 
NERVE FIBER DENSITY BY TOFACITINIB IN A 
MOUSE MODEL OF ATOPIC DERMATITIS
Kristen Sanders, Kent Sakai, Gil Yosipovitch, Tasuku Akiyama
University of Miami, Miami, USA
The JAK inhibitor Tofacitinib has demonstrated significant an-
tipruritic effects in a phase 2 trial of atopic dermatitis patients. 
However, the mechanism behind this antipruritic effect is still 
largely unknown. Dynamic changes in epidermal innervation 
have been observed in atopic dermatitis and may contribute to 
chronic itch. Therefore, we investigated whether Tofacitinib affects 
epidermal innervation in the ovalbumin (OVA) mouse model of 
atopic dermatitis. Adult male C57BL/6 mice received OVA (100 
μg), alum (1 mg), and pertussis toxin (300 pg) on treatment Day 
1, followed by OVA (50 μg sc) on Day 5. On Day 7, Alzet osmotic 
mini-pumps were subcutaneously implanted in the mice. Tofaci-
tinib or vehicle (50% DMSO, 10% PEG 300, and 40% distilled 
water) was delivered at 15 mg/kg/day. Beginning on Day 14, 
topical OVA (100 μl, 0.1%) was applied daily by gauze to shaved 
rostral back skin and covered with a Tegaderm patch. On Days 21 
and 28, the patch was removed, and animals were videotaped to 
assess spontaneous scratching. On both days, Tofacitinib-treated 
mice displayed significantly inhibited spontaneous scratching 
compared to vehicle-treated mice. To test for alloknesis, 5 suc-
cessive innocuous mechanical stimuli were delivered by von Frey 
monofilament (bending force: 0.7 mN) to random sites along 
the border of the treatment area. The alloknesis score (0-5) was 
defined as the number of scratch bouts elicited by the stimulus 
series. Tofacitinib did not reduce alloknesis score compared to 
vehicle. To investigate epidermal nerve fiber density (ENFD), 
mice were perfused on Day 28, and skin was immunostained 
with antibodies against CGRP, a marker for peptidergic nerves, 
or P2X3, a marker for nonpeptidergic nerves. Peptidergic ENFD 
was significantly decreased in the vehicle-treated group compared 
to naive mice. Tofacitinib significantly increased the peptidergic 
ENFD, recovering it to naive skin levels. The nonpeptidergic 
ENFD was significantly increased in the vehicle-treated group 
compared to naive mice. Tofacitinib did not affect the density of 
epidermal nonpeptidergic nerves. The re-innervation of peptideric 
epidermal nerves may activate itch-inhibitory interneurons to sup-
press itch and contribute to the antipruritic effects of Tofacitinib.
OP26
CRISABOROLE OINTMENT PROVIDES EARLY 
RELIEF OF PRURITUS IN TWO PHASE 3 
CLINICAL TRIALS IN PATIENTS WITH MILD OR 
MODERATE ATOPIC DERMATITIS
Emma Guttman-Yasky1, Gil Yosipovitch2, Dedee Murrell3, Jon Ha-
nifin4
1Icahn School of Medicine at Mount Sinai Medical Center, 2University of 
Miami, Miller School of Medicine, USA, 3University of New South Wales, 
Australia, 4Oregon Health and Science University, USA
Introduction: Atopic dermatitis (AD), a chronic inflammatory 
skin disease that affects children and adults, is characterized by 
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intense pruritus, regardless of disease severity. Pruritus-induced 
scratching leads to disease exacerbation that often results in sleep 
disturbance and reduced quality of life. Quick relief of pruritus 
is a key treatment goal. Crisaborole topical ointment, 2%, is 
a novel, nonsteroidal, anti-inflammatory, phosphodiesterase 4 
inhibitor for the treatment of mild to moderate AD. A post hoc 
analysis was performed from 2 identically designed, multicen-
ter, vehicle-controlled, Phase 3 trials evaluating the impact of 
crisaborole on early relief of pruritus stratified by baseline (BL) 
disease severity. Methods: Global disease severity was measured 
by the Investigator’s Static Global Assessment (ISGA) in patients 
≥2 years old with mild (ISGA 2) to moderate (ISGA 3) AD. Pa-
tients were randomly assigned 2:1 to receive crisaborole:vehicle 
twice daily for 28 days. Pruritus was measured on a 4-point scale 
(none [0] to severe [3]), with improvement defined as a score 
of none (0) or mild (1) with a ≥1-grade improvement from BL. 
Early improvement in pruritus was defined as achievement of 
improvement at day 6. Results: Significantly more crisaborole-
treated patients than vehicle-treated patients experienced early 
improvement in pruritus, regardless of BL disease severity (mild 
AD: 59.5% vs 41.3%; p<0.001; moderate AD: 54.7% vs 38.3%; 
p<0.001). At the earliest assessment, at 48 hours, significantly 
more crisaborole-treated patients with mild AD experienced 
improvement in pruritus (48 hours: 37.6% vs 26.9%; p=0.02). 
At day 6, mean percentage change from BL in pruritus severity 
in crisaborole-treated patients with mild AD and in those with 
moderate AD was significantly greater than that in vehicle-treated 
patients (mild AD: –42.9% vs –29.2%; p=0.009; moderate AD: 
–40.9% vs –26.1%; p<0.001). Conclusions: A significant propor-
tion of crisaborole-treated patients experienced early relief of 
pruritus, regardless of BL disease severity. Additionally, patients 
treated with crisaborole experienced greater early reduction in 
pruritus severity than did vehicle-treated patients. Crisaborole 
may represent a promising, novel, topical AD treatment that can 
provide much needed early relief of pruritus for patients with 
mild to moderate AD. 
OP27
NEW INSIGHTS INTO THE ANTI-PRURITIC 
ACTIVITY OF THE NEUROKININ-1 ANTAGONIST 
APREPITANT: PARTIAL ACTIVATION OF EGFR 
SIGNALING IN HUMAN KERATINOCYTES AS 
A MECHANISM FOR REDUCING ERLOTINIB-
INDUCED PRURITUS
Shawn Kwatra1, Cory Nanni2, Yevgeniy Semenov3, Callie Roberts2, 
Madison Krischak2, Madan Kwatra2
1Department of Dermatology, Johns Hopkins University School of Medi-
cine, 2Department of Anesthesiology, Duke University School of Medicine, 
3Division of Dermatology, Washington University School of Medicine, USA
Epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs), 
such as erlotinib, are currently used for the treatment of lung and 
several other cancers. While EGFR-TKI’s are effective anti-cancer 
agents, they produce serious adverse effects on the skin including 
pruritus and acneiform skin eruptions. Aprepitant, an inhibitor of 
the Neurokinin 1 receptor (NK1R), is effective in decreasing itch 
in patients treated with EGFR-TKI’s. The goal of the present study 
is to better understand the mechanism by which NK1R blockade 
reduces the adverse effects caused by the blockade of EGFR in 
keratinocytes. While previous studies have suggested a role for 
mast cells, the role of human keratinocytes remains largely unex-
plored. Towards this goal, human keratinocyte HaCaT cells were 
used as a model system to better understand EGFR signaling using 
Reverse Phase Protein Arrays (RPPA) technology. HaCaT cells 
were stimulated with and without epidermal growth factor (EGF). 
The cell lysate from control and EGF-treated HaCaT cells were 
analyzed by RPPA, which examined expression levels of over 200 
proteins/phosphoproteins. Stimulation of HaCaT cells with EGF 
significantly increased the phosphorylation of several proteins 
including the following: Akt, EGFR, GSK-3 beta, HER2, HSP27, 
JNK, MAPK, MDM2, p90RSK, PKC-betaII, PLC-gamma2, Shc, 
SHP2, Src, and STAT3. The phosphorylation of all of these proteins 
was blocked when HaCaT cells were stimulated with EGF in the 
presence of erlotinib. Interestingly, exposure of HaCaT cells to the 
NK1R blocker aprepitant increased the phosphorylation of EGFR 
as well as Akt. These results were confirmed in human primary 
keratinocytes. Taken together, these data suggest that aprepitant 
may reduce itch and adverse effects of EGFR-TKI’s by augmenting 
EGFR signaling in keratinocytes.
OP28
EFFICACY OF SYSTEMIC TREATMENTS 
OF PSORIASIS ON PRURITUS: A SYSTEMIC 
LITERATURE REVIEW AND META-ANALYSIS
Emilie Brenaut, Chloé Théréné, Thomas Barnetsche, Laurent Mi-
sery
Department of Dermatology, University Hospital of Brest, Brest, France
In the course of the last 30 years, several studies have clearly 
documented that pruritus is a very frequent symptom of psoria-
sis and its impact on the patients’ quality of life. The variety of 
available systemic treatments for psoriasis is increasing rapidly. 
Our objective was to assess their efficacy on pruritus based on a 
systematic literature review. A systematic literature search was 
performed using PubMed and Trip Database (from January 1990 
to September 2016) to find published clinical trials for the treat-
ments of psoriasis, then a meta-analysis was performed. Among 
516 articles identified, 35 studies were retained in the systematic 
review. At baseline, the high prevalence of pruritus (80 to 100%) 
was confirmed. The meta-analysis included 13 trials using a 0 to 
10 itch scale and highlighted that all treatments evaluated had a 
benefic impact on pruritus. Anti Il-17, JAK inhibitors, adalimu-
mab, and apremilast were all shown to be effective in reducing 
pruritus in psoriasis with variable effect size magnitudes. Our 
systematic review highlights that systemic treatments, including 
UVB phototherapy, improve pruritus in psoriasis but that it is not 
necessarily correlated with lesion recovering. Nonetheless, these 
results must be displayed carefully because there are so many 
variable endpoints in different studies.
OP29
RANDOMIZED, DOUBLE-BLIND, PLACEBO-
CONTROLLED STUDY OF MONOCLONAL 
ANTI-IGE ANTIBODY OMALIZUMAB IN THE 
MANAGEMENT OF PRURITUS IN CHRONIC 
SPONTANEOUS URTICARIA IN THE PEDIATRIC 
POPULATION
Barnali Mitra, Biju Vasudevan, Reema Solanki, Debdeep Mitra
Base Hospital New Delhi, India
Chronic spontaneous urticaria (CSU) is defined as the sponta-
neous appearance of itchy wheals, with or without angioedema, 
persisting for ≥6 weeks. It affects 0.5–1% of the global pediatric 
population, but it represents a high burden to patients. Children 
in the age group of 6 to 12 years present frequently with episodic 
pruritic wheals and oral anti-histamnics are mostly insufficient to 
prevent a recurrence. Oral steroids and other immune-suppres-
sives although effective temporarily, are associated with a lot of 
side effects in this age group and are mostly contraindicated. In 
recent years, monoclonal Anti-IgE antibody ‘omalizumab’ has 
been tried in other allergic disorders like atopic dermatitis and 
bronchial asthma in the pediatric age group, however there are no 
studies till date of this novel therapeutic regimen in the pediatric 
age group to control the itching in chronic spontaneous urticaria 
in the pediatric age group. Objective: We sought to evaluate the 
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efficacy and safety of monoclonal Anti-IgE antibody omalizumab 
in patients between the group of 6 to 12 years with moderate-to-
severe chronic idiopathic urticaria who remained symptomatic 
despite H1-antihistamine therapy (licensed doses). Methods: 
This was a double-blind, placebo-controlled trial with children 
between the age group of 6 to 12 years randomized to omalizumab 
or placebo. We randomly assigned 30 children with comparable 
baseline age and serum IgE levels to receive four subcutaneous 
injections, spaced 4 weeks apart, of omalizumab at a dose of 150 
mg or placebo, followed by a 16-week observation period. Mean 
Urticaria activity score (UAS) at baseline was 5.7 points (range, 
4–6 points). Results: Compared with placebo, omalizumab resul-
ted in a statistically significant reduction in FcεRI expression on 
basophils and pDC2 (p<0.001). UAS and serum IgE levels were 
significantly reduced in the Omalizumab group as compared to the 
placebo group both at 16 and 32 weeks. Conclusions: Omalizu-
mab diminished clinical symptoms and signs of chronic idiopathic 
urticaria in children who had remained symptomatic despite the 
use of approved doses of H1-antihistamines. Chronic spontaneous 
urticaria (CSU) is a disease with significant morbidity and relative 
prevalence that has important effects on the quality of life (QoL) 
of those who suffer from it. Omalizumab is a recombinant hu-
manized anti-immunoglobulin E (IgE) antibody that binds to the 
Cε3 domain of the IgE heavy chain and prevents it from binding 
to its high-affinity receptor FcεRI. It has been largely studied in 
the field of asthma and is currently approved for the treatment of 
both adult and pediatric (children; >6-year-old) patients. In addi-
tion, in recent, well-controlled clinical trials in patients with CSU 
resistant to antihistamines, add-on therapy with subcutaneous 
omalizumab significantly reduced the severity of itching, and the 
number and size of hives, and increased patients’ health-related 
QoL and the proportion of days free from angioedema compared 
with placebo, with an excellent tolerance. Thus, omalizumab is 
an effective and well-tolerated add-on therapy for children with 
CSU who are symptomatic despite background therapy with H1 
antihistamines. 
METHODS IN ITCH RESEARCH 
(CLINICAL)
OP30
HOW TO ALTER PLACEBO AND NOCEBO 
EFFECTS IN PATIENTS WITH CHRONIC ITCH?
Andrea Evers
Leiden University, Health, Medical and Neuropsychology Department, Lei-
den, The Netherlands
Increasing evidence demonstrates the neurobiological underpin-
nings and relevance of placebo effects for chronic itch. For ex-
ample, physical complaints, such as itch or pain, can be effectively 
altered by placebo effects, due to induction of expectations of a 
possible beneficial treatment outcome (“Itch already reduces when 
seeing the itchkiller”). The same is true for nocebo effects which 
are induced by expectations of a possible unfavorable treatment 
outcome or side effects. In addition, placebo mechanisms also 
play a role for immune functioning, such as histamine, through 
pharmacological conditioning. In the presentations, recent results 
will be presented to demonstrate the evidence for placebo and 
nocebo effects in itch as well as innovative methods to induce 
or change placebo and nocebo effects. The results have direct 
implications for the treatment of patients with chronic itch. 
Treatment outcomes might be optimized by using both consci-
ous and automatic strategies of optimizing expectancy effects, 
for example, by applying conditioning principles for therapy 
adherence, adding environmental cues to the preferred outcome 
strategies or replacing regular pharmacological treatments partly 
by expectancy interventions.
OP31
METHODS IN ITCH RESEARCH: ARGUMENTS TO 
IMPROVE STANDARDIZATION OF RESEARCH 
METHODS
Joerg Kupfer1, Uwe Gieler2, Stephanie Kiupel1, Christina Schut1
1Institute of Medical Psychology, and 2Department of Dermatology and Al-
lergology, J-L-University, Giessen, Germany
This lecture focuses on two aspects of itch research, where 
greater standardization of research methods would benefit all 
stakeholders: Methods to induce itch and measurement of itch 
(prevalence, chronicity and intensity). Numerous methods of 
itch induction have been developed during the last years. First of 
all, the application of substances like cowhage or histamine has 
to be mentioned. Using the method of direct application on the 
skin is particularly advantageous because the timing (start and 
end) of itch can be controlled more easily. In addition, partial 
invasive procedures such as iontophoresis and skin prick are also 
used. Some studies have shown that the application of cowhage 
is one of the most powerful itch-inducing methods. On the other 
hand, various rather psychologically oriented methods are used 
to induce itch: The provocation of scratch responses by showing 
other people scratching (contagious itch), the presentation of au-
ditory or visual (images or videos) stimuli and the presentation of 
audio-visual stimuli. Especially in patients with chronic itch due to 
atopic dermatitis or psoriasis, these methods seem to be similarly 
effective when certain aspects are considered in the study design. 
In particular, priming on the skin seems to be important to evoke 
a similar intense itch response to audio-visual stimuli compared 
to histamine-evoked itch. In addition to chemical and psycholo-
gical procedures alone, also combinations of both techniques are 
used. However, because right now there are only first approaches 
to standardize the use of these methods, study results, even if the 
same (similar) method to induce itch is used, are hardly compa-
rable. The situation is similar regarding the measurement of itch. 
Fortunately, standardization with regard to the questions that are 
used increases. Therefore, it is expected that study results will be 
more comparable in the future. Nevertheless, epidemiological 
studies on the prevalence of (chronic) itch revealed very different 
results (even in the same country) although the questions used 
were similar or identical. This problem may be caused by missing 
representativeness of the samples. This will be illustrated by the 
presentation of German studies. The prevalence of chronic itch 
is substantially lower if representativeness is given. Conclusions 
arising from this are discussed.
OP32
MEASURING PEDIATRIC ITCH SEVERITY: 
DOES PERSONAL EXPERIENCE WITH CHRONIC 
PRURITUS INFLUENCE PARENT’S ABILITY TO 
BE PROXIES?
Grace Lee1, Sandy François1, Shelby Smith1, Caitlin Haydek1, Ja-
mes Roberts2, Kuang-Ho Chen1, Suephy Chen1
1Emory University, and 2Georgia Institute of Technology, USA
Background: Chronic pruritus (CP) in pediatric patients is a dif-
ficult symptom to measure. The ability of caregivers to accurately 
rate the severity of itch in children is unknown. The previous 
experience of caregivers with itch may influence their ability to 
serve as a proxy for their children. The best duration of recall of 
itch for children is also unknown. Methods: We asked both child-
ren and their caregivers to rate the child’s itch severity using the 
ItchyQuant, a cartoon version of the traditional numerical scale 
used for adults. The scale has been validated in adults and we are 
in the process of validating in children. The child and the parent 
both rated the severity of the child’s itch within the past 7 days 
(“last week”) as well as the day prior (“yesterday”). The difference 
between parent and child’s ratings was the outcome variable in 
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a multivariable linear regression model. Parental experience 
with CP was the primary predictor variable, adjusting for age, 
race, and gender. Results: 231 children ages 6–17 with CP were 
recruited. In the “yesterday” group, parental experience did not 
significantly predict the difference in scores. For “last week,” pa-
rental experience trended significance (beta 1.25, p=0.09), and age 
significantly predicted the difference in scores (beta 0.26, p=0.03). 
Conclusion: The best duration of recall of itch may be “yesterday” 
rather than “last week” given the lack of predictors of difference. 
Parental experience and age influence the difference between child 
and parent assessment of the child’s itch severity, when referring 
to the previous 7 days. The less the parental experience with CP, 
the larger the difference in assessment. Also, for every 3-month 
increase in the child’s age, the larger the difference between the 
parent and child’s ratings. Perhaps the parent is more desensitized 
to the effect of the severity of itch on the child as the child ages. A 
larger study is needed to understand these differences.
OP33
VALIDATION OF THE PEAK PRURITUS 
NUMERICAL RATING SCALE: RESULTS FROM 
CLINICAL STUDIES OF DUPILUMAB IN ADULT 
PATIENTS WITH MODERATE-TO-SEVERE 
ATOPIC DERMATITIS
Gil Yosipovitch1, Matthew Reaney2, Laurent Eckert3, Lauren Nel-
son4, Marci Clark5, Marius Ardeleanu6, Allen Radin6, Abhijit Gad-
kari6
1Miami School of Medicine, Miami, USA, 2Sanofi, Guildford, UK, 3Sanofi, 
Chilly-Mazarin, France, 4RTI Health Solutions, Research Triangle Park, 
5RTI Health Solutions, Ann Arbor, and 6Regeneron Pharmaceuticals, Inc., 
Tarrytown, USA
Objective: To conduct content validation and psychometric as-
sessment of the Peak Pruritus Numerical Rating Scale (PP-NRS) 
for measuring itch in patients with moderate-to-severe atopic 
dermatitis (AD). Methods: The PP-NRS is a single, self-completed 
item to assess the intensity of peak (worst) pruritus during the past 
24 hours: “On a scale of 0 to 10, with 0 being ’no itch‘ and 10 
being ’worst itch imaginable‘, how would you rate your itch at 
the worst moment during the previous 24 hours?” Content valida-
tion included interviews with US adults with AD self-reporting 
moderate-to-severe itch (n=14). Psychometric properties were 
assessed in a phase 2b (P2b) study (n=379; NCT01859988) 
and confirmed using pooled data from two phase 3 (P3) studies 
(n=1,379; NCT02277743, NCT02277769) in moderate-to-severe 
adult AD patients. Participants completed the PP-NRS once 
daily through end of treatment (Week 16). The Analysis includes 
patients receiving ≥1 subcutaneous dose of dupilumab/placebo 
with ≥1 post-baseline PP-NRS assessment. Patient- and clinician-
reported outcome measures (PROs and ClinROs) were used to 
examine cross-sectional (construct and known-groups validity) and 
longitudinal (test-retest and sensitivity to change) measurement 
properties. Results: Interview participants interpreted the PP-NRS 
consistently, and found it relevant, clear, comprehensive, and easy 
to select a response aligned with their personal rating of peak pru-
ritus in the past 24 hours. In the P2b study, large positive baseline 
correlations were observed between PP-NRS and measures of 
similar constructs (Average Pruritus NRS [r=1.00], SCORAD itch 
VAS [r=0.77], Dermatology Life Quality Index (DLQI) itch item 
[r=0.67], p<0.01 for all), and weak-to-moderate correlations with 
measures of different constructs (EASI [r=0.09] and Investigator’s 
Global Assessment (IGA) [r=0.17, p<0.01]). Similar relationships 
were observed in the P3 studies. The PP-NRS differed predictably 
and significantly across known groups (p<0.0001) in P2b and P3. 
Intraclass correlation coefficients of the test-retest analysis were 
≥0.95 in P2b and P3. Moderate-to-strong correlations of change 
were observed on the PP-NRS with PROs (P2b/P3 SCORAD itch 
VAS r=0.77/0.73; DLQI itch item r=0.66/0.64; PCS r=0.71/0.72) 
and ClinROs (EASI, r=0.50/0.46; IGA, r=0.50/0.46) (p<0.01 for 
all). Conclusions: Peak Pruritus NRS is a well-defined, reliable, 
sensitive, and valid scale to assess itch intensity in adult patients 
with moderate-to-severe AD. 
OP34
12-ITEM PRURITUS SEVERITY SCALE: 
DEVELOPMENT AND VALIDATION OF NEW ITCH 
SEVERITY QUESTIONNAIRE
Adam Reich, Agnieszka Bożek, Katarzyna Janiszewska, Jacek C. 
Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Poland
Introduction: Pruritus is a very common subjective symptom, 
predominantly diagnosed based on patient complaints. A validated 
assessment of pruritus intensity is an important, but still difficult 
clinical problem due to a subjective nature of this sensation. Ob-
jective: The aim of this study was the creation and validation of 
new itch severity questionnaire. Material and Methods: A total 
of 148 patients (81 women and 67 men) with pruritic dermatoses 
were asked to assess pruritus intensity using 12-Item Pruritus 
Severity Score (12-PSS) and Visual Analog Scale (VAS). Patients 
were also asked to complete the Dermatology Life Quality Index 
(DLQI) and Hospitality Anxiety and Depression Scale (HADS). 
Test-retest comparison of 12-PSS was conducted in 102 subjects 
who completed the itch questionnaire twice with the 3 to 5 day 
interval. All results were analyzed statistically with Statistica 12.0. 
Results: We have created the 12-PSS assessing pruritus intensity 
(two questions), pruritus extent (one question) and duration (one 
question), influence of pruritus on concentration and patient 
psyche (four questions), and scratching as a response to pruritus 
stimuli (four questions). A maximum scoring was 22 points. The 
results showed good consistency (Cronbach α coefficient 0.81) 
– responses to all single questions significantly correlated with 
a total scoring. A significant correlation was also observed with 
VAS (r=0.58, p<0.001) and quality of life level according to DLQI 
(r=0.53, p<0.001). Test-retest comparison in 102 subjects revealed 
a good reproducibility of achieved results (ICC=0,72). Significant 
differences were observed only in three questions, where the sec-
ond assessment demonstrated significantly lower values. Conclu-
sions: The newly developed pruritus severity questionnaire may 
be used in daily clinical practice in the future.
OP35
CLINICAL BANDINGS OF PATIENT-ORIENTED 
ECZEMA MEASURE (POEM) SCORES AMONG 
JAPANESE ATOPIC DERMATITIS PATIENTS
Makiko Kido-Nakahara, Yumi Yasukochi, Takeshi Nakahara, Rie 
Kuroki, Tetsuya Koga, Toshihiko Mashino, Yuichi Kurihara, Masu-
taka Furue
Department of Dermatology, Graduate School of Medical Sciences, Ky-
ushu University, Japan
The Patient-Oriented Eczema Measure (POEM) (score: 0–28)
is a self-assessed, repeatable measurement tool for the patients 
with atopic dermatitis (AD), which consists of seven questions, 
such as itch, skin dryness and sleep disturbance. With the aim of 
identifying POEM bands that could be used to aid interpretation 
of POEM scores when used in daily medical practice and ascer-
taining whether POEM bandings can be used internationally, we 
sought to stratify POEM scores into four severity bands, clear, 
mild, moderate and severe/very severe, by assessing the relation-
ship between POEM and Visual Analogue Scale (VAS), Verbal 
Rating Scale (VRS) and POEM and Global Question (GQ) in 150 
Japanese AD patients. GQ is a question to evaluate their overall 
AD condition among five different severity grades: clear, mile, 
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moderate, severe and very severe. POEM showed statistically 
significant correlations with GQ, VAS and VRS (r=0.7343,0.7364 
and 0.7049, respectively, p<0.01). The banding for POEM scores 
with the highest kappa coefficient agreement was chosen as the 
most appropriate banding: clear=0–2, mild=3–8, moderate=9–18 
and severe/very severe=19–28. Among the possible candidates 
for POEM bandings, this banding was proven to have the most 
statistically significant correlation of POEM with VAS and VRS 
(p=0.05-0.001). The banding for POEM scores proposed by 
Charman, et al. (2013) included five severity bands: 0–2 (clear/
almost clear), 3–7 (mild), 8–16 (moderate), 17–24 (severe) and 
25–28 (very severe). Our bandings and Charman’s turned out be 
quite similar. POEM is a simple and valuable measure to assess 
the severity of patients’ symptoms and has a potential to become 
applicable to global clinical trials for AD. However, our banding 
results being similar but not exactly the same with that of Char-
man’s imply that larger scale of sample analysis is necessary to 
validate its global use. 
METHODS IN ITCH RESEARCH 
(EXPERIMENTAL)
OP36
METHODS IN EXPERIMENTAL ITCH RESEARCH 
– AN INTRODUCTION
Roman Rukwied
Department of Anesthesiology, Experimental Pain Research, Medical Fa-
culty Mannheim, University of Heidelberg, Mannheim, Germany
The numbers of explorative methods for the study of itch increased 
remarkably over the past few years. The most obvious model is the 
administration of itch-inducing substances (pruritogens) in healthy 
volunteers followed by the recording of magnitude itch sensation. 
Initially, histamine or histamine releasing substances had been 
investigated and over decades of research, a growing number 
of candidates and receptors had been explored and identified to 
play a central role in itch pathogenesis, such as gastrin-releasing 
peptides, lysophosphatidic acids, Mas-related G-protein coupled 
receptors and others. Not only pruritogens but also algogens can be 
used to evoke experimentally itch. By their means, and employing 
sophisticated single nerve fibre recordings, the neuronal circuits 
involved in itch processing could be identified in humans and also 
animals. Indeed, in vivo animal models for itch research attained 
great steps forward over recent years, comprising for instance 
the development of atopic dermatitis-like skin lesion models in 
NC/Nga mice with IgE- and TH2 cell-associated cytokine IL-31 
hyperproduction. Supplementing the methodological port-folio, 
in vitro cell-culture systems also have been introduced, gaining 
insights into the communication between dermal fibroblasts, 
atopic keratinocytes and the neuronal network, thus providing an 
additional tool for studying pathologic itch. 
OP37
RE-INNERVATED HUMAN SKIN EXPLANT AS A 
MODEL FOR IN VITRO STUDIES ON PRURITUS
Nicolas Lebonvallet1, Christelle Le Gall-Ianotto1, Cecilia Brun2, 
Thierry Oddos2, Laurent Misery1
1Laboratory of Neurosciences of Brest, University of Western Brittany, 
Brest, 2Johnson & Johnson Santé Beauté France, Val de Reuil, France
In order to study pruritus in vitro, we adapted a previously publis-
hed re-innervated skin explant model by sensory neurons. This 
model is based on a co-culture between a human skin explant 
(dermis and epidermis) and sensory neurons from dorsal root 
ganglia of rats. After several days of co-culture in transwells, we 
were able to confirm the presence of nerve fibers in the epidermis. 
We showed by IHC that the major actors of itch (PAR-2, TSLP, 
TSLP-R, TRPA1, IL31, IL31-R) were present in neurons and epi-
dermal cells. The functionality of the model was assessed by the 
measurement of TSLP release in the supernatant after incubation 
with a PAR-2 agonist (SLIGKV-NH2). In conclusion, our model 
can be used for studying itch and neurogenic inflammation in vitro.
OP38
PHARMACOLOGICAL AND HISTOCHEMICAL 
CHARACTERIZATION OF A MOUSE MODEL 
OF CHRONIC RENAL FAILURE-ASSOCIATED 
PRURITUS
Tsugunobu Andoh, Shikai Li, Takahito Maki, Daisuke Uta, Yasu-
shi Kuraishi
Department of Applied Pharmacology, Graduate School of Medicine and 
Pharmaceutical Sciences, University of Toyama, Japan
Chronic renal failure (CRF) is a chronic kidney disease with severe 
pruritus called uremic pruritus. Although the pruritus is very severe, 
the underlying mechanisms of the pruritus remain unclear. We have 
developed a mouse model of CRF-associated pruritus. When mice 
was given 5/6 nephrectomy, spontaneous scratching was elicited. 
The scratching was inhibited by mu-opioid receptor antagonist 
naltrexone, suggesting that the behavior is an itch-related behavior. 
H1 histamine receptor antagonist and proteinase-activated receptor 
2-neutralizing antibody did not inhibit CRF-associated scratching. 
Toluidine blue stain of the skin section showed that the number of 
mast cells did not altered between CRF mice and sham-operated 
mice. Thus, mast cells may not contribute CRF-associated scrat-
ching. It is well known that arachidonic acid metabolites is involved 
in pruritus. Both TP thromboxane receptor and BLT leukotriene 
B4 receptor antagonists attenuated CRF-associated scratching, 
suggesting that thromboxane A2 and leukotriene B4 play an im-
portant role in CRF-associated scratching. Interestingly, in skin 
section of CRF mice, the immunoreactivity of plasma component 
increased in CRF mice, but not sham-operated mice, was obser-
ved on primary afferents. In addition, an intradermal injection of 
plasma component of CRF mice elicited scratching. These results 
suggested that plasma component increased in CRF mice is also 
involved in CRF-associated scratching. Taken together with the 
above observation, it is considered that the mouse with CRF is 
useful for the elucidation of the mechanisms of the pruritus and 
for the development of new anti-pruritic drugs.
OP39
DEPRESSIVE BEHAVIOR MANIFESTED IN 
NC/TND MICE SUFFERING FROM ATOPIC 
DERMATITIS
Kenshiro Matsuda1, Shuichi Yanai2, Shogo Endo2, Akane Tanaka1, 
Hiroshi Matsuda1
1Tokyo University of Agriculture & Technology, and 2Tokyo Metropolitan 
Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
Background: Depression is one of the psychological disorders 
complicated in patients suffering from severe atopic dermatitis 
(AD). However, mechanisms of the pathogenesis and specific 
mediators of AD-associated depression are poorly understood. To 
clarify the mechanisms, an animal model suitable for AD is very 
useful. Therefore, we investigated on AD-associated depression 
using NC/Tnd mice which spontaneously develop AD-like skin le-
sions with IgE hyperproducton in the air-unregulated circumstance. 
Method: Behavioral parameters associated with the depressive 
disorder were tested in NC/Tnd mice accompanied with various 
grades of skin lesions. To evaluate depressive behavior, explora-
tory-, anxiety-, and despair-related behavior and preference were 
examined by using each general method. Clinical skin severity 
was scored, and scratching behavior was quantified by using a 
real time image analyzer, a SCLABA-Real system (Noveltec, Inc., 
Japan). Sera obtained from mice with severe AD were injected 
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intravenously into SPF mice without AD symptoms, and immu-
nohistochemistry was performed by using the neural markers of 
hippocampal neurogenesis including anti-double cortin X antibody 
(neuroblast marker), and anti-brain lipid binding protein antibody 
(neural progenitor marker). Results: Depressive behavior became 
obvious relating with aggravation of the clinical aspects of AD in 
NC/Tnd mice. In the open field test, immobility was significantly 
prolonged after the onset of AD, whereas partition and rearing 
behavior were decreased. Sucrose preference was statistically 
decreased relating with severity of the skin lesions. Prolonged 
immobility was observed in the tests of tail suspension and forced 
swimming respectively. On the other hand, SPF NC/Tnd mice 
without AD did not show any significant changes. The number of 
neuroblasts in the dentate gyrus was dramatically reduced in NC/
Tnd mice with the skin lesions, whereas the number of progenitors 
was comparable to that in age-matched SPF controls. Intravenous 
injection of sera obtained from mice with AD not only induced 
depressive behavior but also decreased the number of neuroblasts. 
Conclusion: These findings clearly demonstrated that NC/Tnd 
mice suffering from AD developed depressive behavior with 
impaired hippocampal neurogenesis through the peripheral blood. 
OP40
SENSORY NEURONS CO-OPT CLASSICAL 
IMMUNE SIGNALING PATHWAYS TO MEDIATE 
CHRONIC ITCH
Landon K. Oetjen1, Madison R. Mack1, Jing Feng1, Timothy M. 
Whelan1, Haixia Niu1, Changxiong J. Guo1, Sisi Chen2, Anna M. 
Trier1, Amy Z. Xu1, Shivani V. Tripathi1, Jialie Luo1, Xiaofei Gao1, 
Lihua Yang1, Samantha L. Hamilton1, Peter L. Wang1, Jonathan R. 
Brestoff1, M. Laurin Council1, Richard Brasington1, András Schaf-
fer1, Frank Brombacher3, Chyi-Song Hsieh1, Robert W. Gereau, 
IV1, Mark J. Miller1, Zhou-Feng Chen1, Hongzhen Hu1, Steve Da-
vidson2, Qin Liu1, Brian S. Kim1 
1Washington University School of Medicine, St. Louis,. 2University of Cin-
cinnati College of Medicine, Cincinnati, USA. 3University of Cape Town & 
South African Medical Research Council, Cape Town, South Africa
Mammals have evolved neurophysiologic reflexes such as cough-
ing and scratching to expel invading pathogens and noxious 
environmental factors. It is well established that these responses 
are also associated with chronic inflammatory diseases such as 
asthma and atopic dermatitis. However, the mechanisms by which 
inflammatory pathways promote sensations such as itch remain 
poorly understood. Here, we show that type 2 cytokines directly 
stimulate sensory neurons in both mice and humans. Further, we 
demonstrate that chronic itch is dependent on neuronal IL-4Rα 
and JAK1 signaling. Based on these observations, we show that 
patients with recalcitrant chronic itch markedly improve when 
treated with JAK inhibitors in proof-of-concept clinical studies. 
Thus, signaling mechanisms previously ascribed to the immune 
system may represent novel therapeutic targets within the nervous 
system. Collectively, these studies reveal an evolutionarily con-
served paradigm in which the sensory nervous system employs 
classical immune signaling pathways to influence mammalian 
behavior.
HOT OFF THE BENCH: LATEST NEWS BY 
YOUNG INVESTIGATORS
OP41
REVERSING NOCEBO EFFECTS ON ITCH BY 
CONDITIONING WITH VERBAL SUGGESTION
Danielle Bartels1, Antoinette van Laarhoven1, Michiel Stroo1, Kim 
Hijne1, Kaya Peerdeman1, Rogier Donders2, Peter van de Kerk-
hof2, Andrea Evers1
1Leiden University, Leiden, 2Radboud University Medical Center Nij-
megen, The Netherlands
Background: Nocebo effects are negative treatment effects, unre-
lated to the treatment mechanism, which are induced by patients’ 
expectations of worsening. Nocebo effects are known to contribute 
to the experience of itch, however, it has not yet been investigated 
if nocebo effects can be diminished by positive expectations. In this 
study, we examined whether nocebo effects on itch can be reduced 
by positive expectation induction with respect to electrical itch 
stimuli in healthy subjects. Methods: First, negative expectations 
about itch stimuli were induced in 99 participants by conditioning 
with verbal suggestion (part 1: induction of nocebo effect). Second, 
these participants were randomized to either the experimental group 
or one of the control groups (part 2: reversing nocebo effect). In the 
experimental group, positive expectations were induced by conditio-
ning with verbal suggestion. In the control groups either the negative 
expectation induction was continued or an extinction procedure was 
applied. Results: Positive expectation induction resulted in a signifi-
cantly smaller nocebo effect on itch in comparison with both control 
groups. Mean levels of itch showed that the nocebo effect was even 
reversed, signifying a placebo effect. Conclusions: The current study 
is the first to demonstrate that nocebo effects can be reversed by 
conditioning with verbal suggestion. A better understanding how to 
diminish and reverse nocebo responses might eventually contribute 
to increased treatment effectiveness and improved quality of life 
for patients suffering from chronic itch conditions. 
OP42
AMELIORATION OF ATOPIC-ITCH SENSATION 
IN NC/TND MICE BY BETA-PINENE, THE MAJOR 
COMPONENT CONTAINED IN DISTILLED 
ALPINIA INTERMEDIA GAGNEP EXTRACTS
Yosuke Amagai1, Tetsuyoshi Hamasaki2, Yoshihiro Nomura3, Hiro-
shi Matsuda3, Akane Tanaka3
1Research Fellow of the Japan Society for the Promotion of Science, 2Gray 
Art, Co., Ltd., 3Tokyo University of Agriculture and Technology, Japan
Background: Alpinia (A.) intermedia, a perennial plant that be-
longs to the Zingiberaceae family, has been used in folk medicine 
for a long time in the southern districts of Japan. In this study, we 
investigated whether b-pinene, a major ingredient contained in 
the distilled extracts obtained from A. intermedia, suppress the 
itch sensation and exaggeration of dermatitis in NC/Tnd mice, a 
spontaneous atopic dermatitis model. Methods: Component analy-
ses of the A. intermedia extracts were carried out using headspace 
gas chromatography-mass spectrometry. b-pinene was topically 
applied on the skin of NC/Tnd mice, which were maintained under 
conventional conditions, and parameters including clinical scores, 
scratching behaviors, and transepidermal water loss was evaluated. 
Histological analyses of in vivo samples were also carried out. The 
inhibitory effects of b-pinene on the degranulation of bone marrow-
derived cultured mast cells (BMCMCs) and neurite outgrowth 
of dorsal neurite ganglia (DRGs) as well as involving signaling 
pathways were assessed. Results: The component analysis revealed 
that b-pinene was a major constituent of the A. intermedia extracts. 
In NC/Tnd mice, we observed that topical application with b-pinene 
significantly reduced the severity of dermatitis, transepidermal 
water loss, and scratching behavior. Histological analyses revealed 
that application of b-pinene significantly decreased the number of 
cutaneous mast cells as well as density of PGP-9.5-positive neurons 
in dermis. Adding the b-pinene to cell cultures suppressed degra-
nulation of BMCMCs and neurite outgrowth of DRGs. Signaling 
analyses revealed that b-pinene strongly suppress Stat6 activation 
in DRGs. Conclusion and discussion: The results of this study 
indicate that topical application with b-pinene improved the skin 
condition by suppressing itch sensation and allergic inflammation 
through Stat6-mediated pathways.
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OP43
PROLONGED ANTIPRURITIC EFFECT OF 
BOTULINUM TOXIN TYPE A ON COWHAGE-
INDUCED ITCH
Leigh A. Nattkemper1, C. Stull2, M.J. Lavery2, R. Valdes-Rodriguez2, 
M. McGregory2, R.V. Ramsey3, Y.H. Chen4, H. Mochizuki1, Gil Yosipovitch1
1Department of Dermatology, Miami Itch Center, University of Miami 
Miller School of Medicine, Miami, 2Department of Dermatology and 3De-
partment of Clinical Sciences, Temple University Lewis Katz School of 
Medicine, Philadelphia, USA, 4Biostatistics Unit, National University of 
Singapore Lon Lin School of Medicine, Singapore
Background: Botulinum toxin type A (BoNT/A or Botox®)is 
thought to have an antipruritic effect due to the inhibition of 
acetylcholine and other pruritic factors, such as substance P 
and glutamate. Objectives: To test the itch-relieving effect of 
BoNT/A on cowhage, a non-histaminergic model for chronic itch. 
Methods: In a randomized, single-blind, placebo-controlled trial 
(NCT02639052) Botox® (BoNT/A; 10 units; Allergan) was intra-
dermally injected in a 4x4 cm test area on the volar surface of arm 
of 35 healthy subjects (16 males and 19 females; age 26.8±6.8), 
with a saline control (10 units) injected into the contralateral arm. 
Thermal sensory parameters (warmth and heat thresholds and 
heat pain intensity) and itch intensity after cowhage application 
were examined on the test areas at baseline (before treatment) and 
then 1 week, 1 month, and 3 months after treatment. Results: The 
intradermal injection of BoNT/A reduced cowhage itch intensity 
compared to the saline control at 1 week (p<0.0001), 1 month 
(p<0.0001), and 3 months (p=0.0004). The overall perceived 
itch (AUC; percent change from baseline) was also decreased 
versus saline control at 1 week (p=0.016), 1 month (p=0.015), 
and 3 months (p=0.007). The peak itch intensity was lowered 
with BoNT/A at 1 week (p=0.0002), 1 month (p=0.0001), and 3 
months (p=0.005) compared to the saline treatment. BoNT/A had 
no effect on thermal thresholds or heat pain intensity. Conclusions: 
One treatment of BoNT/A reduced cowhage itch for at least three 
months. These results suggest that BoNT/A is a potential long-
lasting treatment for localized, non-histaminergic itch.
THE WIDE RANGE OF CLINICAL 
PRESENTATIONS OF ITCH 
OP44
AN OVERVIEW OF TREATMENT FOR OPIOID-
INDUCED ITCH
Kenji Takamori1,2, Nobuaki Takahashi1, Mitsutoshi Tominaga1
1Institute for Environmental and Gender Specific Medicine, Juntendo Uni-
versity Graduate School of Medicine, Chiba, 2Department of Dermatology, 
Juntendo University Urayasu Hospital, Chiba, Japan
The μ- and ĸ-opioid systems play pivotal roles in modulating 
pruritus in the central nervous system (CNS). Opioid-induced 
pruritus is a well-known side effect in patients treated for pain 
with morphine and other μ-opioid receptor (MOR) agonists. In 
contrast, MOR antagonists (e.g., naloxone and naltrexone) and k-
opioid receptor (KOR) agonists (e.g., nalfurafine) have been found 
to suppress pruritus in patients with systemic diseases, including 
chronic renal failure and cholestasis. These findings indicate the 
μ-opioid system induces whereas the ĸ-opioid system suppresses 
itch via the CNS. Our previous placebo-controlled, prospective, 
double-blind study demonstrated that opioid ĸ-receptor agonist, 
nalfurafine hydrochloride, effectively reduced intractable pruritus 
in 337 hemodialysis patients. In addition, our recent open-label 
study showed that nalfurafine hydrochloride, orally administered 
to hemodialysis patients at 5 µg per day for 52 weeks, produced 
long-term suppression of pruritus. Moreover, recently we demon-
strated antipruritic efficacy of nalfurafine hydrochloride in chronic 
liver disease patients with intractable pruritus in a randomized, 
double-blind study. Experimentally, it is accepted that B5-I 
neurons, spinal inhibitory interneurons, produce an endogenous 
k-opioid agonist dynorphin acting as KOR-expressing spinal 
itch-selective neurons that suppress itch sensation. Meanwhile, 
peripheral opioid systems may also play important roles in pruritus. 
For example, topical application of μ-opioid receptor antagonist 
(e.g. naltrexone) relieved pruritus in atopic dermatitis patients. Our 
most recent study showed that MOR and KOR were involved in 
itch-related scratching behavior of imiquimod-induced psoriasis-
like dermatitis in mice. In the plenary session, I provide an update 
and overview on treatment of opioid-induced itch.
OP45
PRURITUS IN PATIENTS WITH KIDNEY 
TRANSPLANTS
Thomas Mettang1, Elke Weisshaar2, Jörg Kupfer3
1Department of Nephrology, DKD Helios Clinic, Wiesbaden, 2Department 
of Clinical Social Medicine, Environmental and Occupational Dermato-
logy, University Hospital Heidelberg, Heidelberg, 3Institut for Medical 
Psychology, Justus-Liebig-University Giessen, Giessen, Germany
Background: Uremic pruritus is a frequent and often tormenting 
symptom in patients on dialysis. According to former studies 
pruritus disappears after kidney transplantation. To readdress 
this topic we investigated patients who had previously received 
a kidney transplant and analysed possible correlations between 
pruritus and a series of clinical and laboratory findings in those 
patients with a functional graft without the need of dialysis. Met-
hods: Patients who had received a kidney transplant from 1976 to 
2014 whose follow-up took place in a single centre were asked to 
complete a questionnaire regarding pruritus. Additionally, clinical 
and laboratory parameters routinely and periodically obtained 
as well as current medication were recorded. Correlations were 
calculated using appropriate statistical tools. Results: 74 of 132 
patients on routine follow-up after kidney-transplantation agreed 
to fill in the questionnaire. 8 of these 74 patients reported to suffer 
from a dermatosis and were excluded from the analysis. 11 pat. 
of the remaining 66 (16.7%) reported to suffer from chronic itch. 
The median of the intensity of itch the day of the interview was 
2 (range 0-7) on a numeric rating scale from 0 to 10. Most often 
itch appeared on the extremities (9 of 11), the back (3 of 11) and 
neck (4/11). No association could be found between the preva-
lence of pruritus and the time since transplantation. Additionally, 
there was no association between the history of itch before (ie. 
while on dialysis) and after transplantation. The intensity of itch 
correlated with transplant-function (CKD-epi), serum-creatinine 
and haemoglobin levels. All patients suffering from itch were on 
beta-blockers, none of these patients had alpha-blockers. Con-
clusion: A substantial proportion of patients with functioning 
kidney-transplant suffer from chronic itch although to a minor 
intensity. There seems to be no association between history of 
itch during time on dialysis and after transplantation, suggesting 
a different pathogenesis of itch in transplant patients. Whether the 
use of beta-blockers does play a role in itch of transplant patients 
should be evaluated in a larger cohort.
OP46
URTICARIA AND ITCH
Tabi Leslie
Royal Free Hospital, London, UK
Chronic urticaria (CU) is a disease characterized by pruritic 
weals, angioedema or both, lasting for 6 weeks or longer. It has 
an estimated 1% worldwide prevalence. Quality of life is often 
severely affected, since the associated itching can disturb sleep, 
disrupt or restrict activities, and cause social embarrassment. A 
primary effector of urticaria is the mast cell, which releases hista-
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mine when activated by stimuli that may be either immunological 
or non-immunological. Histamine acts predominantly on H1 and 
H2 receptors, with H1 receptor stimulation leading to a neuronal 
reflex mechanism that causes itch. There are several guidelines 
which outline the classification, diagnosis and management of CU. 
The latest European guidelines categorise CU into two subtypes; 
Chronic spontaneous urticaria (CSU), which is endogenous and oc-
curs without provocation, and chronic inducible urticaria (CIndU), 
where symptoms are induced by a demonstrable stimulus. Diag-
nosis for CSU is made by taking a thorough history, as well as 
blood tests that may exclude an underlying disease. CIndU can be 
confirmed with provocation tests. Differential diagnosis includes 
urticarial vasculitis and autoinflammatory disease, in addition to 
various cutaneous diseases. Assessment tools for the severity of 
CU include the Urticaria Activity Score over 7 days (UAS7), Itch 
Severity Score (ISS), and the CU-2QoL, a disease-specific measure 
of quality of life impairment. The European, UK and US guideli-
nes for CU all have some variation in their step-wise procedures 
for managing the disease. All recommend that second generation 
antihistamines are the mainstay first-line treatment, and dosages 
may be increased by up fourfold. A number of add-on treatments 
are available for patients with CU refractory to antihistamines. 
The European guidelines now recommend that the monoclonal 
anti-IgE antibody, omalizumab, should be the next line of tre-
atment, followed by ciclosporin or montelukast. Short courses 
of systemic corticosteroids may be use as a rescue treatment for 
acute exacerbations, however long-term use is not recommended. 
Potential future treatments for CU include H4 receptor antagonists, 
as well as other anti-IgE and anti-IL-1 biologics.
OP47
ESSENTIAL THROMBOCYTHEMIA WITH 
AQUAGENIC PRURITUS: AN ENTITY WITH 
MORE AGRESSIVE CLINICAL AND BIOLOGICAL 
PROFILE AT THE DIAGNOSIS AND A HIGH 
MORBIDITY DURING THE FOLLOW-UP
Christelle Le Gall-Ianotto1, Ronan Le Calloch2, Aurélie Chau-
veau3, Eric Lippert3, Laurent Misery1, Jean-Christophe Ianotto4
1Laboratory of Interactions Neurons-Epitheliums, University of Brest, 
Brest, 2Department of Hematology, Hospital of Cornouaille, QUimper, 
3Laboratory of Hematology, and 4Department of Clinicval Hematology, 
University Hospital of Brest, Brest, France
Polycythemia vera (PV) and essential thrombocythemia (ET) are 
myeloproliferative neoplasms in which arterial or venous throm-
boses and phenotypic evolutions (leukemia, myelofibrosis) are the 
most recurrent complications. Aquagenic pruritus (AP), induced by 
water contact, is a typical symptom of PV. How ever, we showed 
recently that it also present in ET withdifferent clinical characte-
ristics from those observed in PV patients. In 2008, the presence 
of AP in PV was associated with a lower risk of arterial thrombo-
sis. So, it seemed particularly interesting to analyze the clinical 
impact of the presence of AP in ET patients for such a risk. For 
this, the biological and clinical data of 396 ET patients followed 
in our hospital was used (Observatoire Brestois des NEoplasies 
myéloprolifératives database, OBENE, NCT02897297). So, 42 
(10.6%) of our 396 patients suffered from AP. Interestingly, their 
median age at diagnosis was younger (51.6 vs 63.8 yr, p<0.0001). 
Furthermore, they presented more symptoms as erythrocytosis, hy-
perviscosity, constitutional symptoms and splenomegaly (p<0.01). 
ET with AP were more proliferative (more polycythemic but less 
thrombocythemic, p<0.04 each) and were more difficult to treat 
(2.2 vs 1.1 treatment lines, p=0.005). Concerning the occurrence 
of thrombotic events (arterial or venous) at diagnosis, no signi-
ficant difference between groups was found. In contrast, there 
were more thrombotic events during the follow-up in group with 
AP (30.9 vs 17.2%, p=0.03). The artery/vein rate of thrombotic 
events was also different (50/50 vs 2/3:1/3, p<0.05). Furthermore, 
1/3 of ET with AP had phenotypic evolutions (PV or secondary 
myelofibrosis) against 13.8% in the other group (p=0.0007). Con-
cerning the overall survival of the patients, we noted that ET with 
AP have a lower rate of death (11.9 vs 32.5%, p=0.006) in spite of 
a longest follow-up (12.1 vs 7.7 years, p=0.002). AP is not only 
a PV symptom, but is also present in ET. Furthermore, ET with 
AP were more proliferative, more symptomatic at diagnosis but 
had also higher risk of thrombosis and phenotypic evolution than 
ET without AP. Despite that, these patients have a higher overall 
survival. So, the presence of AP in patients with ET characterizes 
patients with high risk of morbidity (thromboses, phenotypic 
evolution). The systematic determination of the presence of AP 
in ET patients at diagnosis should permit to better identify these 
patients for a better management and follow-up.
OP48
PREVALENCE AND CLINICAL CHARACTERIS-
TICS OF PRURITUS IN PATIENTS WITH 
CUTANEOUS LUPUS ERYTHEMATOSUS
Dominik Samotij1, Justyna Szczęch1, Emiliano Antiga2, François 
Chasset3, Aleksandra Dańczak-Pazdrowska4, Adriana Polańska4, 
Fukumi Furukawa5, Carolyn Kushner6, Hideo Hashizume7, Mo-
hammad Rafiqul Mowla8, Aminul Islam8, Minoru Hasegawa9, Lau-
rent Misery10, Zygmunt Adamski4, Jacek C. Szepietowski1, Victoria 
Werth6, Adam Reich1
1Department of Dermatology, Venereology and Allergology, Wroclaw Med-
ical University, Poland, 2Department of Surgery and Translational Medi-
cine, Section of Dermatology, University of Florence, Italy, 3Department of 
Dermatology and Allergology, Tenon Hospital, Paris, France, 4Department 
of Dermatology, Poznan University of Medical Sciences, Poland, 5Depart-
ment of Dermatology, Wakayama Medical University, Japan, 6Perelman 
School of Medicine, University of Pennsylvania, Philadelphia, USA, 7De-
partment of Dermatology, Shimada Municipal Hospital, Shimada, Japan, 
8Department of Dermatology and Venereology, Chittagong Medical Col-
lege, Pakistan, 9Department of Dermatology,  School of Medicine, Faculty 
of Medical Sciences, University of Fukui, Japan, 10 Department of Derma-
tology, University Hospital of Brest, France
Various inflammatory skin diseases are accompanied by pruritus 
of various severity. However, data on pruritus in patients suffering 
from cutaneous lupus erythematosus (CLE) are very limited. This 
multicenter, prospective, cross-sectional study was undertaken 
to evaluate the prevalence and clinical characteristics of pruritus 
in patients with CLE. The study was based on the questionnaire 
assessing sociodemographic data, clinical subtypes of CLE, as 
well as various clinical aspects of pruritus, including its inten-
sity, accompanying experiences, influence on psyche as well as 
treatment modalities used by patients to alleviate it. Skin lesion 
severity was assessed with CLASI, while systemic symptoms 
were assessed with SELENA-SLEDAI. The study was approved 
by Ethic Committee of Wroclaw Medical University. A total of 61 
completed and verified questionnaires were included for prelimi-
nary analysis. Three (4.9%) patients had acute CLE (ACLE), 14 
(22.9%) subacute CLE (SCLE) and 43 (70.5%) had chronic CLE 
(CCLE). One (1.6%) patient presented clinical features of both 
ACLE and CCLE. Mean activity according to CLASI was 6.0±5.6 
while mean damage was 3.3±4.2 points. Pruritus was reported 
by 46 (75.4%) patients. In contrast, pain within skin lesions was 
experienced by only 8 (13.1%) of CLE patients. The maximum 
pruritus severity measured with Numeric Rating Scale (NRS) was 
5.5±2.4 points, being the most severe in generalized ACLE, but 
the differences were not statistically significant. Most commonly 
pruritus affected scalp (n=22; 47.8%), nose (n=16, 34.8%) as well 
as the rest of the face (n=19; 31.1%) and arms (n=15; 24.6%). 
Significant correlation was observed between Activity CLASI 
score and maximum (r=0.39, p<0,01) as well as average pruritus 
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intensity (r=0.32, p=0.02). Such relationship was not observed for 
pain. No relationship was also found between severity of systemic 
symptoms and reported pain or itch intensity. Based on our results 
we may conclude that pruritus is relatively frequent, but often 
overlooked symptoms in patients with CLE. Further studies are 
needed to better characterize its clinical characteristics and verify 
the efficacy of various treatment modalities.
OP49
CLINICAL CHARACTERISTICS OF AQUAGENIC 
PRURITUS IN POLYCYTHEMIA VERA
Edyta Lelonek1, Łukasz Matusiak1, Tomasz Wróbel2, Jacek Kwiat-
kowski2, Jacek C. Szepietowski1
1Department and Clinic of Dermatology, Venereology and Allergology, and 
Department and Clinic of Hematology, Blood Neoplasms and Bone Mar-
row Transplantation, Wroclaw Medical University, Wroclaw, Poland
Background: Aquagenic pruritus (AP) is one of the main clinical 
features of polycythemia vera (PV). Despite it was described more 
than three decades ago, the knowledge about its clinical characte-
ristic and management still remains scarce. Objectives: This study 
was undertaken to analyze clinical characteristics of AP and its 
associations with laboratory results. Material and Methods: The 
study group consisted of 102 patients with molecularly confirmed 
PV with the mean age of 66.9±12.7 years. Demographic data, data 
on disease history, PV status and treatment modalities were col-
lected. Pruritus intensity was evaluated with visual analogue scale 
(VAS), verbal rating scale (VRS) and a 4-item Itch Questionnaire. 
Moreover, various clinical features of AP (including localization, 
quality, descriptors) and the most common factors responsible 
for its aggravation or alleviation were examined. Participants 
underwent also basic laboratory tests. Results: AP was observed 
in 41.1% individuals. The mean duration of AP was 6.6±8.6 years 
and its onset was noticed in the majority of sufferers before the PV 
diagnosis (52.4%). The mean AP intensity was assessed as 4.8±1.9 
points (VAS) and 6.0±2.9 points (4-item Itch Questionnaire). One 
third of patients with AP avoided any contact with water. Sleep 
disturbances, were observed among 16.7% AP patients. Of note, 
negative correlations between hemoglobin, hematocrit and pruritus 
severity were found. Antipruritic treatment was received only by 
3 patients without any clinical improvement. Conclusions: AP 
seems to be an entity of neglected importance among PV sufferers 
with HGB and HCT serving as major contributors of its intensity.
OP50
CLINICAL CHARACTERISTICS OF PRURITUS IN 
HIDRADENITIS SUPPURATIVA PATIENTS
Lukasz Matusiak, Justyna Szczęch, Karolina Kaaz, Edyta Lelo-
nek, Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Wroclaw, Poland
Background: The growing body of research has indicated pruritus 
as an important hidradenitis suppurativa (HS) feature. Objectives: 
This study was undertaken to evaluate the pruritus and additonally 
pain among HS patients. Material and Methods: The study group 
consisted of 103 (50 females, 53 males) HS patients with the 
mean age of 35.6±13.2 years. The disease severity was assessed 
as 38.0±36.5 points, 9.2±4.6 points and 42/47/14 according to 
HSS (Hidradenitis Suppurativa Score), HSSI (Hidradenitis Sup-
purativa Severity Index) and Hurley I/II/III staging, respectively. 
Pruritus and pain intensity were evaluated with visual analogue 
scale (VAS), numeric rating scale (NRS) and a 4-item Itch Ques-
tionnaire. DLQI was also implemented to assess the QoL issues. 
Moreover, various clinical features of pruritus and the most com-
mon factors responsible for its aggravation or alleviation were 
examined. Results: The pruritus within last seven days before 
examination was reported among 41.7% of HS patients, whereas 
pain was observed in 77.5% individuals. The pruritus severity 
was assessed as 5.0±2.1 points, 5.5±2.3 points, and 4.6±1.9 points 
(for VASmax, NRSmax and 4-item Itch Questionnaire, respectively). 
The pain intensity was evaluated as 7.3±2.4 points (VASmax) and 
7.5±2.5 points (NRSmax). Pruritus was observed predominantly in 
buttocks area (90% of pruritic lesions) and armpits (83% and 87% 
of pruritic lesions). With except for buttocks, pain was distributed 
quite equally between armpits, inguinals, abdomen, chest and 
anogenital area. The presence of pruritus neither had an impact 
on QoL assessed with DLQI, nor did it show interaction with the 
pain in this regard. The pain presence was a crucial contributor 
(p=0.002), even more important than disease severity (p=0.04). 
Nonetheless, the pruritus intensity correlated significantly with 
DLQI. The pain intensity correlated negatively with QoL assessed 
with DLQI and additionally with disease severity. The majority of 
patients described their itch as burning (46.5%), stinging (25.6%) 
or tickling (18.6%). The most common factors exacerbating itch 
intensity were increased sweating, heat and physical activity. 
The pain was reported as the most troublesome symptom of HS 
consecutively outpacing exudation, pruritus, appearance and 
smell. Conclusions: In patients with HS, in addition to pain, the 
pruritus of mild-to-moderate intensity is not uncommon symptom 
associated with the disease adversely affecting the quality of life. 
PATIENTS’ PERSPECTIVES AND PATIENT 
REPORTED OUTCOMES
OP51
PATIENT-REPORTED OUTCOMES: AN INTRO-
DUCTION
Christian Apfelbacher1, Pauline Nelson2
1Medical Sociology, Institute of Epidemiology and Preventive Medicine, 
University of Regensburg, Regensburg, Germany, 2Manchester Business 
School, University of Manchester, Manchester, UK
A patient-reported outcome (PRO) is defined as any report of the 
status of a patient’s health that comes directly from the patient, 
without interpretation of a clinician or anyone else. The measure-
ment of PROs has become an important component of outcomes 
assessment in clinical research, observational health services 
research and - more recently - in routine healthcare. Examples of 
PROs include instruments that measure health-related quality of life 
(HRQOL) such as the ItchyQoL, symptoms or treatment satisfac-
tion. The measurements generated by PRO measures need to be 
valid and relevant for patients, healthcare professionals and other 
stakeholders. This will only be achieved if the development and 
validation is done in a robust way. The development of a PRO is 
a multi-step process, involving a content validity phase and a psy-
chometric testing phase. In this process, it is important to consider 
all measurement properties of the PRO of interest. According to 
the consensus-based taxonomy of the COSMIN (COnsensus-based 
Standards for the selection of health Measurement Instruments) 
group, these are: content validity including face validity, reliability, 
responsiveness, internal consistency, structural validity, measu-
rement error, hypothesis testing, criterion validity, cross-cultural 
validity. Aspects of feasibility such as patient comprehensibility, 
interpretability or completion time also need to be assessed. When 
we think about PRO validation, we often think about the psycho-
metric phase, for instance testing test-retest reliability (stability of 
the measurements over time) by calculating an intra-class correla-
tion coefficient. While PRO studies often give detailed reports of 
the psychometric testing of PROs, those that adequately report on 
content validation are less prominent. In the content validity phase 
in which a PRO is created, three steps are important: (1) definition 
of a conceptual model; (2) generation of content in terms of items 
in relation to that model; and (3) cognitive interviewing to ensure 
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feasibility of the measure. Thus, the development and validation 
of PRO measures for patients with chronic itch as in other clinical 
fields is complex and not restricted to psychometrics alone. It 
requires a mixed-methods approach with appropriate application 
of quantitative and qualitative research and the requisite multidis-
ciplinary expertise to conduct each phase well.
OP52
HIGH LEVELS OF ACTING WITH AWARENESS 
GO ALONG WITH LOW LEVELS OF ITCH 
CATASTROPHIZING: FIRST RESULTS OF A 
CROSS-SECTIONAL STUDY IN PATIENTS WITH 
ATOPIC DERMATITIS
Christina Schut1, Kerry Montgomery2, Kjell Lüßmann1, Andrew 
Thompson2, Uwe Gieler3, Christoph Zick4, Jörg Kupfer1
1Institute of Medical Psychology, Justus-Liebig-University, Gießen, Ger-
many, 2Department of Psychology, University of Sheffield, UK, 3Depart-
ment of Dermatology and Allergology, University Clinic Gießen, Giessen, 
4Department of Dermatology, Rehabilitation Center Borkum Riff, Borkum, 
Germany
Theoretical background: Mindfulness, defined as paying atten-
tion to the present moment on purpose and without judging, 
leads people to react consciously instead of automatically. Mind-
fulness interventions have been shown to have positive effects 
on the skin, quality of life and stress in patients with psoriasis. 
Moreover, recently, naturally occuring levels of mindfulness have 
been shown to be related to anxiety, depression, quality of life 
and skin shame in patients with different skin diseases. Whether, 
naturally occuring levels of mindfulness are also related to itch 
catastrophizing in patients with the chronic itchy skin disease 
atopic dermatitis (AD), is investigated with this study for the first 
time. Methods: 109 ND-patients (44 male, 65 female; mean age: 
45±13 years) filled in the Comprehensive Inventory of Mindful-
ness Experiences (CHIME) and the Itch Cognition Questionnaire 
(ICQ) during the first week of their stay at a rehabilitation clinic on 
Borkum, Germany. In addition, the average itch intensity during 
the last two weeks prior to the stay at the clinic was measured by 
a visual analogue scale (VAS 0–10). Results: Correlation analyses 
revealed that the mindfulness scales „acting with awareness“, „ac-
cepting and non-judgemental orientation“ and „decentering and 
non-reactivity“ significantly negatively correlated with itch cata-
strophizing [acting with awareness: r=–0.368; p≤0.001; accepting 
and non-judgemental orientation: r=–0.196; p=0.044; decentering 
and non-reactivity: r=–0.230; p=0.018]. The regression analysis 
showed that after controlling for age, gender, illness durination 
and itch intensity during the last two weeks, an additional 11.1% 
of the variance of itch catastrophizing was explained by „acting 
with awareness“ [F (2/76) = 24.789; p≤0.001]. Discussion: This 
study was the first to show that different facets of mindfulness 
are negatively related to itch catastrophizing in patients with AD, 
whereby acting with awareness showed the strongest correlations 
with itch catastrophizing. It is striking that this facet of mindfulness 
also showed the strongest correlations with psychological burden 
in patients with different skin conditions in a previous study. In 
our point of view, it would therefore worth to investigate whether 
certain mindfulness techniques aiming to especially increase acting 
with awareness are able to reduce not only itch related cognitions, 
but also scratching in itch inducing situations. 
OP53
DO PLACEBO EFFECTS WORK WHEN 
SUBJECTS KNOW THAT THEY RECEIVE A 
PLACEBO? EFFECTS OF OPEN-LABEL VERBAL 
SUGGESTIONS ON ITCH
Stefanie Meeuwis1, Henriët van Middendorp1, Judy Veldhuijzen1, 
Antoinette van Laarhoven1, Jan De Houwer2, Andrea Evers1
1Faculty of Social and Behavioural Sciences, Institute of Psychology, 
Health, Medical and Neuropsychology unit, Leiden University, Leiden, The 
Netherlands, 2Department of Experimental Clinical and Health Psycho-
logy, Ghent University, Belgium
Negative and positive outcome expectancies, induced by verbal 
suggestions, have been shown to influence subjective symptoms 
such as itch. Although most experimental studies on placebo 
and nocebo effects have only informed participants following 
participation that they received an inert substance (closed-label 
placebo/nocebo), there is a growing body of literature that suggests 
that placebo effects can occur even when it is known that a given 
substance is inert (open-label placebo). An experimental study was 
conducted to investigate the effects of open-label positive verbal 
suggestions on itch. It was expected that open-label positive verbal 
suggestions would reduce itch following a validated itch-inducing 
histamine test. Healthy volunteers (n=92) were randomized 
to either an experimental or a control group. Itch was evoked 
experimentally during a single laboratory session by histamine 
iontophoresis. In the experimental group, participants were told 
that the test would elicit little itch and received information on 
how expectations could influence itch (i.e. open-label positive 
verbal suggestions), whereas in the control group, no suggestions 
were given. Open-label verbal suggestions were found to affect 
itch expectations in this study, but not induced itch. Additionally, 
within the experimental group only, lower post-verbal suggestion 
expected itch was significantly associated with lower self-reported 
itch. These results offer support for open label placebo efficacy 
in itch. Future research might focus on strengthening the verbal 
suggestions used in the current study, for example by using more 
explicit explanations of the role of expectations in itch. Further 
identifying the role of expectations in itch could provide new 
knowledge on how to optimize treatment effects in chronic itch. 
OP54
A QUALITATIVE STUDY TO UNDERSTAND 
PATIENTS’ PERCEPTION OF THE SEVERITY 
OF CHRONIC PRURITUS AND ITS IMPACT ON 
HEALTH-RELATED QUALITY OF LIFE
Jennifer Theunis1, Clementine Nordon2, Ylana Chalem1, Massimi-
liano Orri3, Jesus Cuervo2, Gilles Berdeaux1, Marie Auges1, Vale-
rie Mengeaud1, Laurent Misery4
1Pierre Fabre, 2LASER Analytica, 3CESP, INSERM 1018, 4CHU Brest, 
France
Objectives: To understand how patients suffering from Chro-
nic Pruritus (CP) perceive the severity of CP and its impact on 
health-related quality of life (HRQoL). Methods: A preliminary 
conceptual framework was developed after a systematic literature 
review. It was revised based on qualitative data generated by pa-
tients suffering from CP (underlying skin condition were psoriasis, 
atopic dermatitis, scalp seborrheic dermatitis, urticaria or none, in 
elderly people) during focus groups (FG). Participants’ verbatim 
were textually reported into transcript, which were thematically 
analyzed using qualitative content analyses (inductive approach). 
Results: Nineteen participants from one dermatological center in 
France were interviewed through 3 FG sessions. The severity of 
CP was reported in terms of: (i) intensity of itch (sensation type 
and scratching response), (ii) duration, and (iii) extension. Sub-
domains of interest for HRQoL were organized into: (1) sleep and 
fatigue; (2) coping and anticipation; (3) sexual life; (4) emotions 
and cognitions; (5) concentration; (6) daily activities; (7) cognitions 
attributed to others; (8) social relations; and (9) time spent. These 
sub-domains of interest were consistent across all skin conditions. 
Saturation of concepts was reached after the second FG. Discus-
sion: A comprehensive and clinically sound conceptual framework 
of CP severity and its impact on patients’ HRQoL has been achieved 
through structured literature review and focus groups.
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OP55
THE BURDEN OF CHRONIC ITCH-A QUESTION-
NAIRE BASED EVALUATION OF CLINICAL 
CHARACTERISTICS, ASSOCIATED MORBIDITY 
AND TREATMENT OUTCOMES IN A COHORT OF 
PATIENTS WITH CHRONIC PRURITUS
Ian McDonald1, Imre Szabó Lőrinc2, Attila Szöllősi3, Martin Stein-
hoff1,4
1UCD Charles Institute of Dermatology, St Vincents University Hospital, 
Dublin, Ireland, 2Department of Dermatology and 3Department of Physio-
logy, Faculty of Medicine, University of Debrecen, Debrecen, Hungary, 
4Dept of Dermatology, Hamad Medical Corporation, Qatar University, 
Weil Cornell University Watar, Doha, Qatar
Itch is the most common symptom in dermatology having a sig-
nificant impact on patient’s quality of life. With new treatment 
options on the horizon it is important to clinically differentiate 
patients, evaluating itch independently and with objective mea-
sures. Aims: 1) Characterize clinical features of itch in a cohort 
of patients attending the dermatology department. 2) Evaluate the 
impact of itch on quality of life, sleep and mental health. 3) Evalu-
ate the efficacy of treatments as reported by patients. Methods: Pa-
tients with a diagnosis of prurigo nodularis (PN), atopic dermatitis 
(AD), psoriasis (PSO) and pruritus of undetermined origin (PUO) 
were recruited from the dermatology OPD of SVUH. A pruritus 
questionnaire incorporating the itch VAS was developed. DLQI, 
PSQI and HADS were also used. Results: 73 patients were recrui-
ted. Itch was a symptom for more than 5 years in 62.67%. 45.9% 
reported “always” feeling itchy. 36.49%, the largest group repor-
ted bedtime as the most bothersome time. Heat and stress were 
the commonest exacerbating factors. The mean VAS was 6.69 
indicating moderate to severe itch. This was greatest in patients 
with PN (7.50) and lowest in patients with psoriasis (5.89) with a 
significant difference in severe and very severe itch between the 
two groups (83.3% vs 47.2%, p<0.05). VAS was found to be a 
significant predictor of DLQI, PSQI, and HADS. Importantly it 
remained a significant predictor of DLQI independent of PASI 
(regression coefficient B=1.881, p<0.05). 77.73% of patients had 
abnormal sleep patters (PSQI score > than 5). The mean PSQI was 
highest in patients with PUO and lowest in patients with psoriasis. 
34.7% of patients had a borderline or abnormal HADS for anx-
iety. This was proportionally greatest in patients with PN (50%). 
Most patient’s felt that topical and systemic treatments were only 
partially effective (71.67% and 72.73% respectively). Phototh-
erapy was reported to be the most efficacious treatment overall. 
Conclusion: In this patient cohort itch was found to be a chronic 
symptom. There was significantly less severe itch in patients with 
psoriasis where it had less impact on sleep than the other groups. 
Measurement of itch by VAS was an important predictor of DLQI 
in all groups and was independent of PASI. Systemic and topical 
treatment efficacy remains partial for most patients. This high-
lights the unmet medical need in pruritus treatment and the need 
for its evaluation independent of other disease measures.
OP56
EUROPEAN EADV NETWORK ON ASSESSMENT 
OF SEVERITY AND BURDEN OF PRURITUS 
(PRUNET): VALIDATION OF INSTRUMENTS FOR 
ITCH INTENSITY ITCH-IMPAIRED QUALITY OF 
LIFE IN PRURITIC DERMATOSES IN EUROPE
Claudia Zeidler1, Philipp Bruland2, Claudia Riepe1, Inaki Soto2, 
Sabine Steinke1, Michael Storck2, Martin Dugas2, Sonja Ständer1
1Department of Dermatology, Competence Center for Chronic Pruritus, 
University Hospital of Münster, 2Institute of Medical Informatics, Univer-
sity of Münster, Münster, Germany
Pruritus is a frequent symptom of many dermatoses and leads to 
a restriction of quality of life. There are currently no uniform pro-
cedures for measuring the symptom itself and its consequences in 
patients’ life within Europe. For this reason PruNet was founded, 
which comprises 31 experts from 15 countries. In a consensus 
conference, pruritus-specific instruments were evaluated and se-
lected for the validation study using a Delphi process. The chosen 
questionnaires, itch intensity scales (including visual analog scale, 
numeric rating scale and verbal rating scale), the ItchyQoL and 
5PLQ (both tools for measuring the impairment of quality of life 
in patients with chronic pruritus), were translated into national 
languages and were digitized for tablet application. Validation took 
place in a dermatological collective in Germany, Poland, Austria, 
Switzerland, Spain, France, Turkey, Russia and Italy for 4 weeks. A 
total of 552 (> 50/center) patients with contact dermatitis, prurigo 
nodularis, psoriasis vulgaris, lichen planus or mycosis fungoides/
Sézary syndrome and pruritus >3 on the NRS were included. 
Following the COSMIN checklist, we analyzed the data from all 
countries. All questionnaires showed an excessive consistence, 
an excellent reproducibility, a good concurrent and convergent 
validity. The acceptance of instruments was high among patients 
and physicians involved. By validation of itch specific tools, a 
harmonization is given. This is not only important in daily routine 
to improve the care of patients with itchy dermatoses, but also 
in clinical trials to establish urgently needed new therapeutics in 
order to better compare clinical data.
ITCH AND PAIN
OP57
SPINAL GABA-A RECEPTOR SUBTYPES 
CONTROLLING ITCH
William T. Ralvenius1, Elena Neumann1, Mario A. Acuña1, Mar-
tina Pagani1, Dietmar Benke1, Hendrik Wildner1, Uwe Rudolph2, 
Claude Favrot3, Hanns Ulrich Zeilhofer1
1Institute of Pharmacology and Toxicology, University of Zürich, 2Labo-
ratory of Genetic Neuropharmacology, McLean Hospital, 3Dermatology 
Department, Vetsuisse Faculty, Switzerland
Chronic itch affects about 10% of the general population. Chronic 
itch is in most cases histamine-independent and does as such not 
respond to classical antipruritic compounds. Previous work by 
different groups has demonstrated that the relay of itch signals 
is under the tight control by inhibitory circuits of the spinal 
dorsal horn, which use GABA and/or glycine for synaptic inhi-
bition. Using a battery of GABAA receptor point mutated mice, 
we found that specific pharmacological targeting of alpha2 and 
alpha3GABAA receptors reduces acute histaminergic and non-
histaminergic itch in mice. Systemic treatment with an alpha2/
alpha3GABAA receptor selective modulator alleviated acute and 
chronic oxazolone-induced itch in mice, and chronic itch in dogs 
sensitized to house dust mites. Transsynaptic circuit tracing, im-
munofluorescence and electrophysiological experiments suggest 
that spinal alpha2 and alpha3GABAA receptors as likely molecular 
targets underlying the antipruritic effect. Our results indicate that 
drugs targeting alpha2 and alpha3GABAA receptors are well-suited 
to alleviate itch, including non-histaminergic chronic itch, which 
is a particularly difficult to treat condition.
OP58
OPPOSING EFFECTS OF CERVICAL SPINAL 
COLD BLOCK ON SPINAL ITCH AND PAIN 
TRANSMISSION
Earl Carstens1, Mirela Iodi Carstens1, T. Akiyama2, A. Davoodi1, 
M. Nagamine1
1Neurobiology, Physiology & Behavior, UC Davis, CA, 2Dermatology, Univ 
Miami, USA
Inactivation of descending pathways enhanced responses of 
spinal dorsal horn neurons to noxious stimuli, but little is known 
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regarding tonic descending modulation of spinal itch transmis-
sion. To study effects of cervical spinal cold block on responses 
of dorsal horn neurons to itch- and pain-evoking stimuli, single-
unit recordings were made from superficial dorsal horn neurons 
in pentobarbital-anesthetized mice. 64 units were tested (46% 
wide dynamic range-type, 54% nociceptive-specific). Cold 
block had no effect on mechanically-evoked responses. Ten 
units’ responses to noxious heat were significantly enhanced 
during cold block, while 6 units’ responses were reduced and 
18 unaffected. 26 units responded to mustard oil (AITC), with 
a further significant increase in firing during the 1-min period 
of cold block beginning 1 min after AITC application. Activity 
during cold block was significantly greater compared to the 
same time period of control responses to AITC in the absence 
of cold block (n=39). Id histamine excited 17 units. Cold block 
starting 1 min after id injection of histamine caused a marked 
decrease in firing. The histamine-evoked response during and 
following cold block was significantly lower compared to control 
histamine-evoked responses in the absence of cold block (n=57). 
A similar but weaker depressant effect of cold block was observed 
for dorsal horn unit responses to chloroquine (n=26), for which 
chloroquine-evoked activity during cold block was lower com-
pared to control responses in the absence of cold block (n=25). 
These results indicate that spinal chemonociceptive transmission 
is under tonic descending inhibitory modulation, while spinal 
pruriceptive transmission is under an opposing, tonic descending 
facilitatory modulation.
OP59
RESPONSES SINGLE THALAMIC UNITS TO 
PRURICEPTIVE AND NOCICEPTIVE STIMULI IN 
THE RAT
Glenn Giesler, Brett Lipshetz, Hai Truong, Sergey Khasabov, Do-
nald Simone
Department of Neuroscience, University of Minnesota, USA
Comparatively little is known about processing of pruriceptive 
information in the brain. Indeed, no studies have been perfor-
med in which the responses of individual thalamic neurons have 
been examined to itch-producing stimuli. We characterized the 
responses of more than 50 thalamic neurons in rats activated by 
mechanical stimulation of the cheek. Responses of these neurons 
to pruriceptive stimuli that included intradermal injections of 
serotonin (5-HT), chloroquine, beta alanine and histamine were 
determined. Response by these neurons to nociceptive stimuli 
(pinching of the skin and injection of capsaicin) were also exa-
mined. Seventy-eight percent of thalamic neurons were activated 
by at least one pruriceptive stimulus. Forty-three percent of such 
pruriceptive neurons were recorded in the ventral posterior medial 
nucleus (VPM), 40% in posterior triangular nucleus (PoT) and 
smaller fractions in other posterior thalamic nuclei. More than 
44% of pruriceptive neurons were activated only by noxious 
mechanical stimuli (HT), 39% were activated by innocuous and 
noxious mechanical stimuli (WDR). A small number of neurons 
that responded only to innocuous mechanical stimuli were ac-
tivated by pruriceptive stimuli. Eighty-six percent of pruriceptive 
neurons were activated by injection of histamine, 52% by 5-HT, 
49% by beta alanine, and 31% by chloroquine. Twenty-four per-
cent of examined neurons were activated by a single pruritogen, 
22% by two pruritogens, 19% by three and 11% by all four. These 
results indicate that 1) surprisingly, more than three-fourths of 
thalamic neurons that responded to mechanical stimulation of 
the cheek were also activated by injection of one or more of the 
tested pruritogens; 2) the overwhelming majority of pruriceptive 
thalamic neurons were also activated by nociceptive stimuli; and 
3) pruriceptive thalamic neurons were most frequently located in 
either VPM or PoT. 
OP60
ACUPUNCTURE FOR PAIN MANAGEMENT IN 
EVIDENCE-BASED MEDICINE
Taqee Ansari Mohammed
MAK College of Pharmacy, India
Pain is an enormous and prevalent problem that troubles people 
of all ages worldwide. The effectiveness of acupuncture for pain 
management has been strongly verified by large randomized 
controlled trials (RCTs) and meta-analyses. Increasing numbers 
of patients with pain have accepted acupuncture treatment world-
wide. However, some challenges exist in establishing evidence 
for the efficacy of acupuncture. A more applicable and innovative 
research methodology that can reflect the effect of acupuncture in 
the settings of daily clinical practice needs to be developed Pain is 
“an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage or described in terms of such 
damage. The previous experience of acupuncture research studies 
are invaluable for researchers to recognize the limitations and 
challenges of research designs and would help to move the field 
forward in future research. For example, the design of an adequate 
sham control, involvement of skilled and experienced acupunc-
turists, adequate outcome measures in the clinical trials, and the 
discovery of physiological effects of acupuncture . in basic science 
are all important tasks for acupuncture researchers to address and 
solve. Challenges and future directions of acupuncture research 
for pain conditions in EBM High-quality RCTs and meta-analysis 
have increasingly produced robust evidence of the effectiveness of 
acupuncture for pain conditions, although nonspecific physiologic 
response to the needle insertion and the nature of holistic character 
of acupuncture treatment lead to many challenges in the research 
designs that reflect the daily clinical acupuncture practice, an 
individual patient data meta-analysis was conducted by Andrew 
et al to evaluate the effectiveness of acupuncture for four types of 
chronic pain: back and neck pain, osteoarthritis, chronic headache, 
and shoulder pain. The result reflects that acupuncture was superior 
to sham acupuncture controls and to the usual care controls in all 
four chronic pain conditions.
OP61
ITCH AND PAIN INFLUENCE ON QUALITY 
OF LIFE AND SLEEP DISTURBANCES OF 
HIDRADENITIS SUPPURATIVA PATIENTS
Karolina Kaaz, Łukasz Matusiak, Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Poland
Background: Hidradenitis suppurativa (HS) is a chronic, inflam-
matory, debilitating and suppurative disease of the hair follicle 
manifested by painful abscesses, fistules and scarring lesions. 
HS has great impact on patients’ quality of life. Objectives: This 
study was undertaken to evaluate the influence of itch and pain 
on quality of life of hidradenitis suppurativa patients. Material 
and Methods: The study group consisted of 108 (51 females, 57 
males) HS patients with the mean age of 36.3±12.1 years. The 
mean disease severity was assessed as 34.8±32.1 points, 9.0±4.4 
points and 50/49/9 according to HSS (Hidradenitis Suppurativa 
Score), HSSI (Hidradenitis Suppurativa Severity Index) and 
Hurley I/II/III staging, respectively. Itch and pain intensity were 
evaluated with visual analogue scale (VAS). The quality of life 
was assessed by DLQI. Moreover, sleep abnormalities were 
estimated with Athens Insomnia Scale (AIS), Pittsburgh Sleep 
Quality Index (PSQI) and Epworth Sleepiness Scale (ESS). 
Results: During the course of disease and within three last days 
subjective symptoms were experienced by the following group 
of patients: itch – 66/108 (61.0%) vs. 61 (56.5%) patients and 
pain – 93/108 (86.0%) vs. 88/108 (81.5%) patients, respectively. 
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The mean and maximal severity of itch and pain within three last 
days were assessed as: itch – 4.1±2.9 points, 5.0±2.1 points and 
pain – 4.9±2.9 points, 7.3±2.4 points, respectively. The mean 
QoL was assessed as 13.0±8.0 points. The scores for particular 
sleep abnormalities questionnaires were 5.4±4.3 points, 6.4±3.6 
points and 6.1±3.9 points with regard to AIS, PSQI and SSE, 
respectively. The severity of itch and pain significantly correlated 
with scores obtained by the AIS (R=0.44, p=0.004) and (R=0.39, 
p=0.001), respectively. Moreover, the disease severity assessed 
with HSSI significantly correlated with scores obtained by the 
AIS (R=0.22, p=0.03). Decreased QoL assessed with DLQI 
correlated positively with scores obtained with AIS and PSQI 
(p≤0.0001 for both correlations). Conclusions: Decreased quality 
of life and sleep disturbances in hidradenitis suppurativa patients 
seem to be an underestimated problem and could be related to 
pain and itch experienced during the course of disease.
PRURIGO AND OTHER PRURITIC SKIN 
DISEASES
OP62
PRURIGO AND OTHER PRURITIC SKIN 
DISEASES
Joanna Wallengren
Department of Dermatology, Lund University, Skane University Hospital, 
SUS, Lund, Sweden
Prurigo is a clinically accepted entity of itching papular or no-
dular lesions scattered on skin sites that can easily be scratched. 
Histologically, the hyperkeratotic nodules present with a reduced 
density of intraepithelal nerve fibers and an increased number of 
hypertrophic dermal sensory nerve fibers. The pathologic nerve 
fibers may fire spontaneously to produce itch. There are many exo-
genous and endogenous triggers of itch in prurigo. Toxic agents 
deposited in the skin by parasites, bacteria or topically or orally 
administered drugs can induce itch. In susceptible individuals, 
ultraviolet light can induce changes in epidermal innervation that 
result both in itch generally and in prurigo lesions. Prurigo occurs 
sometimes in atopic patients or during pregnancy. An umbilicated 
type of prurigo may be associated with some internal diseases like 
renal failure, diabetes mellitus or collagen disorders. Malabsorp-
tion due to gluten enteropathy, anorexia nervosa or fasting can 
also induce special types of prurigo. T-cell lymphoma and visceral 
neoplasias are the most common malignancies associated with 
prurigo. Some forms of prurigo may be secondary to scratching 
which destroys epithelial innervation mechanically leading to pat-
hologic firing of damaged nerve fibers. Emotional factors can also 
influence the perception of itch and scratching. There are some 
specialised forms of prurigo with ethnic preference, like prurigo 
pigmentosa in Japan, actinic prurigo (a chronic photodermatitis 
found predominantly in native North and South American Indians) 
or “papular eruptions in black men.” Topical treatment options 
are: corticosteroids (preferentially administered under occlusive 
dressings or intralesionally), calcineurin receptor inhibitors, can-
nabinoid receptor agonist, UVB, cryotherapy, capsaicin or bath 
photochemotherapy. Systemic regimens involve use of PUVA, 
methotrexate, cyclosporin A, arotinoid acid, azathioprine, chloro-
quine, dapsone, minocycline or naltrexone. Psychopharmaca 
targeting transmitters of mood which deteriorate prurigo may 
be useful. Clinical trials of drugs using substance P antagonist 
and interleukin 31 antibody seem promising in treatment of itch. 
Combined sequential treatments for generalised, therapy-resistant 
cases need to be tailored to the exacerbations that occur and to 
maintenance treatment in order to enable the patient to withstand 
the intolerable itch.
OP63
PSORIATIC ITCH 2017
Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Wroclaw, Poland
Itch is the most common symptom in dermatology. Mild to severe 
itch accompanies numerous skin disorders including, but not limi-
ted to atopic dermatitis, eczema, psoriasis, lichen planus, mycosis 
fungoides, Psoriasis is a chronic inflammatory skin diseases, 
affecting 1–3% of general population. For a long time psoriasis 
was considered as a non-pruritic dermatosis. The current 2017 
knowledge shows that itch is a very prevalent symptom of psoriass 
found in 70-80% of patients suffering from this disease. Itch may 
be limited to psoriatic plaques, but in about 30–40% of patients 
may also affect uninvolved skin. The mean severity of pruritus 
assessed according to visual analog scale (VAS) is slightly above 
the five points, indicating that most patients suffer from pruritus of 
moderate severity. Recently it has been documented that itch is the 
most bothersome symptom of psoriasis and is most important fac-
tor contributing to the disease severity. Patients present decreased 
well-being status, they are more depressed and they have higher 
level of stigmatization. The pathogenesis of psoriatic itch is still 
not completely clear and several possible factors may contribute 
to its appearance and exacerbation. One may consider increased 
innervation density and abnormal neuropeptides homeostasis 
as well as disturbed peripheral opioid system. There is no gold 
standard to treat psoriatic itch. According the European guideline 
resolution of skin lesion is crucial for the itch elimination. There-
fore, new biological therapies have been evaluated and it is clear 
that they are of benefit for patients with psoriatic itch. However, 
the holistic approach, including psychological support should be 
offered to this group of subjects.
OP64
NOVEL DEFINITION, CLASSIFICATION AND 
TERMINOLOGY OF CHRONIC PRURIGO
Manuel Pedro Pereira, Sabine Steinke, Sonja Ständer
Department of Dermatology and Center for Chronic Pruritus, University 
Hospital Münster, Germany
Prurigo exists as a term for over two centuries, but has been used 
for many years without well-defined criteria. Due to the multitude 
of possible clinical manifestations, including papular, nodular, 
plaque-type or umbilicated types, a variety of terms has been as-
sociated with prurigo leading to confusion in the dermatological 
routine care and in the scientific literature. Aiming to achieve a 
consensual definition, classification and terminology for chronic 
prurigo, twenty-four European experts of the Task Force Pruritus 
(European Academy of Dermatology and Venereology) met at 
the Department of Dermatology and Center for Chronic Pruritus, 
University Hospital Münster on February 3rd, 2017. The Delphi 
Method was used for the voting and consensus was reached when 
an agreement across ≥75% of the participants was achieved. 
Experts considered chronic prurigo a distinct disease with its 
own pathophysiological mechanisms and clinical presentation. 
‘Chronic prurigo’ was chosen as an umbrella term condensing the 
various presentations of this disease. These may indicate different 
disease stages with papular prurigo often developing into nodular 
prurigo and ultimately to plaque-type prurigo and thus artificial 
separations are avoided by using this generic term. Main criteria for 
the diagnosing chronic prurigo include (i) suffering from chronic 
pruritus for at least 6 weeks, (ii) evidence of prolonged scratching 
in the medical history or upon physical examination and (iii) the 
presence of pruriginous lesions. Regarding its pathophysiological 
mechanisms, the original cause for the itch underlying the CPG 
may be of various origins (dermatological, systemic, neurological, 
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psychiatric/psychosomatic, multifactorial or unknown). However, 
even after treatment of the underlying cause of the itch, CPG may 
persist due to the development of chronicity processes. Especially 
the itch-scratch cycle that ensues plays an important role. There-
fore, these chronicity processes should be targeted when treating 
patients with CPG in order to achieve an improvement of the 
symptoms. Dermatologists should embrace this novel definition, 
classification and terminology of chronic prurigo in order to faci-
litate the communication among clinicians, scientists and patients. 
OP65
APREPITANT, A NK1-ANTAGONIST, ADMINI-
STERED FOR 16 WEEKS REDUCED ITCH AND 
SUPPORTED RESOLUTION OF SKIN LESIONS IN 
A PATIENT WITH CHRONIC PRURIGO
Franz J. Legat, Alexandra Gruber-Wackernagel, Angelika Hofer, 
Klara Waltner, Peter Wolf
Department of Dermatology, Medical University Graz, Austria
Chronic prurigo (CPR) results from the development of an “itch-
scratch cycle”, with chronic pruritus (CP) (> 6 weeks) and repeated 
scratching eventually leading to pruriginous papules, nodules and/
or plaques. To date, medications with additional antipruritic ef-
fects are available only off-label for the treatment of CP or CPR. 
Substance P and its neurokinin-1 (NK1) receptor are believed to 
play an important role in the pathophysiology of itch. Aprepitant, 
a NK1 antagonist, licensed for the treatment of nausea and vo-
miting during highly emetic chemotherapy, was reported to have 
antipruritic effects in prurigo nodularis during short-term use. 
However, long-term itch reduction is required to clear pruriginous 
skin lesions in CPR. We treated a male patient (73 years) suffering 
for more than 20 years from recalcitrant CPR, with permanent itch 
and pruriginous nodular skin lesions on his extremities and trunk, 
with aprepitant 80 mg/day for 16 weeks. Beside emollients with 
menthol, urea, and polidocanol, antipruritic treatments including 
topical corticosteroids, tacrolimus, and capsaicin, as well as oral 
antihistamines were clinically ineffective. Over the years, he 
repeatedly received UVB, UVA1, oral and bath-PUVA therapies. 
Finally, after 2 months of saltwater plus narrowband (NB)-UVB, 
pruritus was still 4.7 on the VAS (0=no itch, 10=worst imaginable 
itch) and extensively excoriated pruriginous skin lesions were 
still present. Within 2 weeks of daily aprepitant 80mg, pruritus 
weakened from 4.7 to 3.3 (34% reduction) and was 3.0 after 6 
weeks. We then added NB-UVB three times per week and after 
further 4 weeks topical corticosteroids, once daily for 2 weeks 
and then every other day for 2 weeks. This further reduced itch 
to 2.2. Eventually, due to the high costs of aprepitant, we reduced 
its dose to 80 mg every other day and stopped it after 2 weeks 
completely. From that time point on, treatment was continued 
with NB-UVB, intermittent topical corticosteroids, and additional 
daily topical calcipotriol. Within further 8 weeks itch was reduced 
to 0.5 and only very few excoriations remained. In conclusion, 
while various previous treatments were insufficient to permanently 
reduce itch in this patient, it appears that the long-term (16 weeks) 
aprepitant treatment was capable of “breaking the itch-scratch 
cycle”, eventually paving the way for additional UV and topical 
treatments to become effective in reducing itch and pruriginous 
lesions in this patient. 
OP66
PERIPHERAL EFFECTS OF TARGETING THE 
NEUROKININ 1 RECEPTOR IN CHRONIC 
PRURIGO
Konstantin Agelopoulos, Falk Rülander, Julia Dangelmaier, To-
bias Lotts, Karin Loser, Sonja Ständer
Department of Dermatology and Center for Chronic Pruritus, University 
Hospital Münster, Münster, Germany
Blocking the neurokinin 1 receptor (NK1R) in chronic pruritus 
has recently been shown to reduce pruritus intensity. Both, central 
effects involving spinal dorsal horn neurons and peripheral effects 
involving cutaneous components are discussed as underlying 
mechanisms. In human skin NK1R may initiate several inflam-
matory reactions like mast cell activation and expression of 
pro-inflammatory cytokines by keratinocytes. Within this study 
we therefore investigated in vivo and in vitro peripheral effects 
mediated by the NK1R antagonists aprepitant and casopitant. For 
the in vivo study 13 patients suffering from the chronic prurigo sub-
type prurigo nodularis (PN) received an oral four weeks treatment 
with aprepitant (80 mg/d). Clinical and immunohistochemical 
parameter were assessed before and after treatment. Furthermore 
expression of NK1R and activation of potential downstream targets 
were measured. Studies were continued in vitro using keratino-
cytes (HaCaT, NHEKs). Cells were stimulated using the NK1R 
activating substance P (SP) with or without pre-treatment with 
aprepitant or casopitant. Again, the effect of NK1R antagonism 
on downstream molecules was assessed. Treatment with aprepi-
tant reduced significantly pruritus intensity in PN patients. This 
was not reflected by histological changes what may be due to the 
short treatment period. Immunohistochemistry revealed altered 
expression of some inflammatory marker suggesting a peripheral 
therapeutic effect. Epidermal NK1R expression was higher in PN 
patients compared to matched healthy controls (n=10); after treat-
ment with aprepitant it increased even more. We speculate that the 
upregulation may be needed to overcome at least in parts the long 
lasting blockage by aprepitant. First analyses of NK1R antagonism 
in keratinocytes in vitro revealed no effect on expression of pro-
inflammatory cytokines. Additionally we analysed downstream 
molecules which can be activated by NK1R and found Erk1/2 to 
be affected. SP induced activation/phosphorylation of Erk1/2 was 
significantly reduced by both, aprepitant and casopitant. This was 
confirmed in vivo as 7 of 9 PN patients showed reduced Erk1/2 
phosphorylation after treatment with aprepitant. In sum, altered 
receptor expression and reduced MAPK activation in vivo and in 
vitro suggests a peripheral mechanism on keratinocytes for the 
observed antipruritic effect of NK1R antagonism.
OP67
NEUROPHYSIOLOGICAL STUDIES ON CHRONIC 
PRURIGO
Manuel Pedro Pereira1, Konstantin Agelopoulos1, Esther Pogatz-
ki-Zahn2, Sonja Ständer1
1Department of Dermatology and Center for Chronic Pruritus, and 2De-
partment of Anesthesiology, Intensive Care and Pain Medicine, University 
Hospital Münster, Münster, Germany
Chronic prurigo (CPG) is a highly burdensome condition, which 
has gained interest in recent years. Recently European experts 
of the EADV Task Force Pruritus reached a consensus on the 
clinical definition and terminology of CPG. However, the un-
derlying pathophysiological mechanisms remain unclear and 
need further clarification. For peripheral itch transmission, both 
mechano-insensitive C-fibers (CMI) activated by histamine and 
mechano- and heat sensitive C-fibers (CMH) activated by cowhage 
play a central role. We compared patients with CPG (n=40) and 
healthy controls (n=40) in their response to cutaneous stimulation 
with cowhage, histamine and a negative control (NaCl) at the volar 
forearm. CPG patients, but not healthy controls, showed enhanced 
itch intensity after stimulation with cowhage in comparison to 
histamine (p<0.01). Additionally the maximal itch intensity after 
cowhage stimulation was significantly higher in CPG patients 
compared to controls (p<0.05), arguing for peripheral sensitiza-
tion of CMH-fibers. The intraepidermal nerve fiber density was 
reduced in CPG patients (n=21) compared to healthy controls 
(n=27). In spite of this finding, quantitative sensory testing 
revealed in an earlier study no differences in thermal detection 
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
1029Lecture abstracts
Acta Derm Venereol 2017
thresholds between patients (n=8) and controls (n=12; p=0.68) 
and thus no impairment of C-fiber function was observed. As 
we could demonstrate in a previous study a normalization of the 
intraepiderrnal nerve fiber density after healing of the prurigo 
lesions, we speculate that the prolonged scratching activity, and 
not an endogenous neuropathy, is responsible for the structural but 
not functional neuronal alterations observed in CPG. Peripheral 
sensitization of CMH-fibers and structural neuronal alterations due 
to prolonged scratching may contribute to the perpetuation of the 
pruritus and of the CPG. 
NEW RECEPTORS, CHANNELS AND 
PATHWAYS FOR ITCH
OP68
NEURAL RECRUITMENT AND MRGPR ACTIVITY 
ARE REQUIRED FOR THE DEVELOPMENT OF A 
MOUSE MODEL OF ATOPIC DERMATITIS
Ethan Lerner, Tuanlian Luo, Ehsan Azimi, Vemuri Reddy, Sarina 
Elmariah
Massachusetts General Hospital / Harvard Medical School, USA
Atopic dermatitis is characterized by chronic inflammation and 
severe itch. In addition to defective barrier function and immune 
dysregulation, altered neural innervation and neurogenic inflam-
mation play less well-characterized but important roles in disease 
pathogenesis. Performing serial in vivo imaging of fluorescently-
labeled peripheral sensory neurons in mice during the evolution 
of an allergic eczema, we show that cutaneous nerves function 
as precursors to the allergic process. Within hours of antigen 
exposure, neuropeptidergic fibers begin to pathfind and expand 
their arbors while vascular and immune changes follow. Neural 
activity was required for the maintenance of nascent fibers and 
development of inflammation. We identify Mrgpr signaling as an 
essential regulator of early neural responses to allergens, priming 
cellular feedback loops that drive allergic eczema and scratching. 
Our data provide critical insights regarding the temporal sequence 
of key cellular events in atopy pathogenesis and prompt a shift in 
the therapeutic paradigm for its management.
OP69
A CENTRAL FEEDBACK NEURAL CIRCUIT 
GATES ITCH-SCRATCHING CYCLE
Yan Gang Sun
Institute of Neuroscience, Chinese Academy of Sciences, China
Itch triggers scratching behavior, which in turn leads to wide-
spread itchiness. Uncontrollable itch-scratching cycles result 
in serious skin and deep tissue damage in patients with chronic 
itch. Itch signal processing is known to be under tonic inhibitory 
control at the spinal level, but the neural circuit mechanism pro-
moting the itch-scratching cycle remains elusive. The fact that 
stress enhances or induces itchiness points to a top-down positive 
feedback circuit in gating spinal itch processing. Here we report 
that a group of tachykinin 1 (Tac1)-expressing glutamatergic 
neurons in the periaqueductal gray (PAG) of the mouse facilitate 
the itch-scratching cycle, through positive-feedback dis-inhibition 
of spinal neurons expressing gastrin-releasing peptide receptor 
(GRPR), the key relay neurons for itch sensation. Activity of Tac1-
expressing neurons in the PAG was elevated during itch-induced 
scratching behavior. Suppressing the activity or ablation of these 
Tac1-expressing neurons greatly impaired itch signal processing. 
Consistently, selective activation of these Tac1-expressing neurons 
induced robust spontaneous scratching behavior by removing the 
inhibition of spinal itch processing via the rostral ventromedial 
medulla (RVM) inhibitory neurons that are known to inhibit spi-
nal interneurons. These results establish that the Tac1-expressing 
neurons in the PAG play a key role in gating itch-scratching cycles, 
through feedback regulation of itch processing in the spinal cord.
OP70
TRPV1 REGULATES PAR-2-EVOKED 
INTRACELLULAR CA2+ RELEASE AND 
INFLAMMATORY MEDIATORS PRODUCTION IN 
DIFFERENTIATED KERATINOCYTES
Olivier Gouin1, Killian L’herondelle1, Raphaele Le Garrec1, Paul 
Buscaglia2, Olivier Mignen2, Christelle Le Gall-Ianotto1, Virginie 
Buhé1, Luc Lefeuvre3, Laurent Misery1, Nicolas Lebonvallet1
1Laboratory of Neurosciences of Brest, University of Western Brittany, 
Brest, 2Canalopathies et Signalisation Calcique, Brest, 3Uriage Dermato-
logical Laboratories, Courbevoie, France
The activation of PAR-2 in keratinocytes enhances inflammation 
through a Ca2+-dependent cytokines expression and release such 
as TSLP. However, studies only used primary keratinocytes from 
the basal stratum of the epidermis to analyze the role of PAR-2 in 
inflammatory process and itch. We investigated the involvement 
of PAR-2 in the intracellular calcium signaling pathways in dif-
ferentiated keratinocytes and consequently inflammatory genes 
modulation. Calcium imaging recordings in Ca2+-free medium 
showed that PAR-2 agonist peptide (SLIGKV) evoked calcium 
release from endoplasmic stores, which was totally inhibited by 
the specific PLC antagonist (U73122). The InsP3R (xestospongin 
C) and TRPV1 antagonist (AMG9810) impaired PAR-2-evoked 
Ca2+ release partially but totally when they were associated. Using 
RT-qPCR to study the inflammatory cytokines RNA expression, we 
demonstrated that SLIGKV induced a 13-folds up-regulation of the 
TSLP expression and by 2-folds expression of IL1-β, TNF-α and 
CXCL2. PAR-2-mediated cytokines up-regulation in the keratino-
cytes was abolished with PAR-2 antagonist (GB83). In addition, 
the blockage of TRPV1 with specific antagonists (AMG9810, 
SB366791 and capsazepin) or with siRNA knockdown of TRPV1 
impaired PAR-2-mediated gene expression. Our findings demon-
strated for the first time that PAR-2 promotes skin inflammation 
in the differentiated keratinocytes through PLC-dependent Ca2+ 
release by both IP3 and TRPV1 channels release and consequently 
inflammatory genes expression.
OP71
SPINAL RELEASE OF GASTRIN RELEASING 
PEPTIDE (GRP) IS REQUIRED FOR SUPRA-
THRESHOLD SYNAPTIC ACTIVATION OF GRP 
RECEPTOR (GRPR)-POSITIVE NEURONS
Martina Pagani
Institute of Pharmacology and Toxicology, University of Zurich, Switzer-
land
Gastrin releasing peptide (GRP) and its cognate receptor (GRPR) 
have been identified as important components in spinal cord 
pruriceptive-processing. However, the functional aspects of 
spinal itch-processing circuits are not well understood. Here, we 
combined electrophysiological and optogenetic approaches to 
functionally characterize GRP- and GRPR-positive neurons and 
to study their synaptic connectivity as well as modulation by GRP. 
We performed whole-cell patch-clamp recordings from GRP and 
GRPR neurons in acute spinal cord slices to characterize their 
intrinsic biophysical properties and firing patterns. We found that 
GRP neurons constitute a rather homogenous population with 
92% of cells showing initial bursting firing. GRPR neurons were 
more heterogeneous comprising delayed (64%) and non-delayed 
(36%) firing subpopulations. We also found that delayed-firing 
GRPR neurons had significantly hyperpolarized resting mem-
brane potentials (RMP), lower input resistances (Ri) and higher 
rheobase compared to GRP neurons. These characteristics are 
consistent with delayed-firing GRPR cells being glutamatergic 
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neurons involved in integrating and transmitting the spinal itch 
information. We then characterized the synaptic connectivity bet-
ween GRP- and GRPR-positive neurons in slices prepared from 
GRP-ChR2 GRPR::eGFP mice and found that GRP neurons were 
synaptically connected to GRPR neurons. Under baseline condi-
tions, light stimulation of ChR2-expressing GRP cells induced 
subthreshold responses in GRPR neurons. Application of 300 
nM GRP caused a slow depolarization of delayed-firing GRPR 
neurons, which often resulted in ongoing action potential firing 
after several minutes. Moreover, in the presence of exogenous 
GRP, the same light stimulation paradigm triggered action potential 
firing in GRPR delayed neurons. Our results represent a detailed 
physiological characterization of GRP- and GRPR-cells involved 
in spinal pruriceptive processing and suggest that GRP boosts the 
functional output from spinal itch-processing circuits.
OP72
EFFECTS OF BURN SIZE ON POST-BURN ITCH 
AND EPIDERMAL NERVE INNERVATION IN MICE
Kent Sakai, Kristen Sanders, Gil Yosipovitch, Tasuku Akiyama
University of Miami, USA
The majority of burn patients suffer from chronic itch, which is often 
resistant to antihistamine treatment. This post-burn itch involves 
sensitization of itch-signaling pathways, leading to ongoing itch 
and alloknesis (touch-evoked itch), but the underlying mecha-
nisms behind post-burn itch are largely unknown. To this end, we 
developed a model of post-burn itch by inducing scald burn injury 
in adult C57BL/6 mice (exposing an area of the shaved back skin 
to boiling water). Because patients with larger burn surface areas 
exhibit more severe itch, we presently investigated if different sizes 
of burn injury (7 mm or 10 mm diameter) affect the time course 
of post-burn itch in mice. We further tested whether a histamine 
H1R antagonist inhibits post-burn itch in mice and whether the 
density of intraepidermal fibers is altered in the scald burn model. 
To assess spontaneous scratching, we videotaped mice on Days 0, 
1, 3, 5, 7, 10, 14, 21, and 28 after the scald burn. The 7 mm scald 
burn caused a transient increase in spontaneous scratch bouts that 
declined within 14 days. The 10 mm scald burn caused two phases 
of post-burn itch: counts of spontaneous scratch bouts increased 
transiently on Days 1, 3, and 5, returned to the basal level by Day 10, 
and increased again on Days 14, 21, and 28. To test for alloknesis, 
a weak von Frey filament (VF; 0.7 mN), which does not elicit any 
scratch response in naïve C57BL/6 mice, was repeatedly applied to 
post-burn skin on Days 0, 1, 3, 5, 7, 14, 21, and 28. The presence or 
absence of evoked hindlimb scratch bouts was noted. VF-evoked 
scratching increased significantly on Days 1 and 3 in the 7 mm 
model and Days 21 and 28 in the 10 mm model. The histamine H1 
receptor antagonist chlorpheniramine was tested on Day 22 but did 
not inhibit spontaneous scratching or alloknesis, suggesting that non-
histaminergic itch pathways are involved in late-phase post-burn 
itch. Finally, post-burn skin was dissected and immunostained with 
Protein Gene Product 9.5 antibody to label nerve fibers. A reduction 
of epidermal nerve fiber density in both the burn site and adjacent 
skin was observed in the 10 mm scald burn model on Day 28. Re-
duced epidermal nerve fiber density may contribute to post-burn itch 
through disinhibition of itch (reduction of pain signals). This new 
animal model appears to be useful for investigations of post-burn 
itch and sensitization of itch-signaling pathways.
OP73
POSSIBLE ROLE OF SATELLITE GLIAL CELL 
DERIVED LIPOCALIN-2 IN THE PATHOGENESIS 
OF ATOPIC DERMATITIS
Nobuaki Takahashi1, Mitsutoshi Tominaga1, Ryohei Kosaka1,2, Hi-
ronori Matsuda1, Yasushi Suga3, Kenji Takamori1,3
1Institute for Environmental and Gender Specific Medicine, Juntendo Uni-
versity Graduate School of Medicine, Chiba, 2Department of Biological 
Science and Technology, Faculty of Industrial Science and Technology, 
Tokyo University of Science, Kat, 3Department of Dermatology, Juntendo 
University Urayasu Hospital, Chiba, Japan
Atopic dermatitis (AD) is a chronic inflammatory skin disease 
with intractable itch. Dorsal root ganglion (DRG) plays an 
important role in signal transduction of itch. It was recently re-
ported that interaction between DRG neurons and satellite glial 
cells (SGC) is involved in pain modulation. However, the role of 
SGC in induction of dermatitis and itch remains unclear. In this 
study, we examined whether SGC derived lipocalin-2 (LCN2) is 
involved in the induction of dermatitis and itch-related behavior 
in AD model NC/Nga mouse. AD-like symptoms were induced 
by application of Dermatophagoides farinae body (Dfb) twice a 
week for 3 weeks. LCN2 gene and protein expression in DRG 
of AD-NC/Nga mice was higher than that of control NC/Nga 
mice. Immunohistochemical analysis revealed that LCN2 was 
co-localized with GLAST, a marker of SGC, in DRG. LCN2-
immunoreactive SGC was significantly increased in the DRG of 
AD-NC/Nga mice. In addition, expression level of LCN2 mRNA 
in the DRG was significantly increased faster than in the spinal 
cord during the process of induction of AD-like dermatitis in NC/
Nga mice. Intrathecally administrated anti-LCN2 antibody (1 
μg/5 μl) twice a week for 3 weeks at the same time as induction 
of AD-like dermatitis in NC/Nga mice reduced dermatitis score 
without inhibiting scratching behavior. This is supported by find-
ing that intrathecal administration of recombinant mouse LCN2 
(1 μg/5 μl) did not induce scratching behavior in NC/Nga mice. 
These results suggest that SGC derived lipocalin-2 is involved in 
the pathogenesis of dermatitis in AD-NC/Nga mice. 
EPIDEMIOLOGY OF ITCH AND QUALITY 
OF LIFE
OP74
EPIDEMIOLOGICAL STUDY ON THE PREVALEN-
CE OF ITCH IN JAPANESE DEMENTIA PATIENTS
Toshiya Ebata1, Lefkos Middleton2, Ryoko Fukuda3, Yoshimasa 
Takase4, Nao Taniguchi5, Kimitoshi Takemura6, Didier LeClercq6, 
Joelle Vaglio7, Michel Poncet7, Akihiko Ikoma6
1Chitofuna Dermatology Clinic, Japan 2Imperial College London, 3Bene-
sse Style Care Co. Ltd., 4Takase Clinic, 5Saint-Care Holding Corporation, 
6Nestle Skin Health SHIELD, 7Galderma R&D
Itch is common in the elderly. Previous epidemiological studies 
show the prevalence of itch in a range from 7 to 37.5% with greater 
than 20% in most cases. However, itch has not been studied in 
dementia patients, since the broadly-used self-evaluation scales are 
not applicable in this population. We conducted a study focusing 
on itch in 148 dementia patients who are receiving medical care 
in nursing homes or at home. For the self-evaluation of itch we 
asked the subjects whether they had itch or not at present and asked 
them to rate their itch on numerical rating scale (NRS). For the 
objective evaluation of itch by others, their caregivers evaluated 
the presence and extent of scratching behavior and we evaluated 
the extent of scratch marks by calculating the body surface area 
where scratch marks exist. We also evaluated the severity of skin 
dryness and sought its correlation with the extent of scratching 
and frequency of skin care using moisturizer. The prevalence of 
itch in the surveyed dementia patients was 37.8% according to 
self-evaluation of itch, whereas nearly 50% according to scratch 
evaluation by others. The higher the dementia severity was, the 
larger percentage of patients could not answer whether they had 
itch or not, or rate the severity of itch. Over 30% of those who de-
nied having itch scratched according to the observation by others. 
Over 70% had dry skin, the severity of which positively correlated 
to the level of scratching. In conclusions, subjective evaluation 
is not sufficient and objective evaluation should be applied to 
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understand the status of itch in dementia patients. Skin dryness 
is an important factor associated with itch in dementia patients. 
OP75
PITFALLS IN PEDIATRIC SELF-REPORTED 
PRURITUS SEVERITY AND QUALITY OF LIFE 
IMPACT
Shelby Smith1, Grace Lee1, Sandy François1, Alix Pijeaux1, Kuang-
Ho Chen1, James Roberts2, Suephy Chen1
1Emory University, 2Georgia Institute of Technology, USA
Introduction: The ability of children to convey a self-report of itch 
severity can be challenging as their cognitive levels may drastically 
vary within a small age range. In response to these challenges, we 
have created the ItchyQuant and pediatric versions of the ItchyQol, 
illustrated scales to measure itch severity and quality of life impact 
of pruritus in children, respectively. A mixed method approach was 
undertaken to assess the feasibility of these scales in younger child-
ren. Methods: Children with itch > 6 weeks, between ages 4–7 years, 
were asked to rate their itch severity on the ItchyQuant scale and es-
timate the quality-of-life impact on the cartoon-annotated ItchyQoL. 
Parents also estimated their child’s itch severity and were asked if 
they agreed with the child’s response. Standardized questions were 
asked by the interviewer to assess ability to comprehend the duration 
of recall (last week). Results: Ninety-seven children with chronic 
pruritus were recruited. A combination of interviewer observations 
and data collection showed three key differences between 4–5-year-
olds and 6–7-year-olds. First, 4–5-year-olds were 40% more likely 
(30% vs. 75% and 36% vs. 75%) to answer questions about the days 
of the week incorrectly compared to the 6–7-year-olds, demonstra-
ting a lack of understanding of time. Second, interviewers noted that 
younger children were 16% (18% vs. 2%) more likely to struggle 
with comprehending questions on the ItchyQoL. 4–5-year-olds 
were also 9% more likely (12% vs. 3%) to be deemed hyperactive 
or distracted during the process. Finally, parents agreed with their 
child’s itch severity rating almost 20% less (64% vs. 45%) in the 
younger group. Conclusion: Our initial investigation has demon-
strated that the current version of the cartoon-annotated ItchyQoL 
is likely too complex for 4–5-year-old patients, while appropriate 
for the 6–7-year-olds. As a result, we have implemented changes to 
account for these cognitive differences by reducing the number of 
items on the ItchyQoL, while also eliminating questions pertaining 
to the prior week. We will begin a pilot study with 4–5-year-old 
patients to test the validity of this new tool. 
OP76
QUALITY OF LIFE IN PATIENTS WITH CHRONIC 
PRURITUS: FROM THE CONCEPTUAL MODEL 
TO ITEMS GENERATION
Jennifer Theunis1, Clementine Nordon2, Ylana Chalem1, Massimi-
liano Orri3, Jesus Cuervo2, Gilles Berdeaux1, Marie Auges1, Vale-
rie Mengeaud1, Laurent Misery4
1Pierre Fabre, 2LASER Analytica, 3CESP, INSERM 1018, 4CHU Brest, 
France
Objectives: To develop a patient-reported questionnaire, measuring 
the severity of Chronic Pruritus (CP) and its impact on health-
related quality of life (HRQoL). Methods: A three-step approach 
was followed: (1) a Conceptual Framework (CF) was developed 
using a systematic literature review and experts’ interviews, to 
render the relevant domains for severity and HRQoL; (2) the CF 
was updated following Focus Groups with 19 patients; (3) a pool 
of items was generated for each domain of interest, and their com-
prehensibility was tested during cognitive debriefing with patients 
(semi-structured interviews; n=21). Results: 155 articles were 
reviewed to develop the preliminary CF addressing 16 domains 
of HRQoL and 7 of severity, and which was clinically validated 
by 2 medical experts. Patients’ verbatim showed some relevant 
differences on severity, between clinical and patients’ perspectives. 
Moreover, a new domain of interest was revealed: the time spent 
anticipating and thinking about CP. A preliminary version of the 
questionnaire was drafted and refined after cognitive debriefing 
sessions. The final version includes 50 items. Discussion: A first 
version of this patient-reported questionnaire was developed 
following international guidelines and namely, using patients’ 
interviews. This questionnaire will measure the severity of CP and 
its impact on HRQoL in a comprehensive manner. 
OP77
CHRONIC ITCH (CI) IN HEMODIALYSIS 
PATIENTS: A FOLLOW-UP STUDY OF GEHIS 
(GERMAN EPIDEMIOLOGICAL HEMODIALYSIS-
ITCH STUDY) ON INCIDENCE AND MORTALITY 
OF PATIENTS WITH CI
Katarzyna Grochulska1, Robert Ofenloch1, Thomas Mettang2, 
Elke Weisshaar1
1Dept. of Clinical Social Medicine, Environmental and Occupational Der-
matology, University Hospital Heidelberg, 2Dept. of Nephrology, DKD He-
lios Klinik, Wiesbaden, Germany
GEHIS (German Epidemiological Hemodialysis Itch Study) is a 
representative cross-sectional cohort conducted in 2013. It contains 
a total of 860 hemodialysis (HD) patients in 25 dialysis units in 
Germany. We showed that 25.1% (n=217) of HD patients suffered 
from current chronic itch (CI). In 2017, four years later, all 860 HD 
patients are currently contacted again to investigate the number of 
new itch cases (incidence) in this cohort. We aim to provide data on 
the incidence and prevalence of CI in this follow-up study, and to 
identify its determinants based on cross-sectional and longitudinal 
analyses. Previous research supports the observation that CI is a poor 
prognostic marker for patients on HD, however, this is now investi-
gated in a representative cohort of HD patients for the first time. 
Patients’ characteristics and CI were assessed with the same patient 
questionnaire as in 2013 investigating e.g. current and previous CI 
(during the last 3 years), severity of CI (visual analogue scale, VAS). 
As this is an ongoing study, results are preliminary and refer to 9 
dialysis units containing 212 HD patients being addressed so far. Of 
those, 46.7% (n=99) had died in the meantime and 11.3% (n=24) 
could not be contacted (e.g. because they had moved to another place 
or because they were not on dialysis treatment anymore due to trans-
plantation). 89 HD patients were investigated, 60.7% of those were 
male and the mean age was 69.0 years (SD 12.4). In 11.2% (n=10) 
CI had developed in the past year, while 13.5% (n=12) reported not 
to suffer from CI anymore, resulting in a one-year prevalence of 
25.8%. The mortality rate was 45.7% in the group suffering from CI 
in 2013 compared to 54.9% in the group without CI, no differences 
between sexes were found. Interestingly, this effect was pronounced 
in patients aged younger 70 years (32.7% mortality in the non-CI 
group vs. 19.0% in the CI group) while the mortality in patients aged 
70 years or older was equal between groups. First results refer to 
an increased incidence of CI in younger HD patients. Preliminary 
analyses hint to a difference in mortality between HD patients with 
and without CI in younger age groups but further analyses are needed 
to see if this can be confirmed in the whole cohort.
OP78
PREVALENCE, CHARACTERISTICS AND BURDEN 
OF PRURITUS IN CHRONIC DERMATOSES
Tomasz Hawro, Katarzyna Przybylowicz, André Ellrich, Max 
Spindler, Karsten Weller, Sabine Altrichter, Ulrich Reidel, Marcus 
Maurer, Martin Metz
Dept. of Dermatology and Allergy, Allergie-Centrum-Charité Charité - 
Universitätsmedizin Berlin, Germany
Many dermatological conditions are associated with pruritus and 
in some of them itch is a hallmark symptom. Crucial data on its 
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prevalence, characteristics including distribution patterns and 
burden are still missing for many dermatoses. Here, we have ana-
lyzed prevalence, characteristics of chronic pruritus, including its 
distribution patterns (body heatmaps), burden of chronic pruritus 
on quality life and the presence of suicidal thoughts in different 
dermatoses. Unselected patients with active dermatoses, that can 
be, reportedly, associated with pruritus and control patients with 
angioedema filled out the study questionnaire including questions 
on pruritus presence, localization, characteristics and the quality 
of life, quality of sleep, sexuality, and suicidal ideations. 880 in- 
and out-patients of dermatology university department with 18 
different dermatological diagnoses returned completed questionn-
aires. Pruritus in the disease course/current pruritus were reported 
by 100%/77% patients with chronic spontaneous urticaria (143), 
88%/73% psoriasis (138), 100%/91% atopic dermatitis (AD, 128), 
100%/78% chronic inducible urticaria (76), 100%/96% prurigo 
(75), 65%/47% cutaneous T cell lymphoma (68), 78%/56% masto-
cytosis (54), 100%/86% pruritus on unaffected skin (30), 45%/28% 
parapsoriasis en plaque (29), 39%/31% cutaneous B cell lymphoma 
(26), 100%/67% bullous pemphigoid (15), 82%/64% lichen planus 
patients (11). The most intense maximal pruritus was reported by 
patients with pruritus on unaffected skin (mean ± SD of maximum 
visual analogue scale = 8 ± 1.4), followed by AD (7.5 ± 2.2). Sui-
cidal thoughts due to pruritus were reported by many patients with 
itchy skin diseases, ranging from 0% in parapsoriasis en plaque 
to 19% in patients with pruritus on unaffected skin and to 22% in 
patients with lichen planus. Taken together, we have visualized, 
for the first time, the localization of pruritus in patients from large 
variety of dermatological diseases. Together with itch intensity, the 
results show a characteristic pattern of pruritus for many diseases. 
This can lead to a better understanding of the pathophysiology of 
itch in these diseases, help in the development of better treatment 
options and can lead to a better management of our patients. Patients 
presenting at a dermatological department should be asked for the 
presence of pruritus, and in individuals reporting about chronic 
pruritus it should be inquired whether suicidal thoughts exist.
NEW IMAGING TECHNIQUES AND 
OTHER ASPECTS OF ITCH
OP79
NEW METHODS IN BRAIN IMAGING 
TECHNIQUES
Clemens Forster
Department of Physiology and Pathophysiology, and Department of Neu-
roradiology, FAU, Erlangen Nuremberg, Erlangen, Germany
Since more than 20 years functional magnetic resonance ima-
ging (fMRI) has been used to image regional cerebral blood 
flow (rCBF). Stimulus related changes of the rCBF have been 
regarded as markers of regions that are involved in the cerebral 
processing of the respective perception. This technique based on 
the BOLD (blood oxygenation level depended) signal identified 
brain regions which generate the sensation of itch. They were 
compare with regions that have been described to be involved 
in the suppression of itch or are activated by pain. It turned out 
that there is a strong overlap of the affected brain areas during 
these experiences, although it is obvious that they clearly evoke 
qualitatively different sensations. It was discussed that this 
overlap is due to the neural basis of itch that for many years has 
been considered as sub-modality of pain and is elicited by weak 
activations of the nociceptors. From this, it was not surprising that 
similar cerebral regions were detected. Beside this intensity model 
population coding was proposed where itch uses its own pathway 
to the brain. An itchy stimulus activates “pruriceptive nociceptors” 
which then transmit their activity to a common network for pain 
and itch. The pivotal question remained: How does the brain code 
the different qualities if not by a pattern of activated brain areas? 
The conclusion was that different temporal activity patterns within 
a functional brain network code the perception quality. Indeed, 
fMRI connectivity analyses showed that during resting state (no 
stimulus, no mental task) a “default mode network” could be de-
tected which refers to a pattern of co-activation across the brain 
regions included in this network. The related connectivity was 
measured by correlation analyses of the BOLD signals. During 
the processing of a stimulus the pattern of co-activation changed. 
New approaches for analyzing the correlations of BOLD signals 
pursue stimulus related changes within such a network. Further, 
they seem to have the potential to detect changes within cerebral 
networks due to a chronic painful or pruritic input. In the presen-
tation a short overview will be given about this technique, how it 
can be used to identify itch related brain network and its changes 
due to chronic conditions. Preliminary findings from patients 
suffering from chronic pruritus will be compared with those from 
healthy subjects. The limitations of this method will be discussed.
OP80
THREE DIMENSIONAL ANALYSIS OF 
CUTANEOUS NERVOUS SYSTEM IN PRURITIC 
ATOPIC DERMATITIS AND PSORIASIS SKIN
Hong Liang Tey
National Skin Centre, Singapore
Intra-epidermal nerve fibre (IENF) count in skin biopsies have 
been used as a reflection of the innervation density of itch-trans-
mitting C nerve fibres in the skin. It is of interest to determine the 
changes in IENF densities in pruritic conditions such as atopic der-
matitis and psoriasis, but previous studies have reported conflicting 
results. The conventional method of determining IENF count is 
by assessing the number of PGP9.5-positive nerve fibres crossing 
the basement membrane per unit length in 50 µm-thick histologi-
cal sections. However, such an approach is 2-dimensional and is 
limited by the thickness of the section examined. We hereby adopt 
a 3-dimensional approach to such an analysis. 12 atopic dermatitis 
and 10 psoriasis patients with an average itch score of >3/10 over 
the prior 1 week were recruited. Skin biopsies from lesional and 
non-lesional areas were obtained, together with biopsies at cor-
responding body sites in 10 healthy volunteers. Immunostaining of 
PGP9.5-positive nerves in the biopsy, followed by optical clearing 
and 3D imaging of tissue sections up to 450 µm was performed. 
The epidermis was then segmented from the 3D image, followed 
by filament tracing of IENF. Analysis of neural density and charac-
teristics of the neural network, such as filament length, number of 
dendrite branches and dendrite straightness, were then performed. 
Preliminary analyses suggest that there were significant differences 
in the innervation densities and neural characteristics in the itchy 
atopic dermatitis and psoriasis lesions compared to non-lesional 
skin and skin from healthy volunteers. This novel method enables 
us to study the cutaneous nervous system in a comprehensive 3D 
manner and serves as a platform in future studies to better identify 
itch receptors co-localising with nerve fibres.
OP81
FUNCTIONAL CONNECTIVITY REVEALS 
ALTERED ACTIVATION OF BRAIN AREAS IN 
CHRONIC CHOLESTATIC PRURITUS
Andreas Kremer1, Theresa Buchwald1,2, Marcel Vetter1, Arnd Dör-
fler3, Clemens Forster2
1Department of Medicine 1, 2Institute for Physiology and Pathophysio-
logy, and 3Deparment of Neuroradiology, Friedrich-Alexander-University 
Erlangen-Nürnberg, Erlangen, Germany
Introduction: Pruritus is a frequent symptom of hepatobiliary 
disorders particularly those with cholestatic features. Although 
various substances including bile salts, endogenous opioids, and 
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lysophosphatidic acid have been controversially discussed as 
potential peripheral pruritogens, the central mechanism involved 
in itch sensation in cholestatic pruritus remains elusive. Methods: 
23 patients with primary biliary cholangitis or primary sclerosing 
cholangitis were investigated in this study. These patients were 
divided into two groups, those patients suffering from spontaneous 
pruritus (SP, n=9) and those without pruritus (WP, n=14). Baseline 
itch intensity was quantified using a questionnaire and a visual 
analogue scale. Functional magnetic resonance imaging (fMRI) 
scans were using a classical connectivity fMRI-design with EPI 
sequences to BOLD signal changes. The first fMRI sequence was 
free from stimulation to detect the default mode (DM) network. 
During the second and third fMRI sequence mild heat pain and 
itch stimuli (histamine iontophoresis) were applied. After each 
run sensory qualities were assessed by questionnaire. Individual 
mean BOLD time courses were extracted from the seed regions left 
posterior insula cortex (lpIC) for exploring an “input” network and 
the PAG for exploring the “output” network. Pearson’s correlation 
coefficients were calculated between the seed regions and other 
regions in a whole brain study. In a 2nd level analysis contrasts 
were calculated between the two patient groups. Results: During 
the DM situation higher functional connectivity (FC) was found 
within the SP group in the “input” network of the lpIC to anterior 
parts of the insular cortex of both hemispheres and to the secondary 
somatosensory cortex S2, while FC to frontal areas was weaker 
in the SP group. Also the output network was enhanced in SP (FC 
of the PAG to thalamus, caudate body and limbic system). During 
histamine FC in the input networks were enhanced in both groups, 
however, FC values were smaller in SP. FC of the output network 
increased more strongly as compared to DM in SP within limbic 
regions while in WP only FC to PAG modulating areas (ACC, IC, 
BA10) were enhanced. Conclusion: The DM network seemed to 
be violated in SP probably due to the continuous pruritic input. 
Accordingly changes within the networks due to an additional 
pruritic stimulus are less pronounced in SP as compared with 
subjects who are not suffering from spontaneous itch. 
OP82
ITCH TRACKER: AN APPLICATION SOFTWARE 
TURNING WEARABLE SMART DEVICES INTO A 
TOOL TO MEASURE NOCTURNAL SCRATCHING
Akihiko Ikoma1, Kimitoshi Takemura1, Didier LeClercq1, Toshiya 
Ebata2
1Nestle Skin Health SHIELD, 2Chitofuna Dermatology Clinic, Japan
Background/objective: Itch is difficult to objectively evaluate. 
Previous studies of actigraphy demonstrated potentials of acce-
lerometers in watch-type devices to help objective evaluation of 
itch severity through measurement of scratching. We have deve-
loped an application software (app), named Itch Tracker, that can 
be installed to broadly-used smartwatches and used to measure 
scratching during night. Clinical studies were conducted to validate 
the app’s reliability. Methods: Two proof-of-concept studies using 
the smartwatch in which the software is installed were carried out. 
In the first study, a total of five patients with atopic dermatitis 
who had moderate or severe itch were hospitalized for one night 
for video-monitoring and smartwatch-recording of scratching 
during night. With the records from the video and smartwatch 
compared, the sensitivity and positive predictive value (PPV) of 
the software were studied. In the second study, twenty patients 
with atopic dermatitis and ten healthy volunteers participated to 
record nocturnal scratching at home for seven consecutive days. 
The correlation of scratching time with the skin severity and self-
evaluated itch severity was studied. Results: In the first study, the 
average sensitivity and PPV were 84.6% and 90.2%, respectively. 
There was a statistically-significant positive correlation between 
smartwatch-detected and video-captured scratching time per hour 
(r=0.90, p<0.001). There was no significant difference in scrat-
ching duration between the dominant and non-dominant arm. In 
the second study, the severity of the lesions (EASI) well correlated 
with smartwatch-detected scratching (r=0.71, p<0.001), but not 
with the self-evaluated itch severity or sleep disturbance. There 
was no statistically-significant correlation between smartwatch-
detected scratching time and self-evaluated itch severity or sleep 
disturbance. Conclusion: The app has been proven to have a high 
validity and reliability in measuring scratching. 
OP83
CHANGES IN TACTILE SENSITIVITY AFTER 
VIEWING ITCH-RELATED IMAGES
Michellie Young, Melanie Burke, Donna Lloyd
University of Leeds, UK
Visually Evoked Itch (VEI) is the phenomenon whereby itch-
related images can create sensations of itch in the absence of any 
physical stimulation. It has been suggested that changes in skin 
sensitivity are involved in the creation of these sensations; this 
study used the Somatic Signal Detection Task (SSDT; Lloyd et 
al., 2008) to investigate whether viewing itch or non-itch images 
affected participants’ tactile sensitivity. In the SSDT, participants 
detect the presence of a near-threshold vibration presented on the 
left index finger on 50% of trials. A LED flashes on 50% of trials, 
which increases the likelihood of both the correct detection (‘hits’) 
and misperception (‘false alarms’) of the vibration. 40 right-handed 
participants (with no pruritic skin conditions) viewed a block of 
itch and a block of non-itch images (counterbalanced between par-
ticipants) interspersed with the SSDT. Their sensitivity threshold 
was measured before each block which was used to set the stimulus 
intensity for the SSDT. Participants also rated the itchiness of the 
images and their scratching behaviour was observed. We found 
that performance on the SSDT significantly differed between the 
itch and non-itch conditions. The hit rate was higher for the itch 
block, both with and without the light. Participants showed greater 
sensitivity during the itch block than the non-itch block, which 
suggests their tactile perception was enhanced following exposure 
to itch images. There was little difference in false alarm rates, 
which indicates that no change in their response criterion occurred; 
viewing either set of images did not create a greater propensity to 
report feeling a vibration overall. Participants’ itchiness ratings and 
scratch frequency were both higher during the itch block, which is 
consistent with the presence of VEI. This indicates that the creation 
of VEI corresponds with a change in tactile sensitivity. Viewing 
itch images appears to prime participants to perform better at de-
tecting a tactile stimulus, without creating a bias towards reporting 
its presence more frequently overall. This may be because these 
images prompt participants to pay greater attention to their skin 
and what is happening to it. This lends weight to an explanation 
of VEI based on altered sensory thresholds for detecting itch. 
OP84
KERATINOCYTE DERIVED CORTISOL REGU-
LATES ITCH-EVOKED ALLERGIC CUTANEOUS 
INFLAMMATION
Ichiro Katayama, Akira Matsumoto, Saori Ochi, Mika Terao, Hi-
royuki Murota
Department of Dermatology, Osaka University Graduate School of Medi-
cine, Japan
Topical glucocorticoid (GC) is commonly used for the manage-
ment of allergic skin diseases such as atopic dermatitis (AD). 
However, serious topical steroid withdrawal syndrome with ac-
celerated itch sensation is occasionally observed shortly after the 
cessation of chronic use of GC, even in now days. We previously 
reported that long-term epicutaneous application of GC and its 
withdrawal induced severe scratching behavior after challenge 
with DNFB in sensitized mice in contrast to control mice. In this 
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model, the expression of preprotachykinin-A (PPT-A) mRNA, a 
precursor of substance P (SP), and inducible nitric oxide synthase 
(iNOS) mRNA in mice was observed both of those molecules are 
known to induce itch. In order to evaluate the factors responsible 
for the augmented scratching behavior, we injected various cy-
tokines (IL-1α, IL-2, IL-3 and TNF-α) subcutaneously into the 
ear of DNFB contact-sensitized mice before DNFB challenge. 
Among the cytokines, only IL-3 and TNF-α significantly increased 
scratching behavior in DNFB contact dermatitis mice. Further-
more, PPT-A mRNA was only expressed in mice pre-injected with 
IL-3 before challenge, but not in those pre-injected with other 
cytokines. Our recent studies suggest that oxidative stresses, such 
as UV-irradiation or exposure to haptens or chemicals induce ac-
tive cortisol via conversion from inactive cortisone by activation 
of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) in the 
skin. Cortisol derived from keratinocytes, which are exposed to 
environmental stimuli, is speculated to minimize damage of the 
skin in a homeostatic fashion. Decreased expression of 11βHSD1 
in keratinocytes has been found in AD and leads to the impair-
ment of the innate host defense response. (Terao M et al. Am J 
Pathol. 2016 ;186(6):1499-510). More recently, we presented that 
increased scratching behavior to chloroquine (CQ) , a ligand to 
Mas related G protein-coupled receptor A3(MrgprA3) is observed 
in K5 HSD11b1 KO mice(cKO), compared with WT (Matsumoto 
A, Murota H et al.). Long term application of topical GC and its 
abrupt withdrawal might modify 11βHSD1 expression in the skin 
and accelerate itch associated skin inflammation. Taken together, 
stress might disrupt homeostasis of the skin not only by impairing 
barrier function of horny layer but also by affecting local innate 
immune response in AD.
FUTURE PERSPECTIVES
OP85
FUTURE PERSPECTIVES IN THE TREATMENT OF 
ITCH
Sonja Ständer
Center for Chronic Pruritus, University Hospital Münster, Germany
The understanding of the mechanisms behind chronic pruritus 
(CP) has increased in the past several years; accordingly CP is 
increasingly becoming considered an indication in clinical tri-
als. According to the online portal clinicaltrials.gov, more than 
280 active study centers are currently recruiting for this indica-
tion, most of which are located in the USA (n=95) and Europe 
(n=77) and are evaluating new substances for various types of 
CP such as uremic pruritus, atopic dermatitis, psoriasis, chronic 
prurigo and epidermolysis bullosa. Two therapeutic concepts can 
be distinguished by analyzing the utilized substances. On one 
hand, new substances are examined for the influence of specific, 
mainly inflammatory-based disease mechanisms (e.g. blocking 
of cytokines) in the acute phase of diseases, during which any 
changes to the pruritus as a symptom of a disease and primary 
endpoint are recorded. Atopic dermatitis and its therapies with 
antibodies against interleukin (IL)-31 or IL-4/IL-13 receptors 
are a representative example for this. On the other hand, central 
mechanisms for neuronal transmission, induction and perception 
of pruritus are addressed in the trials and CP of a systemic cause 
is selected as the primary endpoint. CP in chronic kidney disease 
has thus won recognition as a representative indication. Current 
trial results have shown promising results for mu antagonists/
kappa agonists, neurokinin-1 receptor antagonists, nerve growth 
factor (NGF) antagonists, phosphodiesterase E4 inhibitors and 
histamine 4 receptor antagonists.
OP86
FUTURE PERSPECTIVES IN BASIC RESEARCH 
OF ITCH: MRGPR RECEPTORS AND THE 
BIOLOGY OF ITCH
Xinzhong Dong
Johns Hopkins University School of Medicine, USA 
Primary sensory neurons in dorsal root ganglia (DRG) play an es-
sential role in generating itch by detecting painful and itchy stimuli 
through their peripheral axons in the skin and sending signals to 
the spinal cord via their central axons. We identified a large family 
of G protein-coupled receptors in mice called Mrgprs. Many of 
these receptors are exclusively expressed in distinct subsets of 
DRG neurons. We found that several Mrgprs function as novel 
receptors by directly sensing variety of itchy substances including 
peptides, drugs, amino acids, and proteases. Importantly, the mouse 
works have been confirmed by human psychophysical studies. 
We have genetically labeled and manipulated Mrgpr-expressing 
neurons in DRG and demonstrated for the first time that there is a 
labeled line in DRG for itch coding. On the other hand, itch coding 
in the spinal cord is likely not mediated by labeled line. Besides 
DRG neurons, we are also interested in how mast cells, a type of 
innate immune cells found in many tissues, are involved in itch. 
In addition, we have developed imaging techniques which allow 
us to monitor DRG neuronal activities in vivo and unveil novel 
itch mechanisms.
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PP1
MYELOID GTP-CYCLOHYDROLASE CONTROLS 
ITCH
Caroline Fischer, Katja Zschiebsch, Annett Häussler, Katrin Wat-
schinger, Irmgard Tegeder
Institute for Clinical Pharmacology, Goethe University, Frankfurt, Germany
GTP cyclohydrolase (Gch1) governs the production of the en-
zyme cofactor, tetrahydrobiopterin (BH4), which is essential for 
biogenic amine synthesis, bioactive lipid metabolism and redox 
coupling of nitric oxide synthases (NOS). Inhibition of Gch1 or 
its knockout in nociceptive neurons reduces nociception in various 
models. While these previous studies addressed neuronal Gch1, 
we asked here if Gch1 of myeloid immune cells contributed to 
pain and itch. Hence, we studied behaviour and myeloid cell 
functions in lysozyme M Cre-mediated myeloid specific Gch1 
knockout (LysM-Gch1-/-) and overexpressing mice (LysM-Gch1-
HA). Knockout or overexpression had no effect on nociceptive 
behaviour in various models including formalin, paw inflammation 
and sciatic nerve injury, but LysM driven Gch1 knockout reduced, 
and its overexpression increased the itching response in histamine 
and non-histamine evoked itch models. The anti- and pro-itching 
effects were mediated by inhibition, respective increase, of hista-
mine and serotonin release from mast cells, contributed by respec-
tive changes of nitric oxide, but did not involve hydrogen peroxide 
production. Diaminohydroxypyrimidine (DAHP)-mediated Gch1 
inhibition provided even stronger itch suppression, mediated by 
additionally augmenting itch-suppressing bioactive lipids in the 
skin, a function of BH4-dependent AGMO. Together, these loss- 
and gain-of-function experiments of myeloid-specific Gch1 show 
that itch in the mouse partly depends on Gch1/BH4-dependent 
serotonin and histamine release and AGMO-dependent bioactive 
lipid mediators.
PP2
HISTAMINE IS INVOLVED IN PERIPHERAL 
NERVE ELONGATION INTO EPIDERMIS OF MICE 
WITH ITCHING INDUCED BY SURFACTANT
Yoshihiro Inami1, Atsushi Sato2, Hiroshi Ohtsu2, Yosuke Mano1, 
Yasushi Kuraishi3, Tsugunobu Andoh4
1Fundamental Research Laboratory, Hoyu Co., Ltd., Aichi, 2Tekiju Rehabi-
litation Hospital, Hyogo, 3Research Administration Division, Tokyo Medi-
cal and Dental University, Tokyo, 4Department of Applied Pharmacology, 
University of Toyama, Toyama, Japan
The repetitive act of washing your skin with soaps can lead 
to cutaneous sensory hypersensitivity symptoms. This enhan-
ces itchiness and is induced by several stimuli. However, the 
mechanism and the factors associated with cutaneous sensory 
hypersensitivity induced by soaps remain unclear. Sodium do-
decyl sulphate (SDS) is a synthetic surfactant commonly found 
in laundry detergents, dish detergents and shampoos. In addi-
tion to the increase of the expression of histamine-synthesizing 
enzyme histidine decarboxylase (HDC) and the concentration of 
histamine in the epidermis, our previous report has shown that 
repeated applications of SDS to mouse shaved skin increased the 
density of intraepidermal nerve fibers. These findings suggest that 
histamine may contribute to the induction of neuronal sprouting 
into the epidermis. In this study, we investigated the role of his-
tamine on SDS-induced neuronal sprouting into the epidermis. 
The repeated SDS exposure increased the elongation of peripheral 
nerve fibers into the epidermis in wild type mice, but not in HDC 
knockout mice. In both wild type and HDC knockout mice, the 
expression of nerve growth factor was increased and that of nerve 
repulsion factors semaphorin 3A was decreased. The application 
of histamine increased the total length and the maximum length 
in small-sized, but not large-sized, mouse dorsal root ganglion 
neurons. Therefore, these results suggest that histamine plays an 
important role in intraepidermal nerve fiber elongation in murine 
skin treated repeatedly with SDS. 
PP3
THE EFFECTS OF THE NK-1 RECEPTOR 
ANTAGONIST NETUPITANT ON ITCH MODELS IN 
MICE
Girolamo Calo’1, Anna Rizzi1, Chiara Ruzza1, Claudio Pietra2
1Department of Medical Sciences, Section of Pharmacology, University of 
Ferrara, Italy, 2Helsinn Healthcare SA, Lugano, Switzerland 
Spinal NK-1 receptors play an important role in itch transmission 
and NK-1 antagonists demonstrated antipruritic properties in 
preclinical as well as clinical studies. For example, the NK-1 an-
tagonist aprepitant has been shown in small studies to be effective 
for treating chronic and malignancy-associated pruritus. Netupitant 
is a selective, long lasting and brain penetrant NK-1 receptor an-
tagonist utilized in chemotherapy-induced nausea and vomiting 
therapy in combination with the 5-HT3 antagonist palonosetron. 
Thus, the aim of this study was the investigation of the putative 
antipruritic action of netupitant in mice. Pruritogenic substances 
with different mechanism of action were injected intradermally 
(i.d.) in the rostral part of the mouse back and the number of bouts 
of scratching were counted for 30 min. Substance P (10–100 nmol), 
cloroquine (10–200 nmol), deoxycholic acid (25–250 µg), and 
compound 48/80 (1–50 µg) elicited dose dependent pruritogenic 
effects. From these dose response studies, equieffective doses, 
approximately promoting 100 bouts of scratching in 30 min, 
were selected to be challenged against netupitant 10 mg/kg p.o. 
(2 h pretreatment). The results showed that netupitant reduced 
in a statistically significant manner the pruritogenic effect of all 
substances but not compound 48/80. This latter effect suggests that 
mast cells are not the cell target for the action of SP and that there 
is no involvement of NK-1 receptor signaling in the scratching 
behavior elicited by compound 48/80 in mice. In conclusion these 
results suggest that NK-1 receptor selective antagonist netupitant 
is worthy of development as innovative drug for treating non 
histaminergic itch. 
PP4
OPTOGENETIC ACTIVATION OF SEROTONER-
GIC (5-HT) NEURONS IN THE ROSTRAL 
VENTROMEDIAL MEDULLA (RVM) FACILITATES 
TOUCH-EVOKED SCRATCHING IN A DIET-
INDUCED CHRONIC DRY SKIN MOUSE MODEL
Masanori Fujii1,2, Taylor Follansbee1, Yuma Yasui2, Susumu 
Ohya2, Mirela Iodi Carstens1, Earl Carstens1
1Neurobiology, Physiology & Behavior, University of California, Davis, 
USA, 2Kyoto Pharmaceutical University, Kyoto, Japan
In atopic dermatitis, innocuous mechanical stimuli (e.g., contact 
with wool) often elicit itch sensation (called alloknesis), thus 
contributing to persisting itch. RVM is a brainstem region con-
taining 5-HT neurons descending to the spinal cord. Although the 
descending RVM 5-HT neurons are well known to contribute to 
pain modulation, their role in alloknesis remains unclear. In this 
study, using optogenetics, we examined the effects of selective 
activation of RVM 5-HT neurons on touch-evoked scratching 
and thermal pain sensitivity in a chronic dry skin mouse model. 
We have previously shown that hairless mice fed a special diet 
containing no polyunsaturated fatty acids and no starch develop 
atopic dermatitis-like pruritic dry skin (M. Fujii et al., Exp. 
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Dermatol., 24:108-13, 2015). When this special diet was given 
to C57BL/6 mice, similar dry skin conditions were induced. Al-
loknesis was assessed using 0.7 mN von Frey filaments applied to 
the shaved back skin. The low-threshold mechanical stimulation 
of the skin frequently evoked site-directed scratching in special 
diet-fed C57BL/6 mice with dry skin, although rarely in normal 
mice. To selectively induce a light-activated channel channelr-
hodopsin-2 (ChR2) in RVM 5-HT neurons, we micro-injected a 
Cre-inducible adeno-associated virus carrying ChR2 gene into 
the RVM of Fev-Cre mice in which Cre is expressed in central 
5-HT neurons and then an optic fiber was implanted just above 
the RVM. Blue light (20 Hz, 5 ms pulses) was delivered via the 
implanted optic fiber during behavioral testing. Consequently, 
the optogenetic stimulation significantly increased touch-evoked 
scratching in special diet-fed dry skin mice. On the other hand, 
pain-related thermal response (measured by Hargreaves test) was 
significantly decreased by the stimulation. Therefore, the present 
results suggest that under chronic dry skin conditions activation 
of RVM 5-HT neurons facilitates touch-evoked itch, while inhi-
biting thermal pain. 
PP5
TRPV CHANNELS AND POST-BURN PRURITUS
Hye One Kim, Yong Won Choi, Jee Hee Son, Yong Se Jo, Bo Young 
Jung, Chun Wook Park
Department of Dermatology, Kangnam Sacred Heart Hospital, Japan
Background: Post-burn pruritus is a common distressing sequela 
of burn wounds. Empirical antipruritic treatment often fails to 
have a satisfactory outcome because the mechanism has not been 
fully elucidated. Transient receptor potential (TRP) channels are 
considered to be related to pathway of pruritus. Methods: Sixty-
five burn patients with (n=40) or without (n=25) pruritus were 
investigated, including skin biopsies. Keratinocytes and fibroblasts 
from those samples were separated. Immunohistochemical stain-
ing for TRPV3 and TRPA1; and immunofluorescence staining for 
TSLP, TSLPR, loricrin, involucrin, b-SMA, and TGF-a, were 
performed on samples of burn scars and normal skin. Real-time 
PCR and western blotting were done. We measured intracellular 
Ca2+ levels in keratinocytes from scars with or without pruritus, 
following TRPV3 activation and blocking, and measured the ef-
fects of PAR2 agonist on TRPV3 function. Expressions of TSLP 
after TRPV3 activation in keratinocytes were measured by western 
blotting and real-time PCR. Results: In immunohistochemical and 
immunofluorescence staining, TRPV3, TSLP, and TSLPR stained 
more intensely the epidermis of the burn scars of post-burn-pruritus 
patients, than that of non-pruritic-burn patients. Real time-PCR 
showed that mRNA of TRPV3 and TSLP were significantly 
more abundant in keratinocytes from pruritic burn scars than in 
keratinocytes from non-pruritic burn scars. In addition, mRNA 
and protein levels of PAR2, NK1R, TSLP, and TSLPR were also 
significantly increased in pruritic burn scars. With TRPV 3 acti-
vation, intracellular Ca2+ concentrations were more significantly 
increased in keratinocytes from pruritic burn scars than in those 
from non-pruritic ones. In keratinocytes from pruritic burn scars, 
PAR2 activation markedly potentiated opening of TRPV3 chan-
nels. TRPV3 activation itself resulted in little increase of Ca2+ 
influx with PAR2 inhibition in keratinocytes. In keratinocytes 
from all samples, PLC-β, PKA, PKCs, and PKD inhibitor mark-
edly reduced intracellular Ca2+ level by TRPV3 activation, as well 
as by PAR2 activation. TRPV3 activation also increased mRNA 
and protein expression of TSLP in keratinocytes. Conclusions: In 
conclusion, we confirmed that TRPV3 of keratinocytes and PAR2, 
NK1R, TSLP, and TSLPR were highly expressed in pruritic burn 
scars. In addition, it seemed that PAR2 sensitized TRPV3 chan-
nels with PKA, PKC, PKD signaling pathways. It also seemed 
that TRPV3 activation induced TSLP expression.
PP6
EFFECT OF [LEU11]-HK-1-DERIVED PEPTIDES 
ON SCRATCHING BEHAVIOR IN MICE WITH 
CHRONIC ITCH
Hideki Funahashi1, Yu Miyahara1, Ayaka Haruta-Tsukamoto1, 
Rumi Nakayama-Naono2, Toshikazu Nishimori1, Yasushi Ishida1
1Division of Psychiatry, Department of Clinical Neuroscience, Faculty of 
Medicine, University of Miyazaki, 2Division of Anatomy and Cell Biology, 
Tohoku Medical and Pharmaceutical University, Japan
Hemokinin-1 (HK-1) is a mammalian tachykinin peptide con-
sisting of 11 amino acids. Recently, we demonstrated that the 
pretreatment with [Leu11]-HK-1, in which Met at the C-terminal 
of HK-1 was replaced by Leu, produced a decrease in scratching 
induced by both intrathecal administration of HK-1 and intrader-
mal injection of some pruritogens such as histamine or serotonin. 
However, it is not clarified whether [Leu11]-HK-1-derived peptides, 
in which a part of amino acids was replaced of by D-tryptophan 
(D-Trp), change the effective duration on scratching behavior in 
mice with chronic itch. Therefore, to clarify the effect of [Leu11]-
HK-1-derived peptides in mice with chronic itch, [Leu11]-HK-1 
or [D-Trp9]-[Leu11]-HK-1 was intrathecally injected after painting 
of diphenylcyclopropenone on the nape. Scratching in mice with 
chronic itch was attenuated by administration of [Leu11]-HK-1 until 
30 minutes, while the effect lasted until 24 hours after intrathecal 
injection of [D-Trp9]-[Leu11]-HK-1. These results indicate that 
D-Trp in [Leu11]-derived peptides plays a crucial role in the ef-
fective duration on scratching behavior in mice with chronic itch.
PP7
SEROTONIN RECEPTOR SUBTYPES INVOLVED 
IN CALCIUM INFLUX IN CULTURED RAT 
DORSAL ROOT GANGLION NEURONS
Dan Domocos1, Tudor Selescu1, Earl Carstens2, Mirela Iodi Car-
stens2, Alexandru Babes1
1University of Bucharest, Romania, 2Neurobiology, Physiology & Behavior, 
University of California, Davis, USA 
Serotonin (5-HT) mediates both pain and itch in the peripheral 
nervous system. Our aim was to identify the specific 5-HT receptor 
subtypes expressed in the rat dorsal root (DRG) and trigeminal 
(TG) ganglion neurons. We used calcium microfluorimetry and the 
patch clamp technique to investigate the action of 5-HT in primary 
cultures of rat sensory neurons. DRG and TG were dissected out 
from adult male Wistar rats and dissociated neurons were cultured 
on glass coverslips. After 24 h, the cells were loaded with Calcium 
Green-1 AM and imaged while being chemically stimulated using 
a fast-exchange superfusion system. The calcium responses to 
5-HT (50 μM) were classified as transient and sustained accord-
ing to their kinetics. The selective 5-HT3 antagonist granisetron 
(1 μM) completely inhibited transient responses while the 5-HT3 
agonist SR 57227 (1–10 μM) elicited similar responses in the same 
neurons. The non-selective agonist 5-Carboxamidotryptamine (5-
CT, 50 μM) induced only sustained responses, solely in neurons 
that were sensitive to 5-HT. The same kinds of responses were 
elicited by the 5-HT1A and 5-HT7 agonist 8-OH-DPAT (10 μM) 
but were not inhibited by the 5-HT7 antagonist SB269970 (1–10 
μM). The 5-HT1A receptor antagonist WAY-100,635 (100 nM) 
was able to irreversibly inhibit the sustained responses evoked 
by 5-HT. As 5-HT1A is a metabotropic receptor, we investigated 
the intracellular pathways leading to the sustained calcium influx. 
The broad-spectrum Transient Receptor Potential channel blocker 
Ruthenium Red did not inhibit the sustained responses. Nor did 
the more selective antagonists: CIM 0216 (1 μM), A967079 (5–10 
μM) and HC-067047 (0.5 μM) for TRPM3, TRPA1 and TRPV4 
respectively. The adenylyl cyclase activator forskolin (10 μM) or 
the cAMP analog, 8-Br-cAMP (10 μM) did not affect the sustained 
responses to 5-HT. Voltage clamp experiments were carried out in 
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5-HT-sensitive DRG neurons pre-selected with calcium imaging, 
and revealed only transient currents (5-HT3-like) at a holding po-
tential of -80 mV. These currents were inhibited by granisetron (10 
nM). In conclusion, our results suggest that the transient responses 
are mediated by the 5-HT3 ion channel while the sustained re-
sponses are likely mediated by the 5-HT1A metabotropic receptor. 
This is supported by the inhibitory effect of WAY-100,635 and by 
the calcium influx elicited by 8-OH-DPAT and 5-CT.
PP8
RESISTANCE TO SEROTONIN-INDUCED ITCH IN 
CHOLESTATIC MICE
Sattar Ostadhadi1, Nazgol-Sadat Haddadi1, Arash Foroutan1, Eh-
san Azimi2, Sarina Elmariah2, Ahmad-Reza Dehpour1
1Experimental Medicine Research Center, Tehran University of Medical 
Sciences, Tehran, Iran, 2Department of Dermatology, Cutaneous Biology 
Research Center, Massachusetts General Hospital, Boston, USA
Introduction: Cholestatic itch can be severe and significantly 
impair the quality of life of patients. Serotonin system is impli-
cated in cholestatic itch; however, the pruritogenic properties 
of serotonin have not been evaluated in cholestatic mice. Here, 
we investigated the serotonin-induced itch in cholestatic mice. 
Methods: Cholestasis was induced by bile duct ligation (BDL). 
Serotonin, sertraline or saline were administered intradermally to 
the rostral back area in BDL and sham-operated (SHAM) mice, 
and itch was assessed by quantification of hind paw scratching 
bouts towards the injection site over one hour after treatments. 
Results: Bile duct ligated mice had significantly increased 
scratching responses to saline injection on the 7th day after sur-
gery. Additionally, serotonin or sertraline significantly induced 
scratching behavior in BDL mice compared to saline at day 7 
after surgery, while it did not induce itch at day 5. The scratching 
behavior induced by serotonin or sertraline was significantly less 
in BDL mice compared to SHAM mice. Likewise, the locomotor 
activity of BDL or SHAM mice was not significantly different 
from un-operated (UNOP) mice on 5th and 7th day, suggesting that 
the scratching behavior was not affected by motor dysfunctions. 
Conclusion: Despite the potentiation of evoked itch, a resistance 
to serotonin-induced itch is developed in cholestatic mice.
PP9
GLOBAL GENE EXPRESSION PROFILING IN 
PRURIGO NODULARIS
Konstantin Agelopoulos1, Tobias Lotts1, Heike Conrad2, Martin 
Dugas3, Sonja Ständer1
1Department of Dermatology and Center for Chronic Pruritus, University 
Hospital Münster, Münster, 2Cluster of Excellence: Nanoscale Microscopy 
and Molecular Physiology of the Brain, Georg-August University Götting-
en, 3Institute of Medical Informatics, University Hospital Münster, Müns-
ter, Germany
Prurigo nodularis (PN) is a subtype of chronic prurigo (CPG). It is 
characterized by continuous scratching that leads to multiple itchy 
nodules. Although CPG shows a high negative impact on daily life 
quality, effective therapies are still not available. A deeper insight 
into affected pathways and involved genes may help to define new 
therapeutic targets. Therefore, we performed global gene expres-
sion profiles in PN patients and matched healthy controls (HC). 
Biopsies from 5 PN patients (lesional = PL; healthy/non-lesional = 
PH) and 5 HCs (healthy = HH) were included. Expression profiles 
were generated using Affymetrix Human Gene 1.0 ST Arrays. 
Due to the small sample size data processing was done using the 
R/Bioconductor package limma. Deregulated genes were defined 
with an absolute log2-fold change >1 and a p-value < 0.05. For 
pathway analysis we made use of Reactome, a free open source 
database. A first analysis revealed 276 deregulated genes (DEG) 
between PL and PH, 376 DEGs between PL and HH and only 
58 genes were found to be differentially expressed between PH 
and HH. Different settings for overlapping DEGs like PL/PH vs. 
HH (n=9) and PL vs. PH/HH (n=223) were calculated. Pathway 
analysis revealed DEGs of the latter comparison to be enriched 
in various pathways like signalling by interleukins, signalling 
by NGF, formation of the cornified envelope and others. Further 
analyses of the data are underway and may provide an even deeper 
knowledge of molecules and pathways involved in PN pathology. 
PP10
ROLE OF CYSTEINYL LEUKOTRIENES AND THE 
CYSLTR2 RECEPTOR IN PRURICEPTION
Tiphaine Voisin1, Amelie Bouvier1, Yoshihide Kanaoka2, K. Frank 
Austen2, Isaac M. Chiu1
1 Department of Microbiology and Immunobiology, Harvard Medical 
School, 2 Division of Rheumatology, Immunonology, and Allergy, Brigham 
and Women’s Hospital, Boston, , USA
Itch is associated with allergic skin diseases such as atopic der-
matitis with few effective treatments. The molecular and cellular 
mechanisms underlying pruriceptor neuron activation and sensi-
tization in allergic conditions are not well understood. Cysteinyl 
leukotrienes (Cys-LTs) are eicosanoid lipid mediators released 
by immune cells that play a prominent role in lung inflammation 
in asthma and skin inflammation in atopic dermatitis. Here we 
investigate the role of Cys-LTs and their signaling through the 
Cysltr2 receptor in itch. LTC4 synthase (LTC4S) is the enzyme that 
initiates the production of three Cys-LTs: LTC4, LTD4, and LTE4. 
LTC4 and LTD4 have been found to signal through the type 1 cys-
LT receptor (Cysltr1) or type 2 receptor (Cysltr2) with different 
affinities. Using transcriptional profiling analysis of somatosensory 
neurons, we find that Cysltr2 is highly enriched in pruriceptor 
neurons that co-express IL31ra and Nppb. We hypothesize that 
neuronal Cysltr2 acts to detect Cys-LTs in the skin released by 
immune cells during allergic inflammation. We first test whether 
Cys-LTs activates sensory neurons and produces itch-associated 
behaviors in mice. Using calcium imaging, we show that LTC4 
activates a subpopulation of sensory neurons that also responds to 
capsaicin. Intradermal cheek injection of LTC4 triggers scratching 
in mice, and this itch behavior is decreased in Cysltr2-/- mice. 
N-methyl LTC4 (NMLTC4), the nonhydrolyzable form of LTC4, 
also induced neuronal activation and itch dependent on Cysltr2. 
By contrast, LTD4 did not produce itch or neuronal activation. 
We are testing the functional relevance of this signaling pathway 
in mouse models of atopic dermatitis and skin inflammation. 
Our study implicates LTC4 as a relevant endogenous ligand for 
triggering pruriceptor neurons through Cysltr2 to produce itch.
PP11
PHARMACOLOGICAL EVIDENCE FOR THE 
INVOLVEMENT OF ATP-SENSITIVE POTASSIUM 
CHANNELS IN CHLOROQUINE-INDUCED 
SCRATCHING BEHAVIOR IN MICE
Nazgol-Sadat Haddadi, Sattar Ostadhadi, Arash Foroutan, Ah-
mad-Reza Dehpour
Experimental Medicine Research Center, Tehran University of Medical Sci-
ences, Tehran, Iran
Introduction: Chloroquine (CQ) evokes itch in human and 
scratching behavior in rodents through a histamine-independent 
pathway. Chloroquine directly excites peripheral sensory neurons 
which convey itch signals to the central nervous system. It has been 
revealed that ATP-sensitive potassium channels (KATP channels) are 
important in regulating neuronal excitability. Thus, we aimed to 
investigate the involvement of KATP channels in CQ-induced itch 
which may also reveal a linkage between metabolic state of cells 
and itch. Materials and Methods: Intradermal (id) injection of CQ 
at dose of 400 µg/site induced the scratching behavior. The KATP 
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channel openers, diazoxide (DZX) and minoxidil (MIN), and a KATP 
channel blocker, glibenclamide (GLI), were administered intraperi-
toneally (IP) before CQ. Then, itch was assessed by quantification 
of hind paw scratching bouts towards the injection site. Quantitative 
reverse transcription-PCR (qRT-PCR) was also used to investigate 
the possible changes in dermal expression of Kcnj8 and Kcnj11, 
the genes encoding the KATP channels. Results: Either DZX (10 mg/
kg, IP) or MIN (10 mg/kg, IP) significantly attenuated CQ-induced 
scratching behavior in mice. Moreover, pretreatment with GLI (3 
mg/kg, IP) significantly reversed the anti-pruritic effects of DZX 
and MIN. Our findings of qRT-PCR analysis also show that the 
expression of Kcnj8 is decreased after CQ injection. Conclusion: 
We suggest that KATP channels are involved in CQ-induced itch.
PP12
MODELING OF ITCH SENSITIZATION FOR 
HISTAMINERGIC AND NON-HISTAMINERGIC 
ITCH? – BOTH UVB- AND NGF-INDUCED 
SENSITIZATION SELECTIVELY INCREASE PAIN, 
BUT NOT ITCH, ELICITED BY HISTAMINE AND 
COWHAGE
Silvia Lo Vecchio1, Hjalte H. Andersen1, Jesper Elberling2, Lars 
Arendt-Nielsen1
1Laboratory for Experimental Cutaneous Pain Research, SMI®, Depart-
ment of Health Science and Technology, Faculty of Medicine, Aalborg 
University, 2Department of Dermato-allergology, Copenhagen University 
Hospital, Gentofte, Copenhagen, Denmark
Itch sensitization to pruritic chemical provocations and mechanical 
stimuli has been found in patients with chronic itch, e.g. atopic 
dermatitis. The precise mechanisms behind such itch sensitiza-
tion are unclear as is the circumstances influencing the ability of 
inflammatory perturbations to cause pain and/or itch sensitization 
as well as spontaneous itch and pain. We used two well-established 
human models of nociceptive sensitization to explore how pre-
established unspecific inflammation (induced by epidermal UVB-
damage) and non-inflammatory neurotrophic pain sensitization 
(induced by intradermal NGF-injections) altered sensitivity to 
chemical (histamine and cowhage) and mechanically-evoked itch. 
For the UVB experiment, 20 healthy volunteers (10F/10M) were 
included. Six volar forearm spots (2cm in diameter) were irradi-
ated with increasing UVB-doses (up to 2 x minimal erythemal 
dose) and two spots acted as controls. For the NGF-experiment 
16 healthy volunteers (5F/11M) were included and 2 μg of NGF 
were injected (4x50 μl blebs in 2 cm diameter areas) into both 
volar forearms, while saline were used as control. Pain sensitivity 
measurements were conducted to validate models. Subsequently, 
itch was evoked using histamine (1%) and cowhage spicules in the 
primary hyperalgesic areas and itch/pain was scored on a visual 
analog scale. Hyperknesis was measured with von Frey filaments. 
Both the UVB- and the NGF-model induces robust primary painful 
hyperalgesia (p<0.01) and mild hyperknesis (p<0.05), but neither 
of the models increases itch rating to chemical itch provocations. 
Contrarily, significant increases specifically for pain ratings were 
observed. This suggests that these models do not appropriately 
mimic itch sensitization of inflammatory dermatoses and that 
rather distinct and perhaps prolonged inflammatory processes are 
involved in clinically observed itch sensitization.
PP13
EXPRESSION OF UBIQUITIN C-TERMINAL 
HYDROLASE L1/PGP9.5 IN PSORIASIS: 
INTERPLAYS BETWEEN AXONAL NERVE 
TERMINALS SND EPIDERMAL KERATINOCYTES 
IN TRANSMISSION OF ITCH
Piotr Kupczyk1, Marcin Hołysz2, Mariusz Gajda3, Adam Reich4, 
Jacek C. Szepietowski4
1Department of Pathomorphology, Faculty of Medicine, Silesian Piast 
Wroclaw Medical University, Wroclaw, 2Department of Biochemistry and 
Molecular Biology, Karol Marcinkowski University of Medical Sciences, 
Poznan, 3Department of Histology, Jagiellonian Medical College, Jagiel-
lonian University, Krakow, 4Department of Dermatology, Venereology and 
Allergology, Silesian Piast Wroclaw Medical University, Wroclaw, Poland
Introduction: Itch is unpleasant sensation occurring in psoriasis, 
multisystem immunegenetic skin disease. Itch transmission is 
mediated via skin C-fibers, axonal terminals of dorsal root gang-
lion (DRG) neurons. However, in chronic skin neuroinflammation 
enhanced transmission of itch might by induced not only by outgro-
wing and disordering nerve terminals, but additional modulate via 
abnormal activity of neuro-immune-endocrine cells: fibroblasts, 
Langerhance, melanocytes, and keratinocytes. For identification 
and distribution of skin nerve fibers, as well neuro-immune-
endocrine cells protein gene product 9.5 (PGP9.5), biochemically 
Ubiquitin C-terminal hydrolase L1 (UCHL1) is commonly used. 
UCHL1 gene and PGP9.5 protein (UCHL1/PGP9.5 system) 
belongs to the deubiquitinase enzyme (DUBs) family, which is 
responsible for cleave of C-terminal peptide adducts as well as N-
terminally conjugated ubiquitin from substrate proteins. UCHL1/
PGP9.5 is widely expressed in the Central Nervous Sysytem 
(CNS), while its disorders are linked with neurodegeneration, 
cancer, impaired immune functions, tissue injury and pain-related 
sensations. It seems that disordered interplays between neuronal 
and non-neuronal cells via common UCH-L1/PGP9.5 expression 
might control skin neuro-immune-endocrine status and escalate 
itch. Material and Methods: The 20 skin punch biopsies from 
non-lesional and lesional site of the skin were obtained from 
psoriasis patients and 20 normal skin of healthy individuals. Gene 
expression was performed using real-time PCR, whereas protein 
level was estimated by immunofluorescence microscopy. Results: 
Fluorescence microscopy imaging demonstrate impaired distribu-
tion of PGP9.5 nerves in non-lesion and lesions itchy skin (basing 
on VAS score) comparing to skin without itch and control group. 
Additionally, significant relations between non-neuronal PGP9.5 
expression within basal keratinocytes and suprabasal keratinocytes 
with itch were also observed. In contrast, real-time PCR gene ex-
pression results demonstrate significant downregulation of UCHL1 
mRNA in non-lesional and lesional skin in itchy group compare 
to skin without itch and control group. Conclusions: We believed, 
that this unusual and impaired expression pattern between UCHL1 
transcript and its protein PGP 9.5 may demonstrate new findings 
about peripheral innervations and neuro-immune-endocrine cells 
in molecular aspect of psoriatic itch. 
PP14
MEASURING SCRATCHING AND SLEEPING 
BEHAVIOR BESIDES PRURITUS INTENSITY: 
DEVELOPMENT OF A NEW, ALL-ENCOMPASSING 
PRURITUS SYMPTOMS SCORE – THE “ITCH-
CONTROLLED-DAYS SCORE”
Sabine Steinke, Henk Wassmann, Frederik Braun, Kirstin Menne, 
Nani Osada, Laurie Burke, Christine Blome, Claudia Zeidler, Mat-
thias Augustin, Sonja Ständer
Department of Dermatology, University Hospital Münster, Germany
Background: Besides pruritus intensity different associated 
symptoms as sleeping or scratching behavior have been shown 
to affect the disease burden and quality of life of chronic pruritus 
(CP) patients. A newly developed questionnaire aimes to measure 
a variety of pruritus-relevant symptoms and to evaluate the control 
of pruritus within clinical routine and research. Methods: Within 
the development part of the study structured patient interviews 
helped to identify the parameters defining an itch controlled day 
(p= 89 CP patients). After item generation, feasibility-check and 
item reduction, the Itch-Controlled-Days (ICD) questionnaire 
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was created with nine items on pruritus intensity, sleeping and 
scratching behavior. The score was tested and validated in 60 
patients. Results: Retest-reliability was excellent (Cronbach’s 
alpha >0.95; intraclass correlation coefficient > 0.9; Cohen’s kappa 
>0.8). Spearman-Rho correlation analysis and Mann-Whitney-
U testing showed moderate to strong convergence of pruritus 
intensity values (VAS, VRS, NRS) and quality of life (ItchyQoL, 
DLQI) (all p<0.01). The 9 items of the ICD questionnaire allow 
to calculate a score from 0 to 22. Conclusion: The measurement 
of different pruritus- relevant symptoms within one single score 
helps to assess the itch control easily and systematically.
PP15
THE USE OF A DERMOCOSMETIC TO MANAGE 
PRURITUS RELATED TO SKIN DISEASES: AN 
OBSERVATIONAL STUDY
Sandrine Virassamynaik1, Bernard Chadoutaud2, Charlène Ey-
dieux2, Julie Riviere2, Michèle Sayag1
1NAOS, Laboratoire Bioderma, 2ClinReal Online
Introduction: Pruritus is defined as an unpleasant sensation resul-
ting in an urge to scratch. Pruritus is the most common symptom 
in dermatology, affecting over one-third of the world population. 
Pruritus may be occasional or chronic, local or widespread, and 
related to various skin diseases such as atopic dermatitis, psoriasis 
and urticaria. It is sometimes related to cutaneous dryness, as is the 
case for senile pruritus. The Skin Relief™ technology associated to 
enoxolone were developed to have a significant action on pruritus. 
It inhibits the release of pruritic mediators like Thymic Stromal 
Lymphopoietin, Nerve Growth Factor and histamine. And so, it 
reduces nerve fibre activation. In this context, the was to assess 
the efficacy of an antipruritic spray to quickly calm the itching 
including Skin relief™ technology. This product was tested in 
4 dermatological diseases: atopic dermatitis, psoriasis, chronic 
urticaria and senile pruritus. Material/Methods: An observatio-
nal, prospective and multicentre study was performed in Poland 
including 120 patients (30 subjects in each group). The product 
was sprayed many times as needed on the body and face during 
21 days. Efficacy assessments on pruritus were performed at D0 
and D21 by using 5-D pruritus scale (5 to 25), by scoring itching 
sensations and skin conditions with numerical scale (0 to 9). 
Tolerance was also assessed. Results: The analyzed population 
included 118 subjects (63 males and 55 females) with a mean age 
of 41 years old (±27). The product was applied 2.5 times a day on 
average. A significant decrease of 5-D pruritus scale (–40%) and 
sensations of itching (–63%) was observed between D0 and D21. 
In parallel, a significant improvement of skin conditions: dryness 
(–52%), roughness (–53%), scales (–58%), suppleness (+26%). 
It relieves pruritus in 21 seconds on average and the effect lasts 
half a day in 56% of subjects. The majority of the subjects were 
very satisfied by the product (98% of patients). And, the product 
was well-tolerated in 99.2% of subjects. Conclusions: This study 
confirms the interest to use an antipruritic spray in chronic skin 
diseases: atopic dermatitis, psoriasis, chronic urticaria and senile 
pruritus. This product can be considered as effective, safe and 
easy to use. 
PP16
ITCH AS ACCOMPANYING SYMPTOM IN 
VITILIGO
Elkham Karaev
Republican Scientific-Research Institute of Dermatology and Venereology
Purpose of research: Identification of the prevalence rate and basic 
characteristics of pruritus in the patients with vitiligo. Material 
and Methods: Material used in this research included ambulatory 
cards and application-questionnaires of the patients with various 
forms of vitiligo, referred for medical care in the first quarter of 
2017. Results of research: The ambulatory cards and application-
questionnaires were obtained from 124 patients with vitiligo, of 
them 118 (95%) patients noted skin pruritus as accompanying 
symptom in disease. Of 118 patients men were 39 (about 33%), 
women – 79 (about 67%). Localized form of vitiligo occurred in 
101 patients, generalized form – in 17 patients. Fifty-six patients 
noted appearance of pruritus at the basis of occurrence of depig-
mented spots, in 38 patients the pruritus appeared before and in 
24 patients after formation of vitiligo focuses. Localized form 
of pruritus was revealed in 115 patients, generalized form was 
found only in 3 at the age of 44, 53 and 55 years. The gradually 
progressive skin pruritus was noted in 97 patients, in 21 patients 
the pruritus was found rarely. Episodic pruritus appearance was 
observed in 85 patients, cyclicity was noted in 33, at the same 
time 78 patients observed intensification/appearance of pruritus 
at the night or after nervous-psychological stress. Analysis of the 
accompanying disease revealed 58 patients suffering from anemia 
of various stage of severity, 47 – with pathology of endocrine 
system (all 3 patients with generalized pruritus suffered due to 
diabetes mellitus), 24 – from diseases of hepatobiliary system, 
and 12 from diseases of urinary excretive system and others. On 
the background of the basic disease treatment 85 patients noted 
disappearance of pruritus, in 33 the treatment of vitiligo had no 
influence of the elimination of skin pruritus. Conclusion: Thus, 
on the basis of vitiligo the pruritus mostly frequent occurred in 
females, developed on the background of depigmentation, expres-
sed looking like episodic, limited, gradually intensifying form and 
disappeared on the basis of the main disease treatment.
PPI7
PREVALENCE AND MAGNITUDE OF ITCH 
IN ADOLESCENT ATOPIC DERMATITIS: 
RETROSPECTIVE SURVEY OF FIRST-YEAR 
UNIVERSITY STUDENTS
Yosuke Okuda1, Mayuko Tahara1, Hiroyuki Murota1, Ichiro Ka-
tayama1, Keiko Yamauchi-Takihara2
1Department of Dermatology, Osaka University Graduate School of Medi-
cine, and 2Health Care Centre, Osaka University, Osaka, Japan
Recent epidemiological studies revealed the increased number of 
adolescent subjects with atopic dermatitis. The picture of Japanese 
adolescent subjects with atopic dermatitis is poorly understood. 
Thus, we conducted the questionnaire survey to investigate the 
prevalence of Japanese adolescent subjects with atopic dermatitis, 
and to evaluate the magnitude of itch in 1st-year university students 
with atopic dermatitis. On 2016, 1st-year students of our university 
answered the self-completed questionnaire about both the past 
history of allergies and the demographic factors in a retrospective 
manner. Finally, 3,135 sheets were effectively analyzed. In total, 
13.2 % of students had a history of diagnosed as atopic dermatitis. 
Nearly half of the subjects with atopic dermatitis had the protrac-
ted clinical course since childhood. At the health examination of 
1st-year students, all students with atopic dermatitis got clinical 
examination by specialist in dermatology. Magnitude of itch was 
evaluated by visual analogue scale. Magnitude was somewhat 
lower than we expected, probably because of their successs in 
university entrance exam.
PP18
IS ITCH A SYMPTOM OF CUTANEOUS 
LEISHMANIASIS?
Tizita Yosef Kidane
Department of Dermatology, Abbid Ababa University, Addis Ababa, Ethio-
pia
Cutaneous leishmaniasis is a parasitic infection caused by dif-
ferent species of the obligate intracellular protozoa Leishmania. 
This disease is transmitted through the bite of an infected female 
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sandfly. It occurs in a variety of clinical forms depending on the 
subspecies of the Leishmania involved, and the immunological 
status of the host. In addition to the classical clinical presentation, 
which is usually non itchy entity, several unusual and atypical 
clinical features of the disease are being reported these days. In this 
report, I describe a rare variant of cutaneous leishmaniasis initially 
associated with itch, resembling squamous cell carcinoma-like 
leishmaniasis. This case report alerts to the existence of atypical 
forms of cutaneous leishmaniasis. In our case, the lesion of the 
patient clinically mimicked squamous cell carcinoma and were as-
sociated with itch. It should be kept in mind that the wide spectrum 
of clinical variants of cutaneous leishmaniasis can occur and icth, 
although rarely, may be a symptom of the disease.
PP19
ASSESSMENT OF PRURITUS AMONG PATIENTS 
WITH VIRAL HEPATITIS B AND C
Anna Biernacka1, Dawid Niżyński1, Małgorzata Inglot2, Adam 
Reich3
1Students’ Scientific Circle of Experimental Dermatology, Department of 
Dermatology, Venereology and Allergology, 2Department of Infectious Di-
seases, Hepatology and Acquired Immune Deficiencies, 3Department of 
Dermatology, Venereology and Allergology, Wroclaw Medical University, 
Wroclaw, Poland
Introduction: Itching is an unpleasant subjective sensation that 
leads to scratching. It is a common symptom of skin diseases but 
may also occur in various systemic diseases. Objective: The aim 
of the study was the clinical characteristics of itch accompanying 
viral hepatitis B and C. Material and Methods: Screening was 
performed among 110 people infected with HBV, HCV or both. 
A total of 22 (20%) patients aged 25–68 years with pruritus were 
included for further analysis. The study was based on an ques-
tionnaire containing questions about general health, duration of 
liver disease and its clinical picture, accompanying illnesses, 
medications and pruritus. Results: In the analyzed group, 9 patients 
ere diagnosed with type B hepatitis, whereas in 13 hepatitis type C 
was stated. The duration of liver disease ranged from 3 to 22 years. 
In 15 (68.2%) patients liver cirrhosis was documented; one (4.5%) 
patient suffered from hepatocellular carcinoma. The most common 
site of pruritus was the trunk (n=13, 59.1%), generalized pruritus 
was observed in 3 (13.6%) patients. Secondary skin lesions were 
found in 14 (63.6%) people. The most common period of pruritus 
occurrence was night and evening, the least common pruritus was 
noted in the morning. Conclusions: Pruritus affects about one fifth 
of patients with viral hepatitis, most commonly in those subjects 
with long-term disease duration and significant liver failure. 
PP20
DESCENDING INHIBITION OF ITCH AND PAIN 
IN HUMANS – EXPERIMENTAL PARADIGMS FOR 
ASSESSING ENDOGENOUS ITCH INHIBITION 
EFFICACY
Hjalte Holm Andersen1, Antoinette van Laarhoven1,2, Jesper El-
berling3, Lars Arendt-Nielsen1
1Laboratory for Experimental Cutaneous Pain Research, SMI, Department 
of Health Science and Technology, Faculty of Medicine, Aalborg Uni-
versity, Denmark, 2Health, Medical and Neuropsychology Unit, Faculty 
of Social and Behavioral Sciences, Leiden University, The Netherlands, 
3Department of Dermato-Allergology, Copenhagen University Hospital, 
Herlev-Gentofte, Copenhagen, Denmark
Endogenous descending pain inhibition is reduced in chronic pain 
states signified by lowered conditioned pain modulation (CPM) ef-
ficacy. In parallel, patients with chronic itch may exhibit decreased 
endogenous descending inhibition of itch (CIM) and pain, but little 
is known about descending inhibition of itch and techniques to 
evoke conditioned modulation of itch. We systematically assessed 
CPM and CIM of experimentally elicited itch and pain. Twenty-
six healthy volunteers were tested. Conditioning stimulations 
comprised cold pressor-induced pain and histamine-evoked itch. 
Test stimuli were conducted with electrical paradigms designed to 
evoke itch or pain. Five conditions were investigated; 1) itch mo-
dulation by contralateral itch; 2) itch modulation by contralateral 
pain; 3) itch modulation by ipsilateral pain; 4) pain modulation by 
contralateral pain (i.e. a standard CPM-paradigm; positive control 
condition), and 5) pain modulation by contralateral itch (negative 
control condition). Conditioning itch stimulation did not signifi-
cantly affect the mean itch ratings (although an insignificant trend 
was observed), however, the mean itch intensity was significantly 
decreased by both contra- and ipsilaterally applied conditioning 
pain stimulation, signifying a pain-evoked CIM-effect. Mean 
pain ratings were significantly reduced by the conditioning pain 
stimulus, but not by the conditioning itch stimulus. Descending 
itch inhibition could not be significantly evoked by conditioning 
itch stimulation, but can be efficiently evoked with conditioning 
pain stimulation. These results suggest a hierarchical prioritization 
in favour of pain-induced central descending inhibition of both 
itch and pain in humans. Future studies assessing endogenous 
inhibition efficacy of itch in patients with chronic itch could fa-
vourably apply a design assessing pain-evoked itch modulation 
(“pain inhibiting itch” paradigm).
PP21
PRURITUS IN PATIENTS HOSPITALIZED IN 
THE DEPARTMENT OF DERMATOLOGY, 
JAGIELLONIAN UNIVERSITY MEDICAL 
COLLEGE - A THERAPEUTIC APPROACH
Magdalena Spałkowska1, Agata Radko2, Maciej Nowak2, 
Małgorzata Werynowska2, Anna Wojas-Pelc1
1Department of Dermatology, and 2Scientific Students’ Society, Jagiello-
nian University Medical College in Cracow, Poland
Introduction: The presence of pruritus is common in dermatolo-
gical patients. The treatment of itch involves moisturizing agents, 
as well as topical and systemic drugs. Antihistamines are often 
effective in treating the itch sensation, however the age- and 
concomitant disease-related limitations should be taken into 
consideration when implying the treatment. Aim: The aim of the 
study was to assess the range of the problem of pruritus and to 
highlight the need for special cautions that should be taken during 
the treatment of this symptom.Material and Methods: We analyzed 
clinical data of 310 patients hospitalized in the Department of 
Dermatology, Jagiellonian University Medical College in Krakow, 
Poland between January and March 2016. 102 of 310 patients 
(32.9%) presented with pruritus – 66 women and 36 men, aged 
18–86. Results: The most common group of patients with pruritus 
were middle-aged (35–64 year old) individuals (45%), followed 
by elderly patients (31.4%). The most common cause of itch 
were allergic diseases (45.1%), most commonly atopic dermatitis 
(15.7%). 50% of patients were treated with oral antihistamines (1st 
and/or 2nd generation). Localized pruritus was observed in 75.5% 
of patients, generalized in 24.5%. 35.5% of patients described 
pruritus as severe. Intensity of pruritus was higher in patients 
with generalized than with localized itch (56% vs 29%; p=0.013) 
and those patients received antihistamines more commonly (64% 
with intense pruritus vs 42% with nonintense; p=0.04). Elderly 
patients received topical treatment and have been treated with other 
systemic drugs more often (97% vs 81% for topical treatment; 
p=0.035; 44% vs 23% for other drugs; p=0.03). Elderly subjects 
had significantly higher levels of creatinine, urea and glucose 
(p<0.05 each). Conclusions: Antihistamines are frequently used 
in the management of pruritus. However, in the group of elderly 
patients more caution should be taken when implying such tre-
atment. Use of antihistamines requires careful assessment of the 
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risk of pharmacological interactions and their effects on central 
nervous system. The choice of the drug and its dosage should be 
adjusted to the hepatic and kidney function.
PP22
ASSESSMENT OF SKIN PROBLEMS AMONG 
PATIENTS WITH INFLAMMATORY BOWEL 
DISEASE: IS PRURITUS A MAJOR FINDING?
Marta Idzior1, Beata Jastrząb1, Marta Laskowska1, Katarzyna 
Neubauer2, Adam Reich3
1Students’ Scientific Circle of Experimental Dermatology, Department of 
Dermatology, Venereology and Allergology, 2Department of Gastroentero-
logy and Hepatology, and 3Department of Dermatology, Venereology and 
Allergology, Wroclaw Medical University, Wroclaw, Poland
Introduction: Patients with inflammatory bowel diseases (IBD) 
often requires prolonged immunosuppression. Such treatment 
may result in various dermatological complications as itching 
which can be very heavy for patients. Objective: The aim of this 
study was to analyze the prevalence of dermatological conditions 
in patients with IBD with special emphasis on pruritus. Materials 
and Methods: The study included patients with IBD hospitali-
zed in gastroenterological department. All patients underwent a 
thorough medical history and physical examination. Based on 
achieved data the stratified questionnaire evaluating their skin 
condition, and previous treatment was completed by investigators. 
All data were analyzed statistically. Results: The results showed 
that questionnaire is a valuable research tool which allow to 
identify significant dermatological problems in patients with 
inflammatory bowel disease. About 20% of patients with IBD 
suffered from pruritus (19.5%), which the third most common 
dermatological ailment in this population of patients after xerosis 
(46.5%) and hair loss (20.9%). Patients also stressed the need 
for dermatological consultations during diagnosis and treatment 
of IBD. Conclusions: Such “trivial” problem as itching might 
be neglected by the gastroenterologist or GP but it can be very 
problematic for patient. It is the reason why patients with IBD 
require proper evaluation of skin problems and the dermatologist 
should be included in the diagnostic and therapeutic team super-
vising patients with IBD 
PP23
VALIDITY AND RELIABILITY OF VARIOUS 
INSTRUMENTS FOR ITCH INTENSITY MEASURE-
MENT IN PATIENTS WITH CHRONIC PRURITUS: 
A PROSPECTIVE, MULTICENTER STUDY IN 
KOREA
Yong Hyun Jang1, Gyeong-Hun Park2, Byung-Soo Kim3, Kap-sok 
Li4, Chang Ook Park5, Hye One Kim6, Hei Sung Kim7, Min Soo 
Jang8, Kyung Duck Park9, Eun Jin Doh10, Dong Hun Lee10, Yang 
Won Lee11, Seong Jin Kim12, Do Won Kim1
1Department of Dermatology, Kyungpook National University School of 
Medicine, Daegu, 2Department of Dermatology, Dongtan Sacred Heart 
Hospital, Hallym University College of Medicine, Hwaseong, 3Department 
of Dermatology, Pusan National University School of Medicine, Busan, 
4Department of Dermatology, College of Medicine, Chung-Ang Univer-
sity, Seoul, 5Department of Dermatology, Severance Hospital, Cutaneous 
Biology Research Institute, Yonsei University College of Medicine, Seoul, 
6Department of Dermatology, Kangnam Sacred Heart Hospital, Hallym 
University College of Medicine, Seoul, 7Department of Dermatology, In-
cheon St. Mary’s Hospital, The Catholic University of Korea, Incheon, 8De-
partment of Dermatology, Kosin University College of Medicine, Busan, 
9Department of Dermatology, College of Medicine, Catholic University of 
Daegu, Daegu, 10Department of Dermatology, Seoul National University 
College of Medicine, Seoul, 11Department of Dermatology, Konkuk Uni-
versity School of Medicine, Seoul, 12Department of Dermatology, Chonnam 
National University Medical School, Gwangju, Korea
Background: Despite its high prevalence and significant impact 
on quality of life, a valid assessment of chronic pruritus remains 
elusive due to its subjectivity and multifactorial nature. Various 
tools have been used over time to provide a more reliable and 
accurate evaluation of pruritus. Pruritus intensity can be measu-
red using the Visual Analog Scale (VAS), Numeric Rating Scale 
(NRS), Verbal Rating Scale (VRS), and various multidimensional 
questionnaires including Itch Severity Scale (ISS). However, to 
date, no single method has been recognized as a gold standard. 
Objective: In this study, we evaluated validity and reliability of 
VAS, NRS, VRS and ISS and relation to a pruritus-specific quality 
of life instrument, IcthyQoL. Methods: A total of 419 patients 
with chronic pruritus (215 males, 214 females, mean age 46.58 
years) recorded their pruritus intensity on VAS (100-mm line), 
NRS (0–10), VRS (four-point) and ISS scales. Re-test reliability 
was analyzed after three hours. In addition, IcthyQoL survey was 
conducted on all patients. Results: Correlation of VAS, NRS and 
VRS by Spearman’s correlation coefficient showed statistically 
significant high values. ISS showed a low intercorrelation validity 
with these three tools. However, ISS correlated strongly with 
IchyQoL compared to VAS, NRS, and VRS. Statistical correla-
tion of the three hours’ difference was also the highest in ISS. 
Re-test reliability of VAS, NRS and VRS was similar and lower 
than ISS. Conclusion: Since pruritus is a subjective symptom of 
multifactorial trait, its assessment may be challenging. The best 
way to assess the itch intensity should be studied.
PP24
EVALUATION OF THE CLINICAL CHARACTERIS-
TICS OF PRURITUS IN PATIENTS WITH PSORIA-
SIS USING THE JAPANESE VERSION OF THE 5-D 
ITCH SCALE
Yozo Ishiuji1, Yoshinori Umezawa1, Norie Aizawa1, Sanae Inoku-
chi1, Akihiko Asahina1, Koichi Yanaba1, Toshiya Ebata2, Hidemi 
Nakagawa1
1Department of Dermatology Jikei University School of Medicine, 2Chito-
funa Dermatology Clinic, Japan
The prevalence of pruritus in the patients with psoriasis has ranged 
from 64% to 97%. Pruritus leads the patients with psoriasis to 
scratch and it may trigger new eruptions. Thus, the management of 
pruritus is important to avoid aggravation of psoriasis by scratch-
ing. It is needed to assess pruritus in the psoriatic patients for the 
choice of appropriate treatments. Currently, only a few resources 
are available to measure pruritus. However, these scales do not 
obtain the multidimensional aspects of pruritus. The 5-D itch scale 
is a new simple self-administered questionnaire. It consists of five 
sections that measure duration, degree, direction, disability and 
distribution of itching. To examine the clinical characteristics of 
pruritus in patients with psoriasis using the Japanese version of 
the 5-D itch scale. A total of 69 patients with psoriasis (44 men 
and 25 women), all between 23 and 80 years of age, participated 
in this study (mean±SD; 54.6±15.6). The Japanese version of the 
5-D itch scale was administered to these patients. In addition, we 
evaluated the disease severity and quality of life (QOL) by the 
severity of psoriasis (psoriasis area and severity index [PASI]) 
and the dermatology life quality index (DLQI), respectively. The 
mean and standard deviation of 5-D score was 10.1±4.3 with 
the scores ranging between 5 and 22. The mean PASI score was 
6.4±7.3 with the scores ranging between 0 and 28. Our data are 
currently under analysis and will be expected to give the char-
acterization and correlation of pruritus, the disease severity and 
QOL in Japanese patients with psoriasis. The 5-D is a reliable, 
multidimensional measure of itching that has been validated in 
patients with psoriasis. The 5-D should be useful as a new tool 
for the evaluation of psoriatic pruritus.
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PP25
A UGANDAN GIRL WHO HAD TO ENDURE 
THIRTEEN YEARS OF ITCHY RASHES WITHOUT 
SEEING A DERMATOLOGIST: A CASE REPORT 
FROM THE NEW GEROLD JÄGER SKIN CLINIC 
IN KABALE, UGANDA
Leo Odongo
Gerold Jäger Skin Clinic in Kabale Regional Referral Hospital, Uganda
Background: Gerold Jäger skin clinic in Kabale is an initiative of 
Dr. Leo Odongo, a 33-year-old Ugandan trained dermatologist 
who, in the last five months, has been doing voluntary work of 
establishing the fourth university skin clinic in Uganda, where he 
is currently volunteering as a dermatologist in Kabale Regional 
Referral Hospital in South-Western Uganda. Uganda has less than 
fifteen trained dermatologists. The clinic is named after Prof. Dr. 
Gerold Jäger, who established the field of dermatology in Uganda 
and who also supervised Dr. Odongo´s Master´s degree Disserta-
tion in Dermatology. We report here about a 13 -year-old girl who 
has suffered from the itch without getting access to a dermatologist 
until she was rescued by the new skin clinic in Kabale. History: A 
13-year-old girl in whom the mother reports very itchy recurrent 
rashes on the body since early childhood. The itchy rash was later 
associated with itchy eyes. No history of asthma. However, there 
is positive family history of atopy. Mother sought treatment for the 
girl from many health workers, none of whom was a dermatologist. 
She was then given wrong advice and wrongly stopped from eating 
several food items. She was advised to smear herbal products, cow 
ghee and cow milk on the girl as remedy. Despite all these, the itchy 
rashes kept on recurring with increasing itch and discomfort for 
the girl. The mother was then told of the new clinic that had been 
opened in Kabale where she brought the girl to us for treatment. 
Findings on physical examination: We found the girl had dryness 
of skin with multiple scratch marks on the trunk and extremities 
with the face less affected. There was marked lichenification at the 
flexure surfaces (especially the antecubital fossae and the popliteal 
fossae). Atopic dermatitis was diagnosed. We treated the girl with 
two-weeks course of topical betamethasone ointment 0.1% applied 
twice daily. We recommended stoppage of use of herbal products, 
ghee and cow milk application on the girl’s skin and resumption of 
eating of the foods she had been wrongly stopped from eating. We 
reviewed the girl after two weeks of treatment and she had marked 
improvement in her symptoms. Itching had ceased completely 
and her quality of life had improved greatly. Conclusion: In our 
respective capacity we can all contribute something to the care 
of people who are tormented with itch. With the voluntary work 
of Dr. Leo Odongo, the girl was rescued from the torment of itch.
PP26
ITCH IN PSORIASIS – IS AGE AN IMPORTANT 
FACTOR?
Radomir Reszke, Rafał Białynicki-Birula, Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Poland
Introduction: The suspected lifespan of the population has in-
creased in recent years. Itch is the most common symptom in 
dermatology present in the majority of patients with psoriasis. 
As the frequency of chronic itch increases with the age, it will 
constitute important issue in elderly patients suffering from this 
common dermatosis. Objective: To assess detailed itch characte-
ristic in patients with psoriasis vulgaris with a special emphasis on 
age status. Material and Methods: The study included 67 conse-
cutive inpatients hospitalized in the Department of Dermatology, 
Venereology and Allergology, Wroclaw Medical University due 
to psoriasis vulgaris. A detailed history was taken. A physical 
examination of the skin including the evaluation of Psoriasis 
Area and Severity Index (PASI), Body Surface Index (BSA) 
and Physician’s Global Assessment (PGA) was performed. The 
presence of chronic itch was assessed, including the location, 
severity, variation during the day, influencing factors and impact 
on daily activities and sleep. Dermatology Life Quality Index 
(DLQI) and 6 Item Stigmatization Scale (6ISS) questionnaires 
were filled by the patient. A statistical analysis was performed. 
Results: Among 67 patients, 31.3% were women and 68.7% were 
men. The mean age was 55.5±15.3 years; 70.1% of participants 
were aged less than 65 years, while 29.9% were aged 65 and over. 
The mean time of the onset of disease was 19.5 years, whereas 
the mean PASI, BSA and PGA scores were 15.9, 32% and 2.1, 
respectively (no statistical differences between groups aged below 
65 years and over 65 years; p=0.68; p=0.92; p=0.80; respectively). 
Chronic pruritus was present in 71.6% patients; no differences 
were observed between age groups. The mean pruritus intensity 
in the last 3 days was 5.7 points; no differences were observed 
between age groups (5.6 vs. 6.1 points; respectively; p=0.46). In 
patients aged 65 and over cold ambient temperature reduced the 
itch intensity statistically more common than in individuals aged 
below 65 (86.7% vs. 24.2%; respectively; p=0.01); the mood 
decrease due to itch was also more prevalent in the former age 
group (73.3% vs. 60.6%; respectively; p=0.02). Conclusion: Itch 
is a common and relevant phenomenon in people suffering from 
psoriasis vulgaris. In the majority of aspects its characteristic did 
not differ according to the age group, while several aspects of itch 
were different, implying that aging may influence clinical features 
of itch in psoriatic subjects.
PP27
RELATIONSHIP BETWEEN PRURITUS AND 
SERUM LIPOCALIN-2 IN PATIENTS WITH 
PSORIASIS
Norie Aizawa1, Yozo Ishiuji1, Sanae Inokuchi1, Koichi Yanaba1, Yo-
shinori Umezawa1, Akihiko Asahina1, Nobuaki Takahashi2, Mits-
utoshi Tominaga2, Kenji Takamori2, Hidemi Nakagawa1
1Department of Dermatology, The Jikei University School of Medicine. To-
kyo, 2Institute for Environmental and Gender Specific Medicine, Juntendo 
University Graduate School of Medicine. Chiba, Japan
Background: Lipocalin-2 (LCN2) is a member of the highly hete-
rogeneous secretory protein also known as neutrophil gelatinase-
binding lipocalin (NGAL). It is mainly secreted from activated 
neutrophils and is known to be associated with neurodegeneration, 
cancer metastasis and inflammatory responses. It has been reported 
that serum LCN2 concentration increases in psoriasis patients, and 
decreases in patients with atopic dermatitis. A previous study also 
shows that astrocyte-derived LCN2 is involved in enhancement on 
spinal itch in the mouse model of atopic dermatitis. Recently the 
relationships between serum LCN2 concentration and pruritus have 
been reported in patients with psoriasis. Objective: This study was 
performed to examine the correlation between serum LCN2 level 
and pruritus in psoriasis or in atopic dermatitis patients. Methods: 
Serum LCN2 concentrations were measured in psoriasis patients, 
atopic dermatitis patients and healthy controls using enzyme-
linked immunosorbent assay (ELISA). The itch intensity was 
assessed with visual analog scale (VAS), and the disease severity 
was measured by psoriasis area and severity index (PASI) and 
scoring atopic dermatitis (SCORAD). Correlation was examined 
between serum LCN2 with VAS, PASI and SCORAD. Results: 
Serum LCN2 concentrations were significantly elevated in pso-
riatic patients and atopic dermatitis patients compared to healthy 
controls. In the psoriatic patients, serum LCN2 concentrations were 
significantly correlated with VAS, but not with PASI. In contrast, 
there was no correlation between serum LCN2 concentration and 
VAS, SCORAD in atopic dermatitis patients. Conclusion: These 
findings suggest that LCN2 is associated with the pruritus of pso-
riasis patients. Serum LCN2 levels may be a useful clinical marker 
for pruritus assessment in the patients with psoriasis. 
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PP28
EVALUATION OF THE CLINICAL CHARACTERIS-
TICS OF PRURITUS IN PATIENTS WITH DERMA-
TOMYOSITIS USING THE JAPANESE VERSION 
OF THE 5-D ITCH SCALE
Yozo Ishiuji1, Yoshinori Umezawa1, Norie Aizawa1, Sanae Inoku-
chi1, Akihiko Asahina1, Koichi Yanaba1, Toshiya Ebata2, Hidemi 
Nakagawa1
1Department of Dermatology Jikei University School of Medicine, 2Chito-
funa Dermatology Clinic, Japan
Dermatomyositis (DM) is a type of idiopathic inflammatory my-
opathy. The pathogenesis is considered to be microangiopathy 
affecting skin and muscle. The cutaneous manifestations of DM 
are the most important symptoms of this disease. The skin signs are 
various such as heliotrope rash, Gottron’s papules, paronychium 
erythema, poikiloderma, the V-neck sign, the shawl sign, cuticular 
overgrowth, mechanic’s hands, photosensitivity and so on. Pruritus 
is one of the cardinal symptoms that DM patients often complain. 
It is known to significantly affect daily life and correlates with 
a worse quality of life. To evaluate pruritus is very important to 
improve their quality of life. However, the precise characteristics 
of pruritus in patients with DM are unknown. The aim of current 
study is to evaluate the clinical characteristics of pruritus in pa-
tients with DM. Pruritus was assessed by Japanese version of 5-D 
itch scale. The 5-D itch scale is a new simple self-administered 
questionnaire. It consists of five sections that measure duration, 
degree, direction, disability and distribution of itching. Recently, 
DM has been categorized into several disease subsets based on 
the various myositis-associated autoantibodies such as anti-Jo-1 
antibody, anti-Mi-2 antibody, anti-transcriptional intermediary 
factor 1 gamma (TIF1γ) antibody, anti-melanoma differentiation-
associated gene 5 product (MDA5) antibody. We examine the 
relationship between pruritus and myositis-associated autoantibod-
ies. In addition, DM is associated with internal malignancy. We 
also examine the relationship between pruritus and the presence 
of internal malignancy. Our data are currently under analysis and 
will be expected to give the prevalence and characterization of 
pruritus in Japanese patients with DM.
PP29
THE NEED FOR LINGUISTICALLY AND 
CULTURALLY ADAPTED STANDARD 
QUESTIONNAIRES TO ASSESS ITCH: 
PRELIMINARY STUDY AND PERSPECTIVES
Deok-Hee Kim-Dufor1, Adèle Poulaliou2, Laurent Misery2
1CNRS, UMR 6285 Lab-STICC, 2Department of Dermatology, University 
Hospital, Brest, France
Itch is defined as an unpleasant sensation leading to the need to 
scratch. Nonetheless, the meaning is not necessarily the same de-
pending on languages, cultures and historical periods. For patients 
and even doctors, it is not always evident to differentiate itch from 
close sensations such as pain, burning, tingling, tickling, prickling, 
tightness or stinging, and it is not obvious that the borders between 
these sensations are the same in all languages. The presented study 
is a preliminary framework for the creation of standard and validated 
questionnaires considering cross-cultural and linguistic adaptations. 
Twenty-seven languages classified into 6 language families are 
included in our study. The adequate understanding of the sensations 
experienced by patients is undeniably crucial in the patient-doctor 
relationship and indispensable for clinical trials, investigations 
into quality of life, psychological studies and pathophysiological 
research. The presented preliminary study confirms the need and 
proposes a method for the creation of standard and validated ques-
tionnaires. The next step will be a study with interviews of patients 
that would describe their symptoms in their own language in order 
to validate translations of questionnaires in all studied languages.
PP30
DETECTION OF PRESENCE IGG1-IGG4, IGE, IGA, 
IGM, C3C, C1Q AND FIBRINOGEN DEPOSITS 
UNDER DIRECT IMMUNOFLUORESCENCE 
STAINING IN ELDERY PATIENTS WITH 
PRURITIC DERMATOSES
Natalia Zdanowska, Agnieszka Owczarczyk-Saczonek, Joanna 
Czerwińska, Martyna Bieniek-Kobuszewska, Waldemar Placek
Department of Dermatology, Sexually Transmitted Diseases and Clinical 
Immunology, University of Warmia and Masuria, Municipal Hospital in 
Olsztyn, Poland
Background: Pruritic dermatoses of the eldery pose a diagnostic 
and therapeutic challenge. Prodromal phase of bullous pemphigoid 
(BP) should be considered in patients with extensive pruritus and 
skin lesions of polymorphic appearence and urticaria-like plaques, 
eczema-like papules and dermatitis herpetiformis-like lesions. 
Early recognition of prodromal BP may decrease progression of 
the disease. While the pathogenicity of IgG autoantibodies to BP 
180 kDa has been demonstrated in BP, the role of IgE autoanti-
bodies remains unclear. Objectives: The purpose of the study was 
to assess the presence of tissue-bound IgG1-IgG4, IgE, IgM, IgA, 
C3c, C1q and fibrinogen deposits in eldery patients with various 
pruritic dermatoses who had never experienced clinically apparent 
blisters, and their correlation with distinct clinical features. Ma-
terials and Methods: In this retrospective study we assessed the 
presence of IgG1-IgG4, IgE, IgM, IgA, C3c, C1q and fibrinogen 
deposits as detected by direct immunofluorescence microscopy 
of skin biopsy speciemens obtained from 33 eldery patients (>60 
years old). Clinical features at time of diagnosis were noted. 
Patients with acute or chronic, mild to intense pruritus, who 
had never experienced blisters and patients who didn’t have any 
other known dermatological disorder were included to the study. 
Results: IgG1-IgG4 and IgE deposits were present in 1 patient 
and were localized in epidermis. Deposits of IgG2 and IgG3, 
IgG4, IgE in dermoepidermal junction were present in 1 patient. 
Deposits of IgE in epidermis were found in 3 patients, IgM and 
C1q in 4 patients. Deposits of C3c and C3c, IgG1 and fibrinogen 
were present in 1 patient. The most common clinical presentation 
was itch with no skin lesions (14 patients), prurigo nodularis-like 
lesions (8 patients), urticaria-like lesions (5 patients), eczema-
like lesions (3 patients), dermatitis herpetiformis-like lesions (2 
patients) and lichen planus-like lesions (1 patient). Conclusion: 
Our findings show that presence of tissue-bound IgG1-IgG4, IgE, 
IgA, IgM, C3c, C1q and fibrinogen deposits provide additional 
information in some patients, Prospective studies indicating cor-
relation between presence of circulating IgE and IgG with tissue-
bound deposits of autoantibodies are needed, same as designation 
of specificity of autoantibodies with distinct clinical features and 
course of disease. 
PP31
VALIDATION OF JAPANESE VERSION OF 
ITCHYQOL IN CHRONIC PRURITUS PATIENTS
Toshiya Ebata1, Yuko Hayakawa1, Akishi Momose2, Yuko Higak3, 
Suephy C. Chen4
1Chitofuna Dermatology Clinic, Tokyo, 2Jusendo Clinic, Fukushima, 3Wa-
kamatsu-cho Mental and Skin Clinic, Tokyo, Japan, 4Department of Der-
matology, Emory University, Atlanta, USA
Chronic pruritus (CP) has such a negative impact on quality of life 
(QoL) of the patients. Hence, it is important to monitor the extent of 
QoL impairment in the course of treatment of CP. ItchyQoL is the 
first pruritus-specific QoL instrument developed in 2008 and wi-
dely used in the English and German speaking countries. We here 
report a validation of the Japanese version of ItchyQoL (ItchyQoL-
JPN). ItchyQoL-JPN was created through the standard protocol 
including backward translation. A total of 100 adult patients with 
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CP (atopic dermatitis 68, uremic pruritus 18, other dermatitis 6, 
prurigo 4, chronic urticarial 4) participated in the study to test re-
liability, validity and responsiveness of ItchyQoL-JPN. Reliability 
was demonstrated by internal consistency (Cronbach alpha: 0.81) 
and test-retest reproducibility (intraclass correlation coefficient: 
0.89, p<0.001). ItchyQoL-JPN showed face and content validity. 
Convergent validity was demonstrated by positive correlation of 
ItchyQoL-JPN with itch intensity measured with a visual analogue 
scale (VAS, 0=no itch and 10=the worst itch imaginable) (r=0.46, 
p<0.001) and Skindex-16 (r=0.85, p<0.001), a widely used QoL 
instrument of skin diseases in Japan. Changes in ItchyQoL-JPN 
over the course of 2 to 3months correlated well with changes 
in VAS (r=0.70, p<0.001) showing a good responsiveness. The 
results from the present study suggest that ItchyQoL-JPN may 
make it possible to evaluate the QoL impairment of the Japanese 
patients with CP.
PP32
DIFFERENCES IN FACTORS THAT DRIVE 
PRURITUS QUALITY OF LIFE BETWEEN ASIAN 
AMERICANS AND OTHER RACES
Kevin Luk1, Alix Pijeaux1, Kuang-Ho Chen2, Glenda Wrenn2, Cas-
sandra Quave1, Sarah Chisolm1, Seema Kini1, Suephy Chen1,3
1Department of Dermatology, Emory University School of Medicine, 2De-
partment of Psychiatry and Behavioral Science, Morehouse School of Med-
icine & Women’s Center of Excellence for Specialty Care Education, At-
lanta Veterans Administration Medical Center, 3Division of Dermatology, 
Atlanta Veterans Administration Medical Center, USA
Racial disparities in pruritus quality of life (QoL) have been 
reported. Our data from a veterans population indicated that 
non-whites have greater pruritus-specific QoL impact. Asian or 
Pacific Islanders (API) more commonly report certain pruritic 
conditions and seek medical care for pruritus, but the etiology 
of this disparity remains unclear. API are traditionally grouped 
into one population or grouped as “Other”, but are in reality a 
heterogeneous group. We investigated potential factors mediating 
this disparity in an API population of 43 itchy and 29 non-itchy 
subjects. Surveys assessing QoL (ItchyQoL) and itch severity 
were given to itchy subjects, and demographics and medical 
distrust to all subjects. The API group had a mean itch severity 
score of 4.19 (SD 2.62), which is lower than that of the veterans 
(5.2, SD 2.3). As in the veteran group, itch severity was a signi-
ficant predictor of QoL. However, in the API group, years since 
immigration was an additional predictor for functional impact, and 
sex for emotional impact (p < 0.05). As in the veterans group, itch 
had disproportionately higher emotional rather than functional or 
symptomatic impact on QoL among API. Statistically significant 
differences in individual ItchyQoL item means between itchy 
API and veterans of different races were also found among all 
three subscales. Qualitatively, we found certain ItchyQoL items 
to be drivers under each subscale. APIs had higher concern for 
scratching and seasonal aggravation for symptomatic impact; 
sleep disturbance for functional impact; and concern that their 
pruritus would last forever for emotional impact. Finally, we 
found differences in medical system distrust between itchy and 
non-itchy subjects; compared to the non-itchy API, itchy subjects 
felt less comfortable telling their physicians “anything” (Z –2.34, 
p=0.019). Interestingly, itchy API more strongly disagreed that 
“their physicians pretended to know something he/she did not 
know” (Z –2.55, p=0.011) or “if a mistake was made in their 
treatment, their doctor would try to hide it from them” (Z –2.08, 
p=0.037). Despite a small homogenous cohort, these preliminary 
results merit further exploration of potential differences between 
API ethnicities and related sociocultural factors that may mediate 
these disparities in pruritus. 
PP33
INVESTIGATING RACIAL DISPARITIES IN 
PRURITUS QUALITY OF LIFE IN PEDIATRIC 
PATIENTS
Alix Pijeaux, Grace Lee, Shelby Smith, Sandy Francois, Kuang-Ho 
Chen, Suephy Chen
Emory University School of Medicine, Atlanta, GA, USA
Introduction: Racial disparities in the quality of life (QoL) impact 
of chronic pruritus (CP, >6 weeks) have previously been reported 
in adults, with non-whites reporting worse QoL impact even 
after adjusting for itch severity. Although racial disparities in CP 
prevalence have been described in children, differences in QoL 
impact remain unclear. This study investigates racial differences 
in QoL impact in children with CP. Methods: 8-17 year olds 
with CP were recruited from the Emory Clinic (n=153). Subjects 
completed the pediatric ItchyQoL, a 35-item survey that measu-
res the symptomatic, emotional, and functional QoL impact of 
itchy skin in children (validation pending). Race was reported by 
guardian, and subsequently categorized as “Black” or “Nonblack”. 
Results: A total of 153 patients were recruited of which 89 were 
Nonblack. Nonblack children were nearly 3 times more likely to 
report having felt different from other kids their age, because of 
itchy skin, compared to Black children (Odds Ratio 2.9; 95% CI 
1.258–6.981). In none of the other ItchyQoL items did nonblack 
children significantly differ from blacks. Interestingly, when 
race was categorized as “White” and “Nonwhite”, there were no 
significant differences in any of the items. Conclusion: The fact 
that nonblack children were more likely to feel different from 
peers than black children may be due to the high prevalence of 
atopic dermatitis in black children. Black children would see that 
their friends itch as much as they do. The fact that categorization 
of White vs. Nonwhite did not yield differences suggest that the 
Hispanic and Asian populations may not differ significantly from 
Whites in their QoLimpact. Further investigation is indicated to 
elucidate possible etiologies for these initial findings, such as 
cultural perception and social implications of itch in children. 
PP34
DOES PRE-SCRATCHING REDUCE THE ITCH 
TRANSMISSION?
Ravi Chandra Kopparaju, Chih-Cheng Chen
Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan /Taiwan 
International Graduate Program in Interdisciplinary Neuroscience, Natio-
nal Yang-Ming University and Academia Sinica, Taipei, Taiwan
Itch is an unpleasant sensation caused by pruritogen transmitted by 
sensory neurons to the spinal dorsal horn and then to higher brain 
center, which eventually induces the desire to scratch. The act of 
scratching and variable noxious counter stimuli like noxious heat 
and painful sensations relieve the itch sensation. However, it is not 
clear whether the noxious stimuli prior to injection of pruritogen 
could effectively reduce the itch sensation. Here we observed 
antipruritic effect produced by brief noxious stimuli applied on 
mouse skin prior to pruritogen. This effect was accomplished by 
We demonstrated that application of noxious stimuli (e.g., pas-
sive scratching) on the nape skin of mild anesthetized prior to 
prutrinogen could significantly reduce itch response. Similar itch 
reduction was observed in the nape and cheek skin models, when 
intradermal injection of capsaicin was given prior to prutinogen. 
The antipruritic effect produced by brief noxious stimuli lasted 
for more than 20 minutes. We further demonstrated that passive 
scratching of mice led to phosphorylation of ERK in cervical 
DRG neurons and enhanced c-Fos expression in lamina II of the 
cervical spinal dorsal horn. Taken together, noxious stimuli prior 
to pruritogen challenges are effective to diminish itch responses 
by neural modulation at the spinal cord level, although possible 
involvement of supraspinal control cannot be excluded. 
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PP35
THE RELATIONSHIP BETWEEN STRESS AND 
ITCH IN GERMAN UNIVERSITY STUDENTS
Stephanie Kiupel1, Joerg Kupfer1, Uwe Gieler2, Sophia Kottlors1, 
Gil Yosipovich3, Christina Schut1
1Institute of Medical Psychology, and 2Clinics for Dermatology and Aller-
gology, Justus-Liebig-University, Gießen, Germany, 3Department of Der-
matology and Cutaneous Surgery, Miller School of Medicine at University 
of Miami, USA
Background: Attending university is often accompanied by dif-
ferent stressors like taking exams or financial strain. In addition, 
itch and stress are related in patients with atopic dermatitis. A 
recent US-study found that stress and itch are linked in univer-
sity students. However, the previous study did not differentiate 
between students with and without skin diseases and with acute 
or chronic itch. Therefore, the aim of the current study is to in-
vestigate whether the relationship between stress and itch differs 
between these groups. Methods: 794 students (135 male) filled 
in a web-based version of the Perceived Stress Questionnaire 
(PSQ) to measure perceived stress during the last month and a 
modified version of the Self-Reported Skin Questionnaire (SRSQ) 
to measure different skin symptoms, including itch. Itch inten-
sity during the last four weeks was measured by a visual analog 
scale ranging from 0–10. Correlation analyses were conducted 
to investigate the relationship between stress and itch intensity 
in students with and without skin diseases and acute or chronic 
itch. Results: In 252 students, itch did not occur during the last 
month (35 with skin disease). Of the students who reported itch, 
442 had acute itch (139 with skin disease), 100 had chronic itch 
(66 with skin disease). We found a significant relationship between 
stress and itch intensity in students who had no skin disease and 
acute itch (r=0.196; p=0.002) as well as in students who had no 
skin disease, but reported chronic itch (r=0.367; p=0.033). The 
correlation between stress and itch intensity in students who have 
been diagnosed with a skin disease and had chronic itch was not 
significant (r=0.166; p=0.186). Also, the relationship in students 
with a clinical diagnosis of a skin disease and acute itch was not 
significant (r=0.053; p=0.57). Discussion: This study investigated 
the relationship between stress and itch in German students, dif-
ferentiating between students with and without skin diseases and 
with acute or chronic itch. Interestingly, we only found significant 
relationships between stress and itch intensity in students without a 
skin disease, no matter if they had chronic or acute itch. The finding 
that stress and itch intensity were not related in students with a 
skin disease could partly be explained by the fact that we did not 
distinguish between itch related and non-itch related skin diseases.
PP36
SUMATRIPTAN, THE ANTI-MIGRANOUS DRUG, 
SUPPRESSES SEROTONIN-INDUCED ITCH: THE 
POSSIBLE INVOLVEMENT OF OPIOIDERGIC 
SYSTEM
Nazgol-Sadat Haddadi1, Arash Foroutan1, Sattar Ostadhadi1, 
Saeed Shakiba1, Khashayar Afshari1, Maryam Daneshpazhooh2, 
Ahmad-Reza Dehpour1
1Experimental Medicine Research Center, and 2Department of Dermato-
logy, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
Introduction: Serotonin (5-hydroxytryptamine or 5-HT) is a neu-
rotransmitter in itch. In Addition, impaired serotonin signaling is 
linked to variety of itch conditions. Intradermal injection of 5-HT 
induces scratching behavior in mice through stimulation of 5-HT 
receptors. Previous studies have demonstrated that activation of 
5-HT1B/1D receptors inhibits neurotransmission. Therefore, we 
investigated if sumatriptan, a selective 5-HT1B/1D receptors 
agonist, has inhibitory effects on serotonin-induced itch in mice. 
Materials and Methods: Serotonin was injected intradermally into 
the rostral back of mice, and itch was assessed by quantification 
of hind paw scratching bouts towards the injection site. Then, 
the effect of sumatriptan, GR-127935, a selective 5-HT1B/1D 
receptors antagonist, and opioid receptor antagonists on 5-HT-
induced itch was assessed. Results: Intradermal and intraperitoneal 
administration of sumatriptan significantly reduces 5-HT-induced 
scratching behavior in mice. While intradermal injection of 
GR-127935 reverses the anti-pruritic effects of sumatriptan. In 
addition, our findings show that intradermal and intraperitoneal 
naltrexone (NTX), a non-specific opioid receptor antagonist, and 
methylnaltrexone (MNTX), a peripherally acting opioid receptor 
antagonist, significantly decrease the 5-HT-induced scratching 
behavior. Additionally, combined treatment with sub-effective 
doses of sumatriptan and an opioid receptor antagonist, naltrexone, 
decreases 5-HT-evoked scratching activity. Conclusion: Suma-
triptan inhibits 5-HT-induced itch by activating the peripheral 
5-HT1B/1D receptors. Moreover, peripheral opioid receptors 
have role in serotonin-induced itch, and anti-pruritic effects of 
sumatriptan seem to involve the peripheral opioid system. Thus, 
5-HT1B/1D receptors agonists may be useful to treat a variety 
of pathologic itch conditions with impaired serotonergic system.
PP37
DEFINING A RESPONDER ON THE PEAK 
PRURITUS NUMERICAL RATING SCALE (NRS) 
IN PATIENTS WITH MODERATE-TO-SEVERE 
ATOPIC DERMATITIS: DETAILED ANALYSIS 
FROM RANDOMIZED TRIALS OF DUPILUMAB
Eric Simpson1, Abhijit Gadkari2, Laurent Eckert3, Matthew Rea-
ney4, Marius Ardeleanu2, Adeline Abbé3, Michael Andria2
1Oregon Health & Science University, Portland, 2Regeneron Pharmaceu-
ticals, Inc., Tarrytown, USA, 3Sanofi, Chilly-Mazarin, France, 4Sanofi, 
Guildford, UK
Rationale: To empirically derive estimates of responder defi-
nitions for the Peak Pruritus Numerical Rating Scale (NRS) 
in moderate-to-severe atopic dermatitis (AD), and to apply 
these to determine benefit of dupilumab on itch. Methods: Re-
sponder definition estimates were computed using anchor- and 
distribution-based methods from a phase 2b randomized study 
of dupilumab (NCT01859988). The anchor-based analysis used 
the following anchors at Week (W) 16: 1-point improvement 
on the Pruritus Categorical Scale (PCS); patients achieving 
50%−74%, 75%−89%, 90%−100% improvement in Eczema 
Area and Severity Index (EASI) (EASI 50−74, EASI 75−89, 
EASI 90−100, respectively); patients achieving an Investigator’s 
Global Assessment (IGA) score of ≤1 (IGA 0/1), or an IGA 
improvement of ≥2 points. For the distribution-based method, 
one half-SD of the mean Peak Pruritus NRS score at baseline 
was used. Post-hoc cumulative distribution functions (CDFs) of 
Peak Pruritus NRS at W2 and W16 were plotted for patients with 
moderate-to-severe AD receiving dupilumab 300 mg every week 
(qw) (n=462) or every other week (q2w) (n=457), or placebo 
(n=460) using data from two phase 3 randomized, double-blind, 
placebo-controlled trials of dupilumab (SOLO 1: NCT02277743; 
SOLO 2: NCT02277769). Results: The responder definition 
estimate based on the patient-reported PCS was 2.6; estimates 
based on clinician-reported anchors (EASI and IGA) ranged 
from 2.2 to 4.2, with the highest estimates derived from the 
most stringent clinical criteria (EASI 90–100 and IGA 0/1). The 
one-half SD estimate was much lower at 0.76. In SOLO 1, the 
CDF plots showed clear separation between the two dupilumab 
groups and the placebo group across the full range of observed 
response thresholds (W2: –4 to 0; W16: −8 (dupilumab q2w)/ 
−7 (dupilumab qw) to 0). In SOLO 2, a similar separation was 
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observed (W2: −5 to 0; W16: −7 to 0). Across both phase 3 trials, 
more dupilumab- vs placebo-treated patients were classified as 
responders at W2 and W16 using thresholds derived from the 
phase 2b study. Treatment groups had similar rates of treatment-
emergent adverse events (TEAEs) (SOLO 1: 65%–73%; SOLO 
2: 65%–72%). Commonly-occurring TEAEs were AD exacer-
bations and injection-site reactions. Conclusions: Peak Pruritus 
NRS response can be defined as a reduction of ≥3–4 points. The 
CDFs demonstrate that dupilumab had a clinically meaningful 
impact on itch in moderate-to-severe AD patients. 
PP38
SIGNIFICANCE OF IL-31 EXPRESSION IN SKIN 
AND IN SERUM IN PATOMECHANISM OF 
PRURITUS IN CTCLS
Berenika Olszewska1, Anton Żawrocki2, Marta Malek1, Jo-
lanta Gleń1, Magdalena Lange1, Roman Nowicki1, Małgorzata 
Sokołowska- Wojdyło1
1Clinic of Dermatology, Venerology and Allergology, and 2Department of 
Pathology, Medical University of Gdańsk, Gdańsk, Poland
Primary cutaneous T-cell lymphoma (CTCL) is a chronic disease 
accompanied by persistent pruritus which responds poorly to 
antihistamines and therefore significantly reduces quality of life. 
Diagnosing especially early stage of mycosis fungoides (MF) is 
difficult as it resemble inflammatory dermatoses such as atopic 
dermatitis or eczema. Not only the pathogenesis of the disease 
but also the pathomechanism of pruritus in CTCL in not fully 
understood. Due to unclear and conflicting reports about role 
of IL-31 in pathogenesis of pruritus accompanying CTCL, we 
ought to develop the subject of IL-31 in CTCL. We conducted 
research over study group of 51 patients with MF and 40 heal-
thy volunteers. Majority of CTCLs were diagnosed at the time 
of collecting skin biopsies and blood specimens. Expression of 
IL-31 was evaluated in formalin-fixed paraffin-embedded biopsy 
specimens from CTCL patients and healthy individuals by means 
of immunohistochemical staining. Serum IL-31 levels in CTCL 
patients were determined by the enzyme-linked immunosor-
bent assay methodology. The IL-31 serum and skin level was 
significantly higher in CTCL patients than in control group. We 
found lack of significant difference in IL-31 serum and skin level 
between pruritic and non-pruritic MF patients and no correlation 
between IL-31 serum , skin level and pruritus severity. Due to 
our conflicting results that are not in line with current state of 
knowledge about role of IL-31 in pruritus in CTCL, we decided 
to repeat the research. Four years after garnering samples and 
data we were able to verify diagnoses once more and conduct 
research over a solid group of CTCL patients. We investigated 
the correlation between the IL-31 skin levels, IL-31 serum levels, 
pruritus and stage of the disease. 
PP39
SUMATRIPTAN ATTENUATES CQ-INDUCED 
SCRATCHING THROUGH NO-PATHWAY
Khashayar Afshari, Nazgol-Sadat Haddadi, Sattar Ostadhadi, 
Saeed Shakiba, Arash Foroutan, Ahmad-Reza Dehpour
Experimental Medicine Research Center, Tehran University of Medical Sci-
ences, Tehran, Iran
Introduction: Chloroquine (CQ) induces histamine-independent 
itch in human and mice. We recently reported the role of in-
tradermal nitric oxide (NO)/ cyclic guanosine monophosphate 
(cGMP) pathway in CQ-evoked scratching behavior in mice. 
Chloroquine stimulates neuronal nitric oxide synthase (nNOS) 
activity to over-producing NO in the skin. Sumatriptan, the 
5-hydroxytryptamine 1b/1d receptors (5-HTR1b/1d) agonist, 
is used to treat migraine and cluster headaches. According to 
previous studies, sumatriptan inhibits NOS activity and inhibits 
neurotransmission. Thus, we investigated the effect of sumatriptan 
on CQ-induced scratching behavior. Materials and Methods: The 
rostral back model of itch was used. Chloroquine was injected 
intradermally into the nape of the neck and scratching behavior 
was evaluated by measuring the number of bouts in 30 minutes. 
Then, the effect of local and systemic administration of sumatrip-
tan on scratching behavior was assessed. Finally, sub-effective 
doses of sumatriptan and a non-selective NO synthase inhibitor, 
L-N-nitro arginine methyl ester (L-NAME), was administered 
before intradermal CQ. Results: Intraperitoneal and intradermal 
administration of sumatriptan attenuates CQ-induced itch which 
reversed by intradermal GR-127935, the selective 5-HTR1b, and 
5-HTR1d antagonist. Co-administration of sub-effective doses of 
sumatriptan and L-NAME significantly decreased the scratching 
behavior. Conclusion: Sumatriptan suppresses CQ-induced itch 
by activating 5-HT1b/1d receptors. This effect probably mediates 
through NO pathway.
PP40
REDUCTION OF PRURITUS IN ONCOLOGICAL 
PATIENTS RECEIVING EGFRI THERAPY
Dominika Ragin, Katarzyna Nowacka, Barbara Zegarska
Department of Cosmetology and Aesthetic Dermatology, Nicolaus Co-
pernicus University Ludwik Rydygier Collegium Medicum in Bydgoszcz, 
Poland
EGFR inhibitors are targeted agents used for treatment of ma-
lignancies characterised by overexpression of EGF receptor. 
e.g. colorectal, pancreatic and breast cancer, non-small cell lung 
cancer or head and neck cancer. Due to the impact on differen-
tiation and growth of epithelial cells, EGFR inhibitors induce a 
number of side effects, including pruritus. While treating with 
EGFRI, pruritus usually occurs during the first three months of 
therapy in approximately half of the patients. Itching is most 
likely associated with the EGFRI drugs due to their influence on 
substance P activation, which is one of the major neuromediators 
of pruritus. Itching may accompany xerosis, a side effect which 
often occurs during the treatment. It is likely to be located in 
areas affected with papulopustular rash - the most common side 
effect of EGFRI treatment. Pruritus is unlikely to require EGFRI 
dose alteration or a drug change. Nevertheless, it significantly 
decreases QoL of the patients. As a result, it is vital to reduce 
itching using topical and systemic treatment and to instruct pa-
tients on the proper skin care. Basic management is focused on 
decreasing the pruritus by regaining the proper structure of the 
epidermal barrier. Cosmetics rich in greasing and moisturizing 
components, as well as emollients, should be used. Delivering 
physiological lipid mixtures, substances with occlusive properties 
and humectants would diminish transepidermal water loss. Cos-
metics which dehydrate and irritate the skin, such as retinoids, 
alkaline soaps or alcohol containing mixtures, should be exclu-
ded. Moreover, patients are expected to avoid overexposure to the 
UV, synthetic clothing and perfumes. Depending on the severity 
of pruritus, different recommendations for reducing itching of 
various etiologies exist. Topical steroids or 1–3% menthol are 
commonly used, yet first of all, topically applied drugs aimed at 
reducing the coexisting papulopustular rash should be selected. 
Antihistamines and lidocaine applied topically are probably not 
efficient enough, thus they are not recommended. Systemic tre-
atment includes non-sedating second-generation antihistamines. 
Research is being conducted on efficiency of antiepileptic agents 
in providing pruritic relief. 
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
1047Poster abstracts
Acta Derm Venereol 2017
PP41
LYSOPHOSPHATIDIC ACID INDUCES ITCH AND 
PAIN IN HUMANS DEPENDING ON THE MODE OF 
APPLICATION
Margareta Miriam Düll1, Lina Wurm1, Vivien Ries2, Martina 
Stengel1, Peter W. Reeh2, Michael J. Fischer3, Barbara Namer2, 
Andreas E. Kremer1
1Department of Medicine 1 and Institute of Physiology and Pathophysio-
logy, and 2Institute of Physiology and Pathophysiology, Friedrich-Alexan-
der-University Erlangen-Nürnberg, Germany, 3Center for Physiology and 
Pharmacology, Medical University of Vienna, Austria
Introduction: Hepatobiliary disorders involving cholestasis are 
frequently accompanied by pruritus. Lysophosphatidic acid (LPA) 
has recently been identified as potential mediator of this agonizing 
symptom. Serum levels of the LPA forming enzyme ATX correla-
ted with itch intensity in pruritic patients and intradermal injection 
of LPA induced scratching behaviour in mice. This study aimed 
to further investigate the involvement of LPA and bile salts in itch 
signalling using psychophysics and microneurography. Methods: 
Psychophysical testing and microneurography were performed on 
32 healthy volunteers and 22 cholestatic patients with primary 
biliary cholangitis and primary sclerosing cholangitis. LPA and 
the bile salts, taurocholate (TC) and taurolithocholate (TLC), were 
applied intradermally via heat-inactivated cowhage spicules or 
intradermal injections. Histamine, capsaicin and the vehicle SIF 
served as control applications. The flare reaction was determined 
by laser Doppler imaging. Sensitization and desensitization of 
nerve endings by LPA were tested using thermal, mechanical 
and electrical stimuli. Electrophysiological recordings of single 
primary C-fibres were performed in healthy human subjects at 
the peroneal nerve. Results: In psychophysics, focal application 
of LPA caused itch (mean±SEM; 1.4±0.4 vs. 0.3±0.2; p<0.001), 
whereas the injection of LPA induced dose-dependent pain and heat 
hyperalgesia. Neither the TRPV1 inhibitor BCTC nor the TRPA1 
blocker A967079 reduced LPA-mediated symptoms. In some 
patients with PBC and PSC, LPA injection caused itching instead 
of pain. LPA induced a sensitization to heat, while responses to 
cold, mechanical and electrical stimuli remained unchanged. In 
contrast, neither TC nor TLC induced any substantial sensation in 
healthy volunteers and cholestatic patients. In microneurography, 
human nociceptors, mechano-sensitive (CM, n=22 of 34) and 
mechano-insensitive (CMi, n=9 of 11), were both activated by 
LPA injection. While CM were excited rather weakly, medium 
or strong responses to the injection could be observed in few 
fibres, mainly histamine-responsive CMi. Conclusion: LPA ac-
tivated human nociceptors and produced itch and pain in humans 
depending on the mode of application. Presumably the focal 
activation of nociceptors according to the spatial contrast theory 
accounts for the itch sensation. A small subgroup of nociceptors, 
i.e. histamine-responsive CMi, could be further involved in LPA 
mediated perceptions.
PP42
ANGIOLYMPHOID HYPERPLASIA WITH 
EOSINOPHILIA – A CASE OF PERSISTENT 
PRURITUS OF THE SCALP
Patrycja Gajda1, Adriana Rakowska1, Joanna Czuwara1, Mariusz 
Sikora1, Małgorzata Jabłońska2
1Department of Dermatology Medical University of Warsaw, 2Individual 
Specialist Medical Practice Małgorzata Jabłońska, Poland
Background: Angiolymphoid hyperplasia with eosinophilia 
(ALHE) is an uncommon benign vascular and inflammatory 
disorder that typically occurs in young adults. ALHE usually 
presents as a group of several red-brown or violaceous papules or 
small nodules localized on the head or neck, and the ears area. A 
probably role in the pathogenesis of the disease is a mechanical 
injury. Objective: We report a rare case of ALHE in a 38-year-old 
female with several nodules involving the occipital and parietal 
area with accompanying persistent pruritus. Case report: The 
first violaceus nodules in the occipital area appeared in 2011 
and they spontaneously resolved after a few months. Since 
2014, progressively increasing nodular lesions with a maximum 
diameter of 1 cm in the occipital and parietal region with conco-
mitant persistent pruritus not responding to topical steroids and 
cryotherapy. Results: In the physical examination a number of 
nodular lesions were found in the scalp, strongly bleeding after 
mechanical irritation. The trichoscopy showed nodules with 
a normal hair-shafts and cloud-vessels on a homogenous pink 
background. Histopathological examination revealed clusters of 
proliferating capillaries and cellular infiltrate, localized around 
the blood vessels, composed mainly of lymphocytes and large 
number of eosinophils. Triamcinolone injections of 10 mg/ml 
were used for the treatment. A significant reduction of the pruri-
tus was achieved, which stopped appearance of new skin lesions 
and partial resolve of the previous ones. Conclusion: ALHE is 
considered an atypical vascular tumor but numerous factors sug-
gest that it is an unusual reactive process. In our case, the disease 
was most likely stimulated by persistent itch. Reduction of the 
pruritus stopped the progression of the disease.
PP43
THE PROBLEM OF THE ITCH IN SURGICAL 
ONCOLOGY - DO WE KNOW EVERYTHING 
ABOUT THE PREVENTION, DIAGNOSIS AND 
TREATMENT?
Katarzyna Nowacka1, Maciej Nowacki2, Wojciech Zegarski2, Do-
minika Ragin1, Barbara Zegarska1
1Chair of Cosmetology and Aesthetic Dermatology, and 2Chair and De-
partment of Surgical Oncology, Ludwik Rydygier’s Collegium Medicum in 
Bydgoszcz, Nicolaus Copernicus University in Torun, Oncology Centre - 
Professor Franciszek Łukaszczyk Memorial Hospital in Bydgoszcz, Poland
Introduction: The surgical oncology is stiill developing. In re-
cent years a significant number of new and innovative treatment 
alike diagnostic options has been introduced into the clinic. 
Beside the still obtained better prognostic and general overcome 
results there is stiil a big need to create in this specific medical 
speciality a new types and forms of suportive care and treatment 
options. To the one of such problematic fields in current surgcal 
oncology becomes the still not fully resolved problem of the Itch 
in oncologic patients. Aim: The aim of this study was to anylze 
the general incidence of itch in surgical oncology patients alike 
possible diagnostic and therapeutic options developed globaly 
to resolve this problem.Additionaly we have assed the possible 
future development ways and new creating ideas which could be 
important in nexy years. Material and Methods: In this study we 
have performed an comperhesive review analyzis of scientific 
papers, recomendations and gudelines reffering to the problem 
of the itch in surgical oncology. In this study we have collect also 
the clinical data from the reference center for surgical oncology 
of patients in which the problem of the itch has been diagnosed. 
Our material concerned the time period of 2002 and 2017. During 
our analyzis we have also searched the informations about pos-
sible development in this problematic field. Results: In this study 
we have presented the most common types of cases in which 
itch has been reported and which should be imortant in futher 
dermatological deliberations in the field of surgical oncology. 
The most common and detailed materials has been found using 
the open scientific data bases. Conclusion: The problem of the 
itch in surgical oncology patients is still important and not fully 
resolved. More specific scientific analyzis and targeted programs 
should be performed in the future. 
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PP44
WHAT ARE PRURITOGENS OF CHRONIC KIDNEY 
DISEASE ASSOCIATED PRURITUS
Akishi Momose1, Michihiro Yabe1, Shigetoshi Chiba1, Kenjirou 
Kumakawa1, Yasauo Shiraiwa1, Tomomi Kusumi2, Hiroki Mizu-
kami3
1Department of Urology, Jusendo General Hospital, 2Department of Patho-
logy, Aomori General Hospital, 3Department of Pathology and Molecular 
Medicine, Hirosaki University Graduate School of Medicine, Japan
In peripheral mechanism of pathophysiology of chronic kidney 
disease (CKD) associated pruritus (CKD-aP), the pruritogens, the 
modulators and the receptors of CKD-aP are important. To date, 
many pruritogens originated keratinocyte, macrophage/monocyte, 
mast cell, lymphocyte and so forth in the skin of patients with 
many skin diseases (e.g., atopic dermatitis) have been discovered. 
This study was undertaken to analyze the expressions of prurito-
gens in the skin of CKD patients with and without CKD-aP. The 
study included 16 subjects on CKD stage 5 (10 with CKD-aP 
and 6 without pruritus) from 2004 to 2006, 23 subjects (13 with 
CKD-aP and 10 without pruritus) from 2007 to 2009, 29 subjects 
(14 with CKD-aP and 15 without pruritus) from 2010 to 2012 
and 20 subjects (10 with CKD-aP and 10 without pruritus) from 
2013 to 2016. The degree of pruritus was scored with Shiratori’s 
classification of itch in japan. Skin samples were obtained at the 
forearm or elbow during formation of the arteriovenous fistula 
surgeons. The expression of pruritogen in the skin was studied 
with immunohistochemistry. The expressions of acethylcholine 
(Ach), nerve growth factor (NGF), histamine, interleukin 6 (IL-6), 
β-endorphin, adenosine triphosphate (ATP), substance P, vasoac-
tive intestinal peptide (VIP), leukotriene B4 (LTB4) and calpain 
in the skin were studied as pruritogens. The expressions of Ach, 
NGF, β-endorphin, IL-6 and calpain were positively stained in 
the skin of CKD patients with and without CKD-aP. But, there 
was no difference in the intensity of expressions of Ach, NGF, 
β-endolphin, IL-6 and calpain between studied groups. This study 
indicates that the unique pruritogens of CKD-aP may not exist and 
that the receptors are more important than pruritogen in peripheral 
mechanism of pathophysiology of CKD-aP.
PP45
THE FATAL COURSE OF CHRONIC ITCH 
(CI): GENERALIZED CI AS A FIRST SIGN OF 
MALIGNANCY RESEMBLING PARANEOPLASTIC 
SENSOMOTORIC NEUROPATHY
Minaya Beigi1, Michael Haeberle2, Andreas Gschwendtner3, Elke 
Weisshaar1
1Department of Clinical Social Medicine, Environmental and Occupatio-
nal Dermatology, University Hospital Heidelberg, 2Private Practice for 
Dermatology, Kuenzelsau, 3Institute of Pathology, Caritas Hospital, Bad 
Mergentheim, Germany
Malignancies can be accompanied by paraneoplastic syndromes 
or symptoms. They can be caused by an indirect effect of ma-
lignancy and may be the first sign of an underlying malignancy. 
“Paraneoplastic itch” is used to describe itch in patients with 
haematological and/or solid tumour malignancies. Paraneoplastic 
neurological syndromes (PNS), defined as a group of rare neuro-
logical disorders, may occur. We present a 68-year-old male who 
developed chronic itch (CI) on normal looking skin (head, arms, 
shoulder, thighs) in December 2015. CI was of burning, stinging 
and sharp character and was suspected as possible neuropathic itch. 
The patient’s history revealed a good response of CI to a course 
of systemic corticosteroids applied once. He was advised to get a 
full body check-up (Internal Medicine, Neurology) which he was 
reluctant to do. Four months later he had lost 10 kg of weight and 
developed nausea, vomiting and neurological symptoms. Electro-
neurography revealed a severe sensomotoric polyneuropathy. To 
detect a potential underlying malignancy, imaging examinations 
(e.g. chest X-ray, ultrasound of the abdomen, pelvis CT scan) 
and lumbar puncture were performed. While imaging showed no 
evidence of a tumour, lumbar puncture revealed the presence of 
Anti-Hu antibodies, the most frequently identified paraneoplastic 
antibodies. Therefore, a close follow-up scheme was set up to 
detect the underlying malignancy. In November 2016, mediastinal 
lymph node biopsy proved lymph node metastasis by a large cell 
neuroendocrine carcinoma (LCNEC) which is a rare subgroup of 
high grade neuroendocrine tumors, typically of pulmonary origin. 
The diagnosis requires the presence of a neuroendocrine pattern 
and a positive staining with neuroendocrine markers (chromo-
granin A, synaptophysin, CD 56) in immunohistochemistry which 
was demonstrated in our case. However, the primary carcinoma 
location was never detected in our patient. In spite of chemo-
therapy, the patient died in April 2017. It is most likely that CI was 
the first paraneoplastic symptom, triggered by the neuroendocrine 
tumour. The most probable cause of paraneoplastic symptoms is 
an indirect effect through various mediators including immune and 
humoral mechanisms. A falsely initiated immune reaction could 
also explain the good response of CI to a therapy with systemic 
steroids. It should be remembered that CI without concomitant 
skin changes followed by neurological symptoms can be caused 
by a yet undiagnosed malignancy. 
PP46
FUNCTIONAL CHANGES IN THE CEREBRAL 
NETWORKS FOR ITCH AND BURNING PAIN
Clemens Forster1, Verena Vierow1, Miriam Rank1, Ralf Ringler2, 
Hermann O. Handwerker1
1Physiology 1, FAU Erlangen, 2University of Applied Science Amberg-
Weiden, Germany
From many functional imaging studies a general notion evolved 
that the processing of painful or itchy input is based on activity 
changes in cerebral networks. In this study we focused on the 
modulation of those networks using functional imaging in com-
bination with functional connectivity (FC) analyses. According to 
our hypothesis the behavior of the resting state network is changed 
during itch and pain. For pain the skin of the right forearm of 18 
healthy subjects was pretreated by topical application of capsaicin 
(0.05% for 30 minutes). This lead to heat pain by temperatures 
of less than 50oC due to thermal hyperalgesia. The stimulation 
temperature was 1oC above the individual pain threshold. Itch was 
induced by iontophoresis of histamine into the skin of the volar 
forearm. In two fMRI sessions itch and pain were assessed using 
a connectivity fMRI-design with EPI sequences. The first run was 
free from stimulation to detect the default mode network. During 
the second fMRI sequence itch or pain stimuli were applied, 
respectively. The 2nd session was not earlier than 2 weeks later. 
Individual mean MRI (BOLD) time courses were extracted from 
the seed regions left posterior insula for exploring an “input” net-
work and the PAG for exploring the “output” network. Pearson’s 
correlation coefficients were calculated between the seed regions 
and other regions in a whole brain study. In a 2nd level analysis 
contrasts were calculated between resting state and itch or pain 
conditions. Under itch the FC with the posterior insular cortex 
predominantly increased to frontal areas (BA8, BA9, BA45). In 
BA8 and BA45 the changes were also correlated with the indivi-
dual ratings of itch. The FC with the PAG increased within pACC, 
subgenual parts of the ACC, and the left amygdala, while the con-
nectivity decreased to the caudate body and the frontal lobe (BA 
6). Under pain the FC of the posterior insula increased with many 
brain regions but decreased with the PAG, indicating a negative 
feedback between endogenous pain inhibition and cortical pain 
input. Enhanced FC was found of the PAG with medial frontal 
regions (BA 10), posterior parts of the anterior cingular cortex 
(pACC) and the left amygdala while the coupling decreased to the 
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thalamus and S2 (BA 40). Besides the interesting result indicating 
a negative feedback between pain input (but not itch input) and 
output of the pain control system, our results indicate that cerebral 
networks processing pain and itch are not identical.
PP47
INVOLVEMENT OF SPINAL MICROGLIA IN 
THE PATHOGENESIS OF IMIQUIMOD-INDUCED 
PSORIASIS-LIKE DERMATITIS MODEL MICE
Ryohei Kosaka1, Mitsutoshi Tominaga1, Nobuaki Takahashi1, Hi-
ronori Matsuda1, Yasuhiro Tomooka2, Chiharu Nishiyama2, Kenji 
Takamori1,3
1Institute for Environmental and Gender Specific Medicine, Juntendo Uni-
versity Graduate School of Medicine, Chiba, 2Department of Biological 
Science and Technology, Faculty of Industrial Science and Technology, 
Tokyo University of Science, Katsushika-ku, 3Department of Dermatology, 
Juntendo University Urayasu Hospital, Chiba, Japan
Intractable itch is a symptom of psoriasis that impairs patients’ 
quality of life, for which existing treatment is largely ineffective. 
Recent studies have revealed the involvement of spinal glial cells, 
such as microglia and astrocytes, in the sensitization and enhan-
cement of itch in atopic dermatitis-like model mice. However, the 
roles of spinal glial cells in psoriatic itch remain unclear. Therefore, 
this study was performed to investigate the roles of spinal microglia 
and astrocytes in the pathological process of psoriatic itch using 
an imiquimod (IMQ)-induced psoriasis-like dermatitis model 
mouse (IMQ-treated mice). C57BL/6J mice received daily topical 
application of IMQ to their rostral back skin for five days. They 
exhibited worsening scores of dermatitis and increased scratching 
behavior and transdermal water loss (TEWL) in a time-dependent 
manner, with these values reaching a peak at day 4 or day 5. Our 
immunohistochemical analyses showed morphological changes of 
spinal microglia in the IMQ-treated mice compared with that in 
control mice. Hypertrophied microglia were transiently increased 
from day 2 to day 3. These findings suggest that spinal microglia 
are associated with the pathological process of psoriasis.
PP48
ANTIPRURITIC EFFECT OF THERMAL GRILL 
ILLUSION ON HISTAMINE-EVOKED ITCH IN 
HUMANS
Daniele Riccio, Mark Brendstrup Bødker, Justina Rusteikaitè, 
Janne Djernis Christensen, Mia Birkholm Lausten, Anders Lindby 
Nørgaard, Hjalte Holm Andersen, Laura Petrini, Lars Arendt-
Nielsen, Parisa Gazerani
Department of Health Science and Technology, Faculty of Medicine, Aal-
borg University, Denmark
Itch is an unpleasant sensation that causes a desire to scratch. An 
effective and safe treatment for itch is still lacking. It is known 
that counter-stimuli including noxious thermal stimuli can inhibit 
itch. Recently, central neuronal processing underlying this inhi-
bition has been elucidated. Noxious thermal stimuli, however, 
can lead to skin damage and therefore would not be suitable 
at clinic. Therefore, it would be optimal to use counter stimuli 
within non-noxious thermal range. This can be achieved by using 
thermal grill illusion (TGI). Hence, the aim of this pilot study 
was to investigate the effect of mixed temperatures (not noxious 
thermal stimuli of 18°C and 41°C) produced by a custom-made 
thermal grill on histamine-evoked itch in healthy volunteers. The 
effect of cold application alone (18°C) on itch intensity was also 
investigated. Histamine dihydrochloride (1.0%, Allergopharma, 
Reinbek, Germany) was applied in 8 healthy subjects (age 24±0.38 
years) with a standard skin prick lancet on the volar forearm. Itch 
intensity was recorded over time for up to 15 minutes on a visual 
analogue scale (VAS 0–10, 0 no itch, 10 worst itch imaginable). 
TGI significantly reduced the itch intensity (p<0.05), while inno-
cuous cold application alone did not show any significant effect 
(p>0.05). This is the first report presenting the itch-relieving ef-
fect of thermal grill on histamine-evoked itch model in humans. 
It is therefore proposed that thermal grill would be beneficial in 
itch relief at clinic. Further studies are planned in our group to 
test this hypothesis with application of a newly developed mobile 
thermal grill device. 
PP49
SECONDARY GENERALIZED BRACHIORADIAL 
PRURITUS SUCCESSFULLY TREATED WITH 
GABAPENTIN
Małgorzata Małek1, Laura von Dücker1, Sonja Ständer2, Dorothée 
Nashan1, Hartmut Ständer1
1Hautklinik, Klinikzentrum Mitte, Dortmund, 2Center for Chronic Pruritus, 
University-Hospital Münster, Germany
 Brachioradial pruritus (BRP) is a rare type of chronic pruritus that 
is usually localized at the dorsolateral part of the arms. We report 
on 79-year-old man who suffered from severe pruritus located on 
the dorsolateral sides of both arms occurring after an apoplectic 
stroke. After some years of different topical treatments, systemic 
corticosteroids and antihistamines without success, pruritus be-
came even worse and generalized to the whole body. No underlying 
disease for the generalization could be found. Quality of life was 
reduced and sleeping was disturbed; NRS was 8-10. Intraepidermal 
nerve fiber density of the lower leg was significantly reduced. 
Therefore we started a systemic treatment with gabapentin which 
could be slowly increased up to 1200 mg/d. This therapy was well 
tolerated and the NRS reduced to 3. This case report shows for 
the first time that an apoplectic stroke can trigger brachioradial 
pruritus which subsequently generalized. The neuropathic nature 
of the pruritus was demonstrated via intraepidermal nerve fiber 
density. Gabapentin was an effective and well tolerated therapy in 
the patient. It could be speculated that an earlier systemic therapy 
with gabapentin could probably have prevented the secondary 
generalization of the pruritus.
PP50
MORPHOLOGICAL AND MOLECULAR 
EVOLUTIONAL ANALYSES OF ITCH FOCUSED 
ON THE GASTRIN-RELEASING PEPTIDE SYSTEM 
IN MAMMALS
Keiko Takanami1, Keita Satoh1, Kazuyoshi Murata2, Tatsuya Saka-
moto1, Hirotaka Sakamoto1
1Ushimado Marine Institute, Graduate School of Natural Science and 
Technology, Okayama University, Ushimado, Setouchi, Okayama, 2Natio-
nal Institute for Physiological Sciences, Nishigonaka, Myodaiji, Okazaki, 
Japan
Gastrin-releasing peptide (GRP) is a 29-amino acid peptide in 
rodents and 27 residues in primates. We focused on GRP as an itch 
neuronal marker in the somatosensory system. We found that GRP 
was expressed in the small-sized primary afferents and projected to 
the caudal part of the spinal trigeminal nucleus and all level of the 
spinal dorsal horn in rats. These findings suggested that GRP is an 
important neuropeptide for itch transmission not only in the spinal 
somatosensory system but also in the trigeminal somatosensory 
system. GRP receptor mRNA and protein were expressed in the 
regions where GRP immunoreactive fibers appeared to terminate 
in rats. Immunoelectron microscopy showed that GRP-positive 
terminals contain many clear round vesicles and dense-cored 
vesicles. Furthermore, we used 3-dimentional scanning electron 
microscopy (3-D SEM) combined with immunohistochemistry 
to analyze the 3-D ultrastructure of the itch-mediating synaptic 
formation in the spinal dorsal horn. The 3-D SEM analysis revealed 
that GRP terminals connected with many postsynaptic components 
than we expected. These results suggest that neural networks 
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controlling the itch transmission are extraordinary complex in 
the spinal cord. Next, we had the question of how organism ac-
quires the itch sensation during evolution and why we possess an 
unpleasant itch sensation. To address these questions, we utilized 
the phylogenetic and comparative analyses using Asian house 
musk shrews, mice, rats and macaque monkeys. We found that 
the deduced amino acid sequence of GRP-10 which is a possible 
C-terminal-fragment of mature GRP had highly been conserved 
among mammals. Immunohistochemical analysis showed that the 
expression and distribution of GRP were consistent across mam-
mals such as primitive eutherians, rodents, and primates. These 
results suggest that this system may be a conserved property for 
itch-mediating function in mammals. 
PP51
BRACHIORADIAL PRURITUS IN A YOUNG 
CAUCASIAN WOMAN AS A SYMPTOM OF 
CERVICAL RADICULOPATHY
Justyna Szczęch, Adam Reich
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Poland
Brachioradial pruritus is a rare pruritic condition, described for 
the first time by Waisman in 1968. Up to date the etiology of this 
disease remains unclear, however, this type of pruritus is frequently 
classified as neurologic itch. We report a 29-year-old Caucasian 
woman suffering from pruritus of the upper arms affecting the 
skin overlying the proximal head of the brachioradialis muscles. 
First symptoms of the disease appeared 10 years before admis-
sion to the hospital. Patient reported presence of severe itch with 
periodically visible pruritic papules on the upper arms. Clinically, 
all skin lesions were assessed as secondary to scratching. Ac-
cording to patient history, pruritus exacerbations were connected 
with sun exposure. Although the patient was a young woman, she 
also complained about severe pain of cervical spine. Magnetic 
resonance of cervical spine revealed a pressure on a dural sac at 
then level if C6/C7. In addition, herniated discs at C3/C4 and C5/
C6 level were described. Patient started pregabalin treatment with 
significant improvement of the symptoms within several weeks. 
Our case presentation further supports the idea that brachioradial 
pruritus is an example of neuropathic itch related to the damage 
of nervous system at the level of cervical spine.
PP52
A MULTINATIONAL CROSS-SECTIONAL 
STUDY ON THE PREVALENCE AND CLINICAL 
PRESENTATION OF PRURITUS IN CUTANEOUS 
LUPUS ERYTHEMATOSUS: AN OVERVIEW
Dominik Samotij1, Justyna Szczęch1, Emiliano Antiga2, Adam 
Chasset3, Aleksandra Dańczak-Pazdrowska4, Fukumi Furukawa5, 
Aminul Islam6, Carolyn Kushner7, Takaharu Ikedam5, Minoru 
Hasegawa8, Hideo Hashizume9, Adriana Polańska4, Laurent Mi-
sery10, Mohammad Rafiqul Mowla11, Aleksandra Lesiak12, Zygmunt 
Adamski4, Jacek C. Szepietowski1, Daisuke Tsuruta13, Victoria 
Werth14, Adam Reich1
1Department of Dermatology, Venereology and Allergology, Wroclaw Med-
ical University, Poland, 2Department of Surgery and Translational Medi-
cine, Section of Dermatology, University of Florence, Italy, 3Department of 
Dermatology and Allergology, Tenon Hospital, Paris, France, 4Department 
of Dermatology, Poznan University of Medical Sciences, Poland, 5Depart-
ment of Dermatology, Wakayama Medical University, Japan, 6Department 
of Dermatology and Venereology, Chittagong Medical College, Pakistan, 
7Perelman School of Medicine, University of Pennsylvania, Philadelphia, 
USA, 8Department of Dermatology,  School of Medicine, Faculty of Medi-
cal Sciences, University of Fukui, Japan, 9Department of Dermatology, 
Shimada Municipal Hospital, Shimada, Japan, 10Department of Dermato-
logy, University Hospital of Brest, France, 11Department of Dermatology 
and Venereology, Chittagong Medical College, Pakistan, 12Department 
of Dermatology, Pediatric Dermatology and Dermatological Oncology, 
Medical University of Lodz, Lodz, Poland, 13Department of Dermatology, 
Osaka City University, Japan, 14Perelman School of Medicine, University 
of Pennsylvania, Philadelphia, USA
Pruritus is an important symptom frequently accompanying vari-
ous inflammatory skin conditions. Some recent data have indica-
ted, that it may also be associated with autoimmune connective 
tissue diseases, including systemic sclerosis, dermatomyositis and 
cutaneous lupus erythematosus (CLE), however, studies on the 
true prevalence and clinical characteristics of pruritus in CLE are 
very limited. For that reason we have organized a multinational, 
prospective, cross-sectional study in order to precisely assess the 
prevalence, intensity, and clinical characteristics of pruritus in 
adult patients suffering from various subtypes of CLE. We have 
selected centers from various continents with special interest 
in CLE diagnostics and treatment to cover possible differences 
between races and climate including Europe (6 centers), North 
America (1 center) and Asia (5 centers). As the first step of the 
study we have developed a questionnaire assessing various as-
pects of pruritus as well as including sociodemographic data, data 
on the subtypes of CLE and severity of cutaneous (with CLE Area 
and Severity Index) as well as systemic symptoms (SELENA-
SLEDAI). The subjects’ well-being and health-related quality 
of life was determined using Dermatology Quality of Life Index 
(DLQI) and EuroQol Five Dimensions Questionnaire (EQ-5D). 
The preliminary questionnaire was sent to participating centers 
for comments. After including all comments we have prepared a 
final version of the questionnaire which was approved by Local 
Ethic Committee. Subsequently, it was sent to all participating 
centers along with an electronic database file to facilitate the 
data caption. Preliminary data from the study will be presented 
during the congress. 
PP53
PILOT STUDY OF VENOUS ULCER ITCH: 
ANALYSIS OF WOUND FLUID AND SERUM
Julia Paul1, Stewart Graham1
1Oakland University, Rochester, 2Beaumont Research Institute, Royal Oak, 
Michigan, USA
Purpose/Hypothesis: We aimed to use metabolomics for bio-
chemical profiling of wound fluid and serum from persons with 
venous ulcers that itched compared to those that did not. We 
hypothesized that using metabolomics we would identify signifi-
cant differences in the metabolome of biomatrices, increasing our 
overall understanding of the biochemistry of wound related itch, 
while uncovering potential biomarkers for those at greatest risk 
of developing itch. Background: Venous ulcer itch is a recognized 
clinical problem which has been inadequately characterized and 
which can result in great distress for persons with chronic venous 
ulcers. The pathophysiology and etiology of wound-related itch 
have not been determined. Methods: Specimens of wound fluid and 
serum were obtained from 21 patients with venous ulcers (14 male, 
16 white, age range 47–85 years). The sample was divided between 
case (itch, n=10) and controls (no itch, n=11) based on self-report. 
Wound assessments and patient interviews were conducted for 
comparison of wound characteristics between persons with and 
without wound-related itch. Metabolomic analysis of serum was 
conducted using targeted mass spectrometry coupled with liquid 
chromatography (LC-MS/MS; Biocrates p180) and proton nuclear 
magnetic resonance spectroscopy (1H NMR). Wound fluid was 
analyzed using LC-MS/MS (Biocrates p180). Results: Intensity 
of wound-related itch episodes ranged from 2 to 10 (mean=8). 
Selected compounds converged to form predictive models of itch 
for wound fluid (p<0.3) and serum (p<0.2). Logistic regression for 
wound fluid produced a predictive algorithm with AUC = 0.919, 
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using concentrations of citrulline, threonine, serine and asparagine. 
Pathways significantly perturbed in wound fluid include methane, 
cyanoamino acid, and sulfur metabolism. ROC analysis was used 
to produce a model for serum using betaine and PC ae C424, with a 
predictive accuracy of 82.6%. Pathways significantly perturbed in 
serum include glycolysis/gluconeogenesis, nitrogen metabolism, 
and tyrosine metabolism. Conclusion: This study demonstrates the 
potential of using metabolomics for identification of those at risk of 
developing venous ulcer itch while increasing our understanding of 
the pathophysiology of wound related itch. A more comprehensive 
understanding of how and why some patients develop itch will 
allow us to develop therapeutic agents for strategic intervention.
PP54
THE BIBLIOMETRICS OF ITCH: 2017 UPDATE
Melissa McEnery-Stonelake1, Jeffrey D. Bernhard2,3
1Department of Dermatology, University of Alabama at Birmingham, Bir-
mingham, Alabama, 2Division of Dermatology, Department of Medicine, 
University of Massachusetts Medical School and UMass Memorial Health 
Care, Worcester, Massachusetts, 3Kuchnir Dermatology & Dermatologic 
Surgery, Shrewsbury, Massachusetts, USA
In 1834, only 1 article about itch/pruritus was published (Lancet, 
1834, 23, 59–62); this number has increased substantially to a 
high of 198 articles in 2015. Pruritus continues to be used more 
frequently than itch in article titles. The common misspelling - 
pruritis – still manages to evade correction from time to time. 
During 2015–2016, Acta Dermato-Venereologica again published 
the largest number of itch articles, followed by Current Problems 
in Dermatology, Handbook of Experimental Pharmacology and 
Scientific Reports. Schmelz and colleagues’ 1997 paper was the 
most cited itch article during 2015–2016 (J Neurosci, 1997, 17, 
8003–8008), whereas Foster and colleagues published the most 
cited itch article of papers published in 2015–2016 (Neuron, 2015, 
85, 1289–1304). During 2015–2016, itch papers appeared twice 
in Nature Communications, twice in Nature Medicine, 8 times in 
Pain, twice in PNAS, once in Science, and not at all in Lancet, 
Nature or NEJM, for a total of 15 total published in key journals, as 
compared to 10 papers during 2011–2012. Yosipovitch, with 2,201 
total citations, is the most cited author of itch articles overall, fol-
lowed by Schmelz and Kuraishi. Yosipovitch is the author with the 
highest h-index, which measures an author’s cumulative impact. 
PP55
TREATMENT OF SEVERE ATOPIC DERMATITIS 
WITH OMALIZUMAB: EXPERIENCE OF A 
PORTUGUESE IMMUNOALLERGOLOGY 
DEPARTMENT 
Rita Aquiar, Ana Mendes, Ana Célia Costa, Fátima Duarte, Estrel-
la Alonso, Amélia Spínola, Elisa Pedro, Manuel Pereira-Barbosa
Hospital De Santa Maria CHLN, Portugal
Introduction: Controlling severe eczema is not always possible 
despite the optimization of therapy. Omalizumab is associated with 
improvement in cutaneous symptoms and quality of life (QoL) 
in patients (pts) with atopic dermatitis (AD). This study aims to 
evaluate the efficacy and QoL of pts under omalizumab. Methods: 
Pts with severe AD refractory to the recommended therapy, were 
evaluated for treatment with omalizumab. The clinical response 
was assessed by the therapy used and by the questionnaires: 
SCORAD (Scoring Atopic Dermatitis) and DLQI (Quality of Life-
Dermatology Index). Data from SCORAD and DLQI at 12 months 
(T12) were compared with the initial treatment phase (T0). Data 
were analyzed using SPSS, version 17®, p-value <0.05. Results: 24 
atopic patients (14 men) with severe AD, mean age 31 years. Total 
IgE 8835 (2296–21691) KU/l. All patients were given montelukast 
10 mg/day, topical and oral corticosteroids, topical calcineurin 
inhibitors and anti-H1 antihistamines. 7 patients sensitized to 
Dermatophagoid mites underwent Immunotherapy (IT) for 16 
(6–36) months prior to treatment without clinical improvement. 
12 patients receiving cyclosporine, 2 patients with azathioprine, 
and 1 with Ig G unresponsive. Omalizumab was administered sc, 
300–600 mg every 2 weeks in an average of 16 (12–73) months. 
From the comparison between T0 and T12 it was found that the 
medication was reduced in dose and in the number of drugs, 
systemic corticosteroid therapy was suspended without clinical 
re-referral and the mean SCORAD increased from 65.5 (T0) to 
28.5 (T12). 15 of 24 patients had a complete improvement (65.2%) 
and 6 (26.1%) patients had a partial response, although the mean 
treatment time from initiation of treatment to initial improvement 
was variable. 1 patient (4.3%) did not improve. There were no sys-
temic adverse reactions and 1 patient had exuberant local reaction 
Analysis of the DLQI score showed that cutaneous pathology. has 
a moderate-severe QoL effect in 12 out of 24 pts, ie in 50% of 
pts. In T12 the AQLQ showed that AD had a moderate effect on 
patients’ QoL (mean score of 6.6) compared to T0 (mean score 
of 21), which had an extremely severe impact on QoL. QoL did 
not show a significant correlation with duration of Omalizumab, 
p=0.04. Conclusion: Omalizumab was effective in the treatment of 
AD and appears to be a safe alternative when patients with severe 
AD are refractory to other therapies. The treatment demonstrated 
an improvement in QoL in patients’ perception.
PP56
CHRONIC PRURIGO MASKS THE FINDING OF A 
BULLOUS PEMPHIGOID
Caroline-Donata Forner, Jan Ehrchen, Claudia Zeidler, Sonja 
Ständer
Competence Center Chronic Pruritus, Departement of Dermatology, Uni-
versity Hospital Münster, Germany
Chronic prurigo (CPG) is a severe disease which might be triggered 
by a variety of diseases such as dermatological, but also systemic, 
neurological, psychiatric/psychsomatic, multifactorial disorders 
or unknown causes. All these diseases have in common to induce 
pruritus which results in scratching of the skin finally establishing 
a chronic itch-scratch-cycle leading to CPG. To illustrate this, 
we present a case of a 61-year-old female patient with CPG for 
more than 6 years. In addition to itch, she reported experiencing 
burning and painful sensations in the skin triggered by warmth. 
The CPG was initially localized at the left foot; however, a few 
months later, it became generalized to the remaining integument. 
Additionally, the patient reported a highly intense pruritus (10/10 
on the visual analog scale). On inspection the whole integument 
displayed pruriginous nodules; other lesions such as blisters were 
not present. Concomitant diseases included stomach ulcers, chro-
nic pancreatitis and spondylosis with chronic pain. A histological 
examination revealed alterations typically found in CPG. Direct 
immunofluorescence showed IgG and C3 deposits in the basal 
membrane, while the indirect immunofluorescence showed an IgG 
titer of 1:8,000, thus leading to the diagnosis of bullous pemphi-
goid. Previous therapy consisted of azathioprine 50 mg daily (this 
discontinued due to pancreatitis), minocycline 200 mg daily and 
doxycycline 200 mg daily. Under a cyclic therapy with intravenous 
methylprednisolone 500 mg for 3 days every four weeks and over 
1.5 years and dapsone 100 mg daily the bullous pemphigoid was 
controlled and antibodies could no longer be detected. However, 
the CPG and the associated pruritus persisted. We initiated a th-
erapy with cyclosporine and naloxone intravenous. Due to this, the 
pruritus intensity decreased from initial 10 to 1. This case report 
demonstrates that chronic prurigo is a disease which can be trig-
gered by other pruritic diseases as in this case bullous pemphigoid. 
Once CPG is established, the therapy of the underlying etiology is 
not sufficient to cure CPG. This needs an own approach. However, 
our case also advocates thorough diagnostics of CPG patients in 
order to unmask potential associated diseases. 
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PP57
ITCH ASSOCIATED WITH HYPERPLASTIC 
PAPILLOMATOUS SKIN LESIONS COMPLICATED 
BY SQUAMOUS CELL CARCINOMA IN A PATIENT 
WITH NETHERTON SYNDROME
Anna Waśkiel1, Adriana Rakowska1, Tomasz Demkow2, Małgorzata 
Olszewska1, Lidia Rudnicka1
1Department of Dermatology, Medical University of Warsaw, 2Department 
of Uro-Oncology, M. Sklodowska-Curie Memorial Cancer Center and In-
stitute of Oncology, Warsaw, Poland
Introduction: Netherton syndrome is a rare autosomal recessive 
disorder in the group of inherited ichthyoses. The case of the 
disease is serine protease inhibitor Kazal- type 5 (SPINK5) gene 
mutations which result in absence or, rarely, decreased expression 
of the encoded protein lymphoepithelial Kazal-type-related inhi-
bitor (LEKTI) in the epidermis and stratified epithelia. Netherton 
syndrome is characterized by congenital ichthyosiform dermatitis, 
linearis circumflexa, atopic diathesis and trichorrhexis invaginata 
(„bamboo hair“). Cases of patients with Netherton syndrome 
with associated hyperplastic papillomatous skin lesions or non-
melanoma skin cancers were described in the literature. Aim: 
We present a patient with Netherton syndrome and hyperplastic 
papillomatous skin lesions associated with itch and complica-
ted by squamous cell carcinoma. Case report: An 18-year-old 
patient with Netherton syndrome was referred to our hospital. 
Ichthyosiform erythroderma appeared immediately after birth and 
persisted throughout his life. At the age of 8, itching, hyperplastic 
papillomatous skin lesions occurred in the groin area and have 
been growing progressively. Nodular skin lesions on the scrotum 
developed at the age of 14 and wide excision was performed im-
mediately. Histopathological examination of the surgical specimen 
revealed cytopathic effect related to Human Papillomavirus (HPV) 
infection and confirmed diagnosis of squamous cell carcinoma. 
During admission, the patient had scaling erythroderma involving 
the entire skin surface. Complete loss of scalp hair, eyebrows and 
eyelashes was observed. Hyperplastic papillomatous skin lesions 
were presented in the genitoanal area. The anogenital lesions were 
associated with itch (5 in VAS, 5 points in Itch questionnaire). 
Laboratory investigations revealed increased serum level of total 
IgE (732 IU/ml). Emollients were recommended to reduce itch. 
Conclusion: In patients with Netherton syndrome treatment stra-
tegies should include the control of itch.
PP58
PROPERTIES OF PRURITUS AND RELATED 
FACTORS AMONG ELDERLY RESIDENTS OF 
PANTI WERDHA, PUBLIC NURSING HOMES IN 
INDONESIA
Dianis Wulan Sari1, Takeo Minematsu2, Mikako Yoshida1, Abe Ma-
satoshi3, Hiromi Sanada1
1Department of gerontological nursing/wound care management, The Uni-
versity of Tokyo, 2Department skincare science, Graduate school of Medi-
cine, The University of Tokyo 3Sapporo Skin Clinic, Hokkaido, Japan
Background: Pruritus is a crucial problem in aging societies. In 
the bedridden and cognitively impaired elderly patients, it is dif-
ficult to assess cases of pruritus due to the lack of macroscopic 
abnormalities. The purposes of this study were to explore the 
skin properties related to pruritus and to identify the factors 
associated with them. Methods: This cross-sectional study was 
conducted in Panti Werdha, public nursing homes for elderly in 
Indonesia. Basic characteristics and itching data were obtained 
by interview, and skin properties including barrier function and 
inflammation were direct examination by skin blotting, skin 
microscopy, stratum corneum (SC) hydration, and skin pH. The 
pruritus-related skin properties and associated factors including 
basic characteristics and skincare behaviors were analyzed. Re-
sults: The average participant age was 74 years. Prevalence of 
itching on whole body was 69.1%, and 50.3% of those manifesting 
itching on the left forearm diagnosed pruritus. SC hydration, skin 
pH, albumin, nerve growth factor β (NGFβ), skin with hair, skin 
with scales, and skin with sweat gland were related with pruritus 
(p = 0.007, 0.012, <0.001, <0.001, 0.049, <0.001 and <0.001, 
respectively). SC hydration and skin pH were associated with 
clothing change frequency (β =0.135 and β=–0.137, p <0.05). 
Albumin was associated with age (β=–0.130, p = 0.044). NGFβ 
was associated with cumulative lifetime sun exposure at work 
(β=0.145, p=0.026) and bathing duration (β=–0.151, p=0.022). 
Skin microscopy; skin with hair was associated with age (AOR 
0.5, 95% CI 0.3–0.9) and sex (AOR 1.8, 95% CI 1.0–3.2). Skin 
with scales was associated with bathing frequency (AOR 0.3, 95% 
CI 0.1–0.8). Skin with sweat gland was associated with bathing 
frequency (AOR 3.3, 95% CI 1.3–8.0). Conclusion: Albumin and 
NGFb in skin blotting were possible indicators of skin assessment 
method for pruritus.
PP59
EXPRESSION OF IL-31 IN URAEMIC PRURITUS
Marta Pelc, Maria Kozioł, Jacek C. Szepietowski
Department of Dermatology, Venereoology and Allergology, Wroclaw Med-
ical University, Wroclaw, Poland
Uraemic pruritus is a bothersome symptom in about 40% of pa-
tients undergoing dialysis therapy. Its etiopathogenesis remains 
not fully explained. In recent years attention has been paid to 
the role of interleukin 31 (IL-31) in the pathogenesis of chronic 
pruritus, especially in patients with atopic dermatitis. Preliminary 
studies suggest elevated serum IL-31 levels in patients suffering 
from uraemia. Therefore, this research project aims to determine 
the expression of IL-31 in the skin of patients with uraemic itch. 
The study was based on archived collection of biopsy material 
(21 skin biopsies from adult patients with pruritus and 20 biopsies 
of patients free from itching in chronic kidney disease). IL-31 
expression was demonstrated by immunohistochemistry using 
commercially available IL-31 antibodies. There was no signifi-
cant difference in overall IL-31 expression between patients with 
and without pruritus. However, significant difference (p=0.02) 
was noted in the distribution of IL-31 expression in both studied 
groups. IL-31 expression showed two patterns being expressed 
through the whole epidermis and mainly in the suprabasal layers 
of the epidermis. In patients with uraemic pruritus IL-31 expres-
sion was significantly more common (p=0.01) across the whole 
epidermis than limited to the suprabasal layers of the epidermis. 
No significant relationship between IL-31 expression and sex, age 
of patients and hemodialysis duration was found. A trend towards 
the relationship of IL-31 expression and severity of itch assessed 
according to visual analog scale (VAS) was noted (p=0.09). In 
conclusion it seems that IL-31 expression is more pronounced in 
patients with uraemic pruritus compared to those free from this 
symptom, but there is a need for further studies to clarify the exact 
role of IL-31 in uraemic pruritus.
PP60
DIFFERENTIATED RESISTANCE TRAINING AND 
EXERCISE TREATMENT FOR NEUROPATHIC 
ITCH - A PRELIMINARY STUDY
Matthias Fischer, Elke Weisshaar
Department of Clinical Social Medicine, University Hospital Heidelberg, 
Germany
Neuropathic itch means localized chronic itch (CI) with stinging, 
burning and sharp sensations usually affecting the corresponding 
dermatomes of the skin. Secondary generalization of CI has been 
described. A high correlation between changes seen on magnetic 
resonance tomography (MRT) such as nerve compression or da-
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
1053Poster abstracts
Acta Derm Venereol 2017
mage due to e.g. spinal pathology, degenerative changes and the 
symptoms of localized CI like brachioradial pruritus (BRP) was 
demonstrated. Exercising involving a non-pharmacologic active 
range of motion and strengthening of muscles as well as stretching 
muscles is a main strategy of treating neuropathic pain caused by 
e.g. herniated disc. Improvement of notalgia paresthetica (NP), 
another variant of neuropathic itch, by exercises was described in 
a case report. Potential explanations include changes of affected 
muscles by either shortening or lengthening of muscles being in-
volved, reduction in the angle of affected nerves and reducing the 
pressure on nerves by extension of the spine. Effective therapies 
for neuropathic itch are limited and non-pharmacological treat-
ments are lacking. Recently, strength training was introduced as a 
so-called differentiated resistance training and exercise treatment 
focusing on the spine. By combining new results of sports science 
with itch research, a preliminary study was started to investigate 
the effect of differentiated resistance training and exercise treat-
ment of the spine (focusing on the back) for treating neuropathic 
itch. As a first step, the training design has the patients passively 
loosening up soft tissue (muscles and fascia) around the cervical 
and thoracic spine and actively warming up the shoulder girdle 
as a preparation for the actual strength training. Step two requires 
the patients to go through a series of resistance training exercises, 
such as lateral flexion, flexion and extension of the cervical spine, 
scapula elevation and depression, as well as scapula retraction, 
full extension of the spine (erector spinae) and arm adduction 
(latissimus dorsi). The primary outcome measure is itch (severity, 
quality, itch-related quality of life (ItchyQol)). The secondary 
outcome measures are general well-being (SF SF-12), muscle 
strength and mobility. We present the design, development and 
progress of a training program for neuropathic itch and report 
results of the first patients.
PP61
A STUDY OF PRURITUS IN PATIENTS WITH 
PSORIASIS ATTENDING DERMATOLOGY OPD OF 
A TERTIARY CARE HOSPITAL
Asit Mittal, Manju Meena
RNT Medical College, Udaipur
Objective: To assess the burden of pruritus in patients suffering 
from psoriasis . Materials and Methods: All the consecutive newly 
diagnosed patients of Psoriasis not on any anti psoriasis treatment 
were included in the study. A detailed history and examination 
was performed to know the extent and severity of psoriasis using 
Psoriasis Area Severity Index (PASI) score. The global assessment 
of pruritus was done by using preformed questionnaire and itch 
assessment scales (Four-item itch questionnaire and Behaviour 
rating scale). Results: Total 150 patients (91M, 59F) were enrolled. 
91 patients were having plaque type, 32- guttate, 14 sebo-psoriasis 
(3 exclusively scalp involvement) , 8 - palmoplantar, 1 – pustular, 
1- erythroderma. Age at presentation ranged from 2 years to 76 
years. 101 patients were having mild psoriasis (PASI ≤ 10) whereas 
49 patients were having moderate to severe psoriasis (PASI > 10). 
130/150 (86.67%) patients were having pruritus of variable seve-
rity. 20 patients had no pruritus at all and their major concern was 
unsightly appearance of lesions and associated dryness. According 
to Four-item itch questionnaire (FIIQ) out of a maximum score of 
19, following pruritus scores were recorded:
 Score 3 4 5 6 8 9 10 11 14 15 16 17 18
 No of Pt 5 22 52 21 3 5 7 3 2 2 3 3 1
 According to BRS (max 5) following score were observed:
 BRS Score 0 1 2 3 4
 No of Pt 20 48 50 30 2
There was no significant association found between Pruritus score 
and severity of Psoriasis, duration of Psoriasis, morphological 
patterns of Psoriasis, and site of Psoriasis. 
PP62
NOVEL MICRONEEDLE TREATMENT FOR 
KELOIDS: EFFECTS ON LESIONAL VOLUME, 
PAIN AND ITCH
Hong Liang Tey, Colin Weixuan Tan
National Skin Centre, Singapore
Background: Itch and pain are common symptoms of keloids and 
significantly impact the quality of life of patients. Current thera-
peutic options are limited. The first-line option is intra-lesional 
corticosteroid injections which, due to the sensitivity of keloids, is 
painful and precludes treatment in many patients. Other available 
therapies are limited by cost, inconvenience and a lack of accep-
tability or tolerability. We developed triamcinolone-embedded 
dissolving microneedles as a novel therapy for keloids. We aim to 
determine the effects of a 1-month therapy on keloidal size, pain 
and itch. Materials and Methods: The study was a single-blind, 
intra-individual controlled 8-week clinical trial. Patients with 
keloids on the trunk or limbs with a diameter of 1-2cm and at least 
1cm apart were recruited. Two keloids were treated with either 
(i) once-daily, self-administered injections with triamcinolone-
loaded, dissolving hyaluronic acid microneedles or (ii) control with 
no intervention. For the intervention group, subjects were to stop 
treatment after 4 weeks. Evaluations were performed at baseline, 
4 weeks and 8 weeks. Outcome measures were (i) volume of the 
keloids objectively determined by a 3-dimensional scanner and (ii) 
pain and itch scores on numerical scales. Results: Twenty-eight 
patients (24 males) were recruited but one defaulted. Preliminary 
analyses revealed that the mean keloid size was significantly 
reduced in the intervention group after 4 weeks of treatment. The 
mean reduction in size in the intervention group was also signi-
ficantly greater than that in the control group. At 8 weeks (after 
stopping treatment for 4 weeks), the mean size in the intervention 
group increased to near that at the baseline. With respect to pain 
and itch, the intervention group demonstrated progressive and 
significant lower scores at 4 and 8 weeks compared to baseline. 
There were no side effects registered. Conclusions: Treatment 
with triamcinolone-embedded dissolving microneedles resulted in 
significant reduction in the size and pain and itch scores of keloids. 
PP63
MEDICAL CARE OF PATIENTS WITH CHRONIC 
PRURITUS IN THE PRIVATE DERMATOLOGICAL 
PRACTICE IN GERMANY – POSSIBILITIES AND 
LIMITATIONS
Hartmut Ständer1, Sonja Ständer2
1Dermatology Bad Bentheim / Clinical Center Dortmund, Department of 
Dermatology, 2University Hospital Münster, Center for Chronic Pruritus, 
Münster, Germany
Chronic pruritus has a high point prevalence of 36.2% and can 
be considered a frequent symptom in the private dermatological 
practice. The medical care of these patients can be based on the 
revised S2k German Guideline for Chronic Pruritus what was 
completed in 2016. Under the current healthcare policies and 
economic conditions of the private dermatological practice in 
Germany, it is challenging to follow the therapy recommendations 
of the guideline as therapies require experience and are frequently 
off-label. A collaboration with specialists or itch centers is desi-
rable. Another area can be easily followed such as for example a 
structured establishment of the patient medical history via pruritus 
questionnaires, intensity scales or questionnaires for quality of life. 
This simple procedure provides a time-saving, standardized basis 
for additional diagnostics and serves as a basis for cooperation 
with a specialized center. Furthermore, a basic examination and 
appropriate blood tests, microbiological swabs and skin biopsies 
could be performed in the practice, where it is also possible to 
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commence basic stage 1 therapeutic measures in accordance with 
the German Guideline. Nonetheless, further measures require the 
support of a specialized center and, in the private practice, can only 
be implemented in individual cases. Innovative approaches such 
as teledermatological techniques will facilitate the collaboration 
between care givers.
PP64
THE BURDEN OF AQUAGENIC PRURITUS IN 
POLYCYTHEMIA VERA
Edyta Lelonek, Łukasz Matusiak1, Tomasz Wróbel2, Jacek Kwiat-
kowski2, Jacek C. Szepietowski1
1Department and Clinic of Dermatology, Venereology and Allergology, and 
2Department and Clinic of Hematology, Blood Neoplasms and Bone Mar-
row Transplantation, Wroclaw Medical University, Wrocław, Poland
Background: Aquagenic pruritus(AP) has significant influence 
on sufferers’ quality of life (QoL). Material and Methods: This 
study analyzed an impact of AP on patient well-being among 
102 patients with polycythemia vera (PV). Pruritus intensity was 
evaluated with visual analogue scale (VAS), verbal rating scale 
(VRS) and a 4-item Itch Questionnaire. Moreover, psychosocial 
aspects of AP were assessed with Hospital Anxiety and Depres-
sion Scale (HADS), EQ-5D and itch-specific QoL questionnaire 
(ItchyQoL). Results: AP of mean duration 6.6±8.6 years and 
intensity assessed as 4.8±1.9 points (VAS) was present in 42/102 
individuals. The prevalence of depression and anxiety among AP 
patients was 23.8% and 9.5%, respectively. The depression was 
more frequent in AP group (vs. non-AP). Moreover, AP sufferers 
had higher HADS-anxiety scoring than patients without pruritus 
(p=0.005). The negative correlation between AP duration and 
EQ-5D-VAS was found. The ItchyQol score of 37.3±12.3 points 
was influenced by AP extent (p=0.01) and duration of its episodes 
(p=0.02). Conclusions: Summarizing, AP means an additional 
burden in PV patients negatively influencing their QoL
PP65
ENDOCANNABINOID RECEPTOR 1 GENE 
POLYMORPHISMS HAVE NO ASSOCIATION 
WITH UREMIC PRURITUS
Monika Heisig1, Łukasz Łaczmański2, Adam Reich1, Jacek C. Sze-
pietowski1
1Department of Dermatology, Venereology and Allergology, and 2Depart-
ment of Endocrinology and Diabetology, Wroclaw Medical University, 
Wroclaw, Poland
Uremic pruritus (UP) is a common symptom in hemodialysis 
patients. Its etiology is still not fully understood and that is why 
there is no specific treatment. The endocannabinoid system 
plays a role in many pathological conditions. Moreover, there is 
reliable evidence on the association between cannabinoid system 
and pruritus. We aimed to evaluate weather genetic variations 
in the endocannabinoid receptor 1 (CNR1) gene can affect UP. 
The rs12720071, rs806368, rs1049353, rs806381, rs10485170, 
rs6454674, and rs2023239 polymorphisms of the CNR1 gene 
were genotyped in 159 hemodialysis patients and 150 healthy 
controls using two multiplex polymerase chain reactions the 
mini-sequencing technique. No statistically significant rela-
tionship was found in any of the evaluated genotypes between 
patients with and without UP, even after excluding patients with 
diabetes and dyslipidemia. There were no differences between 
patients with UP and the control group. However, in the group 
of all HD patients a significantly higher incidence of GA geno-
type and lower incidence in GG genotype in the polymorphism 
rs806381s was revealed versus the control group (p=0.04). It 
seems that polymorphisms of the CNR1 gene are not associated 
with uremic pruritus.
PP66
MYCOSIS FUNGOIDES AS THE CAUSE OF 
UNSPECIFIED ITCHING FOR 4 YEARS
Anastasiia Titenko1, Yulia Krinitsina1, Viktoria Onipchenko2, Vera 
Pahomova2, Irina Sergeeva1
1Novosibirsk State National Research University, 2Novosibirsk Regional 
Clinical Hospital of Dermatology and Venerology, Russia
In dermatological practice, patients suffering from chronic un-
specified pruritus are often found. The first diagnosis is usually 
scabies, hives, atopic dermatitis. Lymphomas of the skin are also 
accompanied by intense itching, however, the diagnosis in most 
cases is stopped up to several months and even years. We present 
a clinical case of a patient suffering from chronic itching for 4 
years with a wide range of differential diagnosis A woman, born 
in 1937, first applied to the Novosibirsk Regional Dermatology 
and Venerology Clinic in January 2013 with complaints of intense 
skin itching. On examination, the skin is clean. A year later, in 
July 2014, against a background of itching, rashes appeared in the 
form of inflammatory papules on the skin of the thighs, the flexural 
surfaces of the elbow joints, the abdomen. The diagnosis of aller-
gic dermatitis was established, treatment with antihistamines was 
prescribed, the effect was not given. During the year, the itching 
persisted, the patient was diagnosed with chronic eczema, atopic 
dermatitis, but the traditional therapy for these diseases was inef-
fective. By the end of 2015, the rashes took the form of a universal 
erythroderma accompanied by intense itching. A histological 
examination of the skin showed a picture of chronic dermatitis. 
In March 2016, a diagnosis of clinical cutaneous lymphoma was 
made on the basis of a clinical picture, but repeated skin biopsy 
again indicated chronic dermatitis. A bone marrow biopsy with no 
pathological abnormalities. In November 2016, the board issued a 
diagnosis of clinical cutaneous lymphoma, a lymph node biopsy 
was performed, which showed a lymphoproliferative disease. 
In February 2017, a fungal mycosis T4N2MxB0 with total skin 
lesions, with affected axillary lymph nodes, characterized by slow 
progressing course was diagnosed. This clinical case demonstrates 
that cutaneous lymphomas can mimic many benign dermatoses 
at the clinical and histological levels. If the patient has an intense 
itch that does not lend itself to traditional therapy, for a long time, 
doctor should think about the diagnosis of cutaneous lymphoma. 
PP67
OCCUPATIONAL ASPECTS OF SCABIES
Michael Häberle1, Arno Rütten2
1Dermatological Practice Künzelsau, 2Dermatopathology Friedrichshafen/
Bodensee, Dermatological Practice Künzelsau, Germany
Ten employees and 6 residents with dementia in an old folks 
home simultaneously developed itching rashes, especially on 
the abdomen and arms. Scabies was diagnosed by dermatoscopy 
and biopsy. One seniorresident, who had moved from another 
nursing home 6 months earlier, was identified as the source of 
the infection. She had been treated for eczema of some months. 
Elderly people suffering from dementia need a regular procedure, 
transferring them from bed to armchair and back, twice daily, 
by lifting. Intensive skin contact is inevitable during this proce-
dure, which explains clinical signs on abdominal skin. Overall, 
18 elderly care nurses, 6 contact persons und 10 residents were 
examined for scabies. Clinics were organized at 6 am, 1 pm and 
9 pm in order to cover all shifts. Topical therapy was performed 
using 5% permethrin in a greasy ointment. Immediate notifica-
tion to local health authorities of outbreaks of infections diseases 
is mandatory as required by German legislation. A sophisticated 
strategy is essential: The dermatologist, management, staff and 
the health authorities establish a time schedule for examinations, 
treatments, follow-ups, quarantine period and informative mee-
tings. The chain of infection must to be interrupted as soon as 
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possible. Staff rotation is interrupted, and all affected persons must 
be treated simultaneously. Contaminated textiles must be washed 
at 60°C, protective clothing is provided for the staff. Handouts 
are helpful for cooperation. Statutory accident insurance provides 
compensations for infected staff members as required by German 
legislation. Scabies is listed as an occupational disease (BK 3101).
PP68
PRURITUS IN PATIENTS WITH ACUTE HEART 
FAILURE
Malgorzata Ponikowska1, Jan Biegus2, Robert Zymlinski2, Jacek 
C. Szepietowski1
1Department of Dermatology, Venerology and Allergology. Wrocław Medi-
cal University. Wroclaw, 21 Department of Cardiology, Centre for Heart 
Disease, 4th Military Hospital, 2Department of Heart Diseases, Medical 
University, Wroclaw, Poland
Background: Pruritus is a common and distressing symptom, 
often complicating non-dermatological systemic diseases such 
as chronic kidney disease, hepatobiliary or hematological disor-
ders. As previously reported (Niklasson O et al, Br J Dermatol 
2015;172:1541-6.) pruritus was postulated to also be common 
among patients with stable, chronic heart failure (HF) with the 
prevalence of itching at some point at 3-month follow-up period 
reaching 40%. Objectives: Our study was set-up to investigate 
the prevalence of pruritus in patients admitted to the Department 
of Cardiology due to acute HF. We also aimed to provide clinical 
characteristics of patients reporting pruritus and explore potential 
underlying causes. Material and Methods: We prospectively re-
cruited 87 consecutive patients with acute HF (65 (74.7%) men, 
mean age: 67±5 years, left ventricular ejection fraction: 36±5%) 
who received standard cardio-vascular therapy and were studied 
before hospital discharge. Pruritus was assessed using the visual 
analogue scale (VAS), numeral rating scale (NRS), specially 
constructed questionnaire regarding connection between pruritus 
and cardiac disease, therapy and other factors, as well as Der-
matology Life Quality Index (DLQI). Results: The prevalence 
of itching during the entire cardiac disease was 16% (14 out of 
87 subjects). From that group 10 out of 14 patients reported itch 
occurring during the last 3 days – in those subjects pruritus was 
scored at 5.4 on VAS and 5.5 on NRS. The remaining 4 subjects 
stated that itching occurred at some point in the past during the 
entire cardiac disease, but not at the present hospitalization. In the 
majority (71%) of patients pruritus was limited to a certain area 
of the skin, mostly lower and upper limbs (50%). Noteworthy, 9 
out of 16 patients that experienced itching had increased level of 
bilirubin and half of this group suffered from anemia. Both these 
factors are proven to contribute to the development of pruritus. 
Based on our study and clinical experience we do not see a signi-
ficant connection between pruritus and HF. 
PP69
COLONIZATION OF SKIN AND MUCOUS 
MEMBRANES BY S. AUREUS IN ATOPIC 
DERMATITIS PATIENTS – IS THERE A LINK WITH 
ITCH PATHOGENESIS?
Leszek Blicharz1, Zbigniew Samochocki1, Paulina Usarek2
1Department of Dermatology, and 2Department of Clinical Microbiology, 
Medical University of Warsaw, Poland
Introduction: Pathogenesis of itch in atopic dermatitis (AD) 
remains unclear. Nevertheless, altered microbiome composition 
is proposed as one of the factors contributing to epithelial barrier 
damage, increased local and systemic inflammation and intensifi-
cation of pruritus. Numerous reports suggest that both skin lesions 
and other regions of the human body show selective expansion 
of S. aureus and simultaneous reduction of other components of 
the natural microflora. Indeed, S. aureus strains can be a source 
of local and systemic factors that potentially exacerbate skin 
inflammation and itch. Aim of the study: To assess the relation 
between S. aureus colonization and itch severity in AD. Methods: 
A total of 33 patients (19 males/14 females, mean age = 31 years) 
with AD were enrolled in the trial. Every subject presented for an 
interview and clinical examination (confirmation of AD diagnosis, 
disease severity assessment based on SCORAD scale). Swabs 
were taken from lesional and non-lesional skin and from anterior 
nares. Bacterial cultures on Chapman media were then performed. 
Morphologically distinct colonies were identified with the help 
of mass spectrometry. Additionally, a professional microbiologist 
assessed concentration of S. aureus colonies in the cultures (a scale 
of 0-3 points). Control group consisted of 33 sex- and age-matched 
healthy individuals. Results were analyzed statistically. Results: 
Overall percentage of cultures positive for S. aureus in the study 
group was 64% for anterior nares (vs 11% in control group), 79% 
for lesional skin and 58% for non-lesional skin (vs 6% in control 
group). We aimed to establish the association between results of 
microbiological tests and selected parameters of the SCORAD 
scale related with itch (excoriation and subjective evaluation of 
sleep loss and pruritus). Patients colonized by S. aureus showed 
higher values of these parameters. Spearman correlation ratio was 
also calculated to assess the impact of colony concentration on 
the intensity of the symptoms. Rho was remarkably high for ex-
coriation. In case of subjective parameters rho reflected moderate 
correlation with colony concentration of S. aureus. Conclusions: 
S. aureus colonization of AD patients is associated with increased 
pruritus. Furthermore, colonization intensity is positively cor-
related with SCORAD scale parameters expressing itch. Our 
research suggests that new therapeutic and prophylactic measures 
are needed to improve itch control in atopic eczema. 
PP70
ITCH AND PAIN INFLUENCE ON QUALITY OF 
LIFE OF ATOPIC DERMATITIS AND PSORIASIS 
PATIENTS
Karolina Kaaz, Łukasz Matusiak, Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Wroclaw, Poland
Background: Atopic dermatitis (AD) and psoriasis (Ps) are com-
mon chronic, inflammatory and recurrent skin diseases. They both 
are accompanied by subjective symptoms, such as itch and pain. 
AD and Ps have great impact on patients’ quality of life. Sleep is 
a important, active process of lives of human. Objectives: This 
study was undertaken to evaluate the influence of itch and pain on 
quality of life of atopic dermatitis and psoriasis patients. Material 
and Methods: The study group consisted of 100 (42 females, 58 
males) AD patients with mean age of 39.2±15.4 years and 100 (39 
females, 61 males) Ps patients with mean age 44.1±15.8 years. 
The mean disease severity was assessed as 33.6±10.7 points and 
13.5±8.4 points according to SCORAD (Scoring Atopic Der-
matitis) and PASI (Psoriasis Area Severity Index), respectively. 
Itch and pain intensity were evaluated with visual analogue scale 
(VAS). The quality of life was assessed by DLQI. Moreover, sleep 
abnormalities were estimated with Athens Insomnia Scale (AIS), 
Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness 
Scale (ESS). Results: During the course of disease and within three 
last days subjective symptoms were experienced by the following 
group: AD: itch – 100% vs. 100% patients; pain – 43% vs. 38% 
patients and Ps: itch – 95% vs. 95% patients and pain – 18% vs. 
16%, respectively. The mean itch and pain severity within three 
last days was estimated as: AD: 7.1±2.7 points and 5.3±2.9 points 
and Ps: 6.4±2.8 points and 1.2±3.0 points, respectively. The mean 
QoL was assessed as: AD: 16.4±7.9 points and Ps: 12.8±7.5 
points. The scores for particular sleep abnormalities questionn-
aires were 10.5±5.5 points, 8.3±4.2 points and 7.9±4.8 points in 
AD and 7.4±5.2 points, 8.1±4.8 points and 7.1±4.8 points in Ps, 
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with regard to AIS, PSQI and ESS, respectively. The severity 
of itch significantly correlated with scores obtained by the AIS 
(r=0.44, p<0.001) and (r=0.34, p<0.001), ESS (r=0.35, p<0.001) 
and (r=0.24, p=0.014), for AD and Ps respectively. Moreover, 
decreased QoL correlated significantly with severity of itch and 
pain AD (r=0.45, p<0.001), (r=0.36, p=0.026) and Ps (r=0.32, 
p<0.001), (r=0.5, p<0.001), respectively. Conclusions: Itch can 
affect the quality of sleep of AD and Ps patients. Improving sleep 
quality of dermatological patients may improve their quality of life.
PP71
NODULAR PRURIGO AS FIRST MANIFESTATION 
OF PRIMARY BILIARY CHOLANGITIS 
SUCCESSFULLY TREATED WITH RIFAMPIN AND 
SERTRALINE
Piotr Parcheta1, Piotr Stepien2, Dorota Zarebska-Michaluk2, Bea-
ta Krecisz1
1Department of Dermatology, and 2Department of Infectious Diseases, 
Kielce Voivodeship Hospital, Kielce, Poland
Primary biliary cholangitis (PBC) is an immune-mediated chronic 
cholestatic liver disease with a slowly progressive course Prurigo 
nodularis is characterized by extremely pruritic nodules with well-
defined clinical symptoms and histopathological findings. Disorder 
is caused by a variety of pathomechanisms Pruritus is one of the 
most difficult symptoms to treat in the course of PBC. Often, it can 
be severe and refractory to multiple treatments, and significantly 
affects the quality of life of the patient There is evidence to sug-
gest that rifampicin is an effective treatment for pruritus in patients 
with chronic cholestatic liver disease. It is used as a second line of 
therapy in the PBC. Rifampicin can cause hepatitis in about 7% 
of patients treated for cholestatic liver disease. Serotonin is fourth 
line agent in PBC. Antipruritic effect has been demonstrated in a 
case series. We report the case of a 42-year-old woman present 
with pruritic papules and nodules on her legs, arms and trunk de-
veloped over the past 2 years. After wide spectrum of diagnostic 
procedures we found significant elevation liver and cholestatic 
enzymes, IgM and AMA antibodies. Skin biopsy confirmed nodular 
prurigo. Patient was examined and reffered do Infectious Diseases 
Department. Diagnosis of PBC was conifrmed. We start therapy 
with rifampin 150 mg once daily with amelioration of the itch. 
After 4 weeks of therapy, patient developed hepatotoxicity. Due 
to side effect, rifampin was stoped. The patient then received 50 
mg sertraline once daily with rapid and significant improvement.
PP72
ITCH IN NON-MELANOMA SKIN CANCERS.
Iwona Chlebicka, Jacek C. Szepietowski
Department of Dermatology, Venereology and Allergology, Wroclaw Medi-
cal University, Wroclaw, Poland
Itch is one of the most important symptoms in dermatology. Its 
presence has been proven in many diseases which during many 
years were defined as non-itching disorders. However there are not 
many studies examining prevalence, intensity, type, duration this 
important symptom in patients with BCC and SCC. The authors 
of this study exam correlation between intensity of itch and type 
of cancer, age of patients, location of lesion and previous treat-
ment. The mterial are patients treated because of non-melanoma 
skin cancer (NMSC) in Ward of Plastic Surgery in Department 
of Dermatology, Venereology and Allergology, Wroclaw Medical 
University between June 2016 and May 2017. For the analysis 
were included 175 patients operated because of NMSC (89 women 
and 86 men). In 90.3% the histological diagnosis was BCC. Itching 
in lesion was reported in 37% ptients with BCC (45% male patients 
but only 29%f emale). 61%patients with SCC reported itch and/or 
pain. It seems there is relationship between presence and intensity 
of itch and superficial type of BCC, extrafacial location and males.
PP73
GENDER DISPARITY IN THE PSYCHOSOCIAL 
EFFECT OF CHRONIC ITCH ON CHILDREN
Sandy François1, Grace Lee1, Shelby Smith1, Alix Pijeaux1, Kuang-
Ho Chen1, James Roberts2, Suephy Chen1
1Emory University, 2Georgia Institute of Technology, USA
Background: Dermatologic conditions can have a significant 
impact on the quality of life (QoL) but little is known about the 
psychosocial effects of chronic itch on children. Moreover, there 
is published literature regarding greater emotive expressivity of 
girls vs. boys. We hypothesized that girls would demonstrate higher 
emotional impact from chronic pruritus than boys. Methods: Child-
ren between the ages of 6–17 who experience chronic itch (6 weeks 
or longer) were recruited and administered a panel of surveys 
including pediatric versions of the ItchyQoL, a self-report of the 
QoL impact from chronic pruritus. There is a younger child (6–7 
years) and older child (8–17 years) version that we are currently 
validating. For this analysis, only the items related to emotional 
impact were analyzed. Proportions were used to determine distin-
ctive emotional concepts. Chi-square and Fisher’s exact test were 
used to assess the possible difference between genders in the two 
age groups. Results: There were 67 (6–7 year-olds) with 29 boys 
and 38 girls and 164 (8–17-year-olds) with 102 girls and 62 boys. 
For the 6–7 year-olds, 34 % expressed sadness, 30% were mad and 
15% were scared due to their itchy skin. For the older children, 
23% were sad, 33% were angry and 12% were scared. Of note 
in the older group, 65% were frustrated, 50% were driven crazy 
and 39% were embarrassed by their itchy skin. Between genders, 
there was no significant difference in the 6–7 age group. For the 
8–17 age group, girls were more embarrassed (p= 0.02) and more 
worried (p=0.03) than boys. Conclusion: A third of the younger 
group was saddened and scared due to their chronic itch; a lower 
percentage of (pre)adolescents expressed those feelings. A third 
of all subjects voiced anger and the majority of (pre)adolescents 
experienced frustration. There were no gender differences in the 
younger group. In the (pre)adolescent group, girls expressed more 
embarrassment and worry than boys. It should be noted that certain 
concepts tested were specific to each age group; frustration, driven 
crazy and embarrassment were not tested in the younger group. 
These findings give us insight on the emotional aspects elicited 
from chronic pruritus in children. Emotional support tailored 
to these concepts may be helpful, paying particular attention to 
embarrassment and worry in older girls. A larger scaled study is 
needed to further assess these concepts.
PP74
BOTH NARROWBAND-UVB AND BROADBAND-
UVB ARE EQUALLY EFFECTIVE IN REDUCING 
ITCH IN CHRONIC PRURITUS PATIENTS
Franz J. Legat1, Angelika Hofer1, Alexandra Gruber-Wackerna-
gel1, Franz Quehenberger2, Klara Waltner1, Peter Wolf1
1Department of Dermatology, and 2Institute for Medical Informatics, Sta-
tistics and Documentation, Medical University Graz, Graz, Austria
Chronic pruritus (CP) (> 6 weeks) significantly reduces the pa-
tients’ quality of life. Repeated scratching and development of 
an “itch-scratch cycle” may lead to chronic prurigo (CPR) with 
pruriginous papules and nodules. Treatment of CP is difficult 
and, to date, there are no licensed treatments for CP or CPR. 
Phototherapy with broadband (BB)-UVB has previously been 
shown to reduce CP in patients with renal insufficiency (RI). In 
recent years, however, due to superior efficacy of narrowband 
(NB)-UVB over BB-UVB in the treatment of psoriasis, atopic 
dermatitis, and vitiligo, NB-UVB has almost completely replaced 
BB-UVB in phototherapy units and private dermatological offices. 
Though, clinical experience suggests NB-UVB to be effective in 
reducing pruritus e.g., in patients with RI or CPR, there has not 
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been a study comparing it with BB-UVB. Thus, we investigated 
the effects of BB-UVB versus NB-UVB in reducing pruritus in 
patients with CP. 49 patients consented and were randomly assig-
ned to BB-UVB or NB-UVB. After testing for individual minimal 
erythema dose (MED) with the respective light source, patients 
were whole-body UV-treated 3x per week for 6 weeks in equally 
looking BB-UVB or NB-UVB cabins (starting dose 50% MED, 
UV-dose increments 20% per week). Before, weekly during, and at 
the end of treatment, patients evaluated their pruritus using a visual 
analogue scale (VAS) ranging from 0 (=no itch) to 10 (=worst 
imaginable itch). 38 patients with CP (23F, 15M; median age 65y, 
range 20–85 years) received at least 4 weeks of UV-treatment 
(BB-UVB: 18; NB-UVB: 20) and were eligible for final evalua-
tion. Of these 38 patients, 35 had either CPR or secondary scratch 
lesions, and 3 had no skin lesions. BB-UVB reduced pruritus VAS 
from 6.05 (2.2–10) to 2.10 (0–7.5) (median reduction 67.2%), and 
NB-UVB from 6.75 (1.1–10) to 1.20 (0–8.7) (median reduction 
80.7%). Testing for non-inferiority (equality range up to 20% of 
the relative treatment effect, asymptotic Wilcoxon-Mann-Whitney 
Test) indicated that NB-UVB was not inferior to BB-UVB in the 
ability to reduce pruritus (p=0.0037). In conclusion, NB-UVB 
proofed to be equally effective as BB-UVB in reducing pruritus 
in CP patients and both phototherapeutic modalities showed very 
strong antipruritic activity at a grade (itch reduction by 70–80%) 
that is hardly reached by any other treatment option available 
nowadays. Thus, like in other conditions NB-UVB can also be 
administered in CP patients with great overall efficacy. 
PP75
ITCHYQOL ASSESSMENT IN PSORIASIS 
VULGARIS: CORRELATION ANALYSIS 
OF PATIENT BASELINE DATA FROM A 
RANDOMIZED CONTROLLED TRIAL (PSORITUS)
Sonja Ständer, Karin Loser, Dieter Metze, Jürgen Zimmermann, 
Thomas A. Luger
Center for Chronic Pruritus, Department of Dermatology, University Hos-
pital Münster, Germany
Background: Pruritus is a frequent complaint in psoriasis vulga-
ris (PV) and has impact on the quality of life (QoL) of patients. 
The DLQI is a standard instrument commonly used in psoriasis. 
DLQI is discussed to show correlations of QoL with the pruritus 
intensity in psoriasis. So far no data are available on use of an 
itch-specific QoL instrument, ItchyQol, in PV. Methods: Patients 
with moderate to severe PV and intense pruritus were assigned 
to treatment with Secukinumab within a randomized controlled 
trial (PSORITUS). The present correlation analysis comprised 
assessment of PSORITUS baseline data including the results of 
the ItchyQol questionnaire, itch intensity VAS, comorbidities and 
demographic data. Results: 130 patients with PV were included: 
46 (34.5%) females; age range 24–75 years, median: 49 years. 
Patients suffered since 18.5 years (median) from PV; 13.8% had 
psoriasis arthritis. PASI was 20.9 (median), VAS worst 24 h was 
8.1 (median); VAS average 24 h was 7.2 (median). ItchyQol score 
ranged from 33 to 110 with a mean of 78.7 (SD 17.4; median: 
83); DLQI ranged from 3.0 to 30 (mean: 17.8, SD 7.9; median: 
18.5). ItchyQol showed moderate to strong correlations with VAS 
worst, VAS average, and DLQI. The multiple linear regression 
analysis showed significant dependency of QoL as measured by 
ItchyQol for parameter as follows: female gender (estimate of 
5.81 ItchyQol-points worse QoL than males), VAS average 24 h, 
duration of PV and health-related patient needs as measured by 
the Patient Need Questionnaire (part of Patient Benefit Index). 
Conclusion: ItchyQol assessment demonstrated that patients with 
psoriasis vulgaris are highly burdened by pruritus. Itch intensity 
and ItchyQol are correlating with each other influencing patient’s 
needs and treatment expectations. 
PP76
IMPERVIOUSNESS TO GENDER CARTOON 
ANNOTATION IN SELF REPORTED PRURITUS 
OUTCOMES
Suephy Chen1, James Roberts2
1Emory University, 2Georgia Institute of Technology, USA
The ItchyQuant and the pediatric versions of the ItchyQoL are 
cartoon-annotated in an attempt to assist young children to un-
derstand the concepts behind self-rated itch severity and quality of 
life (QoL) impact of chronic pruritus (CP, itch lasting >6 weeks). 
A cartoon of a young boy dominates both the ItchyQuant and 
ItchyQoL, leading to worry that girls may not relate to the instru-
ments. In this study, we sought to discern any gender differences 
in the internal consistency and central tendencies (mean, median, 
etc.) of the ItchyQOL. Method: The ItchyQuant and ItchyQoL were 
administered to 6–7-year-old and to 4–5-year-old children with 
CP. Internal consistency for the ItchyQoL was calculated using 
Cronbach’s alpha across all children in a given age cohort and 
then separately by gender within that same age cohort. Differen-
ces in central tendency between genders were evaluated using an 
ANOVA for comparison of means, a Wilcoxon Rank Sum test, and 
a test of the mean number of scores per gender group which were 
above the overall median score (i.e., a median test). Correlation 
between ItchyQuant and ItchyQoL scores were explored for each 
gender using Spearman rank order correlations. A p-value <0.05 
was considered statistically significant. Results: 70 6–7-year-old 
(32 boys and 38 girls) and 33 4–5-year-old (13 boys and 20 girls) 
completed the instruments. The ItchyQoL’s Cronbach’s alpha did 
not differ substantially between boys, girls, and overall (0.81, 0.86, 
and 0.84, respectively) in the 6–7-year-old group. The overall mean 
for boys and girls was 5.59 and 5.37, which was not significantly 
different according to an ANOVA. The Rank Sum test did not 
reveal significant differences, nor did the median test (51% vs 
49% above the median score). The ItchyQuant scores correlated 
with the ItchyQoL significantly and similarly between boys and 
girls (0.56 and 0.49, p<0.01 for both). In the 4–5-year-old age 
group, analogous results were found. Conclusion: Although the 
majority of the items in the ItchyQoL and the ItchyQuant were 
depicted by cartoons of young boys, there does not appear to be 
a gender difference in the ItchyQOL properties of interest when 
aggregated over items. It appears that girls can relate the instrument 
to themselves as well as boys. 
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«PSEUDOALLERGIC» REACTIONS ON SKIN AND 
MUCOUS MEMBRANE: IS IT A PSYCHOSOMATIC 
PHENOMENON?
Andrey Lvov, Dmitry Romanov, Anastasia Tereshenko, Svetlana 
Bobko
Moscow research and practical center of dermatovenereology and cosme-
tology, Russia
The variety of skin sensations associated with mental disorders 
is rather wide and cause problems in diagnostics and treatment. 
Recently the application of patients with complains on itch of the 
skin and mucous membrane becomes more and more often. Glos-
salgia and glossopyrosis or Burning mouth syndrome is associated 
with dysgeusia, paresthesia, dysesthesia, xerostomia, among the 
therapeutic approaches clonazepam, psychotherapy, capsaicin 
and gabapentin are mentioned in literature (Liu YF. et al., 2017, 
Vellappally S., 2016). Skin with a greater density of epidermal 
innervation is more susceptible for the development of cutaneous 
sensory disorder (Gupta M.A. et al., 2013). Burning mouth syn-
drome may be associated with higher scores for depressive and 
anxiety symptoms (Davies S.J. et al., 2016). In 2016-2017 17 
patients (average age 41.94 years old) applied with complains on 
different sensations of the skin and mucous membrane without or 
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with rash on skin. The patients were consulted by allergologists 
and other specialist and directed to our center. Dermatovenereo-
logist and psychiatrist in detail examined the patients. Among 
the diagnosis 8 patients had glossalgia, 5 patients had urticaria, 
2 patients – somatoform itch and 2 patients – amplified itch at 
the base of atopic dermatitis. Psychiatric equivalents of itch and 
other sensations (burning, tingling, tickling, pricking, prickling, 
tightness, stinging and others) were widely presented and were 
the sign of different psychodermatological interventions. The 
manifestation of rash as a variant of psychogenic «pseudoallergic 
reactions» in form of urticum, papules was noticed. The use of 
psychotropic drugs (antipsychotics and others) is necessary in 
such cases and shows its efficacy.
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A NEW TOOL FOR MODELLING STINGING 
TEST IN VITRO: A COMPARATIVE EVALUATION 
WITH IN VIVO RESULTS USING A BACTERIAL 
POLYSACCHARIDE
Mehdi Sakka1, Raphael Leschiera1, Christelle Le Gall-Ianotto1, 
Olivier Gouin1, Killian L’herondelle1, Jean-Luc Philbé2, Florent 
Yvergnaux2, Thibaut Saguet2, Jean-Luc Carré1, Laurent Misery1, 
Nicolas Lebonvallet1
1Laboratory of Neurosciences of Brest, University of Western Brittany, 
Brest, 2BioEurope – Groupe Solabia, Anet, France
Stinging test is an in vivo classic protocol that evaluates sensitive 
skin and tests molecules, actives, formula or ingredients on soo-
thing sensation. In practice, stinging test is made using lactic acid 
at 10 or 5 percent % placed on nasolabial fold right and left of the 
face of volunteers. After begin a stinging sensation, a placebo is 
deposited on one side and potential soothing on the other side. 
To predict the probable soothing sensation of a product before 
in vivo testing and to modelize effect on the skin, we developed 
a culture and co-culture model based on acid lactic test and 
substance P (SP) release using human keratinocytes and PC12 
cells. In order to predict a calming effect, we used a bacterial 
polysaccharide present in Fucogel® in in vivo stinging test and 
our in vitro model. Keratinocytes and PC12 cells were placed on 
a 96-wells plate. PC12 cells were differentiated using NGF for 3 
days and keratinocytes were maintained one day in proliferation 
medium before application of lactic acid or polysaccharide or 
both. Firstly, ideal concentration of acid lactic (10%, 5%, 1%, 
0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.07%, 0.04%, 0%) has been 
determined to release SP without cytotoxicity on keratinocytes 
and PC12 cells. We showed a release of SP for all conditions with 
lactic acid. The release of SP was significant from 0.1% of lactic 
acid without toxicity for PC12 cells and keratinocytes. When 
pH was neutralized, lactic acid doid not provoke SP release. On 
keratinocytes, 0.1% lactic acid induced a cytosolic calcium entry 
whereas prior pH neutralization did not. At these concentrations of 
lactic acid, 0.1% of polysaccharide induced a significant decrease 
of SP release on two cellular types and in co-culture without 
modified the pH of the medium. In vivo, stinging test associated 
with Fucogel® application was followed by a decrease by 30% of 
prikling intensity versus placebo on 19 women volunteers from 
21 to 69 years old. Our in vitro model is ethically interesting and 
is adapted for cosmetic ingredients screening because there is no 
animal experimentation. Furthermore, Fucogel® has an interesting 
soothing activity revealed by in vivo stinging test and our new in 
vitro stinging test based on SP release.
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EARLY ONSET OF ANTIPRURITIC EFFECTS 
WITH SERLOPITANT FOR CHRONIC PRURITUS: 
POST HOC ANALYSIS RESULTS FROM A 
RANDOMIZED, MULTICENTER, PLACEBO-
CONTROLLED PHASE 2 CLINICAL TRIAL
Sonja Ständer1, Gil Yosipovitch2, Joe Hirman3, Paul Kwon4
1Center for Chronic Pruritus, Department of Dermatology, University Hos-
pital Münster, Münster, Germany; 2Miami Itch Center, Department of Der-
matology, University of Miami School of Medicine, Miami, Florida, USA; 
3Pacific Northwest Statistical Consulting, Inc., Woodinville, Washington, 
USA; 4Menlo Therapeutics Inc., Menlo Park, California, USA
Introduction: Chronic pruritus, a prevalent symptom of a variety 
of underlying conditions, can significantly impact quality of life. 
Many chronic pruritus therapies have limited efficacy, and some 
are associated with undesirable safety/tolerability issues. Immedia-
te relief of itch is an initial treatment goal for chronic pruritus. The 
neuropeptide substance P and its receptor, neurokinin 1 receptor 
(NK1-R), play a role in the pathogenesis of chronic pruritus. The 
NK1-R antagonist serlopitant was shown to provide statistically 
significant improvement in chronic pruritus when given once 
daily for 6 weeks compared with placebo and was safe and well 
tolerated in a phase 2 clinical trial (NCT01951274). Here, we 
show evidence that the onset of antipruritic effects with serlopi-
tant begins in the first few days of initiating treatment. Material/
Methods: Key eligibility criteria were treatment-unresponsive 
or -refractory pruritus lasting ≥6 weeks and baseline itch Visual 
Analog Scale (VAS) score ≥7. Patients were randomized 1:1:1:1 
to receive serlopitant 0.25 mg, 1 mg, 5 mg, or placebo. After a 
loading dose of 3 tablets at baseline, patients took 1 tablet daily for 
6 weeks. Change from baseline on study days 1 to 14 was analy-
zed, with the difference in average change from baseline between 
the serlopitant and placebo groups tested using a t-test. Results: 
Two hundred fifty-seven patients were randomized to serlopitant 
0.25 mg (n=64), 1 mg (n=64), or 5 mg (n=65), or placebo (n=64); 
baseline characteristics were comparable. The mean change from 
baseline VAS itch score was significantly greater with serlopitant 
1 mg beginning on day 2 and 5 mg beginning on day 3 than with 
placebo. The antipruritic effects of serlopitant were sustained to 
week 6; the percentage change from baseline VAS itch score was 
significantly greater with serlopitant 1 mg (–41.4; p=0.022) and 
5 mg (–42.5; p=0.013) at week 6 compared with placebo (–28.3). 
Conclusions: Serlopitant provided statistically significant impro-
vement in chronic pruritus beginning as early as day 2 with the 1 
mg dose and day 3 with the 5 mg dose compared with placebo. 
The improvements in the experience of pruritus with serlopitant 
were sustained to week 6 with the 1 mg and 5 mg doses.
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